

# Hepatocellular carcinoma

Lancet, The

391, 1301-1314

DOI: [10.1016/s0140-6736\(18\)30010-2](https://doi.org/10.1016/s0140-6736(18)30010-2)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Microwave or radiofrequency ablation: clinically equivalent?. The Lancet Gastroenterology and Hepatology, 2018, 3, 291-292.	3.7	6
2	Sorafenib-Induced Radiation in-Field Skin (SIRIS) Reaction: Unexpected Complication in Elder Hepatocellular Carcinoma Patients Received Sorafenib and Concurrent Radiation Therapy. International Journal of Gerontology, 2018, , .	0.7	1
3	EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. Journal of Hepatology, 2018, 69, 182-236.	1.8	6,153
4	Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology, 2018, 68, 723-750.	3.6	3,096
5	Transcriptomic analyses of chemokines reveal that down-regulation of XCR1 is associated with advanced hepatocellular carcinoma. Biochemical and Biophysical Research Communications, 2018, 496, 1314-1321.	1.0	12
6	Clinical and prognostic significance of circulating levels of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma. Oncotarget, 2018, 9, 37721-37732.	0.8	16
7	Expansion of the hepatocellular carcinoma Milan criteria in liver transplantation: Future directions. World Journal of Gastroenterology, 2018, 24, 3626-3636.	1.4	38
8	A new tumor-associated antigen prognostic scoring system for spontaneous ruptured hepatocellular carcinoma after partial hepatectomy. Cancer Biology and Medicine, 2018, 15, 415.	1.4	4
9	The current role of laparoscopic resection for HCC: a systematic review of past ten years. Translational Gastroenterology and Hepatology, 2018, 3, 68-68.	1.5	20
10	Innovative treatment for hepatocellular carcinoma (HCC). Translational Gastroenterology and Hepatology, 2018, 3, 78-78.	1.5	12
11	Postoperative adjuvant transarterial chemoembolization for multinodular hepatocellular carcinoma within the Barcelona Clinic Liver Cancer early stage and microvascular invasion. Hepatobiliary Surgery and Nutrition, 2018, 7, 418-428.	0.7	59
12	Refining surgical therapy of liver cancer in cirrhosis: etiology makes the difference. Translational Gastroenterology and Hepatology, 2018, 3, 104-104.	1.5	0
13	The first-line treatment for unresectable hepatocellular carcinoma patients: lenvatinib versus sorafenib, or beyond?. Hepatobiliary Surgery and Nutrition, 2018, 7, 221-224.	0.7	12
14	De novo hepatocellular carcinoma in the context of new direct acting antivirals: time seems to start talking. AME Medical Journal, 2018, 3, 103-103.	0.4	0
15	Abnormal expression of <i>HMGB-3</i> is significantly associated with malignant transformation of hepatocytes. World Journal of Gastroenterology, 2018, 24, 3650-3662.	1.4	10
16	Misconceptions Surrounding Hepatocellular Carcinoma. Clinical Liver Disease, 2018, 12, 154-159.	1.0	0
17	MicroRNAâ€²223 promotes hepatocellular carcinoma cell resistance to sorafenib by targeting FBW7. Oncology Reports, 2018, 41, 1231-1237.	1.2	11
18	What Chinese Medicine Can Do for Liver Cancer?. , 0, , .		0

#	ARTICLE	IF	CITATIONS
19	Aberrant Metabolism in Hepatocellular Carcinoma Provides Diagnostic and Therapeutic Opportunities. <i>Oxidative Medicine and Cellular Longevity</i> , 2018, 2018, 1-13.	1.9	106
21	Complications of Transarterial Chemoembolization (TACE) in the Treatment of Liver Tumors. <i>Cirug�a Espa�ola (English Edition)</i> , 2018, 96, 560-567.	0.1	24
22	Potential of ramucirumab in treating hepatocellular carcinoma patients with elevated baseline alpha-fetoprotein. <i>Journal of Hepatocellular Carcinoma</i> , 2018, Volume 5, 91-98.	1.8	10
23	Evaluation and prediction of hepatocellular carcinoma prognosis based on molecular classification. <i>Cancer Management and Research</i> , 2018, Volume 10, 5291-5302.	0.9	19
24	HCC in Cirrhotics With Retained Liver Function and Absent Portal Hypertension: Still a Surgical Disease. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 1405.	0.4	0
25	Microsurgical Technique of Locoregional Injection into the Hepatic Artery in Tumor-Bearing Mice. <i>European Surgical Research</i> , 2018, 59, 339-348.	0.6	3
26	Preoperative diagnosis and prediction of hepatocellular carcinoma: Radiomics analysis based on multi-modal ultrasound images. <i>BMC Cancer</i> , 2018, 18, 1089.	1.1	95
27	MYO18B promotes hepatocellular carcinoma progression by activating PI3K/AKT/mTOR signaling pathway. <i>Diagnostic Pathology</i> , 2018, 13, 85.	0.9	19
28	Ginkgolic acid suppresses the invasion of HepG2 cells via downregulation of HGF/c�Met signaling. <i>Oncology Reports</i> , 2019, 41, 369-376.	1.2	13
29	Complicaciones de la quimioembolizaci�n transarterial (QETA) en el tratamiento de los tumores hep�ticos. <i>Cirug�a Espa�ola</i> , 2018, 96, 560-567.	0.1	28
30	Natural product pectolarigenin inhibits proliferation, induces apoptosis, and causes G2/M phase arrest of HCC via PI3K/AKT/mTOR/ERK signaling pathway. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 8633-8642.	1.0	25
31	Prognosis of Spontaneous Bacterial Peritonitis in Hepatocellular Carcinoma Patients. <i>Journal of Korean Medical Science</i> , 2018, 33, e335.	1.1	5
32	Overexpressing lncRNA <em>SNHG16</em>; inhibited HCC proliferation and chemoresistance by functionally sponging hsa-miR-93. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 8855-8863.	1.0	71
33	SKA1 overexpression is associated with poor prognosis in hepatocellular carcinoma. <i>BMC Cancer</i> , 2018, 18, 1240.	1.1	28
34	The Role of Radiologic Modalities in Diagnosing Nonalcoholic Steatohepatitis (NASH) and Fibrosis. <i>Current Hepatology Reports</i> , 2018, 17, 324-335.	0.4	8
35	Safety and efficacy of cytotoxic chemotherapy in hepatocellular carcinoma after first-line treatment with sorafenib. <i>BMC Cancer</i> , 2018, 18, 1250.	1.1	6
36	Dysregulation of Nrf2 in Hepatocellular Carcinoma: Role in Cancer Progression and Chemoresistance. <i>Cancers</i> , 2018, 10, 481.	1.7	135
37	Overexpression of RALY promotes migration and predicts poor prognosis in hepatocellular carcinoma. <i>Cancer Management and Research</i> , 2018, Volume 10, 5559-5572.	0.9	15

#	ARTICLE	IF	CITATIONS
38	Carbon-13 radiotherapy for HCC: A potential tool to fulfil an unmet gap in the treatment algorithms?. <i>Liver International</i> , 2018, 38, 2132-2133.	1.9	0
39	CircSLC3A2 functions as an oncogenic factor in hepatocellular carcinoma by sponging miR-490-3p and regulating PPM1F expression. <i>Molecular Cancer</i> , 2018, 17, 165.	7.9	64
40	CDCA5 overexpression is an Indicator of poor prognosis in patients with hepatocellular carcinoma (HCC). <i>BMC Cancer</i> , 2018, 18, 1187.	1.1	29
41	Mitofusin-2 acts as biomarker for predicting poor prognosis in hepatitis B virus related hepatocellular carcinoma. <i>Infectious Agents and Cancer</i> , 2018, 13, 36.	1.2	13
42	A novel long-sustaining system of apatinib for long-term inhibition of the proliferation of hepatocellular carcinoma cells. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 8529-8541.	1.0	26
43	Role of Endoglin (CD105) in the Progression of Hepatocellular Carcinoma and Anti-Angiogenic Therapy. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3887.	1.8	48
44	Carcinogenesis on the background of liver fibrosis: Implications for the management of hepatocellular cancer. <i>World Journal of Gastroenterology</i> , 2018, 24, 4436-4447.	1.4	105
45	Genomic analysis of small nucleolar RNAs identifies distinct molecular and prognostic signature in hepatocellular carcinoma. <i>Oncology Reports</i> , 2018, 40, 3346-3358.	1.2	15
46	A model combining TNM stage and tumor size shows utility in predicting recurrence among patients with hepatocellular carcinoma after resection. <i>Cancer Management and Research</i> , 2018, Volume 10, 3707-3715.	0.9	30
47	Hypoxia inducible factor 1 $\alpha$ in hepatocellular carcinoma with cirrhosis: Association with prognosis. <i>Pathology Research and Practice</i> , 2018, 214, 1987-1992.	1.0	18
48	Aspirin and Chemoprevention: Have We Arrived?. <i>JAMA Oncology</i> , 2018, 4, 1668.	3.4	5
49	The Impact of Direct-acting Antiviral Therapy for Hepatitis C on Hepatocellular Carcinoma Risk. <i>Current Hepatology Reports</i> , 2018, 17, 377-384.	0.4	14
50	Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, iv238-iv255.	0.6	663
51	Sestrin 2 confers primary resistance to sorafenib by simultaneously activating AKT and AMPK in hepatocellular carcinoma. <i>Cancer Medicine</i> , 2018, 7, 5691-5703.	1.3	30
52	Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy. <i>Seminars in Liver Disease</i> , 2018, 38, 379-388.	1.8	62
53	circRNA_104075 stimulates YAP-dependent tumorigenesis through the regulation of HNF4a and may serve as a diagnostic marker in hepatocellular carcinoma. <i>Cell Death and Disease</i> , 2018, 9, 1091.	2.7	182
54	High Expression of Glycolytic Genes in Cirrhosis Correlates With the Risk of Developing Liver Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2018, 6, 138.	1.8	56
55	Regorafenib: a promising treatment for hepatocellular carcinoma. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1941-1948.	0.9	17

#	ARTICLE	IF	CITATIONS
56	Plexin C1 Marks Liver Cancer Cells with Epithelial Phenotype and Is Overexpressed in Hepatocellular Carcinoma. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2018, 2018, 1-9.	0.8	7
57	Reply. <i>Gastroenterology</i> , 2018, 155, 1275-1276.	0.6	0
58	Tim-3 expression and its role in hepatocellular carcinoma. <i>Journal of Hematology and Oncology</i> , 2018, 11, 126.	6.9	89
59	Tumor Location Influences Oncologic Outcomes of Hepatocellular Carcinoma Patients Undergoing Radiofrequency Ablation. <i>Cancers</i> , 2018, 10, 378.	1.7	36
60	Clinical Case Panel: Treatment Alternatives for Inoperable Hepatocellular Carcinoma. <i>Seminars in Radiation Oncology</i> , 2018, 28, 295-308.	1.0	4
61	Extracellular Vesicles in Hepatobiliary Malignancies. <i>Frontiers in Immunology</i> , 2018, 9, 2270.	2.2	29
62	Genomewide identification of a novel six-lncRNA signature to improve prognosis prediction in resectable hepatocellular carcinoma. <i>Cancer Medicine</i> , 2018, 7, 6219-6233.	1.3	32
63	STARD13 is positively correlated with good prognosis and enhances 5-FU sensitivity via suppressing cancer stemness in hepatocellular carcinoma cells. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 5371-5381.	1.0	15
64	Prognostic role of alpha-fetoprotein response after hepatocellular carcinoma resection. <i>World Journal of Clinical Cases</i> , 2018, 6, 110-120.	0.3	31
65	Long-term remission in advanced stage hepatocellular carcinoma? A chance for cure?. <i>Memo - Magazine of European Medical Oncology</i> , 2018, 11, 185-192.	0.3	6
66	Surveillance for Early-Stage Hepatocellular Carcinoma by Ultrasound Plus Alpha-Fetoprotein Measurement: More Details, More Significance. <i>Gastroenterology</i> , 2018, 155, 1274-1275.	0.6	3
67	Serial MRI Imaging Reveals Minimal Impact of Ketogenic Diet on Established Liver Tumor Growth. <i>Cancers</i> , 2018, 10, 312.	1.7	14
68	Long non-coding RNA DSCR8 acts as a molecular sponge for miR-485-5p to activate Wnt/ $\beta$ -catenin signal pathway in hepatocellular carcinoma. <i>Cell Death and Disease</i> , 2018, 9, 851.	2.7	110
69	LncRNA miR503HG is a new player in hepatocellular carcinoma metastasis. <i>Non-coding RNA Investigation</i> , 0, 2, 51-51.	0.6	1
70	Hydroxylase Activity of ASPH Promotes Hepatocellular Carcinoma Metastasis Through Epithelial-to-Mesenchymal Transition Pathway. <i>EBioMedicine</i> , 2018, 31, 287-298.	2.7	38
71	Multimodality treatment of hepatocellular carcinoma: How field practice complies with international recommendations. <i>Liver International</i> , 2018, 38, 1624-1634.	1.9	25
72	Locoregional versus systemic therapy – robust positive data remain elusive. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 537-538.	12.5	3
73	Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond. <i>Cancer Treatment Reviews</i> , 2018, 68, 16-24.	3.4	124

#	ARTICLE	IF	CITATIONS
74	Glycine N-methyltransferase deletion in mice diverts carbon flux from gluconeogenesis to pathways that utilize excess methionine cycle intermediates. <i>Journal of Biological Chemistry</i> , 2018, 293, 11944-11954.	1.6	37
75	Bardoxolone Methyl Suppresses Hepatitis B Virus Large Surface Protein Variant W4P-Related Carcinogenesis and Hepatocellular Carcinoma Cell Proliferation Via the Inhibition of Signal Transducer and Activator of Transcription 3 Signaling. <i>Pharmacology</i> , 2018, 102, 105-113.	0.9	7
76	Alkaline ceramidase 3 promotes growth of hepatocellular carcinoma cells via regulating S1P/S1PR2/PI3K/AKT signaling. <i>Pathology Research and Practice</i> , 2018, 214, 1381-1387.	1.0	31
77	A systematic review comparing outcomes of surgical resection and non-surgical treatments for patients with hepatocellular carcinoma and portal vein tumor thrombus. <i>Hpb</i> , 2018, 20, 1119-1129.	0.1	35
78	Extracellular Vesicles as Carriers of Non-coding RNAs in Liver Diseases. <i>Frontiers in Pharmacology</i> , 2018, 9, 415.	1.6	29
79	A new apatinib microcrystal formulation enhances the effect of radiofrequency ablation treatment on hepatocellular carcinoma. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 3257-3265.	1.0	38
80	EMT-related long non-coding RNA in hepatocellular carcinoma: A study with TCGA database. <i>Biochemical and Biophysical Research Communications</i> , 2018, 503, 1530-1536.	1.0	26
81	Hepatocellular Carcinoma with Portal Vein Tumor Involvement: Best Management Strategies. <i>Seminars in Liver Disease</i> , 2018, 38, 242-251.	1.8	95
82	Review article: systemic treatment of hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 598-609.	1.9	131
83	Decreased expression of peroxisome proliferator-activated receptor alpha indicates unfavorable outcomes in hepatocellular carcinoma. <i>Cancer Management and Research</i> , 2018, Volume 10, 1781-1789.	0.9	36
84	Multicentric Assessment of the Hong Kong Liver Cancer Staging System in Chinese Patients Following Transarterial Chemoembolization. <i>CardioVascular and Interventional Radiology</i> , 2018, 41, 1867-1876.	0.9	1
85	Sorafenib for Advanced Hepatocellular Carcinoma: A Real-Life Experience. <i>Digestive Diseases</i> , 2018, 36, 377-384.	0.8	23
86	Tumor Molecular Profiling for an Individualized Approach to the Treatment of Hepatocellular Carcinoma: A Patient Case Study. <i>Biomedicines</i> , 2018, 6, 46.	1.4	5
87	microRNA-19a-3p promotes tumor metastasis and chemoresistance through the PTEN/Akt pathway in hepatocellular carcinoma. <i>Biomedicine and Pharmacotherapy</i> , 2018, 105, 1147-1154.	2.5	82
88	CD31 regulates metastasis by inducing epithelial to mesenchymal transition in hepatocellular carcinoma via the ITGB1-FAK-Akt signaling pathway. <i>Cancer Letters</i> , 2018, 429, 29-40.	3.2	70
89	17-beta-hydroxysteroid dehydrogenase 13 inhibits the progression and recurrence of hepatocellular carcinoma. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2018, 17, 220-226.	0.6	23
90	Comparison of local tumor control in patients with HCC treated with SBRT or TACE: a propensity score analysis. <i>BMC Cancer</i> , 2018, 18, 807.	1.1	27
91	Tumor Suppressor Down-Regulation Promotes Hepatocyte Proliferation: A New GANKster on the Block. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2018, 6, 345-346.	2.3	0

#	ARTICLE	IF	CITATIONS
92	miRâ€383 promotes cholangiocarcinoma cell proliferation, migration, and invasion through targeting IRF1. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 9720-9729.	1.2	31
93	Transarterial Radioembolization Following Chemoembolization for Unresectable Hepatocellular Carcinoma: Response Based on Apparent Diffusion Coefficient Change is an Independent Predictor for Survival. <i>CardioVascular and Interventional Radiology</i> , 2018, 41, 1716-1726.	0.9	6
94	Long nonâ€coding RNA expression profile can predict early recurrence in hepatocellular carcinoma after curative resection. <i>Hepatology Research</i> , 2018, 48, 1140-1148.	1.8	56
95	JMJD6 promotes hepatocellular carcinoma carcinogenesis by targeting CDK4. <i>International Journal of Cancer</i> , 2019, 144, 2489-2500.	2.3	52
96	Preoperative prealbumin level as an independent predictor of long-term prognosis after liver resection for hepatocellular carcinoma: a multi-institutional study. <i>Hpb</i> , 2019, 21, 157-166.	0.1	31
97	Microvascular invasion predicts a poor prognosis of solitary hepatocellular carcinoma up to 2Âcm based on propensity score matching analysis. <i>Hepatology Research</i> , 2019, 49, 344-354.	1.8	44
98	Safety of laparoscopic hepatectomy in patients with hepatocellular carcinoma and portal hypertension: interim analysis of an open prospective study. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2019, 33, 811-820.	1.3	26
99	Perioperative and long-term outcomes of laparoscopic versus open liver resection for hepatocellular carcinoma with well-preserved liver function and cirrhotic background: a propensity score matching study. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2019, 33, 206-215.	1.3	29
100	Isolated Peritoneal Recurrence After Liver Resection for Hepatocellular Carcinoma. <i>Journal of Gastrointestinal Cancer</i> , 2019, 50, 678-680.	0.6	0
101	In Vitro Performance of Published Glypican 3-Targeting Peptides TJ12P1 and L5 Indicates Lack of Specificity and Potency. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2019, 34, 498-503.	0.7	5
102	Case Study: Advanced Hepatocellular Carcinoma With Tumor Thrombus. <i>Clinical Liver Disease</i> , 2019, 13, 162-164.	1.0	2
103	SNAIL Promotes the Cholangiocellular Phenotype, but not Epithelialâ€Mesenchymal Transition, in a Murine Hepatocellular Carcinoma Model. <i>Cancer Research</i> , 2019, 79, 5563-5574.	0.4	12
104	Combined Treatments in Liver Ablations. <i>Digestive Disease Interventions</i> , 2019, 03, 126-132.	0.3	0
105	A network pharmacology-based study on the anti-hepatoma effect of Radix Salviae Miltiorrhizae. <i>Chinese Medicine</i> , 2019, 14, 27.	1.6	14
106	&lt;p&gt;Chelidonine enhances the antitumor effect of lenvatinib on hepatocellular carcinoma cells&lt;/p&gt;. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 6685-6697.	1.0	7
107	Biology and significance of alphaâ€fetoprotein in hepatocellular carcinoma. <i>Liver International</i> , 2019, 39, 2214-2229.	1.9	327
108	A global view of hepatocellular carcinoma: trends, risk, prevention and management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 589-604.	8.2	2,482
109	Reactive oxygen species-responsive nanoparticles based on a thioacetal-containing poly(Î2-amino ester) for combining photothermal/photodynamic therapy and chemotherapy. <i>Polymer Chemistry</i> , 2019, 10, 4746-4757.	1.9	19

#	ARTICLE	IF	CITATIONS
110	Immunotherapy in Hepatocellular Carcinoma: Is There a Light at the End of the Tunnel?. <i>Cancers</i> , 2019, 11, 1078.	1.7	36
111	Contrast-enhanced US in Local Ablative Therapy and Secondary Surveillance for Hepatocellular Carcinoma. <i>Radiographics</i> , 2019, 39, 1302-1322.	1.4	30
112	Insights into the success and failure of systemic therapy for hepatocellular carcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 617-630.	8.2	132
113	Atypical Appearance of Hepatocellular Carcinoma and Its Mimickers: How to Solve Challenging Cases Using Gadoteric Acid-Enhanced Liver Magnetic Resonance Imaging. <i>Korean Journal of Radiology</i> , 2019, 20, 1019.	1.5	36
114	Dual CCR5/CCR2 targeting: opportunities for the cure of complex disorders. <i>Cellular and Molecular Life Sciences</i> , 2019, 76, 4869-4886.	2.4	81
115	Hepatectomy promotes recurrence of liver cancer by enhancing IL-11-STAT3 signaling. <i>EBioMedicine</i> , 2019, 46, 119-132.	2.7	66
116	MicroRNA-519c-3p promotes tumor growth and metastasis of hepatocellular carcinoma by targeting BTG3. <i>Biomedicine and Pharmacotherapy</i> , 2019, 118, 109267.	2.5	22
117	Liver cancer. <i>British Journal of Healthcare Assistants</i> , 2019, 13, 322-328.	0.1	0
118	Whole transcriptome analysis of chemically induced hepatocellular carcinoma using RNA sequencing analysis. <i>FEBS Open Bio</i> , 2019, 9, 1900-1908.	1.0	3
119	&lt;p&gt;SNHG15: a promising cancer-related long noncoding RNA&lt;/p&gt;. <i>Cancer Management and Research</i> , 2019, Volume 11, 5961-5969.	0.9	48
120	M1 Macrophages Induce PD-L1 Expression in Hepatocellular Carcinoma Cells Through IL-1 $\beta$ Signaling. <i>Frontiers in Immunology</i> , 2019, 10, 1643.	2.2	117
121	Clinical conditions and treatment requirements for long-term survival among hepatitis B-related hepatocellular carcinoma initially treated with chemoembolization. <i>Cancer Medicine</i> , 2019, 8, 5097-5107.	1.3	7
122	Sorafenib with Transarterial Chemoembolization Achieves Improved Survival vs. Sorafenib Alone in Advanced Hepatocellular Carcinoma: A Nationwide Population-Based Cohort Study. <i>Cancers</i> , 2019, 11, 985.	1.7	32
123	Five-Years Outcome Analysis of 142 Consecutive Hepatocellular Carcinoma Patients Treated with Doxorubicin Eluting Microspheres 30 $\mu$ m: Results from a Single-Centre Prospective Phase II Trial. <i>CardioVascular and Interventional Radiology</i> , 2019, 42, 1551-1562.	0.9	18
124	MEG3-derived miR-493-5p overcomes the oncogenic feature of IGF2-miR-483 loss of imprinting in hepatic cancer cells. <i>Cell Death and Disease</i> , 2019, 10, 553.	2.7	36
125	The risk of liver cancer in autoimmune liver diseases. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591986191.	1.4	23
126	Nek2 augments sorafenib resistance by regulating the ubiquitination and localization of $\beta$ -catenin in hepatocellular carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 316.	3.5	32
127	Antipsychotic agent pimozide promotes reversible proliferative suppression by inducing cellular quiescence in liver cancer. <i>Oncology Reports</i> , 2019, 42, 1101-1109.	1.2	9



#	ARTICLE	IF	CITATIONS
128	Intestinal dysbacteriosis-induced IL-25 promotes development of HCC via alternative activation of macrophages in tumor microenvironment. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 303.	3.5	58
129	Biological functions and clinical applications of exosomal non-coding RNAs in hepatocellular carcinoma. <i>Cellular and Molecular Life Sciences</i> , 2019, 76, 4203-4219.	2.4	51
130	A nomogram predicting the prognosis of young adult patients diagnosed with hepatocellular carcinoma: A population-based analysis. <i>PLoS ONE</i> , 2019, 14, e0219654.	1.1	7
131	Resection vs Ablation for Multifocal Hepatocellular Carcinomas meeting the Barcelona-Clinic Liver Cancer A Classification: A Propensity Score Matching Study. <i>Journal of Cancer</i> , 2019, 10, 2857-2867.	1.2	7
132	Proteomic profiling in liver cancer: another new page. <i>Translational Gastroenterology and Hepatology</i> , 2019, 4, 47-47.	1.5	8
133	A Simple-to-Use Nomogram for Predicting the Survival of Early Hepatocellular Carcinoma Patients. <i>Frontiers in Oncology</i> , 2019, 9, 584.	1.3	38
134	Hepatocellular carcinoma with duodenal invasion resected subsequent to multimodal therapies: A case report. <i>International Journal of Surgery Case Reports</i> , 2019, 60, 348-352.	0.2	4
135	A human liver cell atlas reveals heterogeneity and epithelial progenitors. <i>Nature</i> , 2019, 572, 199-204.	13.7	744
136	Comparison of lipiodol infusion and drug-eluting beads transarterial chemoembolization of hepatocellular carcinoma in a real-life setting. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 905-912.	0.6	17
137	&lt;p&gt;Stereotactic body radiotherapy as the initial treatment for hepatocellular carcinoma with extensive inferior vena cava and atrium tumor thrombus&lt;/p&gt;. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 5299-5303.	1.0	1
138	In silico analysis excavates potential biomarkers by constructing miRNA-mRNA networks between non-cirrhotic HCC and cirrhotic HCC. <i>Cancer Cell International</i> , 2019, 19, 186.	1.8	17
139	Sesn3 deficiency promotes carcinogen-induced hepatocellular carcinoma via regulation of the hedgehog pathway. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2019, 1865, 2685-2693.	1.8	16
140	Identifying potential drug targets in hepatocellular carcinoma based on network analysis and one-class support vector machine. <i>Scientific Reports</i> , 2019, 9, 10442.	1.6	17
141	The molecular mechanism of LncRNA34a-mediated regulation of bone metastasis in hepatocellular carcinoma. <i>Molecular Cancer</i> , 2019, 18, 120.	7.9	49
142	Texture analysis of multi-phase MRI images to detect expression of Ki67 in hepatocellular carcinoma. <i>Clinical Radiology</i> , 2019, 74, 813.e19-813.e27.	0.5	28
143	&lt;p&gt;The prognostic value of LINC01296 in pan-cancers and the molecular regulatory mechanism in hepatocellular carcinoma: a comprehensive study based on data mining, bioinformatics, and in vitro validation&lt;/p&gt;. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 5861-5885.	1.0	4
144	Hepatocellular Carcinoma Growth Retardation and PD-1 Blockade Therapy Potentiation with Synthetic High-density Lipoprotein. <i>Nano Letters</i> , 2019, 19, 5266-5276.	4.5	40
145	Multidisciplinary Management of Patients with Unresectable Hepatocellular Carcinoma: A Critical Appraisal of Current Evidence. <i>Cancers</i> , 2019, 11, 873.	1.7	19

#	ARTICLE	IF	CITATIONS
146	&lt;p&gt;miR-3691-5p promotes hepatocellular carcinoma cell migration and invasion through activating PI3K/Akt signaling by targeting PTEN&lt;p&gt;. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 4897-4906.	1.0	14
147	Magnetic resonance texture analysis for the identification of cytokeratin 19-positive hepatocellular carcinoma. <i>European Journal of Radiology</i> , 2019, 117, 164-170.	1.2	22
148	Hepatocellular carcinomas: evolution to sorafenib resistance through hepatic leukaemia factor. <i>Gut</i> , 2019, 68, 1728-1730.	6.1	6
149	PCL&acirc;DOX microdroplets: an evaluation of the enhanced intracellular delivery of doxorubicin in metastatic cancer cells <i>via in silico</i> and <i>in vitro</i> approaches. <i>New Journal of Chemistry</i> , 2019, 43, 12241-12256.	1.4	4
150	Postoperative adjuvant sorafenib improves survival outcomes in hepatocellular carcinoma patients with microvascular invasion after R0 liver resection: a propensity score matching analysis. <i>Hpb</i> , 2019, 21, 1687-1696.	0.1	57
151	Rethinking the Role of Radiation Therapy in the Treatment of Unresectable Hepatocellular Carcinoma: A Data Driven Treatment Algorithm for Optimizing Outcomes. <i>Frontiers in Oncology</i> , 2019, 9, 345.	1.3	10
152	HEG1 indicates poor prognosis and promotes hepatocellular carcinoma invasion, metastasis, and EMT by activating Wnt/Î²-catenin signaling. <i>Clinical Science</i> , 2019, 133, 1645-1662.	1.8	56
153	Stereotactic image&acirc;guided microwave ablation of hepatocellular carcinoma using a computer&acirc;assisted navigation system. <i>Liver International</i> , 2019, 39, 1975-1985.	1.9	50
154	The Y<sub>SZ,Planck</sub> &acirc; Y<sub>SZ,XMM</sub> scaling relation and its difference between cool-core and non-cool-core clusters. <i>Research in Astronomy and Astrophysics</i> , 2019, 19, 104.	0.7	0
155	Ethnic Differences in Labour Market Outcomes&acirc;The Role of Language-Based Discrimination. <i>European Sociological Review</i> , 0, , .	1.3	5
156	Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response. , 2019, 7, 267.		156
157	MicroRNA-3163 targets ADAM-17 and enhances the sensitivity of hepatocellular carcinoma cells to molecular targeted agents. <i>Cell Death and Disease</i> , 2019, 10, 784.	2.7	48
158	Safety and efficacy of hepatic arterial infusion chemotherapy with raltitrexed and oxaliplatin post-transarterial chemoembolization for unresectable hepatocellular carcinoma. <i>Journal of Interventional Medicine</i> , 2019, 2, 91-96.	0.2	3
159	New warning signs on the road: 5-hydroxymethylcytosine-based liquid biopsy for the early detection of hepatocellular carcinoma. <i>Gut</i> , 2019, 68, 2103-2104.	6.1	3
160	Outcomes of hepatocellular carcinoma patients treated with sorafenib: a meta-analysis of Phase III trials. <i>Future Oncology</i> , 2019, 15, 3411-3422.	1.1	21
161	Update on hepatocellular carcinoma: Pathologists&acirc;TM review. <i>World Journal of Gastroenterology</i> , 2019, 25, 1653-1665.	1.4	100
162	Cabozantinib for the treatment of hepatocellular carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 847-855.	1.1	12
163	The strengths and weaknesses of gross and histopathological evaluation in hepatocellular carcinoma: a brief review. <i>Surgical and Experimental Pathology</i> , 2019, 2, .	0.2	7

#	ARTICLE	IF	CITATIONS
164	The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5237.	1.8	68
165	Chemotherapeutic perfusion of portal vein after tumor thrombectomy and hepatectomy benefits patients with advanced hepatocellular carcinoma: A propensity score-matched survival analysis. <i>Cancer Medicine</i> , 2019, 8, 6933-6944.	1.3	14
166	Preoperative serum albumin is associated with intra-abdominal infection following major hepatectomy. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2019, 26, 479-489.	1.4	17
167	EYA4 inhibits hepatocellular carcinoma by repressing MYCBP by dephosphorylating $\beta$ -catenin at Ser552. <i>Cancer Science</i> , 2019, 110, 3110-3121.	1.7	13
168	DNA methylation of individual repetitive elements in hepatitis C virus infection-induced hepatocellular carcinoma. <i>Clinical Epigenetics</i> , 2019, 11, 145.	1.8	31
169	Landscape and Dynamics of Single Immune Cells in Hepatocellular Carcinoma. <i>Cell</i> , 2019, 179, 829-845.e20.	13.5	897
170	Risk of recurrence of hepatocellular carcinoma in patients treated with interferon-free antivirals. <i>Gastroenterology &amp; Hepatology (English Edition)</i> , 2019, 42, 502-511.	0.0	3
171	Five Core Genes Related to the Progression and Prognosis of Hepatocellular Carcinoma Identified by Analysis of a Coexpression Network. <i>DNA and Cell Biology</i> , 2019, 38, 1564-1576.	0.9	37
172	Radioembolization for the Treatment of Primary and Metastatic Liver Cancers. <i>Nuclear Medicine and Molecular Imaging</i> , 2019, 53, 367-373.	0.6	21
173	AEG-1/miR-221 Axis Cooperatively Regulates the Progression of Hepatocellular Carcinoma by Targeting PTEN/PI3K/AKT Signaling Pathway. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5526.	1.8	17
174	A Novel Online Calculator Based on Serum Biomarkers to Detect Hepatocellular Carcinoma among Patients with Hepatitis B. <i>Clinical Chemistry</i> , 2019, 65, 1543-1553.	1.5	53
175	CACYBP Enhances Cytoplasmic Retention of P27Kip1 to Promote Hepatocellular Carcinoma Progression in the Absence of RNF41 Mediated Degradation. <i>Theranostics</i> , 2019, 9, 8392-8408.	4.6	24
176	miR-219 regulates liver cancer stem cell expansion via E-cadherin pathway. <i>Cell Cycle</i> , 2019, 18, 3550-3561.	1.3	14
177	miR-223 overexpression inhibits doxorubicin-induced autophagy by targeting FOXO3a and reverses chemoresistance in hepatocellular carcinoma cells. <i>Cell Death and Disease</i> , 2019, 10, 843.	2.7	73
178	Adjuvant transarterial chemoembolization for patients with hepatocellular carcinoma after radical hepatectomy: a real world study. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 1403-1411.	0.6	12
179	Non-SMC condensin I complex subunit H enhances proliferation, migration, and invasion of hepatocellular carcinoma. <i>Molecular Carcinogenesis</i> , 2019, 58, 2266-2275.	1.3	27
180	Comparing outcomes following total neoadjuvant therapy and following neoadjuvant chemoradiation therapy in patients with locally advanced rectal cancer. <i>EClinicalMedicine</i> , 2019, 16, 23-29.	3.2	19
181	The Application of Shallow Seismic in the Exploration of Aeolian Sand Strata. <i>IOP Conference Series: Earth and Environmental Science</i> , 2019, 310, 032066.	0.2	0

#	ARTICLE	IF	CITATIONS
182	Sigma $\alpha$ 1 receptor protects against ferroptosis in hepatocellular carcinoma cells. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 7349-7359.	1.6	111
183	Exosomal miR-21 regulates the TETs/PTENp1/PTEN pathway to promote hepatocellular carcinoma growth. <i>Molecular Cancer</i> , 2019, 18, 148.	7.9	113
184	&lt;p&gt;NCAPG Promotes The Proliferation Of Hepatocellular Carcinoma Through PI3K/AKT Signaling&lt;/p&gt;. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 8537-8552.	1.0	97
185	Anti-Cancer Effects of 3, 3 $\beta$ -Diindolylmethane on Human Hepatocellular Carcinoma Cells Is Enhanced by Calcium Ionophore: The Role of Cytosolic Ca <sup>2+</sup> and p38 MAPK. <i>Frontiers in Pharmacology</i> , 2019, 10, 1167.	1.6	30
186	Therapeutic hierarchy in hepatocellular carcinoma: A dispute of evidence versus practice. <i>Liver International</i> , 2019, 39, 1622-1623.	1.9	1
187	Vandetanib-eluting Radiopaque Beads: Pharmacokinetics, Safety, and Efficacy in a Rabbit Model of Liver Cancer. <i>Radiology</i> , 2019, 293, 695-703.	3.6	16
188	Early Therapeutic Vaccination Prediction of Hepatocellular Carcinoma via Imaging OX40-Mediated Tumor Infiltrating Lymphocytes. <i>Molecular Pharmaceutics</i> , 2019, 16, 4252-4259.	2.3	9
191	HBV DNA levels impact the prognosis of hepatocellular carcinoma patients with microvascular invasion. <i>Medicine (United States)</i> , 2019, 98, e16308.	0.4	6
192	Nemorosone inhibits the proliferation and migration of hepatocellular carcinoma cells. <i>Life Sciences</i> , 2019, 235, 116817.	2.0	19
193	A Practical Guideline for Hepatocellular Carcinoma Screening in Patients at Risk. <i>Mayo Clinic Proceedings Innovations, Quality &amp; Outcomes</i> , 2019, 3, 302-310.	1.2	58
194	Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma. <i>Cancer Research</i> , 2019, 79, 4326-4330.	0.4	99
195	Cytosolic phospholipase A2 $\pm$ modulates cell-matrix adhesion <i>via</i> the FAK/paxillin pathway in hepatocellular carcinoma. <i>Cancer Biology and Medicine</i> , 2019, 16, 377.	1.4	15
196	Inhibition of Glyoxalase-I Leads to Reduced Proliferation, Migration and Colony Formation, and Enhanced Susceptibility to Sorafenib in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2019, 9, 785.	1.3	12
197	Preoperative transcatheter arterial chemoembolization for surgical resection of huge hepatocellular carcinoma (â‰¥10Åcm): a multicenter propensity matching analysis. <i>Hepatology International</i> , 2019, 13, 736-747.	1.9	51
198	Local delivery of arsenic trioxide nanoparticles for hepatocellular carcinoma treatment. <i>Signal Transduction and Targeted Therapy</i> , 2019, 4, 28.	7.1	75
199	Prognostic role of serial alpha-fetoprotein levels in hepatocellular carcinoma treated with locoregional therapy. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 1132-1137.	0.6	6
200	Serum Serotonin as a Potential Diagnostic Marker for Hepatocellular Carcinoma. <i>Journal of Interferon and Cytokine Research</i> , 2019, 39, 780-785.	0.5	7
201	Safety and effectiveness of multi-antenna microwave ablation-oriented combined therapy for large hepatocellular carcinoma. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481986296.	1.4	12

#	ARTICLE	IF	CITATIONS
202	Sorafenib attenuated the function of natural killer cells infiltrated in HCC through inhibiting ERK1/2. <i>International Immunopharmacology</i> , 2019, 76, 105855.	1.7	10
203	Stereotactic body radiation therapy for early-stage hepatocellular carcinoma – a systematic review on outcome. <i>Acta Oncologica</i> , 2019, 58, 1706-1713.	0.8	30
204	Identification of a novel DNA repair-related prognostic signature predicting survival of patients with hepatocellular carcinoma. <i>Cancer Management and Research</i> , 2019, Volume 11, 7473-7484.	0.9	37
205	Stereotactic radiofrequency ablation of subcardiac hepatocellular carcinoma: a case-control study. <i>International Journal of Hyperthermia</i> , 2019, 36, 875-884.	1.1	21
206	Obesity and liver cancer. <i>Annals of Hepatology</i> , 2019, 18, 810-815.	0.6	58
207	Simplified nomograms based on platelet-associated models for survival prediction in Asian hepatocellular carcinoma patients after surgery. <i>Surgical Oncology</i> , 2019, 30, 131-138.	0.8	4
208	SREBP-1 inhibitor Betulin enhances the antitumor effect of Sorafenib on hepatocellular carcinoma via restricting cellular glycolytic activity. <i>Cell Death and Disease</i> , 2019, 10, 672.	2.7	77
209	Review about the multi-target profile of resveratrol and its implication in the SGK1 inhibition. <i>European Journal of Medicinal Chemistry</i> , 2019, 183, 111675.	2.6	20
210	Combined transarterial chemoembolization and radiotherapy as a first-line treatment for hepatocellular carcinoma with macroscopic vascular invasion: Necessity to subclassify Barcelona Clinic Liver Cancer stage C. <i>Radiotherapy and Oncology</i> , 2019, 141, 95-100.	0.3	17
211	Circ_0015756 promotes proliferation, invasion and migration by microRNA-7-dependent inhibition of FAK in hepatocellular carcinoma. <i>Cell Cycle</i> , 2019, 18, 2939-2953.	1.3	31
212	IL-11 drives postsurgical hepatocellular carcinoma recurrence. <i>EBioMedicine</i> , 2019, 47, 18-19.	2.7	5
213	CASC15 promotes epithelial to mesenchymal transition and facilitates malignancy of hepatocellular carcinoma cells by increasing TWIST1 gene expression via miR-33a-5p sponging. <i>European Journal of Pharmacology</i> , 2019, 860, 172589.	1.7	26
214	Pharmacotherapeutic options for biliary tract cancer: current standard of care and new perspectives. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 2121-2137.	0.9	7
215	Anti-tumoral activity of single and combined regorafenib treatments in preclinical models of liver and gastrointestinal cancers. <i>Experimental and Molecular Medicine</i> , 2019, 51, 1-15.	3.2	52
216	Effect of Hepatitis Viruses on the Nrf2/Keap1-Signaling Pathway and Its Impact on Viral Replication and Pathogenesis. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4659.	1.8	33
217	Matrine prevents the early development of hepatocellular carcinoma like lesions in rat liver. <i>Experimental and Therapeutic Medicine</i> , 2019, 18, 2583-2591.	0.8	4
218	Silencing of TAZ inhibits the motility of hepatocellular carcinoma cells through autophagy induction. <i>Cancer Management and Research</i> , 2019, Volume 11, 8743-8753.	0.9	2
219	Intratumoral IL-12 Gene Therapy Inhibits Tumor Growth In A HCC-Hu-PBL-NOD/SCID Murine Model. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 7773-7784.	1.0	10

#	ARTICLE	IF	CITATIONS
220	Real-world role of performance status in surgical resection for hepatocellular carcinoma: A multicenter study. <i>European Journal of Surgical Oncology</i> , 2019, 45, 2360-2368.	0.5	10
221	<p>STAT gene family mRNA expression and prognostic value in hepatocellular carcinoma</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 7175-7191.	1.0	18
222	The Role of Nrf2 in Liver Disease: Novel Molecular Mechanisms and Therapeutic Approaches. <i>Frontiers in Pharmacology</i> , 2018, 9, 1428.	1.6	177
223	Adoptive cell transfer therapy for hepatocellular carcinoma. <i>Frontiers of Medicine</i> , 2019, 13, 3-11.	1.5	45
224	Secalonic Acid-F, a Novel Mycotoxin, Represses the Progression of Hepatocellular Carcinoma via MARCH1 Regulation of the PI3K/AKT/β-catenin Signaling Pathway. <i>Molecules</i> , 2019, 24, 393.	1.7	29
225	Should we invariably follow the current guidelines to treat our HCC patients?. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2019, 18, 301-302.	0.6	0
226	Is R1 vascular hepatectomy for hepatocellular carcinoma oncologically adequate? Analysis of 327 consecutive patients. <i>Surgery</i> , 2019, 165, 897-904.	1.0	40
227	Gross and microscopic changes of liver neoplasms and background hepatic structures following neoadjuvant therapy. <i>Journal of Clinical Pathology</i> , 2019, 72, 112-119.	1.0	1
228	Weighing the benefits of hepatocellular carcinoma surveillance against potential harms. <i>Journal of Hepatocellular Carcinoma</i> , 2019, Volume 6, 23-30.	1.8	16
229	Disease-related proteins determination based on surface-enhanced Raman spectroscopy. <i>Applied Spectroscopy Reviews</i> , 2019, 54, 856-872.	3.4	10
230	Association Between Noninvasive Fibrosis Markers and Postoperative Mortality After Hepatectomy for Hepatocellular Carcinoma. <i>JAMA Network Open</i> , 2019, 2, e187142.	2.8	21
231	Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: A multicentre observational study. <i>Journal of Hepatology</i> , 2019, 70, 893-903.	1.8	153
232	&lt;p&gt;Overexpressed pepsinogen C is associated with poor prognosis in human hepatocellular carcinoma: a tissue microarray study&lt;/p&gt;. <i>Cancer Management and Research</i> , 2019, Volume 11, 2927-2934.	0.9	5
233	&lt;p&gt;Adjuvant trans-arterial chemoembolization after hepatectomy significantly improves the prognosis of low-risk patients with R0-stage hepatocellular carcinoma&lt;/p&gt;. <i>Cancer Management and Research</i> , 2019, Volume 11, 4065-4073.	0.9	12
234	&lt;p&gt;lncRNA CADM1-AS1 inhibits cell-cycle progression and invasion via PTEN/AKT/GSK-3&beta; axis in hepatocellular carcinoma&lt;/p&gt;. <i>Cancer Management and Research</i> , 2019, Volume 11, 3813-3828.	0.9	13
235	Tumour-associated macrophages in hepatocellular carcinoma: Pressing the metabolic switch to prevent T cell responses. <i>Journal of Hepatology</i> , 2019, 71, 243-245.	1.8	4
236	CircABCC2 Regulates Hepatocellular Cancer Progression by Decoying MiR-665. <i>Journal of Cancer</i> , 2019, 10, 3893-3898.	1.2	23
237	Systemic Treatment Options in Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2019, 8, 427-446.	4.2	89

#	ARTICLE	IF	CITATIONS
238	Current options and future possibilities for the systemic treatment of hepatocellular carcinoma. <i>Hepatic Oncology</i> , 2019, 6, HEP11.	4.2	24
239	A long non-coding RNA TSLD8 inhibits hepatocellular carcinoma by stabilizing WWOX. <i>Biochemical and Biophysical Research Communications</i> , 2019, 516, 526-532.	1.0	4
240	Identification of prognostic markers for hepatocellular carcinoma based on miRNA expression profiles. <i>Life Sciences</i> , 2019, 232, 116596.	2.0	45
241	A liver-specific lncRNA, FAM99B, suppresses hepatocellular carcinoma progression through inhibition of cell proliferation, migration, and invasion. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2027-2038.	1.2	21
242	Transcatheter arterial embolization in hepatic tumor hemorrhage. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 917-924.	0.6	4
243	Adjuvant cytokine-induced killer cell immunotherapy for hepatocellular carcinoma: a propensity score-matched analysis of real-world data. <i>BMC Cancer</i> , 2019, 19, 523.	1.1	24
244	Reply to: "Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules" A response. <i>Journal of Hepatology</i> , 2019, 71, 447-448.	1.8	0
245	Ultrasonic Cavitation Ameliorates Antitumor Efficacy of Residual Cancer After Incomplete Radiofrequency Ablation in Rabbit VX2 Liver Tumor Model. <i>Translational Oncology</i> , 2019, 12, 1113-1121.	1.7	6
246	Acidic pH-Activated Gas-Generating Nanoparticles with Pullulan Decorating for Hepatoma-Targeted Ultrasound Imaging. <i>ACS Applied Materials &amp; Interfaces</i> , 2019, 11, 22194-22205.	4.0	31
247	M2 macrophages mediate sorafenib resistance by secreting HGF in a feed-forward manner in hepatocellular carcinoma. <i>British Journal of Cancer</i> , 2019, 121, 22-33.	2.9	92
248	The effect of propranolol on the prognosis of hepatocellular carcinoma: A nationwide population-based study. <i>PLoS ONE</i> , 2019, 14, e0216828.	1.1	14
250	Co-responsive smart cyclodextrin-gated mesoporous silica nanoparticles with ligand-receptor engagement for anti-cancer treatment. <i>Materials Science and Engineering C</i> , 2019, 103, 109831.	3.8	46
251	Elucidation of the Differences in Cinobufotalin's Pharmacokinetics Between Normal and Diethylnitrosamine-Injured Rats: The Role of P-Glycoprotein. <i>Frontiers in Pharmacology</i> , 2019, 10, 521.	1.6	6
252	Liquid Biopsy in Hepatocellular Carcinoma. , 2019, , 87-95.		0
253	A continuous-time hidden Markov model for cancer surveillance using serum biomarkers with application to hepatocellular carcinoma. <i>Metron</i> , 2019, 77, 67-86.	0.6	12
254	The value of indocyanine green clearance assessment to predict postoperative liver dysfunction in patients undergoing liver resection. <i>Scientific Reports</i> , 2019, 9, 8421.	1.6	39
255	Systematic Review and Meta-Analysis of the Utility of Circular RNAs as Biomarkers of Hepatocellular Carcinoma. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2019, 2019, 1-13.	0.8	12
256	Safety and Efficacy of Radiofrequency Ablation for Solitary Hepatocellular Carcinoma (3-5 cm): a Propensity Score Matching Cohort Study. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 1549-1558.	0.9	6

#	ARTICLE	IF	CITATIONS
257	Targeted therapy for hepatocellular carcinoma: Challenges and opportunities. <i>Cancer Letters</i> , 2019, 460, 1-9.	3.2	156
258	Inhibition of glycogen catabolism induces intrinsic apoptosis and augments multikinase inhibitors in hepatocellular carcinoma cells. <i>Experimental Cell Research</i> , 2019, 381, 288-300.	1.2	21
259	Immunotherapy of hepatocellular carcinoma: strategies for combinatorial intervention. <i>Science China Life Sciences</i> , 2019, 62, 1138-1143.	2.3	19
260	MTA2 promotes HCC progression through repressing FRMD6, a key upstream component of hippo signaling pathway. <i>Biochemical and Biophysical Research Communications</i> , 2019, 515, 112-118.	1.0	14
261	Oncofetal HLF transactivates c-Jun to promote hepatocellular carcinoma development and sorafenib resistance. <i>Gut</i> , 2019, 68, 1858-1871.	6.1	79
262	Novel small molecular dye-loaded lipid nanoparticles with efficient near-infrared-II absorption for photoacoustic imaging and photothermal therapy of hepatocellular carcinoma. <i>Biomaterials Science</i> , 2019, 7, 3165-3177.	2.6	44
263	Sorafenib versus hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: a systematic review and meta-analysis. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 845-855.	0.6	23
264	Systemic Treatment for Advanced Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2019, 8, 341-358.	4.2	82
265	&lt;p&gt;Targeting myeloid-derived suppressor cells in the treatment of hepatocellular carcinoma: current state and future perspectives&lt;p&gt;. <i>Journal of Hepatocellular Carcinoma</i> , 2019, Volume 6, 71-84.	1.8	54
266	Analyses of a Panel of Transcripts Identified From a Small Sample Size and Construction of RNA Networks in Hepatocellular Carcinoma. <i>Frontiers in Genetics</i> , 2019, 10, 431.	1.1	14
267	Identification of a molecular subtyping system associated with the prognosis of Asian hepatocellular carcinoma patients receiving liver resection. <i>Scientific Reports</i> , 2019, 9, 7073.	1.6	7
268	LncRNA SNHG1 contributes to sorafenib resistance by activating the Akt pathway and is positively regulated by miR-21 in hepatocellular carcinoma cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 183.	3.5	135
269	Hepatocellular Carcinoma Recurrence in HCV Patients Treated with Direct Antiviral Agents. <i>Viruses</i> , 2019, 11, 406.	1.5	11
270	Identification and validation of a potent multi-mRNA signature for the prediction of early relapse in hepatocellular carcinoma. <i>Carcinogenesis</i> , 2019, 40, 840-852.	1.3	12
271	Tumor Hypervascularity and hand-foot-skin reaction predict better outcomes in combination treatment of TACE and Sorafenib for intermediate hepatocellular carcinoma. <i>BMC Cancer</i> , 2019, 19, 409.	1.1	14
272	Spatiotemporally Light-Activatable Platinum Nanocomplexes for Selective and Cooperative Cancer Therapy. <i>ACS Nano</i> , 2019, 13, 6647-6661.	7.3	46
273	Does postoperative adjuvant transarterial chemoembolization benefit for all patients with hepatocellular carcinoma combined with microvascular invasion: a meta-analysis. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 528-537.	0.6	24
274	Loss of 5â€hydroxymethylcytosine immunohistochemical expression is a useful diagnostic aid for distinguishing hepatocellular carcinoma in cytology fine needle aspiration specimens. <i>Cytopathology</i> , 2019, 30, 492-498.	0.4	3



#	ARTICLE	IF	CITATIONS
275	Co-administration of combretastatin A4 nanoparticles and sorafenib for systemic therapy of hepatocellular carcinoma. <i>Acta Biomaterialia</i> , 2019, 92, 229-240.	4.1	33
276	Microwave ablation assisted by three-dimensional visualization system as local therapy for relapsed hepatoblastoma: a small pilot study. <i>Abdominal Radiology</i> , 2019, 44, 2909-2915.	1.0	10
277	Dgat2 reduces hepatocellular carcinoma malignancy via downregulation of cell cycle-related gene expression. <i>Biomedicine and Pharmacotherapy</i> , 2019, 115, 108950.	2.5	18
278	Hepatocellular Carcinoma: Essentials Interventional Radiologists Need to Know. <i>CardioVascular and Interventional Radiology</i> , 2019, 42, 1262-1270.	0.9	2
279	Overexpression of MTHFD1 in hepatocellular carcinoma predicts poorer survival and recurrence. <i>Future Oncology</i> , 2019, 15, 1771-1780.	1.1	20
280	Assessment of the response of hepatocellular carcinoma to interventional radiology treatments. <i>Future Oncology</i> , 2019, 15, 1791-1804.	1.1	8
281	7â€œDeoxynarciclasine shows promising antitumor efficacy by targeting Akt against hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2019, 145, 3334-3346.	2.3	7
282	Fiveâ€œyear conditional survival for patients with hepatocellular carcinoma in Queensland, Australia. <i>GastroHep</i> , 2019, 1, 61-69.	0.3	0
283	Current status of the combination therapy of transarterial chemoembolization and local ablation for hepatocellular carcinoma. <i>Abdominal Radiology</i> , 2019, 44, 2268-2275.	1.0	27
284	Exosomeâ€œtransmitted p120â€œcatenin suppresses hepatocellular carcinoma progression via STAT3 pathways. <i>Molecular Carcinogenesis</i> , 2019, 58, 1389-1399.	1.3	28
285	Gender disparity in HCC: Is it the fat and not the sex?. <i>Journal of Experimental Medicine</i> , 2019, 216, 1014-1015.	4.2	14
286	Gene profiling of HepG2 cells following nitidine chloride treatment: An investigation with microarray and Connectivity Mapping. <i>Oncology Reports</i> , 2019, 41, 3244-3256.	1.2	9
287	Vps4A mediates the localization and exosome release of $\beta$ 2-catenin to inhibit epithelial-mesenchymal transition in hepatocellular carcinoma. <i>Cancer Letters</i> , 2019, 457, 47-59.	3.2	41
288	GLS1 promotes proliferation in hepatocellular carcinoma cells via AKT/GSK3 $\beta$ /CyclinD1 pathway. <i>Experimental Cell Research</i> , 2019, 381, 1-9.	1.2	32
289	Mutational Processes in Hepatocellular Carcinoma: The Story of Aristolochic Acid. <i>Seminars in Liver Disease</i> , 2019, 39, 334-340.	1.8	24
290	Secreted protein acidic and rich in cysteine promotes epithelialâ€œmesenchymal transition of hepatocellular carcinoma cells and acquisition of cancerstem cell phenotypes. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1860-1868.	1.4	17
291	A Prospective Study of Nut Consumption and Risk of Primary Hepatocellular Carcinoma in the U.S. Women and Men. <i>Cancer Prevention Research</i> , 2019, 12, 367-374.	0.7	16
292	&lt;p&gt;Incidence, risk factors, and prognosis in patients with primary hepatocellular carcinoma and lung metastasis: a population-based study&lt;/p&gt;. <i>Cancer Management and Research</i> , 2019, Volume 11, 2759-2768.	0.9	24

#	ARTICLE	IF	CITATIONS
293	Immunotherapy in hepatocellular carcinoma. <i>Annals of Hepatology</i> , 2019, 18, 291-297.	0.6	66
294	MiR-942-3p Promotes the Proliferation and Invasion of Hepatocellular Carcinoma Cells by Targeting MBL2. <i>Cancer Control</i> , 2019, 26, 107327481984659.	0.7	12
295	Prediction early recurrence of hepatocellular carcinoma eligible for curative ablation using a Radiomics nomogram. <i>Cancer Imaging</i> , 2019, 19, 21.	1.2	65
297	Integrated analysis of a competing endogenous RNA network reveals key long noncoding RNAs as potential prognostic biomarkers for hepatocellular carcinoma. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 13810-13825.	1.2	37
298	PFKFB3/HIF-1 $\alpha$ feedback loop modulates sorafenib resistance in hepatocellular carcinoma cells. <i>Biochemical and Biophysical Research Communications</i> , 2019, 513, 642-650.	1.0	26
299	MicroRNA-196a/-196b regulate the progression of hepatocellular carcinoma through modulating the JAK/STAT pathway via targeting SOCS2. <i>Cell Death and Disease</i> , 2019, 10, 333.	2.7	49
300	Blood-Brain Barrier: Morphology, Regulation, and Pathophysiology. <i>Gene Expression</i> , 2019, 19, 69-87.	0.5	32
301	Short-term and long-term outcomes of liver resection for HCC patients with portal vein tumor thrombus. <i>Cell and Bioscience</i> , 2019, 9, 23.	2.1	17
302	Liver Allocation Policies in the USA: Past, Present, and the Future. <i>Digestive Diseases and Sciences</i> , 2019, 64, 985-992.	1.1	15
303	Positive Immuno-Modulation Following Radiofrequency Assisted Liver Resection in Hepatocellular Carcinoma. <i>Journal of Clinical Medicine</i> , 2019, 8, 385.	1.0	21
304	A comprehensive study of epigenetic alterations in hepatocellular carcinoma identifies potential therapeutic targets. <i>Journal of Hepatology</i> , 2019, 71, 78-90.	1.8	72
305	ARQ-197 enhances the antitumor effect of sorafenib in hepatocellular carcinoma cells via decelerating its intracellular clearance. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 1629-1640.	1.0	23
306	Trough Levels of Everolimus Are Associated With Recurrence Rates of Hepatocellular Carcinoma After Liver Transplantation. <i>Transplantation Proceedings</i> , 2019, 51, 450-453.	0.3	10
307	Cabozantinib and the moving field of systemic treatments in advanced hepatocellular carcinoma. <i>Hepatobiliary Surgery and Nutrition</i> , 2019, 8, 53-55.	0.7	3
308	Development and evaluation of doxorubicin self nanoemulsifying drug delivery system with <i>Nigella Sativa</i> oil against human hepatocellular carcinoma. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2019, 47, 933-944.	1.9	28
309	Postoperative $\alpha$ -fetoprotein response predicts tumor recurrence and survival after hepatectomy for hepatocellular carcinoma: A propensity score matching analysis. <i>Surgery</i> , 2019, 165, 1161-1167.	1.0	13
310	Hepatocellular carcinoma with extrahepatic metastasis: Are there still candidates for transarterial chemoembolization as an initial treatment?. <i>PLoS ONE</i> , 2019, 14, e0213547.	1.1	12
311	Interventional oncology treatments for unresectable early stage HCC in patients with a high risk for intra-procedural bleeding: Is a single-step combined therapy safe and feasible?. <i>European Journal of Radiology</i> , 2019, 114, 32-37.	1.2	8

#	ARTICLE	IF	CITATIONS
312	CT-based peritumoral radiomics signatures to predict early recurrence in hepatocellular carcinoma after curative tumor resection or ablation. <i>Cancer Imaging</i> , 2019, 19, 11.	1.2	120
313	INTS8 accelerates the epithelial-to-mesenchymal transition in hepatocellular carcinoma by upregulating the TGF- $\beta$ signaling pathway. <i>Cancer Management and Research</i> , 2019, Volume 11, 1869-1879.	0.9	8
314	Lysine crotonylation is involved in hepatocellular carcinoma progression. <i>Biomedicine and Pharmacotherapy</i> , 2019, 111, 976-982.	2.5	62
315	Acidic Microenvironment Up-Regulates Exosomal miR-21 and miR-10b in Early-Stage Hepatocellular Carcinoma to Promote Cancer Cell Proliferation and Metastasis. <i>Theranostics</i> , 2019, 9, 1965-1979.	4.6	168
316	Preclinical comparison of regorafenib and sorafenib efficacy for hepatocellular carcinoma using multimodality molecular imaging. <i>Cancer Letters</i> , 2019, 453, 74-83.	3.2	19
317	Expression of IL-26 predicts prognosis of patients with hepatocellular carcinoma after surgical resection. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2019, 18, 242-248.	0.6	8
318	An arsenic trioxide nanoparticle prodrug (ATONP) potentiates a therapeutic effect on an aggressive hepatocellular carcinoma model via enhancement of intratumoral arsenic accumulation and disturbance of the tumor microenvironment. <i>Journal of Materials Chemistry B</i> , 2019, 7, 3088-3099.	2.9	11
319	Frizzled 2-induced epithelial-mesenchymal transition correlates with vasculogenic mimicry, stemness, and Hippo signaling in hepatocellular carcinoma. <i>Cancer Science</i> , 2019, 110, 1169-1182.	1.7	31
320	Novel urokinase-plasminogen activator inhibitor SPINK13 inhibits growth and metastasis of hepatocellular carcinoma in vivo. <i>Pharmacological Research</i> , 2019, 143, 73-85.	3.1	29
321	Efficacy of Hepatic Resection vs. Radiofrequency Ablation for Patients With Very-Early-Stage or Early-Stage Hepatocellular Carcinoma: A Population-Based Study With Stratification by Age and Tumor Size. <i>Frontiers in Oncology</i> , 2019, 9, 113.	1.3	35
322	Transarterial Chemoembolization (TACE) Combined with Sorafenib versus TACE Alone for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Study. <i>Journal of Cancer</i> , 2019, 10, 1189-1196.	1.2	31
323	Abandonment of surveillance, followed by emergency surgery for a second spontaneous rupture of hepatocellular carcinoma: A case report and review of the literature. <i>Clinical Case Reports (discontinued)</i> , 2019, 7, 789-796.	0.2	0
324	Predictors of low risk for dropout from the liver transplant waiting list for hepatocellular carcinoma in long wait time regions: Implications for organ allocation. <i>American Journal of Transplantation</i> , 2019, 19, 2210-2218.	2.6	32
325	Editorial: redrawing the boundaries for surgical intervention in hepatocellular carcinoma—authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 616-617.	1.9	0
326	Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy. <i>Journal of Hematology and Oncology</i> , 2019, 12, 27.	6.9	211
327	Systemic doxorubicin and hepatocellular carcinoma: the end of an era never risen up. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 418-420.	3.7	2
328	Cyclin B2 Overexpression in Human Hepatocellular Carcinoma is Associated with Poor Prognosis. <i>Archives of Medical Research</i> , 2019, 50, 10-17.	1.5	62
329	Controversies in the management of hepatocellular carcinoma. <i>JHEP Reports</i> , 2019, 1, 17-29.	2.6	45

#	ARTICLE	IF	CITATIONS
330	The Role of Fibrosis and Liver-Associated Fibroblasts in the Pathogenesis of Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1723.	1.8	192
331	Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , 2019, 380, 1450-1462.	13.9	2,966
332	Prognostic impact of transcatheter arterial chemoembolization (TACE) combined with radiofrequency ablation in patients with unresectable hepatocellular carcinoma: Comparison with TACE alone using decision tree analysis after propensity score matching. <i>Hepatology Research</i> , 2019, 49, 919-928.	1.8	42
333	Impact of DARC rs12075 Variants on Liver Fibrosis Progression in Patients with Chronic Hepatitis C: A Retrospective Study. <i>Biomolecules</i> , 2019, 9, 143.	1.8	7
334	Identification of survival-related predictors in hepatocellular carcinoma through integrated genomic, transcriptomic, and proteomic analyses. <i>Biomedicine and Pharmacotherapy</i> , 2019, 114, 108856.	2.5	15
335	Increased multimodality treatment options has improved survival for Hepatocellular carcinoma but poor survival for biliary tract cancers remains unchanged. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1660-1667.	0.5	41
336	Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival. <i>Journal of Hepatology</i> , 2019, 70, 1262-1277.	1.8	150
337	Prevention of Hepatocellular Carcinoma by Statins: Clinical Evidence and Plausible Mechanisms. <i>Seminars in Liver Disease</i> , 2019, 39, 141-152.	1.8	16
338	Surgical and oncological outcomes of hepatic resection for BCLC-B hepatocellular carcinoma: a retrospective multicenter analysis among 474 consecutive cases. <i>Updates in Surgery</i> , 2019, 71, 285-293.	0.9	25
339	Concomitant Inhibition of Cytoprotective Autophagy Augments the Efficacy of Withaferin A in Hepatocellular Carcinoma. <i>Cancers</i> , 2019, 11, 453.	1.7	19
340	Prognostic association of demographic and clinical factors with the change rates of symptoms and depression among patients with hepatocellular carcinoma. <i>Supportive Care in Cancer</i> , 2019, 27, 4665-4674.	1.0	8
341	Targeting the mTOR regulatory network in hepatocellular carcinoma: Are we making headway?. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2019, 1871, 379-391.	3.3	27
342	Predictors of Radiation-Induced Liver Disease in Eastern and Western Patients With Hepatocellular Carcinoma Undergoing Proton Beam Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 73-86.	0.4	41
343	Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 454-465.	3.7	36
344	MARCH1 encourages tumour progression of hepatocellular carcinoma via regulation of PI3K/AKT/PCNA/catenin pathways. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 3386-3401.	1.6	24
345	Treatment strategies for locally advanced hepatocellular carcinoma. <i>Translational Gastroenterology and Hepatology</i> , 2019, 4, 12-12.	1.5	14
346	Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date. <i>Journal of Hepatocellular Carcinoma</i> , 2019, Volume 6, 31-39.	1.8	55
347	MiR-122 Targets SerpinB3 and Is Involved in Sorafenib Resistance in Hepatocellular Carcinoma. <i>Journal of Clinical Medicine</i> , 2019, 8, 171.	1.0	37

#	ARTICLE	IF	CITATIONS
348	Should Patients With NAFLD/NASH Be Surveyed for HCC?. Transplantation, 2019, 103, 39-44.	0.5	52
349	Low recurrence rate of hepatocellular carcinoma following ledipasvir and sofosbuvir treatment in a real-world chronic hepatitis C patients cohort. Journal of Viral Hepatitis, 2019, 26, 666-674.	1.0	6
350	Hydrogen Sulfide as a Novel Regulatory Factor in Liver Health and Disease. Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-16.	1.9	42
351	Curcumin Suppresses Hepatic Stellate Cell-Induced Hepatocarcinoma Angiogenesis and Invasion through Downregulating CTGF. Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-12.	1.9	45
352	Excellent Response to Anti-PD-1 Therapy in a Patient with Hepatocellular Carcinoma Intolerant to Sorafenib. Visceral Medicine, 2019, 35, 43-46.	0.5	6
353	Î³Î³ T cells in hepatocellular carcinoma patients present cytotoxic activity but are reduced in potency due to IL-2 and IL-21 pathways. International Immunopharmacology, 2019, 70, 167-173.	1.7	17
354	Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma. Nature, 2019, 567, 257-261.	13.7	613
355	Newly Proposed ALBI Grade and ALBI-T Score as Tools for Assessment of Hepatic Function and Prognosis in Hepatocellular Carcinoma Patients. Liver Cancer, 2019, 8, 312-325.	4.2	88
356	Synchronous hepatectomy and splenectomy vs hepatectomy for selected patients with hepatocellular carcinoma and clinically significant portal hypertension: A systematic review and meta-analysis. Journal of Surgical Oncology, 2019, 119, 964-973.	0.8	9
357	Statin Use After Diagnosis of Hepatocellular Carcinoma Is Associated With Decreased Mortality. Clinical Gastroenterology and Hepatology, 2019, 17, 2117-2125.e3.	2.4	29
358	Tropomodulin $\beta$ 3 promotes liver cancer progression by activating the MAPK/ERK signaling pathway. Oncology Reports, 2019, 41, 3060-3068.	1.2	14
359	Supplementary Sorafenib Therapies for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Journal of Clinical Gastroenterology, 2019, 53, 486-494.	1.1	6
360	HCC in Cirrhotic and Non-cirrhotic Liver: Timing to Surgery and Outcome - State of the Art. , 0, , .		0
361	An Eastern Hepatobiliary Surgery Hospital Microvascular Invasion Scoring System in Predicting Prognosis of Patients with Hepatocellular Carcinoma and Microvascular Invasion After R0 Liver Resection: A Large-Scale, Multicenter Study. Oncologist, 2019, 24, e1476-e1488.	1.9	46
362	<p>A Novel Prognostic Scoring Model Based on Albumin and Î³-Glutamyltransferase for Hepatocellular Carcinoma Prognosis</p>. Cancer Management and Research, 2019, Volume 11, 10685-10694.	0.9	10
363	Quantitative examination of the inhibitory activation of molecular targeting agents in hepatocellular carcinoma patient-derived cell invasion via a novel in vivo tumor model. Animal Models and Experimental Medicine, 2019, 2, 259-268.	1.3	17
364	Contrast-enhanced ultrasound for the diagnosis of hepatocellular carcinoma in advanced chronic liver disease. The Cochrane Library, 2019, , .	1.5	5
365	Cryotherapy for liver metastases. The Cochrane Library, 2019, 7, CD009058.	1.5	11

#	ARTICLE	IF	CITATIONS
366	Preoperative risk stratification for early recurrence of HBV-related hepatocellular carcinoma after deceased donor liver transplantation: a five-eight model development and validation. <i>BMC Cancer</i> , 2019, 19, 1136.	1.1	8
367	Evolving Surgical Options for Hepatocellular Carcinoma. <i>Surgical Oncology Clinics of North America</i> , 2019, 28, 645-661.	0.6	10
368	Systemic Therapy for Primary Liver Tumors. <i>Surgical Oncology Clinics of North America</i> , 2019, 28, 695-715.	0.6	9
369	Machine-learning analysis of contrast-enhanced CT radiomics predicts recurrence of hepatocellular carcinoma after resection: A multi-institutional study. <i>EBioMedicine</i> , 2019, 50, 156-165.	2.7	131
370	Serum Squamous Cell Carcinoma Antigen-Immunoglobulin M complex levels predict survival in patients with cirrhosis. <i>Scientific Reports</i> , 2019, 9, 20126.	1.6	6
371	Emerging trends in modeling human liver disease <i>in vitro</i> . <i>APL Bioengineering</i> , 2019, 3, 040902.	3.3	18
372	Albumin-bilirubin and platelet-albumin-bilirubin grades for hepatitis B-associated hepatocellular carcinoma in Child-Pugh A patients treated with radical surgery. <i>Medicine (United States)</i> , 2019, 98, e17394.	0.4	9
373	MicroRNA-28-5p Regulates Liver Cancer Stem Cell Expansion via IGF-1 Pathway. <i>Stem Cells International</i> , 2019, 2019, 1-16.	1.2	21
374	Update on transarterial approaches to locoregional treatment in hepatocellular carcinoma. <i>Current Opinion in Oncology</i> , 2019, 31, 339-345.	1.1	4
375	IFITM3 upregulates c-myc expression to promote hepatocellular carcinoma proliferation via the ERK1/2 signalling pathway. <i>BioScience Trends</i> , 2019, 13, 523-529.	1.1	16
376	The efficacy of transarterial chemoembolization combined with microwave ablation for unresectable hepatocellular carcinoma: a systematic review and meta-analysis. <i>International Journal of Hyperthermia</i> , 2019, 36, 1287-1295.	1.1	16
377	Musashi2 contributes to the maintenance of CD44v6+ liver cancer stem cells via notch1 signaling pathway. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 505.	3.5	55
378	Increased expression of protease-activated receptors 2 indicates poor prognosis in HBV related hepatocellular carcinoma. <i>Infectious Agents and Cancer</i> , 2019, 14, 39.	1.2	4
379	Antitumor Effects of Quercetin in Hepatocarcinoma In Vitro and In Vivo Models: A Systematic Review. <i>Nutrients</i> , 2019, 11, 2875.	1.7	46
380	HMGCS2 Mediates Ketone Production and Regulates the Proliferation and Metastasis of Hepatocellular Carcinoma. <i>Cancers</i> , 2019, 11, 1876.	1.7	49
381	Conventional versus drug-eluting beads chemoembolization for infiltrative hepatocellular carcinoma: a comparison of efficacy and safety. <i>BMC Cancer</i> , 2019, 19, 1162.	1.1	27
382	Amplified intracellular Ca <sup>2+</sup> for synergistic anti-tumor therapy of microwave ablation and chemotherapy. <i>Journal of Nanobiotechnology</i> , 2019, 17, 118.	4.2	14
383	Cyclin-Dependent Kinase Regulatory Subunit 2 Indicated Poor Prognosis and Facilitated Aggressive Phenotype of Hepatocellular Carcinoma. <i>Disease Markers</i> , 2019, 2019, 1-13.	0.6	14

#	ARTICLE	IF	CITATIONS
384	Mining TCGA Database for Tumor Microenvironment-Related Genes of Prognostic Value in Hepatocellular Carcinoma. <i>BioMed Research International</i> , 2019, 2019, 1-12.	0.9	32
385	In vivo ultrasound thermal ablation control using echo decorrelation imaging in rabbit liver and VX2 tumor. <i>PLoS ONE</i> , 2019, 14, e0226001.	1.1	12
386	Enhancer of zeste 2 polycomb repressive complex 2 subunit promotes sorafenib resistance of hepatocellular carcinoma through insulin-like growth factor 1 receptor. <i>Anti-Cancer Drugs</i> , 2019, 30, 677-684.	0.7	8
387	A Prospective Evaluation of the Reliability and Utility of Quality of Life Measures in Patients With Hepatocellular Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 555-563.	0.6	5
388	Increased expression of long non-coding RNA CCAT2 predicts poorer prognosis in patients with hepatocellular carcinoma. <i>Medicine (United States)</i> , 2019, 98, e17412.	0.4	13
389	Prediction model for hepatocellular carcinoma risk in treatment-naïve chronic hepatitis B patients receiving entecavir/tenofovir. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 865-872.	0.8	44
390	Patterns and Predictors of Mortality After Waitlist Dropout of Patients With Hepatocellular Carcinoma Awaiting Liver Transplantation. <i>Transplantation</i> , 2019, 103, 2136-2143.	0.5	7
391	Embolotherapy of unresectable hepatocellular carcinoma: Eastern perspective. <i>Chinese Clinical Oncology</i> , 2019, 8, 60-60.	0.4	6
392	Surveillance of hepatocellular carcinoma by medical imaging. <i>Quantitative Imaging in Medicine and Surgery</i> , 2019, 9, 1904-1910.	1.1	9
393	Fusion imaging techniques and contrast-enhanced ultrasound for thermal ablation of hepatocellular carcinoma: A prospective randomized controlled trial. <i>International Journal of Hyperthermia</i> , 2019, 36, 1206-1214.	1.1	24
394	Sanguinarine inhibits epithelial-mesenchymal transition via targeting HIF-1/TGF- $\beta$ 2 feed-forward loop in hepatocellular carcinoma. <i>Cell Death and Disease</i> , 2019, 10, 939.	2.7	57
395	Prognostic predictors for patients with hepatocellular carcinoma receiving adjuvant transcatheter arterial chemoembolization. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 836-844.	0.8	12
396	Effectiveness of stereotactic ablative radiotherapy in patients with advanced hepatocellular carcinoma unsuitable for transarterial chemoembolization. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591988900.	1.4	6
397	Gold nanoparticles-loaded anti-miR221 enhances antitumor effect of sorafenib in hepatocellular carcinoma cells. <i>International Journal of Medical Sciences</i> , 2019, 16, 1541-1548.	1.1	22
398	SKA3 Promotes tumor growth by regulating CDK2/P53 phosphorylation in hepatocellular carcinoma. <i>Cell Death and Disease</i> , 2019, 10, 929.	2.7	57
399	Albumin-bilirubin grade may determine the outcomes of patients with very early stage hepatocellular carcinoma after radiofrequency ablation therapy. <i>Journal of the Chinese Medical Association</i> , 2019, 82, 2-10.	0.6	16
400	Systematic review of treatment strategy for recurrent hepatocellular carcinoma. <i>Medicine (United States)</i> , 2019, 98, e17412.	0.4	26
401	Drug-eluting bead transarterial chemoembolization (TACE) vs conventional TACE in treating hepatocellular carcinoma patients with multiple conventional TACE treatments history. <i>Medicine (United States)</i> , 2019, 98, e15314.	0.4	35

#	ARTICLE	IF	CITATIONS
402	A randomized clinical trial of comprehensive education and care program compared to basic care for reducing anxiety and depression and improving quality of life and survival in patients with hepatocellular carcinoma who underwent surgery. <i>Medicine (United States)</i> , 2019, 98, e17552.	0.4	24
403	Clinical significance of down-regulated HINT2 in hepatocellular carcinoma. <i>Medicine (United States)</i> , 2019, 98, e17815.	0.4	7
404	The transjugular approach is a safe and effective alternative for performing portal vein embolization. <i>Medicine (United States)</i> , 2019, 98, e17851.	0.4	1
405	Early recurrence detected in hepatocellular carcinoma patients after transcatheter arterial chemoembolization treatment with plasma cell-free DNA. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 885-892.	0.8	10
406	Second-line Treatments of Advanced Hepatocellular Carcinoma. <i>Journal of Clinical Gastroenterology</i> , 2019, 53, 251-261.	1.1	19
407	Low performance of ultrasound surveillance for the diagnosis of hepatocellular carcinoma in HIV-infected patients. <i>Aids</i> , 2019, 33, 269-278.	1.0	11
408	Extracellular Vesiclesâ€“Encapsulated MicroRNA-125b Produced in Genetically Modified Mesenchymal Stromal Cells Inhibits Hepatocellular Carcinoma Cell Proliferation. <i>Cells</i> , 2019, 8, 1560.	1.8	40
409	Tumorigenesis, diagnosis, and therapeutic potential of exosomes in liver cancer. <i>Journal of Hematology and Oncology</i> , 2019, 12, 133.	6.9	176
410	&lt;p&gt;Image-Guided Percutaneous â€ŽMicrowave Ablation Versus Cryoablation For Hepatocellular Carcinoma In High-Risk Locations: Intermediate-Term Results&lt;/p&gt;. <i>Cancer Management and Research</i> , 2019, Volume 11, 9801-9811.	0.9	13
411	<p>Evaluating the Safety and Efficacy of Nivolumab in Patients with Advanced Hepatocellular Carcinoma: Evidence to Date</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 10335-10342.	1.0	19
412	&lt;p&gt;Identification Of Novel lncRNAs For Detection Of HBV-Associated Hepatocellular Carcinoma&lt;/p&gt;. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 10199-10211.	1.0	4
413	Hepatocellular carcinoma recurrence after liver transplantation in a Brazilian multicenter study: clinical profile and prognostic factors of survival. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 1148-1156.	0.8	30
414	&lt;p&gt;Comparative Effectiveness of Radiofrequency Ablation, Surgical Resection and Transplantation for Early Hepatocellular Carcinoma by Cancer Risk Groups: Results of Propensity Score-Weighted Analysis&lt;/p&gt;. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 10389-10400.	1.0	7
415	&lt;p&gt;Comparison of Microwave Ablation and Transarterial Chemoembolization for Single-Nodule Hepatocellular Carcinoma Smaller Than 5cm: A Propensity Score Matching Analysis&lt;/p&gt;. <i>Cancer Management and Research</i> , 2019, Volume 11, 10695-10704.	0.9	6
416	Long-Term Survival Outcomes After Liver Resection for Binodular Hepatocellular Carcinoma: A Multicenter Cohort Study. <i>Oncologist</i> , 2019, 24, e730-e739.	1.9	8
417	&lt;p&gt;MTF2 Induces Epithelial-Mesenchymal Transition and Progression of Hepatocellular Carcinoma by Transcriptionally Activating Snail&lt;/p&gt;. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 11207-11220.	1.0	14
418	Hand-foot-skin reaction of gradeâ€‰â‰¥â€‰2 within sixty days as the optimal clinical marker best help predict survival in sorafenib therapy for HCC. <i>Investigational New Drugs</i> , 2019, 37, 401-414.	1.2	9
419	Transarterial radioembolization in patients with hepatocellular carcinoma of intermediate B2 substage. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 661-668.	3.3	7



#	ARTICLE	IF	CITATIONS
420	Hepatocellular Carcinoma in Transplantable Child-Pugh A Cirrhotics: Should Cost Affect Resection vs Transplantation?. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 1135-1142.	0.9	6
421	Patients with Barcelona Clinic Liver Cancer Stages B and C Hepatocellular Carcinoma: Time for a Subclassification. <i>Liver Cancer</i> , 2019, 8, 78-91.	4.2	53
422	Proton Pump Inhibitors and Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B or C. <i>Hepatology</i> , 2019, 69, 1151-1164.	3.6	22
423	Multicentre study of the prognostic impact of preoperative bodyweight on long-term prognosis of hepatocellular carcinoma. <i>British Journal of Surgery</i> , 2019, 106, 276-285.	0.1	15
424	A novel seven-miRNA signature for prognosis prediction in hepatocellular carcinoma. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 213-223.	1.2	55
425	Liver resection is justified for multinodular hepatocellular carcinoma in selected patients with cirrhosis: A multicenter analysis of 1,066 patients. <i>European Journal of Surgical Oncology</i> , 2019, 45, 800-807.	0.5	12
426	Targeting glutaminase 1 attenuates stemness properties in hepatocellular carcinoma by increasing reactive oxygen species and suppressing Wnt/beta-catenin pathway. <i>EBioMedicine</i> , 2019, 39, 239-254.	2.7	146
427	Plasminogen activator inhibitor 2 (PAI2) inhibits invasive potential of hepatocellular carcinoma cells in vitro via uPA- and RB/E2F1-related mechanisms. <i>Hepatology International</i> , 2019, 13, 180-189.	1.9	6
428	FAM134B induces tumorigenesis and epithelial-mesenchymal transition via Akt signaling in hepatocellular carcinoma. <i>Molecular Oncology</i> , 2019, 13, 792-810.	2.1	22
429	TRIM29 prevents hepatocellular carcinoma progression by inhibiting Wnt/beta-catenin signaling pathway. <i>Acta Biochimica Et Biophysica Sinica</i> , 2018, 51, 68-77.	0.9	27
430	Using ALBI score at the start of sorafenib treatment to predict regorafenib treatment candidates in patients with hepatocellular carcinoma. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 42-47.	0.6	25
431	Super-Enhancer-Associated Long Noncoding RNA HCCL5 Is Activated by ZEB1 and Promotes the Malignancy of Hepatocellular Carcinoma. <i>Cancer Research</i> , 2019, 79, 572-584.	0.4	97
432	Risk Factors, Patterns, and Outcomes of Late Recurrence After Liver Resection for Hepatocellular Carcinoma. <i>JAMA Surgery</i> , 2019, 154, 209.	2.2	319
433	Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. <i>Cancer Treatment Reviews</i> , 2019, 72, 28-36.	3.4	342
434	High Keratin 8/18 Ratio Predicts Aggressive Hepatocellular Cancer Phenotype. <i>Translational Oncology</i> , 2019, 12, 256-268.	1.7	28
435	Wnt/beta-catenin signalling in liver development, health and disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 121-136.	8.2	341
436	Radiofrequency ablation following artificial ascites and pleural effusion creation may improve outcomes for hepatocellular carcinoma in high-risk locations. <i>Abdominal Radiology</i> , 2019, 44, 1141-1151.	1.0	19
437	A retrospective pilot study to examine the potential of aspartate aminotransferase to alanine aminotransferase ratio as a predictor of postoperative acute kidney injury in patients with hepatocellular carcinoma. <i>Annals of Clinical Biochemistry</i> , 2019, 56, 357-366.	0.8	9

#	ARTICLE	IF	CITATIONS
438	Treatment with direct-acting antivirals for HCV decreases but does not eliminate the risk of hepatocellular carcinoma. <i>Liver International</i> , 2019, 39, 1033-1043.	1.9	65
439	Therapeutic advances for patients with intermediate hepatocellular carcinoma. <i>Journal of Cellular Physiology</i> , 2019, 234, 12116-12121.	2.0	30
440	Diagnostic performance of MR for hepatocellular carcinoma based on LI-RADS v2018, compared with v2017. <i>Journal of Magnetic Resonance Imaging</i> , 2019, 50, 746-755.	1.9	51
441	Association of serum interferon- $\gamma$ levels with hepatocarcinogenesis in chronic hepatitis C patients treated with direct-acting antiviral agents. <i>Hepatology Research</i> , 2019, 49, 500-511.	1.8	8
442	Holmium-166 Radioembolization in Hepatocellular Carcinoma: Feasibility and Safety of a New Treatment Option in Clinical Practice. <i>CardioVascular and Interventional Radiology</i> , 2019, 42, 405-412.	0.9	34
443	Outcomes of radiofrequency ablation as first-line therapy for hepatocellular carcinoma less than 3 cm in potentially transplantable patients. <i>Journal of Hepatology</i> , 2019, 70, 866-873.	1.8	96
444	Improved survival with radiotherapy in hepatocellular carcinoma with major vascular invasion: A propensity-matched analysis of Surveillance, Epidemiology, and End Results database. <i>Cancer Medicine</i> , 2019, 8, 515-526.	1.3	11
445	Endoscopic Cerenkov luminescence imaging and image-guided tumor resection on hepatocellular carcinoma-bearing mouse models. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2019, 17, 62-70.	1.7	33
446	PES1 enhances proliferation and tumorigenesis in hepatocellular carcinoma via the PI3K/AKT pathway. <i>Life Sciences</i> , 2019, 219, 182-189.	2.0	22
447	Correlation of the Stiffness of Hepatocellular Carcinoma and Surrounding Liver Parenchyma by Point Shear Wave Elastography. <i>Journal of Diagnostic Medical Sonography</i> , 2019, 35, 10-15.	0.1	0
448	Integration of microbiology, molecular pathology, and epidemiology: a new paradigm to explore the pathogenesis of microbiome-driven neoplasms. <i>Journal of Pathology</i> , 2019, 247, 615-628.	2.1	70
449	Hepatocellular carcinoma in the setting of alcohol-related liver disease. <i>Journal of Hepatology</i> , 2019, 70, 284-293.	1.8	221
450	Child-Pugh Classification: Time to Abandon?. <i>Seminars in Liver Disease</i> , 2019, 39, 096-103.	1.8	49
451	Efficacy and safety of selective internal radiotherapy versus sorafenib for intermediate-locally advanced hepatocellular carcinoma: a systematic review and meta-analysis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 271-279.	1.4	8
452	History and Evolution of Yttrium-90 Radioembolization for Hepatocellular Carcinoma. <i>Journal of Clinical Medicine</i> , 2019, 8, 55.	1.0	73
453	Primary Care Provider Practice Patterns and Barriers to Hepatocellular Carcinoma Surveillance. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 766-773.	2.4	76
454	Medical oncologists must get more involved in systemic treatment. <i>Annals of Oncology</i> , 2019, 30, 6-8.	0.6	2
455	Multidisciplinary meetings specific to hepatocellular carcinoma: How to proceed?. <i>Journal of Visceral Surgery</i> , 2019, 156, 217-227.	0.4	5

#	ARTICLE	IF	CITATIONS
456	Une r�union de concertation pluridisciplinaire (RCP) sp�cifique pour le carcinome h�patocellulaire (CHC)�: mode d�emploi. Journal De Chirurgie Visc�rale, 2019, 156, 244-255.	0.0	1
457	Recent advances in medical management of hepatocellular carcinoma. Hepatology Research, 2019, 49, 14-32.	1.8	53
458	Overexpression and clinical relevance of the RNA helicase DHX15 in hepatocellular carcinoma. Human Pathology, 2019, 84, 213-220.	1.1	14
459	Exportin� promotes tumor proliferation and invasion in hepatocellular carcinoma. Molecular Carcinogenesis, 2019, 58, 293-304.	1.3	21
460	A modified staging of early and intermediate hepatocellular carcinoma based on single tumour >7�cm and multiple tumours beyond up�to�seven criteria. Alimentary Pharmacology and Therapeutics, 2019, 49, 202-210.	1.9	22
461	Mouse Model for Hepatocellular Carcinoma and Cholangiocarcinoma Originated from Mature Hepatocytes. Methods in Molecular Biology, 2019, 1905, 221-236.	0.4	2
462	Radiation Therapy in HCC: What Data Exist and What Data Do We Need to Incorporate into Guidelines?. Seminars in Liver Disease, 2019, 39, 043-052.	1.8	10
463	A new microwave applicator for laparoscopic and robotic liver resection. International Journal of Hyperthermia, 2019, 36, 75-86.	1.1	9
464	Targeting HSP90 with the small molecule inhibitor AUY922 (luminespib) as a treatment strategy against hepatocellular carcinoma. International Journal of Cancer, 2019, 144, 2613-2624.	2.3	36
465	Radioablation by Image-Guided (HDR) Brachytherapy and Transarterial Chemoembolization in Hepatocellular Carcinoma: A Randomized Phase II Trial. CardioVascular and Interventional Radiology, 2019, 42, 239-249.	0.9	31
466	Surgical Outcomes and Prognostic Factors for Metastatic Spine Hepatocellular Carcinoma. World Neurosurgery, 2019, 122, e1052-e1058.	0.7	4
467	Surveillance for Hepatocellular Carcinoma: Does the Place Where Ultrasound Is Performed Impact Its Effectiveness?. Digestive Diseases and Sciences, 2019, 64, 718-728.	1.1	8
468	PNPLA3 and TM6SF2 variants as risk factors of hepatocellular carcinoma across various etiologies and severity of underlying liver diseases. International Journal of Cancer, 2019, 144, 533-544.	2.3	72
469	CD24 as a Novel Predictive Biomarker in Patients with Hepatocellular Carcinoma: Friend or Foe?. Journal of Investigative Surgery, 2020, 33, 542-543.	0.6	1
470	Silencing of long noncoding RNA HOXD�AS1 inhibits proliferation, cell cycle progression, migration and invasion of hepatocellular carcinoma cells through MEK/ERK pathway. Journal of Cellular Biochemistry, 2020, 121, 443-457.	1.2	20
471	Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma. Hepatology, 2020, 71, 164-182.	3.6	129
472	Tubulin colchicine site binding agent LLO1 displays potent antitumor efficiency both in vitro and in vivo with suitable drug-like properties. Investigational New Drugs, 2020, 38, 29-38.	1.2	5
473	Association between esophagogastric varices in hepatocellular carcinoma and poor prognosis after transarterial chemoembolization: A propensity score matching analysis. Journal of the Formosan Medical Association, 2020, 119, 610-620.	0.8	13

#	ARTICLE	IF	CITATIONS
474	125I Irradiation Stent for Hepatocellular Carcinoma with Main Portal Vein Tumor Thrombosis: A Systematic Review. <i>CardioVascular and Interventional Radiology</i> , 2020, 43, 196-203.	0.9	6
475	A biodegradable multifunctional porous microsphere composed of carrageenan for promoting imageable trans-arterial chemoembolization. <i>International Journal of Biological Macromolecules</i> , 2020, 142, 866-878.	3.6	16
476	Of FACT complex and oxidative stress response: a KEAP1/NRF2-dependent novel mechanism sustaining hepatocellular carcinoma progression. <i>Gut</i> , 2020, 69, 195-196.	6.1	6
477	A combination of Î±-fetoprotein, midkine, thioredoxin and a metabolite for predicting hepatocellular carcinoma. <i>Annals of Hepatology</i> , 2020, 19, 179-185.	0.6	17
478	Postoperative adjuvant transarterial chemoembolization improves the prognosis of hepatocellular carcinoma patients with microvascular invasion: a systematic review and meta-analysis. <i>Acta Radiologica</i> , 2020, 61, 723-731.	0.5	7
479	Clinical application of Albumin-Bilirubin (ALBI) score: The current status. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , 2020, 18, 178-186.	0.8	29
480	Impact of Surveillance in Chronic Hepatitis B Patients on Long-Term Outcomes After Curative Liver Resection for Hepatocellular Carcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 1987-1995.	0.9	3
481	Safety and Efficacy of Drug-Eluting Bead Transarterial Chemoembolization Combined with Apatinib in Patients with Advanced Hepatocellular Carcinoma. <i>Academic Radiology</i> , 2020, 27, 704-709.	1.3	21
482	Targeting PARP and autophagy evoked synergistic lethality in hepatocellular carcinoma. <i>Carcinogenesis</i> , 2020, 41, 345-357.	1.3	31
483	Adjuvant transarterial chemoembolization after curative hepatectomy for hepatocellular carcinoma with microvascular invasion: A systematic review and meta-analysis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020, 44, 142-154.	0.7	16
484	Tissue and serum metabolomic phenotyping for diagnosis and prognosis of hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2020, 146, 1741-1753.	2.3	42
485	Baseline and Post-treatment 18F-Fluorocholine PET/CT Predicts Outcomes in Hepatocellular Carcinoma Following Locoregional Therapy. <i>Digestive Diseases and Sciences</i> , 2020, 65, 647-657.	1.1	7
486	Deep learning with ultrasonography: automated classification of liver fibrosis using a deep convolutional neural network. <i>European Radiology</i> , 2020, 30, 1264-1273.	2.3	77
487	Integrin alpha 7 correlates with poor clinical outcomes, and it regulates cell proliferation, apoptosis and stemness via PTK2-PI3K-Akt signaling pathway in hepatocellular carcinoma. <i>Cellular Signalling</i> , 2020, 66, 109465.	1.7	22
488	ZNF774 is a potent suppressor of hepatocarcinogenesis through dampening the NOTCH2 signaling. <i>Oncogene</i> , 2020, 39, 1665-1680.	2.6	10
489	Duodenum perforated after combination with sorafenib and radiotherapy for retroperitoneal lymph node metastasis of hepatocellular carcinoma. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 760-762.	0.8	1
490	Acute kidney injury after platinum-based transcatheter arterial chemoembolization and transarterial infusion chemotherapy in patients with hepatocellular carcinoma. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 36-43.	0.6	3
491	Genome-wide screening diagnostic biomarkers and the construction of prognostic model of hepatocellular carcinoma. <i>Journal of Cellular Biochemistry</i> , 2020, 121, 2582-2594.	1.2	10

#	ARTICLE	IF	CITATIONS
492	Upregulated calcium-binding tyrosine phosphorylation-regulated protein $\alpha/b$ regulates cell proliferation and apoptosis and predicts poor prognosis in hepatocellular carcinoma. <i>Journal of Cellular Biochemistry</i> , 2020, 121, 2938-2949.	1.2	6
493	MRI-Based Radiomics: Associations With the Recurrence-Free Survival of Patients With Hepatocellular Carcinoma Treated With Conventional Transcatheter Arterial Chemoembolization. <i>Journal of Magnetic Resonance Imaging</i> , 2020, 52, 461-473.	1.9	57
494	The promise of adoptive cellular immunotherapies in hepatocellular carcinoma. <i>Oncolmmunology</i> , 2020, 9, 1673129.	2.1	26
495	Epidemiology of Liver Cancer in Latin America: Current and Future Trends. <i>Seminars in Liver Disease</i> , 2020, 40, 101-110.	1.8	16
496	Hepatocellular carcinoma in older adults: A comprehensive review by Young International Society of Geriatric Oncology. <i>Journal of Geriatric Oncology</i> , 2020, 11, 557-565.	0.5	5
497	Transcriptionally Active Androgen Receptor Splice Variants Promote Hepatocellular Carcinoma Progression. <i>Cancer Research</i> , 2020, 80, 561-575.	0.4	27
498	PDLIM1 Inhibits Tumor Metastasis Through Activating Hippo Signaling in Hepatocellular Carcinoma. <i>Hepatology</i> , 2020, 71, 1643-1659.	3.6	68
499	Fibroblast Growth Factor 19-Mediated Upregulation of SYR-Related High-Mobility Group Box 18 Promotes Hepatocellular Carcinoma Metastasis by Transactivating Fibroblast Growth Factor Receptor 4 and Fms-Related Tyrosine Kinase 4. <i>Hepatology</i> , 2020, 71, 1712-1731.	3.6	36
500	High-throughput screening identified mitoxantrone to induce death of hepatocellular carcinoma cells with autophagy involvement. <i>Biochemical and Biophysical Research Communications</i> , 2020, 521, 232-237.	1.0	15
501	Expression, clinicopathologic and prognostic significance of plasminogen activator inhibitor 1 in hepatocellular carcinoma. <i>Cancer Biomarkers</i> , 2020, 27, 285-293.	0.8	11
502	Use of a novel index, the A-index, and its associated nomogram to predict overall survival rates after resection of primary hepatocellular carcinoma. <i>Clinica Chimica Acta</i> , 2020, 500, 34-41.	0.5	13
503	Impact of overweightness and critical weight loss on overall survival in patients with hepatocellular carcinoma initially treated with chemoembolization. <i>Gastroenterology Report</i> , 2020, 8, 125-133.	0.6	5
504	Albumin-bilirubin grade-based nomogram of the BCLC system for personalized prognostic prediction in hepatocellular carcinoma. <i>Liver International</i> , 2020, 40, 205-214.	1.9	28
505	Comparison of the prognostic value of inflammation-based scores in early recurrent hepatocellular carcinoma after hepatectomy. <i>Liver International</i> , 2020, 40, 229-239.	1.9	48
506	Listeria-based hepatocellular carcinoma vaccine facilitates anti-PD-1 therapy by regulating macrophage polarization. <i>Oncogene</i> , 2020, 39, 1429-1444.	2.6	52
507	The Emerging Role of Long Non-Coding RNAs in the Metastasis of Hepatocellular Carcinoma. <i>Biomolecules</i> , 2020, 10, 66.	1.8	69
508	Dissimilar Appearances Are Deceptive-Common microRNAs and Therapeutic Strategies in Liver Cancer and Melanoma. <i>Cells</i> , 2020, 9, 114.	1.8	14
509	Updated 10-year outcomes of percutaneous radiofrequency ablation as first-line therapy for single hepatocellular carcinoma &lt;math>\%3Acm</math>: emphasis on association of local tumor progression and overall survival. <i>European Radiology</i> , 2020, 30, 2391-2400.	2.3	60

#	ARTICLE	IF	CITATIONS
510	New approaches in viraemic organ transplantation and antiviral therapies. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 78-79.	8.2	3
511	Lenvatinib Versus Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Cost-Utility Analysis. <i>Oncologist</i> , 2020, 25, e512-e519.	1.9	44
512	Utility of diffusion weighted imaging with the quantitative apparent diffusion coefficient in diagnosing residual or recurrent hepatocellular carcinoma after transarterial chemoembolization: a meta-analysis. <i>Cancer Imaging</i> , 2020, 20, 3.	1.2	11
513	Collaborative assembly of doxorubicin and galactosyl diblock glycopolymers for targeted drug delivery of hepatocellular carcinoma. <i>Biomaterials Science</i> , 2020, 8, 189-200.	2.6	20
514	TMPRSS4 Drives Angiogenesis in Hepatocellular Carcinoma by Promoting HB-EGF Expression and Proteolytic Cleavage. <i>Hepatology</i> , 2020, 72, 923-939.	3.6	36
515	Novel lysophosphatidic acid receptor 6 antagonists inhibit hepatocellular carcinoma growth through affecting mitochondrial function. <i>Journal of Molecular Medicine</i> , 2020, 98, 179-191.	1.7	22
516	Tackling hepatocellular carcinoma with individual or combinatorial immunotherapy approaches. <i>Cancer Letters</i> , 2020, 473, 25-32.	3.2	40
517	Intra-procedural dual phase cone beam computed tomography has a better diagnostic accuracy over pre-procedural MRI and MDCT in detection and characterization of HCC in cirrhotic patients undergoing TACE procedure. <i>European Journal of Radiology</i> , 2020, 124, 108806.	1.2	13
518	microRNA-29a regulates liver tumor-initiating cells expansion via Bcl-2 pathway. <i>Experimental Cell Research</i> , 2020, 387, 111781.	1.2	10
519	Ultrasound-Assisted miR-122-Loaded Polymeric Nanodroplets for Hepatocellular Carcinoma Gene Therapy. <i>Molecular Pharmaceutics</i> , 2020, 17, 541-553.	2.3	21
520	Using circulating tumor DNA as a novel biomarker to screen and diagnose hepatocellular carcinoma: A systematic review and meta-analysis. <i>Cancer Medicine</i> , 2020, 9, 1349-1364.	1.3	30
521	microRNA-485-5p inhibits the progression of hepatocellular carcinoma through blocking the WBP2/Wnt signaling pathway. <i>Cellular Signalling</i> , 2020, 66, 109466.	1.7	25
522	TGF- $\beta$ 1 accelerates the hepatitis B virus X-induced malignant transformation of hepatic progenitor cells by upregulating miR-199a-3p. <i>Oncogene</i> , 2020, 39, 1807-1820.	2.6	15
523	miR-541 potentiates the response of human hepatocellular carcinoma to sorafenib treatment by inhibiting autophagy. <i>Gut</i> , 2020, 69, 1309-1321.	6.1	78
524	Epidemiology of Liver Cancer in Africa: Current and Future Trends. <i>Seminars in Liver Disease</i> , 2020, 40, 111-123.	1.8	27
525	Inhibition of Hepatocellular Carcinoma Growth by Ethyl Acetate Extracts of Apulian Brassica oleracea L. and Crithmum maritimum L.. <i>Plant Foods for Human Nutrition</i> , 2020, 75, 33-40.	1.4	18
526	Nomogram based on inflammatory indices for differentiating intrahepatic cholangiocarcinoma from hepatocellular carcinoma. <i>Cancer Medicine</i> , 2020, 9, 1451-1461.	1.3	20
527	Shadows Behind Using Simple Risk Models in Selection of Hepatocellular Carcinoma Patients for Liver Transplantation. <i>Annals of Surgery</i> , 2020, 271, 1124-1131.	2.1	15

#	ARTICLE	IF	CITATIONS
528	Comparing HCC arterial tumour vascularisation on baseline imaging and after lipiodol cTACE: how do estimations of enhancing tumour volumes differ on contrast-enhanced MR and CT?. <i>European Radiology</i> , 2020, 30, 1601-1608.	2.3	8
529	Hepatocellular Carcinoma: Practice Guidelines Update for the Advanced Practice Provider. <i>Journal for Nurse Practitioners</i> , 2020, 16, 64-68.	0.4	0
530	Upregulation of ubiquitin-conjugating enzyme E2Z is associated with human hepatocellular carcinoma. <i>Biochemical and Biophysical Research Communications</i> , 2020, 523, 25-32.	1.0	9
531	Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. <i>Gut</i> , 2020, 69, 1492-1501.	6.1	411
532	Diagnosis of Pre-HCC Disease by Hepatobiliary-Specific Contrast-Enhanced Magnetic Resonance Imaging: A Review. <i>Digestive Diseases and Sciences</i> , 2020, 65, 2492-2502.	1.1	5
533	Assessment of efficacy and safety of the transcatheter arterial chemoembolization with or without apatinib in the treatment of large hepatocellular carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 69-76.	1.1	11
534	Liver Resection for Multiple Hepatocellular Carcinomas. <i>Annals of Surgery</i> , 2020, 272, 145-154.	2.1	61
535	Bimodal Molecule as NIR-CT Contrast Agent for Hepatoma Specific Imaging. <i>Analytical Chemistry</i> , 2020, 92, 1138-1146.	3.2	8
536	miR-1470 regulates cell proliferation and apoptosis by targeting ALX4 in hepatocellular carcinoma. <i>Biochemical and Biophysical Research Communications</i> , 2020, 522, 716-723.	1.0	8
537	Sequential transcatheter arterial chemoembolization and portal vein embolization versus portal vein embolization alone before major hepatectomy for patients with large hepatocellular carcinoma: An intent-to-treat analysis. <i>Surgery</i> , 2020, 167, 425-431.	1.0	18
538	Evaluation of Contrast-enhanced US LI-RADS version 2017: Application on 2020 Liver Nodules in Patients with Hepatitis B Infection. <i>Radiology</i> , 2020, 294, 299-307.	3.6	73
539	Liver Resection Is Justified in Patients with BCLC Intermediate Stage Hepatocellular Carcinoma without Microvascular Invasion. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 2737-2747.	0.9	21
540	Discovery of 5-aryl-3-thiophen-2-yl-1H-pyrazoles as a new class of Hsp90 inhibitors in hepatocellular carcinoma. <i>Bioorganic Chemistry</i> , 2020, 94, 103433.	2.0	8
541	Comprehensive analysis of biological networks and the eukaryotic initiation factor 4A gene as pivotal in hepatocellular carcinoma. <i>Journal of Cellular Biochemistry</i> , 2020, 121, 4094-4107.	1.2	11
542	Skeletal Muscle Mass Influences Tolerability and Prognosis in Hepatocellular Carcinoma Patients Treated with Lenvatinib. <i>Liver Cancer</i> , 2020, 9, 193-206.	4.2	57
543	Advanced Fusion Imaging and Contrast-Enhanced Imaging (CT/MRI+CEUS) in Oncology. <i>Cancers</i> , 2020, 12, 2821.	1.7	14
544	Downstaging to Liver Transplant. <i>Clinics in Liver Disease</i> , 2020, 24, 665-679.	1.0	0
545	Nrf2 in Neoplastic and Non-Neoplastic Liver Diseases. <i>Cancers</i> , 2020, 12, 2932.	1.7	12

#	ARTICLE	IF	CITATIONS
546	The use of minimally invasive biomarkers for the diagnosis and prognosis of hepatocellular carcinoma. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2020, 1874, 188451.	3.3	36
547	The safety and efficacy of lenvatinib combined with immune checkpoint inhibitors therapy for advanced hepatocellular carcinoma. <i>Biomedicine and Pharmacotherapy</i> , 2020, 132, 110797.	2.5	35
548	Influence of NOS3 rs2070744 genotypes on hepatocellular carcinoma patients treated with lenvatinib. <i>Scientific Reports</i> , 2020, 10, 17054.	1.6	4
549	Analysis of Post-Progression Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib. <i>Oncology</i> , 2020, 98, 787-797.	0.9	26
550	A Molecular Subtype Model for Liver HBV-Related Hepatocellular Carcinoma Patients Based on Immune-Related Genes. <i>Frontiers in Oncology</i> , 2020, 10, 560229.	1.3	7
551	Influence of aspirin use on clinical outcomes of patients with hepatocellular carcinoma: a meta-analysis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020, 45, 101545.	0.7	8
552	Identification of MT1E as a novel tumor suppressor in hepatocellular carcinoma. <i>Pathology Research and Practice</i> , 2020, 216, 153213.	1.0	8
553	Overview of Current Progress in Immune Checkpoint Inhibitor Therapy for Advanced Hepatocellular Carcinoma. <i>Technology in Cancer Research and Treatment</i> , 2020, 19, 153303382094748.	0.8	3
554	Hepatocellular Carcinoma: Updates in Pathogenesis, Detection and Treatment. <i>Cancers</i> , 2020, 12, 2729.	1.7	12
555	Serum kynurenine levels are a novel biomarker to predict the prognosis of patients with hepatocellular carcinoma. <i>PLoS ONE</i> , 2020, 15, e0241002.	1.1	13
556	&lt;p&gt;Theabrownin Induces Apoptosis and Tumor Inhibition of Hepatocellular Carcinoma Huh7 Cells Through ASK1-JNK-c-Jun Pathway&lt;/p&gt;. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 8977-8987.	1.0	23
557	Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines. <i>Frontiers in Oncology</i> , 2020, 10, 563249.	1.3	18
558	Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Status and Novel Perspectives. <i>Cancers</i> , 2020, 12, 3025.	1.7	55
559	In-depth characterization of the biomarkers based on tumor-infiltrated immune cells reveals implications for diagnosis and prognosis in hepatocellular carcinoma. <i>Journal of Translational Autoimmunity</i> , 2020, 3, 100067.	2.0	6
560	Analyses of Intermediate-Stage Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization prior to Designing Clinical Trials. <i>Liver Cancer</i> , 2020, 9, 596-612.	4.2	10
561	Targeted Therapy of Hepatocellular Carcinoma Using Gemcitabine-Incorporated GPC3 Aptamer. <i>Pharmaceutics</i> , 2020, 12, 985.	2.0	8
562	Cell-penetrating peptides in oncologic pharmacotherapy: A review. <i>Pharmacological Research</i> , 2020, 162, 105231.	3.1	32
563	&lt;p&gt;Dual-Effect of Magnetic Resonance Imaging Reporter Gene in Diagnosis and Treatment of Hepatocellular Carcinoma&lt;/p&gt;. <i>International Journal of Nanomedicine</i> , 2020, Volume 15, 7235-7249.	3.3	9



#	ARTICLE	IF	CITATIONS
564	Gene therapy for people with hepatocellular carcinoma. The Cochrane Library, 0, , .	1.5	3
565	Relationship between circulating tumor cells undergoing EMT and short-term efficacy following interventional treatment in patients with hepatocellular carcinoma. <i>Journal of Interventional Medicine</i> , 2020, 3, 146-150.	0.2	1
566	A versatile UCST-type composite microsphere for image-guided chemoembolization and photothermal therapy against liver cancer. <i>Nanoscale</i> , 2020, 12, 20002-20015.	2.8	17
567	miR-124-3p Suppresses the Invasiveness and Metastasis of Hepatocarcinoma Cells via Targeting CRKL. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 223.	1.6	17
568	&lt;p&gt;Downstaging of Recurrent Advanced Hepatocellular Carcinoma After Lenvatinib Treatment: Opportunities or Pitfalls? A Case Report&lt;/p&gt;. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 10267-10273.	1.0	7
569	Deep Learning Predicts Overall Survival of Patients With Unresectable Hepatocellular Carcinoma Treated by Transarterial Chemoembolization Plus Sorafenib. <i>Frontiers in Oncology</i> , 2020, 10, 593292.	1.3	23
570	PRIM1 promotes the proliferation of hepatocellular carcinoma cells <i>in vitro</i> and <i>in vivo</i>. <i>Journal of Cancer</i> , 2020, 11, 6601-6611.	1.2	7
571	miR-96 regulates liver tumor-initiating cells expansion by targeting TP53INP1 and predicts Sorafenib resistance. <i>Journal of Cancer</i> , 2020, 11, 6545-6555.	1.2	7
572	SIX4 promotes hepatocellular carcinoma metastasis through upregulating YAP1 and c-MET. <i>Oncogene</i> , 2020, 39, 7279-7295.	2.6	31
573	Precise delivery of obeticholic acid via nanoapproach for triggering natural killer T cell-mediated liver cancer immunotherapy. <i>Acta Pharmaceutica Sinica B</i> , 2020, 10, 2171-2182.	5.7	32
574	Immunotherapy for Hepatocellular Carcinoma: Is Latin America Ready for Primetime?. <i>Clinical Liver Disease</i> , 2020, 16, 96-100.	1.0	0
575	Dose reduction and discontinuation of standard-dose regorafenib associated with adverse drug events in cancer patients: a systematic review and meta-analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592093693.	1.4	71
576	Screening and verification of long noncoding RNA promoter methylation sites in hepatocellular carcinoma. <i>Cancer Cell International</i> , 2020, 20, 311.	1.8	5
577	Hepatitis C-related cirrhosis will be a marginal cause of hospital admissions by 2025. <i>Journal of Hepatology</i> , 2020, 73, 1360-1367.	1.8	12
579	Preoperative prediction for pathological grade of hepatocellular carcinoma via machine learning&quot;based radiomics. <i>European Radiology</i> , 2020, 30, 6924-6932.	2.3	78
580	Radiofrequency-responsive dual-valent gold nanoclusters for enhancing synergistic therapy of tumor ablation and artery embolization. <i>Nano Today</i> , 2020, 35, 100934.	6.2	31
581	Rapid automated diagnosis of primary hepatic tumour by mass spectrometry and artificial intelligence. <i>Liver International</i> , 2020, 40, 3117-3124.	1.9	27
582	Recent advances of GOLM1 in hepatocellular carcinoma. <i>Hepatic Oncology</i> , 2020, 7, HEP22.	4.2	11

#	ARTICLE	IF	CITATIONS
583	Identification of the Novel Oncogenic Role of SAAL1 and Its Therapeutic Potential in Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 1843.	1.7	7
584	Clinical Significance of Adverse Events for Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study. <i>Cancers</i> , 2020, 12, 1867.	1.7	56
585	Efficacy and Safety of the Combination of Pravastatin and Sorafenib for the Treatment of Advanced Hepatocellular Carcinoma (ESTAHEP Clinical Trial). <i>Cancers</i> , 2020, 12, 1900.	1.7	14
586	Facile Fabrication of Nanoparticles with Dual-Targeting Ligands for Precise Hepatocellular Carcinoma Therapy <i>&lt;i&gt;In Vitro&lt;/i&gt;</i> and <i>&lt;i&gt;In Vivo&lt;/i&gt;</i> . <i>Molecular Pharmaceutics</i> , 2020, 17, 3223-3235.	2.3	23
587	Percutaneous radiofrequency ablation of HCC: reduced ablation duration and increased ablation size using single, internally cooled electrodes with an optimized pulsing algorithm. <i>International Journal of Hyperthermia</i> , 2020, 37, 861-867.	1.1	3
588	Spindle and kinetochore-associated protein 2 facilitates the proliferation and invasion of hepatocellular carcinoma via the regulation of Wnt/ $\beta^2$ -catenin signaling. <i>Experimental Cell Research</i> , 2020, 395, 112181.	1.2	8
589	CCNB2, TOP2A, and ASPM Reflect the Prognosis of Hepatocellular Carcinoma, as Determined by Weighted Gene Coexpression Network Analysis. <i>BioMed Research International</i> , 2020, 2020, 1-13.	0.9	9
590	Breath Metabolomics Provides an Accurate and Noninvasive Approach for Screening Cirrhosis, Primary, and Secondary Liver Tumors. <i>Hepatology Communications</i> , 2020, 4, 1041-1055.	2.0	32
591	Impact of systematic segmentectomy for small hepatocellular carcinoma. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2020, 27, 331-341.	1.4	16
592	Prognostic Stratification Based on a Novel Nomogram for Solitary Large Hepatocellular Carcinoma After Curative Resection. <i>Frontiers in Oncology</i> , 2020, 10, 556489.	1.3	6
593	Prognostic significance of controlling nutritional status score- based nomogram for hepatocellular carcinoma within Milan criteria after radiofrequency ablation. <i>Journal of Gastrointestinal Oncology</i> , 2020, 11, 1024-1039.	0.6	10
594	EZH2 facilitates BMI1-dependent hepatocarcinogenesis through epigenetically silencing microRNA-200c. <i>Oncogenesis</i> , 2020, 9, 101.	2.1	16
595	Impact of diseased liver parenchyma on perioperative outcome among patients with hepatocellular carcinoma undergoing hepatectomy: Experience from a developing country. <i>Surgical Oncology</i> , 2020, 35, 236-242.	0.8	0
596	Natural History of Cirrhosis: Changing Trends in Etiology Over the Years. <i>Digestive Diseases</i> , 2021, 39, 358-365.	0.8	10
597	N6-methyladenosine-modified CircRNA-SORE sustains sorafenib resistance in hepatocellular carcinoma by regulating $\beta^2$ -catenin signaling. <i>Molecular Cancer</i> , 2020, 19, 163.	7.9	171
598	&lt;p&gt;Cross-Linked Multimeric Pro-Peptides of Type III Collagen (PC3X) in Hepatocellular Carcinoma â€“ A Biomarker That Provides Additional Prognostic Value in AFP Positive Patients&lt;/p&gt;. <i>Journal of Hepatocellular Carcinoma</i> , 2020, Volume 7, 301-313.	1.8	17
599	Unveiling the mechanism of Astragalus membranaceus in the treatment of gastrointestinal cancers based on network pharmacology. <i>European Journal of Integrative Medicine</i> , 2020, 40, 101249.	0.8	1
600	Stereotactic body radiotherapy versus radiofrequency ablation for hepatocellular carcinoma: a systematic review and meta-analysis. <i>International Journal of Hyperthermia</i> , 2020, 37, 1313-1321.	1.1	16

#	ARTICLE	IF	CITATIONS
601	Radiofrequency ablation versus hepatic resection for recurrent hepatocellular carcinoma: an updated meta-analysis. <i>BMC Gastroenterology</i> , 2020, 20, 402.	0.8	17
602	Imaging Changes and Clinical Complications After Drug-Eluting Bead Versus Conventional Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Multicenter Study. <i>American Journal of Roentgenology</i> , 2021, 217, 933-943.	1.0	22
603	Hepatocellular Senescence: Immunosurveillance and Future Senescence-Induced Therapy in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 589908.	1.3	26
604	Hypoxia induces sorafenib resistance mediated by autophagy via activating FOXO3a in hepatocellular carcinoma. <i>Cell Death and Disease</i> , 2020, 11, 1017.	2.7	49
605	A Novel RNA Binding Protein-Related Prognostic Signature for Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 580513.	1.3	24
606	Hepatocarcinoma Induces a Tumor Necrosis Factor-Dependent Kupffer Cell Death Pathway That Favors Its Proliferation Upon Partial Hepatectomy. <i>Frontiers in Oncology</i> , 2020, 10, 547013.	1.3	7
607	Molecular targets of Yangyin Fuzheng Jiedu Prescription in the treatment of hepatocellular carcinoma based on network pharmacology analysis. <i>Cancer Cell International</i> , 2020, 20, 540.	1.8	7
608	Single-Cell Spatial Analysis of Tumor and Immune Microenvironment on Whole-Slide Image Reveals Hepatocellular Carcinoma Subtypes. <i>Cancers</i> , 2020, 12, 3562.	1.7	21
609	Prohibitin, STAT3 and SH2D4A physically and functionally interact in tumor cell mitochondria. <i>Cell Death and Disease</i> , 2020, 11, 1023.	2.7	17
610	Higher tumor protein kinase D1 correlates with increased tumor size, BCLC stage, CA199 level, AFP level and worse overall survival in hepatocellular carcinoma patients. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101573.	0.7	9
611	Hepatocellular carcinoma: old friends and new tricks. <i>Experimental and Molecular Medicine</i> , 2020, 52, 1898-1907.	3.2	154
612	CircSMYD4 regulates proliferation, migration and apoptosis of hepatocellular carcinoma cells by sponging miR-584-5p. <i>Cancer Cell International</i> , 2020, 20, 556.	1.8	12
613	MTHFR rs1801133 Polymorphism Is Associated With Liver Fibrosis Progression in Chronic Hepatitis C: A Retrospective Study. <i>Frontiers in Medicine</i> , 2020, 7, 582666.	1.2	4
614	Mitophagy promotes sorafenib resistance through hypoxia-inducible ATAD3A dependent Axis. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 274.	3.5	54
615	Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: Analysis adjusted with inverse probability weighting. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1812-1819.	1.4	28
616	&lt;p&gt;Overexpression of &lt;em&gt;GIHCG&lt;/em&gt; is Associated with a Poor Prognosis and Immune Infiltration in Hepatocellular Carcinoma&lt;/p&gt;. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 11607-11619.	1.0	11
617	Postoperative adjuvant TACE-associated nomogram for predicting the prognosis of resectable Hepatocellular Carcinoma with portal vein Tumor Thrombus after Liver Resection. <i>International Journal of Biological Sciences</i> , 2020, 16, 3210-3220.	2.6	22
618	The prognostic value of postoperative circulating cell-free DNA in operable hepatocellular carcinoma. <i>Scandinavian Journal of Gastroenterology</i> , 2020, 55, 1441-1446.	0.6	7

#	ARTICLE	IF	CITATIONS
619	<p>Hsa_circ_0006916 Knockdown Represses the Development of Hepatocellular Carcinoma via Modulating miR-599/SRSF2 Axis. <i>OncoTargets and Therapy</i>, 2020, Volume 13, 11301-11313.</p>	1.0	3
620	<p>Evaluation for the Genetic Association between Store-Operated Calcium Influx Pathway (STIM1 and) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 5 2020, 9, 388.</p>	1.3	1
621	<p>The technique of 3D reconstruction combining with biochemistry to build an equivalent formula of indocyanine green (ICG) clearance test to assess the liver reserve function. <i>BMC Surgery</i>, 2020, 20, 283.</p>	0.6	13
622	<p>Does laparoscopic liver resection provide better outcomes than thermoablation in patients with hepatocellular carcinoma?â€”A systematic review. <i>Laparoscopic Surgery</i>, 2020, 4, 9-9.</p>	0.9	1
623	<p>CK19-positive Hepatocellular Carcinoma is a Characteristic Subtype. <i>Journal of Cancer</i>, 2020, 11, 5069-5077.</p>	1.2	55
624	<p>Management of Adverse Events Associated with Cabozantinib Treatment in Patients with Advanced Hepatocellular Carcinoma. <i>Targeted Oncology</i>, 2020, 15, 549-565.</p>	1.7	12
625	<p>Discovery of methyl 3-((2-((1-(dimethylglycyl)-5-methoxyindolin-6-yl)amino)-5-(trifluoro-methyl)) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 5 inhibitor for combating hepatocellular carcinoma. <i>European Journal of Medicinal Chemistry</i>, 2020, 206, 112697.</p>	2.6	9
626	<p>Circular RNA ciARS regulates ferroptosis in HCC cells through interacting with RNA binding protein ALKBH5. <i>Cell Death Discovery</i>, 2020, 6, 72.</p>	2.0	122
627	<p>Curcumin Suppresses Cell Proliferation, Migration, and Invasion Through Modulating miR-21-5p/ SOX6 Axis in Hepatocellular Carcinoma. <i>Cancer Biotherapy and Radiopharmaceuticals</i>, 2020, , .</p>	0.7	17
628	<p>Circular RNA hsa_circ_0000517 modulates hepatocellular carcinoma advancement via the miR-326/SMAD6 axis. <i>Cancer Cell International</i>, 2020, 20, 360.</p>	1.8	22
629	<p>&amp;lt;p&amp;gt;Paeonol Inhibits Cell Proliferation, Migration and Invasion and Induces Apoptosis in Hepatocellular Carcinoma by Regulating miR-21-5p/KLF6 Axis&amp;lt;/p&amp;gt;. <i>Cancer Management and Research</i>, 2020, Volume 12, 5931-5943.</p>	0.9	15
630	<p>Circulating tumor cells and CXCR4 in the prognosis of hepatocellular carcinoma. <i>Translational Cancer Research</i>, 2020, 9, 1384-1394.</p>	0.4	6
631	<p>Serum Vitamin D Levels and Risk of Liver Cancer: A Systematic Review and Dose-Response Meta-Analysis of Cohort Studies. <i>Nutrition and Cancer</i>, 2021, 73, 1-9.</p>	0.9	44
632	<p>Impact of HIV on the survival of hepatocellular carcinoma in hepatitis C virus-infected patients. <i>Aids</i>, 2020, 34, 1497-1507.</p>	1.0	5
633	<p>TRIB3 promotes hepatocellular carcinoma growth and predicts poor prognosis. <i>Cancer Biomarkers</i>, 2020, 29, 307-315.</p>	0.8	17
634	<p>Radiomics Analysis on Multiphase Contrast-Enhanced CT: A Survival Prediction Tool in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. <i>Frontiers in Oncology</i>, 2020, 10, 1196.</p>	1.3	34
635	<p>A Prognostic Nomogram Based on Immune Scores Predicts Postoperative Survival for Patients with Hepatocellular Carcinoma. <i>BioMed Research International</i>, 2020, 2020, 1-8.</p>	0.9	2
636	<p>Laparoscopic Microwave Thermal Ablation for the Treatment of Hepatocellular Carcinoma in Chronic Hepatic Patients. <i>Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A</i>, 2020, 30, 1072-1075.</p>	0.5	2

#	ARTICLE	IF	CITATIONS
637	Inflammation Score System using Preoperative Inflammatory Markers to Predict Prognosis for Hepatocellular Carcinoma after Hepatectomy: A Cohort Study. <i>Journal of Cancer</i> , 2020, 11, 4947-4956.	1.2	8
638	LncZEB1-AS1 regulates hepatocellular carcinoma bone metastasis via regulation of the miR-302b-EGFR-PI3K-AKT axis. <i>Journal of Cancer</i> , 2020, 11, 5118-5128.	1.2	14
639	Correlation of PD-L1 and SOCS3 Co-expression with the Prognosis of Hepatocellular Carcinoma Patients. <i>Journal of Cancer</i> , 2020, 11, 5440-5448.	1.2	14
640	Value of MRI/CT Image Fusion for Targeting "invisible" Lesions in Stereotactic Microwave Ablation (SMWA) of Malignant Liver Lesions: A Retrospective Analysis. <i>CardioVascular and Interventional Radiology</i> , 2020, 43, 1505-1514.	0.9	9
641	Iatrogenic Arterioportal Fistula Caused by Radiofrequency Ablation of Hepatocellular Carcinoma: Clinical Course and Treatment Outcomes. <i>Journal of Vascular and Interventional Radiology</i> , 2020, 31, 728-736.	0.2	4
642	Systemic adjuvant treatment in hepatocellular carcinoma: tempted to do something rather than nothing. <i>Future Oncology</i> , 2020, 16, 2587-2589.	1.1	42
643	Diagnostic value of the $\hat{\Gamma}^3$ -glutamyltransferase and alanine transaminase ratio, alpha-fetoprotein, and protein induced by vitamin K absence or antagonist II in hepatitis B virus-related hepatocellular carcinoma. <i>Scientific Reports</i> , 2020, 10, 13519.	1.6	14
644	Risk assessment criteria in liver transplantation for hepatocellular carcinoma: proposal to improve transplant oncology. <i>Hepatic Oncology</i> , 2020, 7, HEP26.	4.2	2
645	Long Noncoding RNAs Coregulated by Annexin A7 and JNK in Hepatocellular Carcinoma Cells Identified by Whole-Genome Expression Profiling. <i>BioMed Research International</i> , 2020, 2020, 1-11.	0.9	1
646	Value of artificial ascites to assist thermal ablation of liver cancer adjacent to the gastrointestinal tract in patients with previous abdominal surgery. <i>BMC Cancer</i> , 2020, 20, 763.	1.1	4
647	Homoharringtonine suppresses tumor proliferation and migration by regulating EphB4-mediated $\hat{\Gamma}^2$ -catenin loss in hepatocellular carcinoma. <i>Cell Death and Disease</i> , 2020, 11, 632.	2.7	21
648	<p></p>MCM10 Acts as a Potential Prognostic Biomarker and Promotes Cell Proliferation in Hepatocellular Carcinoma: Integrated Bioinformatics Analysis and Experimental Validation</p></p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 9609-9619.	0.9	8
649	Recent Advances in Liver Cancer Stem Cells: Non-coding RNAs, Oncogenes and Oncoproteins. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 548335.	1.8	15
650	Clinical Role of Newly Developed ALBI and mALBI Grades for Treatment of Hepatocellular Carcinoma. <i>Applied Sciences (Switzerland)</i> , 2020, 10, 7178.	1.3	2
652	Tivozanib mediated inhibition of c-Kit/SCF signaling on Tregs and MDSCs and reversal of tumor induced immune suppression correlates with survival of HCC patients. <i>Oncolmmunology</i> , 2020, 9, 1824863.	2.1	22
653	<p></p>The Hsa_circ_0091579/miR-940/TACR1 Axis Regulates the Development of Hepatocellular Carcinoma</p></p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 9087-9096.	0.9	8
654	Expression of MMP-2 in residual VX2 liver tumor after transcatheter arterial embolization combined with portal venous embolization in an animal model. <i>Journal of Interventional Medicine</i> , 2020, 3, 167-173.	0.2	0
655	Screening and Functional Prediction of Key Candidate Genes in Hepatitis B Virus-Associated Hepatocellular Carcinoma. <i>BioMed Research International</i> , 2020, 2020, 1-13.	0.9	4

#	ARTICLE	IF	CITATIONS
657	Tumor Vessel Targeted Self-Assemble Nanoparticles for Amplification and Prediction of the Embolization Effect in Hepatocellular Carcinoma. <i>ACS Nano</i> , 2020, 14, 14907-14918.	7.3	27
658	microRNA-199a-3p inhibits hepatic apoptosis and hepatocarcinogenesis by targeting PDCD4. <i>Oncogenesis</i> , 2020, 9, 95.	2.1	24
659	Hypothyroidism Is a Predictive Factor for Better Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Undergoing Lenvatinib Therapy. <i>Cancers</i> , 2020, 12, 3078.	1.7	17
660	A Five-Gene Signature for Recurrence Prediction of Hepatocellular Carcinoma Patients. <i>BioMed Research International</i> , 2020, 2020, 1-13.	0.9	6
661	Reply to the letter to the editor "Neutropenia in metastatic colorectal cancer receiving trifluridine/tipiracil" by Colloca et Al.. <i>Annals of Oncology</i> , 2020, 31, 1085-1087.	0.6	0
662	QSOX1 promotes mitochondrial apoptosis of hepatocellular carcinoma cells during anchorage-independent growth by inhibiting lipid synthesis. <i>Biochemical and Biophysical Research Communications</i> , 2020, 532, 258-264.	1.0	3
663	De novo hepatocellular carcinoma in cirrhotic hepatitis C virus: Are directly acting antivirals beneficial?. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101517.	0.7	1
664	Ziyuglycoside II exerts antiproliferative and antimetastasis effects on hepatocellular carcinoma cells. <i>Anti-Cancer Drugs</i> , 2020, 31, 819-827.	0.7	10
665	A novel role of KrÄppel-like factor 8 as an apoptosis repressor in hepatocellular carcinoma. <i>Cancer Cell International</i> , 2020, 20, 422.	1.8	6
666	Clinical Outcomes and Prognosis Factors of Nivolumab Plus Chemotherapy or Multitarget Tyrosine Kinase Inhibitor in Multi-Line Therapy for Recurrent Hepatitis B Virus-Related Hepatocellular Carcinoma: A Retrospective Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 1404.	1.3	8
667	Contrast-enhanced Ultrasound Identifies Patent Feeding Vessels in Transarterial Chemoembolization Patients With Residual Tumor Vascularity. <i>Ultrasound Quarterly</i> , 2020, 36, 218-223.	0.3	8
668	Breath Biopsy Assessment of Liver Disease Using an Exogenous Volatile Organic Compound" Toward Improved Detection of Liver Impairment. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00239.	1.3	34
669	CT Image-Based Texture Analysis to Predict Microvascular Invasion in Primary Hepatocellular Carcinoma. <i>Journal of Digital Imaging</i> , 2020, 33, 1365-1375.	1.6	13
670	Strategy for advanced hepatocellular carcinoma based on liver function and portal vein tumor thrombosis. <i>Hepatology Research</i> , 2020, 50, 1375-1385.	1.8	22
671	TACE combined with microwave ablation therapy vs. TACE alone for treatment of early- and intermediate-stage hepatocellular carcinomas larger than 5 cm: a meta-analysis. <i>Diagnostic and Interventional Radiology</i> , 2020, 26, 575-583.	0.7	21
672	Self-Assembly of a Dual-Targeting and Self-Calibrating Ratiometric Polymer Nanoprobe for Accurate Hypochlorous Acid Imaging. <i>ACS Applied Materials &amp; Interfaces</i> , 2020, 12, 45822-45829.	4.0	75
673	The Impact of Direct-acting Antivirals on Overall Mortality and Tumoral Recurrence in Patients With Hepatocellular Carcinoma Listed for Liver Transplantation: An International Multicenter Study. <i>Transplantation</i> , 2020, 104, 2087-2096.	0.5	12
674	Comparison on the efficacy and prognosis of different strategies for intrahepatic recurrent hepatocellular carcinoma: A systematic review and Bayesian network meta-analysis. <i>International Journal of Surgery</i> , 2020, 83, 196-204.	1.1	31

#	ARTICLE	IF	CITATIONS
675	PIGU promotes hepatocellular carcinoma progression through activating NF- $\kappa$ B pathway and increasing immune escape. <i>Life Sciences</i> , 2020, 260, 118476.	2.0	7
676	PI3K/AKT/mTOR pathway-related long non-coding RNAs: roles and mechanisms in hepatocellular carcinoma. <i>Pharmacological Research</i> , 2020, 160, 105195.	3.1	78
677	Comprehensive analysis of ubiquitin-specific protease 1 reveals its importance in hepatocellular carcinoma. <i>Cell Proliferation</i> , 2020, 53, e12908.	2.4	31
678	Sulfiredoxin-1 is a promising novel prognostic biomarker for hepatocellular carcinoma. <i>Cancer Medicine</i> , 2020, 9, 8318-8332.	1.3	9
679	A novel prognostic models for identifying the risk of hepatocellular carcinoma based on epithelial-mesenchymal transition-associated genes. <i>Bioengineered</i> , 2020, 11, 1034-1046.	1.4	15
680	Effect of Handgrip Strength on Clinical Outcomes of Patients with Hepatocellular Carcinoma Treated with Lenvatinib. <i>Applied Sciences (Switzerland)</i> , 2020, 10, 5403.	1.3	4
681	Effect of sodium cantharidinate/vitamin B6 injection on survival, liver function, immune function, and quality of life in patients with hepatocellular carcinoma. <i>Medicine (United States)</i> , 2020, 99, e21952.	0.4	5
682	Oxysophocarpine suppresses hepatocellular carcinoma growth and sensitizes the therapeutic blockade of anti- $\text{LAG-3}$ via reducing FGL1 expression. <i>Cancer Medicine</i> , 2020, 9, 7125-7136.	1.3	23
683	&lt;p&gt;Traditional Chinese Medicine Xiaoi Jiedu Recipe Suppresses the Development of Hepatocellular Carcinoma via Regulating the microRNA-29a/Signal Transducer and Activator of Transcription 3 Axis&lt;/p&gt;. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 7329-7342.	1.0	7
685	Platelet lysates in Hepatocellular Carcinoma patients after radiofrequency ablation facilitate tumor proliferation, invasion and vasculogenic mimicry. <i>International Journal of Medical Sciences</i> , 2020, 17, 2104-2112.	1.1	7
686	Update on Hepatocellular Carcinoma: a Brief Review from Pathologist Standpoint. <i>Journal of Gastrointestinal Cancer</i> , 2020, 51, 1176-1186.	0.6	19
687	Clinical significance of long non-coding RNA DUXAP8 and its protein coding genes in hepatocellular carcinoma. <i>Journal of Cancer</i> , 2020, 11, 6140-6156.	1.2	11
688	Apatinib-loaded CalliSpheres Beads for embolization in a rabbit VX2 liver tumor: characterization <i>in vitro</i>, pharmacokinetics and tumor response <i>in vivo</i>. <i>Drug Delivery</i> , 2020, 27, 1301-1307.	2.5	12
689	PRL-3 facilitates Hepatocellular Carcinoma progression by co-amplifying with and activating FAK. <i>Theranostics</i> , 2020, 10, 10345-10359.	4.6	11
690	Dietary Iron Overload Differentially Modulates Chemically-Induced Liver Injury in Rats. <i>Nutrients</i> , 2020, 12, 2784.	1.7	15
691	Primary undifferentiated carcinoma with osteoclast-like giant cells in liver and rapidly developing multiple metastases after curative hepatectomy: a case report. <i>International Cancer Conference Journal</i> , 2020, 9, 244-248.	0.2	2
692	Deficiency of pseudogene UPAT leads to hepatocellular carcinoma progression and forms a positive feedback loop with ZEB1. <i>Cancer Science</i> , 2020, 111, 4102-4117.	1.7	6
693	A Prognostic Model for Breast Cancer With Liver Metastasis. <i>Frontiers in Oncology</i> , 2020, 10, 1342.	1.3	7

#	ARTICLE	IF	CITATIONS
694	USP1 Maintains the Survival of Liver Circulating Tumor Cells by Deubiquitinating and Stabilizing TBLR1. <i>Frontiers in Oncology</i> , 2020, 10, 554809.	1.3	11
695	Effects of high-quality nursing care on psychological outcomes and quality of life in patients with hepatocellular carcinoma. <i>Medicine (United States)</i> , 2020, 99, e21855.	0.4	2
696	Splicing factor PRPF6 upregulates oncogenic androgen receptor signaling pathway in hepatocellular carcinoma. <i>Cancer Science</i> , 2020, 111, 3665-3678.	1.7	10
697	Bromodomain-containing protein 9 promotes the growth and metastasis of human hepatocellular carcinoma by activating the TUF1/AKT pathway. <i>Cell Death and Disease</i> , 2020, 11, 730.	2.7	22
698	DNA Primase Subunit 1 Expression in Hepatocellular Carcinoma and Its Clinical Implication. <i>BioMed Research International</i> , 2020, 2020, 1-12.	0.9	0
699	A Hepatocellular Carcinoma Targeting Nanostrategy with Hypoxia-Ameliorating and Photothermal Abilities that, Combined with Immunotherapy, Inhibits Metastasis and Recurrence. <i>ACS Nano</i> , 2020, 14, 12679-12696.	7.3	116
700	<p>Novel mTOR Inhibitor Enhances the Sensitivity of Hepatocellular Carcinoma Cells to Molecular Targeting Agents</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 7165-7176.	1.0	30
701	<p>Circular RNA ZNF609 Promoted Hepatocellular Carcinoma Progression by Upregulating PAP2C Expression via Sponging miR-342-3p</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 7773-7783.	1.0	15
702	Construction and Validation of Novel Diagnostic and Prognostic DNA Methylation Signatures for Hepatocellular Carcinoma. <i>Frontiers in Genetics</i> , 2020, 11, 906.	1.1	7
703	ZNF521 which is downregulated by miR-802 suppresses malignant progression of Hepatocellular Carcinoma through regulating Runx2 expression. <i>Journal of Cancer</i> , 2020, 11, 5831-5839.	1.2	12
704	Long-Term Survival under Arterial Chemoembolization and Sorafenib of a Patient with Hepatocellular Carcinoma and Tumor Atrial Thrombus: A Case Report and Literature Review. <i>Gastrointestinal Tumors</i> , 2020, 7, 156-162.	0.3	0
705	Crosstalk between lncRNA DANCR and miR-125b-5p in HCC cell progression. <i>Tumori</i> , 2021, 107, 504-513.	0.6	9
706	<p>Downregulation of IRAK1 Prevents the Malignant Behavior of Hepatocellular Carcinoma Cells by Blocking Activation of the MAPKs/NLRP3/IL-1 $\beta$ Pathway</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 12787-12796.	1.0	11
707	Dairy Consumption and Liver Cancer Risk: A Systematic Review and Dose-Response Meta-Analysis of Observational Studies. <i>Nutrition and Cancer</i> , 2021, 73, 2821-2831.	0.9	10
708	Prognostic Performance of Albumin-Bilirubin Grade With Artificial Intelligence for Hepatocellular Carcinoma Treated With Transarterial Chemoembolization Combined With Sorafenib. <i>Frontiers in Oncology</i> , 2020, 10, 525461.	1.3	15
709	Identify and Validate the Transcriptomic, Functional Network, and Predictive Validity of FBXL19-AS1 in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 609601.	1.3	4
710	Aging and Chronic Liver Disease. <i>Seminars in Liver Disease</i> , 2020, 40, 373-384.	1.8	21
711	Flavopereirine Inhibits Hepatocellular Carcinoma Cell Growth by Inducing Cell-cycle Arrest, Apoptosis, and Autophagy-related Protein Expression. <i>Anticancer Research</i> , 2020, 40, 6907-6914.	0.5	3



#	ARTICLE	IF	CITATIONS
712	Beyond TNBC: Repositioning of Clofazimine Against a Broad Range of Wnt-Dependent Cancers. <i>Frontiers in Oncology</i> , 2020, 10, 602817.	1.3	16
713	Clinical and Genetic Tumor Characteristics of Responding and Non-Responding Patients to PD-1 Inhibition in Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 3830.	1.7	47
714	Combining Chemistry and Engineering for Hepatocellular Carcinoma: Nano-Scale and Smaller Therapies. <i>Pharmaceutics</i> , 2020, 12, 1243.	2.0	26
715	Current Locoregional Therapies and Treatment Strategies in Hepatocellular Carcinoma. <i>Current Oncology</i> , 2020, 27, 144-151.	0.9	12
716	Sinusoidal Endothelial Cell Progenitor Cells Promote Tumour Progression in Patients with Hepatocellular Carcinoma. <i>Stem Cells International</i> , 2020, 2020, 1-12.	1.2	1
717	The role of associating liver partition and portal vein ligation for staged hepatectomy in unresectable hepatitis B virus-related hepatocellular carcinoma. <i>Annals of Translational Medicine</i> , 2020, 8, 1402-1402.	0.7	5
718	Tivozanib in advanced inoperable hepatocellular carcinoma: considerations for patients with liver cirrhosis. <i>Annals of Translational Medicine</i> , 2020, 8, 1530-1530.	0.7	0
719	BAP31 Promotes Tumor Cell Proliferation by Stabilizing SERPINE2 in Hepatocellular Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 607906.	1.8	20
720	Comprehensive Bioinformatics Analysis of Key Methyltransferases and Demethylases for Histone Lysines in Hepatocellular Carcinoma. <i>Technology in Cancer Research and Treatment</i> , 2020, 19, 153303382098328.	0.8	7
721	Hepatocellular carcinoma immunotherapy: The impact of epigenetic drugs and the gut microbiome. <i>Liver Research</i> , 2020, 4, 191-198.	0.5	8
722	Molecular subtyping of hepatocellular carcinoma: A step toward precision medicine. <i>Cancer Communications</i> , 2020, 40, 681-693.	3.7	40
723	British Journal of Biomedical Science in 2020. What have we learned?. <i>British Journal of Biomedical Science</i> , 2020, 77, 159-167.	1.2	0
724	Transarterial chemoembolization as adjuvant treatment after surgery: The cure of huge hepatocellular carcinoma?. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2021, 20, 205-206.	0.6	0
725	Stratification of portal vein-invaded hepatocellular carcinoma treated with transarterial chemoembolization monotherapy. <i>Journal of Interventional Medicine</i> , 2020, 3, 201-207.	0.2	0
726	Dexamethasone prevents TACE-induced adverse events. <i>Medicine (United States)</i> , 2020, 99, e23191.	0.4	8
727	Strategies for the Delay of Surgery in the Management of Resectable Hepatobiliary Malignancies during the COVID-19 Pandemic. <i>Current Oncology</i> , 2020, 27, 501-511.	0.9	16
728	<p>Long Noncoding RNA PRR34-AS1 Aggravates the Progression of Hepatocellular Carcinoma by Adsorbing microRNA-498 and Thereby Upregulating FOXO3</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 10749-10762.	0.9	15
729	Hypoxia-Inducible Ubiquitin Specific Peptidase 13 Contributes to Tumor Growth and Metastasis via Enhancing the Toll-Like Receptor 4/Myeloid Differentiation Primary Response Gene 88/Nuclear Factor- $\kappa$ B Pathway in Hepatocellular Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 587389.	1.8	22

#	ARTICLE	IF	CITATIONS
730	Atezolizumab plus bevacizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a cost-effectiveness analysis. <i>Cancer Communications</i> , 2020, 40, 743-745.	3.7	29
731	The (Eternal) Debate on Microwave Ablation <i>versus</i> Radiofrequency Ablation in BCLC-A Hepatocellular Carcinoma. <i>In Vivo</i> , 2020, 34, 3421-3429.	0.6	15
732	Circulating Tumor-Cell-Associated White Blood Cell Clusters in Peripheral Blood Indicate Poor Prognosis in Patients With Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 1758.	1.3	32
733	Radiomic Feature-Based Predictive Model for Microvascular Invasion in Patients With Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 574228.	1.3	23
734	Response assessment of hepatocellular carcinoma treated with yttrium-90 radioembolization: inter-reader variability, comparison with 3D quantitative approach, and role in the prediction of clinical outcomes. <i>European Journal of Radiology</i> , 2020, 133, 109351.	1.2	8
735	Repeat hepatic resection VS radiofrequency ablation for the treatment of recurrent hepatocellular carcinoma: an updated meta-analysis. <i>Minimally Invasive Therapy and Allied Technologies</i> , 2020, , 1-10.	0.6	9
736	Prognostic Nomograms for Patients with Hepatocellular Carcinoma After Curative Hepatectomy, with a Focus on Recurrence Timing and Post-Recurrence Management. <i>Journal of Hepatocellular Carcinoma</i> , 2020, Volume 7, 233-256.	1.8	4
737	Recent Updates of Transarterial Chemoembolization in Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8165.	1.8	147
738	Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis: epidemiology, risk factors, clinical implications and treatment. <i>Clinical and Experimental Hepatology</i> , 2020, 6, 170-175.	0.6	6
739	Whole Genome 5-Methylcytosine Level Quantification in Cirrhotic HCV-Infected Egyptian Patients with and without Hepatocellular Carcinoma. <i>International Journal of Cancer</i> , 2020, 2020, 1-8.	0.8	0
740	Irreversible Electroporation for Hepatic Tumors: Protocol Standardization Using the Modified Delphi Technique. <i>Journal of Vascular and Interventional Radiology</i> , 2020, 31, 1765-1771.e15.	0.2	20
741	Lenvatinib-Transarterial Chemoembolization Sequential Therapy as an Effective Treatment at Progression during Lenvatinib Therapy for Advanced Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2020, 9, 756-770.	4.2	50
742	Hepatocellular Carcinoma: A Contemporary Approach to Locoregional Therapy. <i>American Journal of Gastroenterology</i> , 2020, 115, 1733-1736.	0.2	6
743	Exploration of Sorafenib Influences on Gene Expression of Hepatocellular Carcinoma. <i>Frontiers in Genetics</i> , 2020, 11, 577000.	1.1	0
744	Safety and Local Efficacy of Laser Ablation for the Extrahepatic Metastasis of Hepatocellular Carcinoma: An Available Treatment Strategy. <i>Coatings</i> , 2020, 10, 951.	1.2	2
745	Protocolo de estadificación y asignación de tratamiento en el carcinoma hepatocelular. Algoritmo BCLC. <i>Medicine</i> , 2020, 13, 703-706.	0.0	0
746	SPC25 may promote proliferation and metastasis of hepatocellular carcinoma via p53. <i>FEBS Open Bio</i> , 2020, 10, 1261-1275.	1.0	12
747	Hybrid membrane camouflaged copper sulfide nanoparticles for photothermal-chemotherapy of hepatocellular carcinoma. <i>Acta Biomaterialia</i> , 2020, 111, 363-372.	4.1	64

#	ARTICLE	IF	CITATIONS
748	Comparison between Child-Pugh Score and albumin-bilirubin grade in patients treated with the combination therapy of transarterial chemoembolization and sorafenib for hepatocellular carcinoma. <i>Annals of Translational Medicine</i> , 2020, 8, 537-537.	0.7	11
749	Immune Cytolytic Activity for Comprehensive Understanding of Immune Landscape in Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 1221.	1.7	46
750	Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of tumor response in hepatocellular carcinoma after DEB-TACE. <i>European Radiology</i> , 2020, 30, 5663-5673.	2.3	62
751	Metavir Fibrosis Stage in Hepatitis C-Related Hepatocellular Carcinoma and Association with Noninvasive Liver Reserve Models. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 1860-1862.	0.9	1
752	Heterogeneity of exhausted T cells in the tumor microenvironment is linked to patient survival following resection in hepatocellular carcinoma. <i>Oncimmunology</i> , 2020, 9, 1746573.	2.1	21
753	Prognostic impact of 8-hydroxydeoxyguanosine and its repair enzyme 8-hydroxydeoxyguanosine DNA glycosylase in hepatocellular carcinoma. <i>Pathology International</i> , 2020, 70, 533-541.	0.6	8
754	Prognostic Role of Time to Surgery in Hepatocellular Carcinoma at Barcelona Clinic Liver Cancer Stage 0-A. <i>Annals of Surgical Oncology</i> , 2020, 27, 3740-3753.	0.7	2
755	MicroRNA signature in hepatocellular carcinoma patients: identification of potential markers. <i>Molecular Biology Reports</i> , 2020, 47, 4945-4953.	1.0	32
756	Navigating the new landscape of second-line treatment in advanced hepatocellular carcinoma. <i>Liver International</i> , 2020, 40, 1800-1811.	1.9	33
757	Non-Coding RNAs: Regulating Disease Progression and Therapy Resistance in Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 1243.	1.7	11
758	Liquid Biopsies in Hepatocellular Carcinoma: Are We Winning?. <i>Journal of Clinical Medicine</i> , 2020, 9, 1541.	1.0	38
759	The $\beta$ -catenin/TCF-4-LINC01278-miR-1258-Smad2/3 axis promotes hepatocellular carcinoma metastasis. <i>Oncogene</i> , 2020, 39, 4538-4550.	2.6	41
760	Hepatic nodules with arterial phase hyperenhancement and washout on enhanced computed tomography/magnetic resonance imaging: how to avoid pitfalls. <i>Abdominal Radiology</i> , 2020, 45, 3730-3742.	1.0	6
761	Nine-factor-based immunohistochemistry classifier predicts recurrence for early-stage hepatocellular carcinoma after curative resection. <i>British Journal of Cancer</i> , 2020, 123, 92-100.	2.9	10
762	NT5DC2 promotes tumor cell proliferation by stabilizing EGFR in hepatocellular carcinoma. <i>Cell Death and Disease</i> , 2020, 11, 335.	2.7	35
763	Sex difference in the development of hepatocellular carcinoma after direct-acting antiviral therapy in patients with HCV infection. <i>Journal of Medical Virology</i> , 2020, 92, 3507-3515.	2.5	9
764	Loss of SRSF2 triggers hepatic progenitor cell activation and tumor development in mice. <i>Communications Biology</i> , 2020, 3, 210.	2.0	10
765	Association of <i>NOS3</i> and <i>ANGPT2</i> Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study. <i>Clinical Cancer Research</i> , 2020, 26, 4485-4493.	3.2	13

#	ARTICLE	IF	CITATIONS
766	High RPS11 level in hepatocellular carcinoma associates with poor prognosis after curative resection. <i>Annals of Translational Medicine</i> , 2020, 8, 466-466.	0.7	16
767	Integrated nomogram based on five stage-related genes and TNM stage to predict 1-year recurrence in hepatocellular carcinoma. <i>Cancer Cell International</i> , 2020, 20, 140.	1.8	15
768	A four-€long noncoding RNA signature predicts survival of hepatocellular carcinoma patients. <i>Journal of Clinical Laboratory Analysis</i> , 2020, 34, e23377.	0.9	4
769	Comparison of Wait-€List Mortality Between Cholangiocarcinoma and Hepatocellular Carcinoma Liver Transplant Candidates. <i>Liver Transplantation</i> , 2020, 26, 1112-1120.	1.3	9
770	Comparison of hydrochloric acid infusion radiofrequency ablation with microwave ablation in an ex vivo liver model. <i>International Journal of Hyperthermia</i> , 2020, 37, 600-607.	1.1	1
771	Management of hepatocellular carcinoma in the time of COVID-19. <i>Annals of Oncology</i> , 2020, 31, 1084-1085.	0.6	33
772	Cabozantinib as a second-line treatment option in hepatocellular carcinoma. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 623-629.	1.3	8
773	Adipose mesenchymal stromal/stem cells expanded by a GMP compatible protocol displayed improved adhesion on cancer cells in flow conditions. <i>Annals of Translational Medicine</i> , 2020, 8, 533-533.	0.7	8
774	Impact of Surgical Margin on the Prognosis of Early Hepatocellular Carcinoma (€5 cm): A Propensity Score Matching Analysis. <i>Frontiers in Medicine</i> , 2020, 7, 139.	1.2	21
775	Recent Advances: The Imbalance of Immune Cells and Cytokines in the Pathogenesis of Hepatocellular Carcinoma. <i>Diagnostics</i> , 2020, 10, 338.	1.3	14
776	New Arterial Phase Enhancing Nodules on MRI of Cirrhotic Liver: Risk of Progression to Hepatocellular Carcinoma and Implications for LI-RADS Classification. <i>American Journal of Roentgenology</i> , 2020, 215, 382-389.	1.0	8
777	AKR1B10 Inhibitor Epalrestat Facilitates Sorafenib-Induced Apoptosis and Autophagy Via Targeting the mTOR Pathway in Hepatocellular Carcinoma. <i>International Journal of Medical Sciences</i> , 2020, 17, 1246-1256.	1.1	16
778	The Application of Ferroptosis in Diseases. <i>Pharmacological Research</i> , 2020, 159, 104919.	3.1	236
779	Suppressing growth, migration, and invasion of human hepatocellular carcinoma HepG2 cells by <i>Catharanthus roseus</i> €silver nanoparticles. <i>Toxicology in Vitro</i> , 2020, 67, 104910.	1.1	16
780	The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 87.	7.1	433
781	Long-term survival and recurrence after curative resection for hepatocellular carcinoma in patients with chronic hepatitis C virus infection: a multicenter observational study from China. <i>Hpb</i> , 2020, 22, 1793-1802.	0.1	6
782	Diagnostic value of contrast-enhanced ultrasound versus computed tomography for hepatocellular carcinoma: a retrospective, single-center evaluation of 234 patients. <i>Journal of International Medical Research</i> , 2020, 48, 030006052093015.	0.4	15
783	Low expression of organic anion-transporting polypeptide 1B3 predicts a poor prognosis in hepatocellular carcinoma. <i>World Journal of Surgical Oncology</i> , 2020, 18, 127.	0.8	10

#	ARTICLE	IF	CITATIONS
784	&lt;p&gt;Hypoxia-Induced Aquaporin-3 Changes Hepatocellular Carcinoma Cell Sensitivity to Sorafenib by Activating the PI3K/Akt Signaling Pathway&lt;/p&gt;. Cancer Management and Research, 2020, Volume 12, 4321-4333.	0.9	7
785	<p>Development and Validation of Pre- and Post-Operative Models to Predict Recurrence After Resection of Solitary Hepatocellular Carcinoma: A Multi-Institutional Study</p>. Cancer Management and Research, 2020, Volume 12, 3503-3512.	0.9	4
786	Comparison of transcatheter arterial chemoembolization combined with radiofrequency ablation or microwave ablation for the treatment of unresectable hepatocellular carcinoma: a systemic review and meta-analysis. International Journal of Hyperthermia, 2020, 37, 624-633.	1.1	13
787	Weighted Gene Coexpression Network Analysis Reveals the Dynamic Transcriptome Regulation and Prognostic Biomarkers of Hepatocellular Carcinoma. Evolutionary Bioinformatics, 2020, 16, 117693432092056.	0.6	4
788	Characterization of a polysaccharide from Eupolyphaga sinensis walker and its effective antitumor activity via lymphocyte activation. International Journal of Biological Macromolecules, 2020, 162, 31-42.	3.6	23
789	Five recommendations for loco-regional treatments of hepatocellular carcinoma during the COVID-19 pandemic. Digestive and Liver Disease, 2020, 52, 950-952.	0.4	1
790	Evaluation of the diagnostic accuracy of des-gamma-carboxy prothrombin and alpha-fetoprotein alone or in combination for hepatocellular carcinoma: A systematic review and meta-analysis. Surgical Oncology, 2020, 34, 245-255.	0.8	5
791	Is the era of sorafenib over? A review of the literature. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592092760.	1.4	45
792	Diagnostic and prognostic nomograms for bone metastasis in hepatocellular carcinoma. BMC Cancer, 2020, 20, 494.	1.1	40
793	Radiomics-based nomogram using CT imaging for noninvasive preoperative prediction of early recurrence in patients with hepatocellular carcinoma. Diagnostic and Interventional Radiology, 2020, 26, 411-419.	0.7	27
794	The development of early ascites is associated with shorter overall survival in patients with hepatocellular carcinoma treated with drug-eluting embolic chemoembolization. BMC Gastroenterology, 2020, 20, 166.	0.8	5
795	Hepatic arterial infusion of oxaliplatin plus raltitrexed in patients with intermediate&and advanced stage hepatocellular carcinoma: A phase II, single-arm, prospective study. European Journal of Cancer, 2020, 134, 90-98.	1.3	14
796	Understanding fundamentals of hepatocellular carcinoma to design next-generation chitosan nano-formulations: Beyond chemotherapy stride. Journal of Drug Delivery Science and Technology, 2020, 58, 101723.	1.4	0
797	Research on anti-hepatocellular carcinoma activity and mechanism of Polygala fallax Hemsl.. Journal of Ethnopharmacology, 2020, 260, 113062.	2.0	9
798	<p>Computed Tomography-Guided Percutaneous Cryoablation for â€Ž Subcardiac Hepatocellular Carcinoma: Safety, Efficacy, Therapeutic Results and Risk Factors for Survival Outcomes</p>. Cancer Management and Research, 2020, Volume 12, 3333-3342.	0.9	6
799	Mechanisms of RNA N6-Methyladenosine in Hepatocellular Carcinoma: From the Perspectives of Etiology. Frontiers in Oncology, 2020, 10, 1105.	1.3	21
800	Distribution and clinical relevance of phospholipids in hepatocellular carcinoma. Hepatology International, 2020, 14, 544-555.	1.9	7
801	The efficacy, safety, and predictors of outcomes of transarterial radioembolization for hepatocellular carcinoma: a retrospective study. Expert Review of Gastroenterology and Hepatology, 2020, 14, 619-629.	1.4	7

#	ARTICLE	IF	CITATIONS
802	Computational Analysis of Transcriptomic and Proteomic Data for Deciphering Molecular Heterogeneity and Drug Responsiveness in Model Human Hepatocellular Carcinoma Cell Lines. <i>Genes</i> , 2020, 11, 623.	1.0	3
803	Adherence and quality are key for a beneficial HCC surveillance. <i>Liver International</i> , 2020, 40, 751-753.	1.9	2
804	&lt;p&gt;Ramucirumab, A Second-Line Option For Patients With Hepatocellular Carcinoma: A Review Of The Evidence&lt;/p&gt;. <i>Cancer Management and Research</i> , 2020, Volume 12, 3721-3729.	0.9	15
805	Diagnostic value of glypican-3, arginase-1 and hepatocyte paraffin antigen -1 in differentiating hepatocellular carcinoma from intrahepatic cholangiocarcinoma. <i>Translational Cancer Research</i> , 2020, 9, 128-136.	0.4	2
806	LINC01419 promotes cell proliferation and metastasis in hepatocellular carcinoma by enhancing NDRG1 promoter activity. <i>Cellular Oncology (Dordrecht)</i> , 2020, 43, 931-947.	2.1	17
807	Fermentable fiber-induced hepatocellular carcinoma in mice recapitulates gene signatures found in human liver cancer. <i>PLoS ONE</i> , 2020, 15, e0234726.	1.1	4
808	Hydrazinocurcumin and 5-fluorouracil enhance apoptosis and restrain tumorigenicity of HepG2 cells via disrupting the PTEN-mediated PI3K/Akt signaling pathway. <i>Biomedicine and Pharmacotherapy</i> , 2020, 129, 109851.	2.5	14
809	MicroRNA200a enhances antitumor effects in combination with doxorubicin in hepatocellular carcinoma. <i>Translational Oncology</i> , 2020, 13, 100805.	1.7	5
810	Prognosis of microwave ablation for hepatocellular carcinoma: does age make a difference?. <i>International Journal of Hyperthermia</i> , 2020, 37, 688-695.	1.1	7
811	Hepatocellular Carcinoma in a Patient With Hepatic Steatosis. <i>ACG Case Reports Journal</i> , 2020, 7, e00378.	0.2	0
812	HBV induced hepatocellular carcinoma and related potential immunotherapy. <i>Pharmacological Research</i> , 2020, 159, 104992.	3.1	57
813	Molecular Imaging and Therapy of Liver Tumors. <i>Seminars in Nuclear Medicine</i> , 2020, 50, 419-433.	2.5	4
814	Hepatocyte-specific TAK1 deficiency drives RIPK1 kinase-dependent inflammation to promote liver fibrosis and hepatocellular carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 14231-14242.	3.3	40
815	Deep Learning for Accurate Diagnosis of Liver Tumor Based on Magnetic Resonance Imaging and Clinical Data. <i>Frontiers in Oncology</i> , 2020, 10, 680.	1.3	106
816	Big Data-Based Identification of Multi-Gene Prognostic Signatures in Liver Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 847.	1.3	10
817	Factors Associated with Tumor Progression After Percutaneous Ablation of Hepatocellular Carcinoma: Comparison Between Monopolar Radiofrequency and Microwaves. Results of a Propensity Score Matching Analysis. <i>CardioVascular and Interventional Radiology</i> , 2020, 43, 1608-1618.	0.9	8
818	Triterpenoid saponins from <i>Calliandra calothyrsus</i> Meisn. and their antiproliferative activity against two digestive carcinoma human cell lines. <i>FÄ-toterapÄ-Ä</i> , 2020, 146, 104669.	1.1	5
819	Liver transplant mortality and morbidity following preoperative radiotherapy for hepatocellular carcinoma. <i>Hpb</i> , 2020, 22, 770-778.	0.1	11

#	ARTICLE	IF	CITATIONS
820	Iodine-125 Brachytherapy Can Prolong Progression-Free Survival of Patients with Locoregional Recurrence and/or Residual Hepatocellular Carcinoma After Radiofrequency Ablation. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2020, 36, 820-826.	0.7	2
821	Critical review of HCC imaging in the multidisciplinary setting: treatment allocation and evaluation of response. <i>Abdominal Radiology</i> , 2020, 45, 3119-3128.	1.0	9
822	The Changing Epidemiology of Hepatocellular Carcinoma—Experience of a Single Center. <i>BioMed Research International</i> , 2020, 2020, 1-9.	0.9	15
823	Angiopoietin-2 induces angiogenesis via exosomes in human hepatocellular carcinoma. <i>Cell Communication and Signaling</i> , 2020, 18, 46.	2.7	69
824	Assessment of the Effect of Sorafenib on Omega-6 and Omega-3 Epoxyeicosanoid Formation in Patients with Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1875.	1.8	20
825	Poor Prognoses of Young Hepatocellular Carcinoma Patients with Microvascular Invasion: A Propensity Score Matching Cohort Study. <i>Gastroenterology Research and Practice</i> , 2020, 2020, 1-8.	0.7	3
826	The prognostic significance of neutrophil-to-lymphocyte ratio at different time points in patients with hepatocellular carcinoma receiving liver resection. <i>Translational Cancer Research</i> , 2020, 9, 441-457.	0.4	7
827	Adjuvant 131I-metuximab for hepatocellular carcinoma after liver resection: a randomised, controlled, multicentre, open-label, phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 548-560.	3.7	38
828	Upregulated Seizure-Related 6 Homolog-Like 2 Is a Prognostic Predictor of Hepatocellular Carcinoma. <i>Disease Markers</i> , 2020, 2020, 1-8.	0.6	10
829	Does the intermittent Pringle maneuver affect the recurrence following surgical resection for hepatocellular carcinoma? A systematic review. <i>PLoS ONE</i> , 2020, 15, e0229870.	1.1	10
830	Sorafenib treatment has the potential to downstage advanced hepatocellular carcinoma before liver resection. <i>Personalized Medicine</i> , 2020, 17, 83-87.	0.8	15
831	Combination of inflammatory score/liver function and AFP improves the diagnostic accuracy of HBV-related hepatocellular carcinoma. <i>Cancer Medicine</i> , 2020, 9, 3057-3069.	1.3	23
832	A prospective study of the effect of terlipressin on portal vein pressure and clinical outcomes after hepatectomy: A pilot study. <i>Surgery</i> , 2020, 167, 926-932.	1.0	7
833	Human Hepatic Cancer Stem Cells (HCSCs) Markers Correlated With Immune Infiltrates Reveal Prognostic Significance of Hepatocellular Carcinoma. <i>Frontiers in Genetics</i> , 2020, 11, 112.	1.1	10
834	Curative-Intent Therapies in Localized Hepatocellular Carcinoma. <i>Current Treatment Options in Oncology</i> , 2020, 21, 31.	1.3	21
835	microRNA-454 promotes liver tumor-initiating cell expansion by regulating SOCS6. <i>Experimental Cell Research</i> , 2020, 390, 111955.	1.2	8
836	CAMSAP2-mediated noncentrosomal microtubule acetylation drives hepatocellular carcinoma metastasis. <i>Theranostics</i> , 2020, 10, 3749-3766.	4.6	16
837	Sorafenib-Conjugated Zinc Phthalocyanine Based Nanocapsule for Trimodal Therapy in an Orthotopic Hepatocellular Carcinoma Xenograft Mouse Model. <i>ACS Applied Materials &amp; Interfaces</i> , 2020, 12, 17193-17206.	4.0	34

#	ARTICLE	IF	CITATIONS
838	Metabolic Switch in Hepatocellular Carcinoma Patients Treated with Sorafenib: a Proof-of-Concept Trial. <i>Molecular Imaging and Biology</i> , 2020, 22, 1446-1454.	1.3	3
839	&lt;p&gt;Fucoïdan Induces Apoptosis and Inhibits Proliferation of Hepatocellular Carcinoma via the p38 MAPK/ERK and PI3K/Akt Signal Pathways&lt;/p&gt;. <i>Cancer Management and Research</i> , 2020, Volume 12, 1713-1723.	0.9	33
840	&lt;p&gt;HANR Enhances Autophagy-Associated Sorafenib Resistance Through miR-29b/ATG9A Axis in Hepatocellular Carcinoma&lt;/p&gt;. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 2127-2137.	1.0	27
841	Risk Factors for Liver Function Deterioration after Transarterial Chemoembolization Refractoriness in Child-Pugh Class A Hepatocellular Carcinoma Patients. <i>Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The</i> , 2020, 75, 147.	0.2	3
842	<p>Novel Prognostic Nomograms for Predicting Early and Late Recurrence of Hepatocellular Carcinoma After Curative Hepatectomy</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 1693-1712.	0.9	19
843	USP10 Promotes Proliferation of Hepatocellular Carcinoma by Deubiquitinating and Stabilizing YAP/TAZ. <i>Cancer Research</i> , 2020, 80, 2204-2216.	0.4	101
844	A novel targeted GPC3/CD3 bispecific antibody for the treatment hepatocellular carcinoma. <i>Cancer Biology and Therapy</i> , 2020, 21, 597-603.	1.5	14
845	LncRNA FOXD3-AS1 Mediates AKT Pathway to Promote Growth and Invasion in Hepatocellular Carcinoma Through Regulating RICTOR. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2020, 35, 292-300.	0.7	9
846	Enhanced mLST8 Expression Correlates with Tumor Progression in Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2020, 27, 1546-1557.	0.7	12
847	<p>Assessment in the Survival Outcome After Transarterial Chemoembolization Combined with Cryoablation for Hepatocellular Carcinoma (Diameter > 4cm) Based on the Albumin-Bilirubin Grade and Platelet-Albumin-Bilirubin â€Žgrade: â€Ž A Preliminary Study</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 1373-1385.	0.9	4
848	Transarterial (chemo)embolisation versus no intervention or placebo for liver metastases. <i>The Cochrane Library</i> , 2020, 2020, CD009498.	1.5	8
849	Hepatocellular carcinoma surgical and oncological trends in a national multicentric population: the HERCOLES experience. <i>Updates in Surgery</i> , 2020, 72, 399-411.	0.9	18
850	The Function of the HGF/c-Met Axis in Hepatocellular Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 55.	1.8	97
851	Autophagy: A Potential Therapeutic Target of Polyphenols in Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 562.	1.7	56
852	High MMP14 expression is predictive of poor prognosis in resectable hepatocellular carcinoma. <i>Pathology</i> , 2020, 52, 359-365.	0.3	13
853	Aâ€kinase interacting protein 1 (AKIP1) associates with advanced overall disease condition, tumor properties, and unfavorable prognosis in hepatocellular carcinoma patients. <i>Journal of Clinical Laboratory Analysis</i> , 2020, 34, e23213.	0.9	7
854	Comparison of Contrast-Enhanced Ultrasound versus Contrast-Enhanced Magnetic Resonance Imaging for the Diagnosis of Focal Liver Lesions Using the Liver Imaging Reporting and Data System. <i>Ultrasound in Medicine and Biology</i> , 2020, 46, 1216-1223.	0.7	16
855	&lt;p&gt;CircRNA-PTN Sponges miR-326 to Promote Proliferation in Hepatocellular Carcinoma&lt;/p&gt;. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 4893-4903.	1.0	18



#	ARTICLE	IF	CITATIONS
856	Is downstaging a reliable strategy for expanding criteria for liver transplantation in hepatocellular carcinoma?. <i>Lancet Oncology</i> , The, 2020, 21, 867-869.	5.1	4
857	ATPase Inhibitory Factor 1 Promotes Hepatocellular Carcinoma Progression After Insufficient Radiofrequency Ablation, and Attenuates Cell Sensitivity to Sorafenib Therapy. <i>Frontiers in Oncology</i> , 2020, 10, 1080.	1.3	21
858	Lentian-functionalized selenium nanosystems with high permeability infiltrate solid tumors by enhancing transcellular transport. <i>Nanoscale</i> , 2020, 12, 14494-14503.	2.8	29
859	Hybrid Modelling of Transarterial Chemoembolisation Therapies (TACE) for Hepatocellular Carcinoma (HCC). <i>Scientific Reports</i> , 2020, 10, 10571.	1.6	7
860	Identification of FABP5 as an immunometabolic marker in human hepatocellular carcinoma. , 2020, 8, e000501.		29
861	&lt;p&gt;Hypoxia-Induced Placenta-Specific microRNA (miR-512-3p) Promotes Hepatocellular Carcinoma Progression by Targeting Large Tumor Suppressor Kinase 2&lt;/p&gt;. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 6073-6083.	1.0	4
862	&lt;p&gt;A Novel lncRNA NONHSAT053785 Acts as an Independent Risk Factor for Intrahepatic Metastasis of Hepatocellular Carcinoma&lt;/p&gt;. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 5455-5466.	1.0	7
863	The Significance of Circulating Tumor Cells in Patients with Hepatocellular Carcinoma: Real-Time Monitoring and Moving Targets for Cancer Therapy. <i>Cancers</i> , 2020, 12, 1734.	1.7	18
864	miR-124 regulates liver cancer stem cells expansion and sorafenib resistance. <i>Experimental Cell Research</i> , 2020, 394, 112162.	1.2	22
865	Comparing the efficacy and safety of second-line therapies for advanced hepatocellular carcinoma: a network meta-analysis of phase III trials. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482093248.	1.4	10
866	Integrated analysis reveals critical glycolytic regulators in hepatocellular carcinoma. <i>Cell Communication and Signaling</i> , 2020, 18, 97.	2.7	38
867	Overview of distinct 5-methylcytosine profiles of messenger RNA in human hepatocellular carcinoma and paired adjacent non-tumor tissues. <i>Journal of Translational Medicine</i> , 2020, 18, 245.	1.8	40
868	Plasma IP-10 and IL-6 are linked to Child-Pugh B cirrhosis in patients with advanced HCV-related cirrhosis: a cross-sectional study. <i>Scientific Reports</i> , 2020, 10, 10384.	1.6	5
869	Hepatectomy Combined with Diaphragmatic Resection for Hepatocellular Carcinoma with Diaphragmatic Involvement: A Propensity Score-Matched Analysis. <i>Annals of Surgical Oncology</i> , 2020, 27, 4153-4163.	0.7	4
870	Glucose Metabolism and Oxidative Stress in Hepatocellular Carcinoma: Role and Possible Implications in Novel Therapeutic Strategies. <i>Cancers</i> , 2020, 12, 1668.	1.7	54
871	Clinicopathological and molecular analysis of SIRT7 in hepatocellular carcinoma. <i>Pathology</i> , 2020, 52, 529-537.	0.3	6
872	Systemic treatment of hepatocellular carcinoma: from sorafenib to combination therapies. <i>Hepatic Oncology</i> , 2020, 7, HEP20.	4.2	30
873	Preoperative Pathological Grading of Hepatocellular Carcinoma Using Ultrasonics of Contrast-Enhanced Ultrasound. <i>Academic Radiology</i> , 2021, 28, 1094-1101.	1.3	17

#	ARTICLE	IF	CITATIONS
874	A preliminary study of dual-band confocal laser endomicroscopy combined with image mosaic in the diagnosis of liver cancer. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2020, 29, 102250.	1.7	4
875	<i>TP53</i> R249S mutation detected in circulating tumour DNA is associated with Prognosis of hepatocellular carcinoma patients with or without hepatectomy. <i>Liver International</i> , 2020, 40, 2834-2847.	1.9	19
876	Autoantibody signature in hepatocellular carcinoma using seromics. <i>Journal of Hematology and Oncology</i> , 2020, 13, 85.	6.9	27
877	Prognostic Nomogram for Hepatitis B Virus-related Hepatocellular Carcinoma With Adjuvant Transarterial Chemoembolization After Radical Resection. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 20-27.	0.6	9
878	Early Hepatocellular Carcinoma Treated by Radiofrequency Ablation—Mid- and Long-Term Outcomes. <i>Journal of Clinical and Experimental Hepatology</i> , 2020, 10, 563-573.	0.4	13
879	Cucurbitacin E Inhibits Huh7 Hepatoma Carcinoma Cell Proliferation and Metastasis via Suppressing MAPKs and JAK/STAT3 Pathways. <i>Molecules</i> , 2020, 25, 560.	1.7	29
880	Ramucirumab treatment in hepatocellular carcinoma. <i>Chinese Clinical Oncology</i> , 2020, 9, 83-83.	0.4	1
881	Identification of Ppar $\gamma$ -modulated miRNA hubs that target the fibrotic tumor microenvironment. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 454-463.	3.3	32
882	Comparison of clinical features and outcomes between HBV-related and non-B non-C hepatocellular carcinoma. <i>Infectious Agents and Cancer</i> , 2020, 15, 11.	1.2	21
883	Hepatocellular Carcinoma (HCC) in Egypt: A comprehensive overview. <i>Journal of the Egyptian National Cancer Institute</i> , 2020, 32, 5.	0.6	135
884	An Epitope on EGFR Loading Catastrophic Internalization Serve as a Novel Oncotarget for Hepatocellular Carcinoma Therapy. <i>Cancers</i> , 2020, 12, 456.	1.7	0
885	Usefulness of the Contrast-enhanced Ultrasound Liver Imaging Reporting and Data System in Diagnosing Focal Liver Lesions by Inexperienced Radiologists. <i>Journal of Ultrasound in Medicine</i> , 2020, 39, 1537-1546.	0.8	19
886	Nomograms to predict the long-time prognosis in patients with alpha-fetoprotein negative hepatocellular carcinoma following radical resection. <i>Cancer Medicine</i> , 2020, 9, 2791-2802.	1.3	19
887	Efficacy of Cabozantinib and Nivolumab in Treating Hepatocellular Carcinoma with <i>RET</i> Amplification, High Tumor Mutational Burden, and PD-L1 Expression. <i>Oncologist</i> , 2020, 25, 470-474.	1.9	26
888	Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial. <i>Journal of Gastroenterology</i> , 2020, 55, 627-639.	2.3	23
889	Which choice of therapy when many are available? Current systemic therapies for advanced hepatocellular carcinoma. <i>Health Science Reports</i> , 2020, 3, e147.	0.6	4
890	Treatment of Hepatocellular Carcinoma in the Precision Medicine Era: From Treatment Stage Migration to Therapeutic Hierarchy. <i>Hepatology</i> , 2020, 72, 2206-2218.	3.6	107
891	Screening and verification of microRNA promoter methylation sites in hepatocellular carcinoma. <i>Journal of Cellular Biochemistry</i> , 2020, 121, 3626-3641.	1.2	4

#	ARTICLE	IF	CITATIONS
892	Secretory clusterin promotes hepatocellular carcinoma progression by facilitating cancer stem cell properties via AKT/GSK-3 $\beta$ / $\beta$ -catenin axis. <i>Journal of Translational Medicine</i> , 2020, 18, 81.	1.8	33
893	Silencing of long noncoding RNA LEF1 $\beta$ AS1 prevents the progression of hepatocellular carcinoma via the crosstalk with microRNA $\beta$ 136 $\beta$ 5p/WNK1. <i>Journal of Cellular Physiology</i> , 2020, 235, 6548-6562.	2.0	23
894	USP9X promotes the progression of hepatocellular carcinoma by regulating beta-catenin. <i>Irish Journal of Medical Science</i> , 2020, 189, 865-871.	0.8	8
895	Gene Signature for Sorafenib Susceptibility in Hepatocellular Carcinoma: Different Approach with a Predictive Biomarker. <i>Liver Cancer</i> , 2020, 9, 182-192.	4.2	14
896	Activation of mTOR Signaling Pathway in Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1266.	1.8	77
897	Optimizing curative management of hepatocellular carcinoma. <i>Liver International</i> , 2020, 40, 109-115.	1.9	19
898	Synthetic lethality: A promising therapeutic strategy for hepatocellular carcinoma. <i>Cancer Letters</i> , 2020, 476, 120-128.	3.2	17
899	MRI radiomics features predict immuno-oncological characteristics of hepatocellular carcinoma. <i>European Radiology</i> , 2020, 30, 3759-3769.	2.3	97
900	BICD1 functions as a prognostic biomarker and promotes hepatocellular carcinoma progression. <i>Pathology Research and Practice</i> , 2020, 216, 152858.	1.0	5
901	Incidence of microsatellite instability $\beta$ high hepatocellular carcinoma among Japanese patients and response to pembrolizumab. <i>Hepatology Research</i> , 2020, 50, 885-888.	1.8	27
903	Treatment optimization for recurrent hepatocellular carcinoma: Repeat hepatic resection versus radiofrequency ablation. <i>Cancer Medicine</i> , 2020, 9, 2997-3005.	1.3	31
904	Liver resection with thrombectomy for patients with hepatocellular carcinoma and tumour thrombus in the inferior vena cava or right atrium. <i>BJS Open</i> , 2020, 4, 241-251.	0.7	11
905	Development and validation of a novel immune-related prognostic model in hepatocellular carcinoma. <i>Journal of Translational Medicine</i> , 2020, 18, 67.	1.8	70
906	High throughput lipid profiling for subtype classification of hepatocellular carcinoma cell lines and tumor tissues. <i>Analytica Chimica Acta</i> , 2020, 1107, 92-100.	2.6	9
907	Systematic review of hepatic arterial infusion chemotherapy versus sorafenib in patients with hepatocellular carcinoma with portal vein tumor thrombosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1277-1287.	1.4	33
908	$\beta$ IGFBP-3 Is the Key Target of Sanguinarine in Promoting Apoptosis in Hepatocellular Carcinoma $\beta$ . <i>Cancer Management and Research</i> , 2020, Volume 12, 1007-1015.	0.9	6
909	Rap2B knockdown suppresses malignant progression of hepatocellular carcinoma by inactivating the PTEN/PI3K/Akt and ERK1/2 pathways. <i>Molecular and Cellular Biochemistry</i> , 2020, 466, 55-63.	1.4	6
910	C C motif chemokine ligand 16 inhibits the progression of liver cirrhosis via inactivating hepatic stellate cells. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2020, 19, 440-448.	0.6	9

#	ARTICLE	IF	CITATIONS
911	Long non-coding RNA DLGAP1-AS1 facilitates tumorigenesis and epithelial-mesenchymal transition in hepatocellular carcinoma via the feedback loop of miR-26a/b-5p/IL-6/JAK2/STAT3 and Wnt/ $\beta$ -catenin pathway. <i>Cell Death and Disease</i> , 2020, 11, 34.	2.7	69
912	Interobserver Agreement of Magnetic Resonance Imaging of Liver Imaging Reporting and Data System Version 2018. <i>Journal of Computer Assisted Tomography</i> , 2020, 44, 118-123.	0.5	27
913	Screening for Hepatocellular Carcinoma in HIV-Infected Patients: Current Evidence and Controversies. <i>Current HIV/AIDS Reports</i> , 2020, 17, 6-17.	1.1	7
914	Long non-coding RNA <i>SUMO1P3</i> promotes hepatocellular carcinoma progression through activating Wnt/ $\beta$ -catenin signalling pathway by targeting <i>miR-320a</i> . <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 3108-3116.	1.6	19
915	Vagus Nerve Stimulation Alleviates Hepatic Ischemia and Reperfusion Injury by Regulating Glutathione Production and Transformation. <i>Oxidative Medicine and Cellular Longevity</i> , 2020, 2020, 1-15.	1.9	8
916	Novel ADAM-17 inhibitor ZLDI-8 inhibits the metastasis of hepatocellular carcinoma by reversing epithelial-mesenchymal transition in vitro and in vivo. <i>Life Sciences</i> , 2020, 244, 117343.	2.0	24
917	Advances in molecular classification and precision oncology in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020, 72, 215-229.	1.8	311
918	Comparison of immune profiles between hepatocellular carcinoma subtypes. <i>Biophysics Reports</i> , 2020, 6, 19-32.	0.2	1
919	MicroRNA-493a-5p-mediated repression of the <i>MYCN</i> oncogene inhibits hepatic cancer cell growth and invasion. <i>Cancer Science</i> , 2020, 111, 869-880.	1.7	27
920	Complications After Percutaneous Ultrasound-Guided Liver Biopsy. <i>Journal of Ultrasound in Medicine</i> , 2020, 39, 1355-1365.	0.8	29
921	Prognostic Significance and Functional Relevance of Olfactomedin 4 in Early-Stage Hepatocellular Carcinoma. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00124.	1.3	6
922	A radiomics-based biomarker for cytokeratin 19 status of hepatocellular carcinoma with gadoxetic acid-enhanced MRI. <i>European Radiology</i> , 2020, 30, 3004-3014.	2.3	53
923	Bespoken Nanoceria: An Effective Treatment in Experimental Hepatocellular Carcinoma. <i>Hepatology</i> , 2020, 72, 1267-1282.	3.6	37
924	Differential Survival Impact of Diabetes Mellitus on Hepatocellular Carcinoma: Role of Staging Determinants. <i>Digestive Diseases and Sciences</i> , 2020, 65, 3389-3402.	1.1	2
925	Diagnostic role of collagen-III and matrix metalloproteinase-1 for early detection of hepatocellular carcinoma. <i>British Journal of Biomedical Science</i> , 2020, 77, 58-63.	1.2	7
926	Computed tomography-guided radiofrequency ablation combined with transarterial embolization assisted by a three-dimensional visualization ablation planning system for hepatocellular carcinoma in challenging locations: a preliminary study. <i>Abdominal Radiology</i> , 2020, 45, 1181-1192.	1.0	8
927	Imaging of primary malignant tumors in non-cirrhotic liver. <i>Diagnostic and Interventional Imaging</i> , 2020, 101, 519-535.	1.8	13
928	Diabetes, an independent poor prognostic factor of non-B non-C hepatocellular carcinoma, correlates with dihydropyrimidinase-like 3 promoter methylation. <i>Scientific Reports</i> , 2020, 10, 1156.	1.6	7

#	ARTICLE	IF	CITATIONS
929	Measuring the density of iodine depositions: Detecting an invisible residual tumor after conventional transarterial chemoembolization. PLoS ONE, 2020, 15, e0227972.	1.1	3
930	Cell Surface Proteins in Hepatocellular Carcinoma: From Bench to Bedside. Vaccines, 2020, 8, 41.	2.1	7
931	Percutaneous ethanol injection for liver metastases. The Cochrane Library, 2020, 2020, CD008717.	1.5	6
932	Interventional radiology approaches for intra-hepatic cholangiocarcinoma. Chinese Clinical Oncology, 2020, 9, 8-8.	0.4	13
933	Complete response to pembrolizumab in advanced hepatocellular carcinoma with microsatellite instability. Clinical Journal of Gastroenterology, 2020, 13, 867-872.	0.4	16
934	Beneficial body mass index to enhance survival outcomes in patients with early-stage hepatocellular carcinoma following microwave ablation treatment. International Journal of Hyperthermia, 2020, 37, 110-118.	1.1	8
935	The prognostic value of neuromedin U in patients with hepatocellular carcinoma. BMC Cancer, 2020, 20, 95.	1.1	9
936	&lt;p&gt;Berberine Inhibits Growth of Liver Cancer Cells by Suppressing Glutamine Uptake&lt;/p&gt;. OncoTargets and Therapy, 2019, Volume 12, 11751-11763.	1.0	40
937	SP94 Peptide-Functionalized PEG-PLGA Nanoparticle Loading with Cryptotanshinone for Targeting Therapy of Hepatocellular Carcinoma. AAPS PharmSciTech, 2020, 21, 124.	1.5	20
938	Construction and evaluation of a prognosis lncRNA model for hepatocellular carcinoma. Journal of Cellular Biochemistry, 2020, 122, 983.	1.2	5
939	Therapeutic efficacy of thermosensitive Pluronic hydrogel for codelivery of resveratrol microspheres and cisplatin in the treatment of liver cancer ascites. International Journal of Pharmaceutics, 2020, 582, 119334.	2.6	29
940	Efficacy and Toxicity of Stereotactic Body Radiotherapy for Early to Advanced Stage Hepatocellular Carcinoma " Initial Experience From an Australian Liver Cancer Service. Clinical Oncology, 2020, 32, e194-e202.	0.6	17
941	Gelsolin Promotes Cancer Progression by Regulating Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma and Correlates with a Poor Prognosis. Journal of Oncology, 2020, 2020, 1-10.	0.6	19
942	Expression and prognostic significance of epithelial tissue-specific transcription factor ESE3 in hepatocellular carcinoma. International Journal of Clinical Oncology, 2020, 25, 1334-1345.	1.0	3
943	IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation. Future Oncology, 2020, 16, 975-989.	1.1	136
944	Cancer burden of major cancers in China: A need for sustainable actions. Cancer Communications, 2020, 40, 205-210.	3.7	261
945	Percutaneous US-guided MWA of small liver HCC: predictors of outcome and risk factors for complications from a single center experience. Medical Oncology, 2020, 37, 39.	1.2	6
946	Laparoscopic ablation therapies for hepatocellular carcinoma: could specific indications for the laparoscopic approach influence the effectiveness?. Updates in Surgery, 2020, 72, 435-443.	0.9	11

#	ARTICLE	IF	CITATIONS
947	Microbiota-derived SSL6 enhances the sensitivity of hepatocellular carcinoma to sorafenib by down-regulating glycolysis. <i>Cancer Letters</i> , 2020, 481, 32-44.	3.2	15
948	Multicentre prospective study of drug-eluting bead chemoembolisation safety using tightly calibrated small microspheres in non-resectable hepatocellular carcinoma. <i>European Journal of Radiology</i> , 2020, 126, 108966.	1.2	20
949	Downregulation of thioredoxin-1-dependent CD95 S-nitrosation by Sorafenib reduces liver cancer. <i>Redox Biology</i> , 2020, 34, 101528.	3.9	16
950	Zinc finger protein 703 induces EMT and sorafenib resistance in hepatocellular carcinoma by transactivating CLDN4 expression. <i>Cell Death and Disease</i> , 2020, 11, 225.	2.7	27
951	A novel microwave tool for robotic liver resection in minimally invasive surgery. <i>Minimally Invasive Therapy and Allied Technologies</i> , 2022, 31, 42-49.	0.6	2
952	ALBI versus child-pugh in predicting outcome of patients with HCC: A systematic review. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020, 14, 383-400.	1.4	29
953	Erzhu Qinggan Jiedu Recipe improves the clinical outcome of hepatocellular cancer after surgical resection: a caseâ€“control retrospective study. <i>Internal Medicine Journal</i> , 2021, 51, 853-860.	0.5	8
954	Circular RNA circFBXO11 modulates hepatocellular carcinoma progress and oxaliplatin resistance through miRâ€“605/FOXO3/ABCBI axis. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 5152-5161.	1.6	47
955	Hepatic resection versus transarterial chemoembolization in infiltrative hepatocellular carcinoma: A multicenter study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 2220-2228.	1.4	4
956	Controlling Nutritional Status (CONUT) Score is Associated with Overall Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Cohort Study. <i>Nutrients</i> , 2020, 12, 1076.	1.7	27
957	Pretreatment Heterogeneous Enhancement Pattern of Hepatocellular Carcinoma May Be a Useful New Predictor of Early Response to Lenvatinib and Overall Prognosis. <i>Liver Cancer</i> , 2020, 9, 275-292.	4.2	34
958	Impact of circulating tumor DNA in hepatocellular and pancreatic carcinomas. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 1625-1645.	1.2	14
959	High FLT3 Levels May Predict Sorafenib Benefit in Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 4302-4312.	3.2	10
960	Natural Killer Cell Responses in Hepatocellular Carcinoma: Implications for Novel Immunotherapeutic Approaches. <i>Cancers</i> , 2020, 12, 926.	1.7	42
961	Circular RNA 0016788 displays as a biomarker for tumor progression and poor prognosis in surgical hepatocellular carcinoma patients. <i>Journal of Clinical Laboratory Analysis</i> , 2020, 34, e23300.	0.9	16
962	SDC1 promotes cisplatin resistance in hepatic carcinoma cells via PI3K-AKT pathway. <i>Human Cell</i> , 2020, 33, 721-729.	1.2	17
963	Modulation of SIRT3 expression through CDK4/6 enhances the anti-cancer effect of sorafenib in hepatocellular carcinoma cells. <i>BMC Cancer</i> , 2020, 20, 332.	1.1	19
964	Prognostic and predicted significance of Ubqln2 in patients with hepatocellular carcinoma. <i>Cancer Medicine</i> , 2020, 9, 4083-4094.	1.3	4

#	ARTICLE	IF	CITATIONS
965	Transcriptomic profiling of peroxisome-related genes reveals a novel prognostic signature in hepatocellular carcinoma. <i>Genes and Diseases</i> , 2022, 9, 116-127.	1.5	6
966	Systemic hypoxia potentiates anti-tumor effects of metformin in hepatocellular carcinoma in mice. <i>Acta Biochimica Et Biophysica Sinica</i> , 2020, 52, 421-429.	0.9	4
967	Identification of CELSR2 as a novel prognostic biomarker for hepatocellular carcinoma. <i>BMC Cancer</i> , 2020, 20, 313.	1.1	13
968	Comparison of prognosis between surgical resection and transarterial chemoembolization for patients with solitary huge hepatocellular carcinoma. <i>Annals of Translational Medicine</i> , 2020, 8, 238-238.	0.7	17
969	Comprehensive analysis of the expression of chaperonin containing TCP1 subunits (CCTs) and their influence on prognosis in hepatocellular carcinoma. <i>Translational Cancer Research</i> , 2020, 9, 1867-1883.	0.4	1
970	Multidisciplinary Treatment of Advanced Hepatocellular Carcinoma. <i>Case Reports in Gastroenterology</i> , 2020, 14, 98-102.	0.3	1
971	Statin and the risk of hepatocellular carcinoma in patients with hepatitis B virus or hepatitis C virus infection: a meta-analysis. <i>BMC Gastroenterology</i> , 2020, 20, 98.	0.8	19
972	Early Predictors of Objective Response in Patients with Hepatocellular Carcinoma Undergoing Lenvatinib Treatment. <i>Cancers</i> , 2020, 12, 779.	1.7	24
973	Modulation of the Autophagy-Lysosomal Pathway in Hepatocellular Carcinoma Using Small Molecules. <i>Molecules</i> , 2020, 25, 1580.	1.7	12
974	Inflammation in Primary and Metastatic Liver Tumorigenesis—Under the Influence of Alcohol and High-Fat Diets. <i>Nutrients</i> , 2020, 12, 933.	1.7	15
975	Circular RNA MAN2B2 promotes cell proliferation of hepatocellular carcinoma cells via the miRNA-217/MAPK1 axis. <i>Journal of Cancer</i> , 2020, 11, 3318-3326.	1.2	30
976	The transcription factor ZFH3 is crucial for the angiogenic function of hypoxia-inducible factor 1 $\alpha$ in liver cancer cells. <i>Journal of Biological Chemistry</i> , 2020, 295, 7060-7074.	1.6	15
977	Establishment of a Genomic-Clinicopathologic Nomogram for Predicting Early Recurrence of Hepatocellular Carcinoma After R0 Resection. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 112-124.	0.9	17
978	Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma. <i>Gut</i> , 2021, 70, 157-169.	6.1	57
979	Systemic therapy for advanced hepatocellular carcinoma: targeted therapies. <i>Chinese Clinical Oncology</i> , 2021, 10, 10-10.	0.4	10
980	Fibroblast imaging of hepatic carcinoma with 68Ga-FAPI-04 PET/CT: a pilot study in patients with suspected hepatic nodules. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 196-203.	3.3	73
981	HBV-induced Increased N6 Methyladenosine Modification of PTEN RNA Affects Innate Immunity and Contributes to HCC. <i>Hepatology</i> , 2021, 73, 533-547.	3.6	86
982	Upregulation of Excision Repair Cross-Complementation Group 6-Like (ERCC6L) Promotes Tumor Growth in Hepatocellular Carcinoma. <i>Digestive Diseases and Sciences</i> , 2021, 66, 1097-1109.	1.1	6

#	ARTICLE	IF	CITATIONS
983	Liver-directed therapy for hepatocellular carcinoma. <i>Chinese Clinical Oncology</i> , 2021, 10, 8-8.	0.4	8
984	Local and Regional Therapies for Hepatocellular Carcinoma. <i>Hepatology</i> , 2021, 73, 137-149.	3.6	69
985	Trans-arterial chemoembolization with degradable starch microspheres (DSM-TACE) versus selective internal radiation therapy (SIRT) in multifocal hepatocellular carcinoma. <i>Acta Radiologica</i> , 2021, 62, 313-321.	0.5	9
986	Establishing peripheral PD-L1 as a prognostic marker in hepatocellular carcinoma patients: how long will it come true?. <i>Clinical and Translational Oncology</i> , 2021, 23, 82-91.	1.2	3
987	Prognostic factors of gadoxetic acid-enhanced MRI for postsurgical outcomes in multicentric hepatocellular carcinoma. <i>European Radiology</i> , 2021, 31, 3405-3416.	2.3	5
988	Transarterial chemoembolization with drug-eluting beads in patients with hepatocellular carcinoma: response analysis with mRECIST. <i>Diagnostic and Interventional Radiology</i> , 2021, 27, 85-93.	0.7	3
989	Targeting the Cholecystokinin Receptor: A Novel Approach for Treatment and Prevention of Hepatocellular Cancer. <i>Cancer Prevention Research</i> , 2021, 14, 17-30.	0.7	13
990	Depletion of VPS35 attenuates metastasis of hepatocellular carcinoma by restraining the Wnt/PCP signaling pathway. <i>Genes and Diseases</i> , 2021, 8, 232-240.	1.5	8
991	A predictive model of incomplete response after transarterial chemoembolization for early or intermediate stage of hepatocellular carcinoma: consideration of hepatic angiographic and cross-sectional imaging. <i>Abdominal Radiology</i> , 2021, 46, 581-589.	1.0	4
992	Alpha-fetoprotein-adjusted HCC size criteria are associated with favourable survival after liver transplantation for hepatocellular carcinoma. <i>United European Gastroenterology Journal</i> , 2021, 9, 209-219.	1.6	5
993	Clinical results of active scanning proton therapy for primary liver tumors. <i>Tumori</i> , 2021, 107, 71-79.	0.6	5
994	Letter to the Editor: Predicting Survival After Hepatocellular Carcinoma Resection Using Deep Learning on Histological Slides. <i>Hepatology</i> , 2021, 73, 2077-2078.	3.6	2
995	LI-RADS category 5 hepatocellular carcinoma: preoperative gadoxetic acid-enhanced MRI for early recurrence risk stratification after curative resection. <i>European Radiology</i> , 2021, 31, 2289-2302.	2.3	27
996	Splicing factor SF3B1 is overexpressed and implicated in the aggressiveness and survival of hepatocellular carcinoma. <i>Cancer Letters</i> , 2021, 496, 72-83.	3.2	48
997	Survival Predictability Between the American Joint Committee on Cancer 8th Edition Staging System and the Barcelona Clinic Liver Cancer Classification in Patients with Hepatocellular Carcinoma. <i>Oncologist</i> , 2021, 26, e445-e453.	1.9	17
998	Cancer-associated fibroblasts promote hepatocellular carcinoma progression through downregulation of exosomal miR-150-3p. <i>European Journal of Surgical Oncology</i> , 2021, 47, 384-393.	0.5	59
999	The cost-effectiveness of TheraSphere in patients with hepatocellular carcinoma who are eligible for transarterial embolization. <i>European Journal of Surgical Oncology</i> , 2021, 47, 401-408.	0.5	15
1000	Longitudinal radiomics algorithm of posttreatment computed tomography images for early detecting recurrence of hepatocellular carcinoma after resection or ablation. <i>Translational Oncology</i> , 2021, 14, 100866.	1.7	11



#	ARTICLE	IF	CITATIONS
1001	Mutations and mechanisms of WNT pathway tumour suppressors in cancer. <i>Nature Reviews Cancer</i> , 2021, 21, 5-21.	12.8	235
1002	TERT Promoter Mutation in Serum Cell-Free DNA Is a Diagnostic Marker of Primary Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. <i>Oncology</i> , 2021, 99, 114-123.	0.9	14
1003	Prospective study of Lipiodol distribution as an imaging marker for doxorubicin pharmacokinetics during conventional transarterial chemoembolization of liver malignancies. <i>European Radiology</i> , 2021, 31, 3002-3014.	2.3	10
1004	PSPH induces cell autophagy and promotes cell proliferation and invasion in the hepatocellular carcinoma cell line Huh7 via the AMPK/mTOR/ULK1 signaling pathway. <i>Cell Biology International</i> , 2021, 45, 305-319.	1.4	11
1005	Ubiquitin-specific protease 2a promotes hepatocellular carcinoma progression via deubiquitination and stabilization of RAB1A. <i>Cellular Oncology (Dordrecht)</i> , 2021, 44, 329-343.	2.1	17
1006	Treatment strategy of adding transcatheter arterial chemoembolization to sorafenib for advanced stage hepatocellular carcinoma. <i>Cancer Reports</i> , 2021, 4, e1294.	0.6	3
1007	Radiomics Approaches for Predicting Liver Fibrosis With Nonenhanced <sup>1</sup>-Weighted Imaging: Comparison of Different Radiomics Models. <i>Journal of Magnetic Resonance Imaging</i> , 2021, 53, 1080-1089.	1.9	13
1008	Validation of risk prediction scores for hepatocellular carcinoma in patients with chronic hepatitis B treated with entecavir or tenofovir. <i>Journal of Viral Hepatitis</i> , 2021, 28, 95-104.	1.0	8
1009	Using Quasispecies Patterns of Hepatitis B Virus to Predict Hepatocellular Carcinoma With Deep Sequencing and Machine Learning. <i>Journal of Infectious Diseases</i> , 2021, 223, 1887-1896.	1.9	15
1010	Current trends in vena cava reconstructive techniques with major liver resection: a systematic review. <i>Langenbeck's Archives of Surgery</i> , 2021, 406, 25-38.	0.8	1
1011	Sorafenib induces mitochondrial dysfunction and exhibits synergistic effect with cysteine depletion by promoting HCC cells ferroptosis. <i>Biochemical and Biophysical Research Communications</i> , 2021, 534, 877-884.	1.0	69
1012	CT-based radiomics model to distinguish necrotic hepatocellular carcinoma from pyogenic liver abscess. <i>Clinical Radiology</i> , 2021, 76, 161.e11-161.e17.	0.5	9
1013	Evaluation of Medium-Term Efficacy of Y90 Radiation Segmentectomy vs Percutaneous Microwave Ablation in Patients with Solitary Surgically Unresectable <sup>4</sup> Hepatocellular Carcinoma: A Propensity Score Matched Study. <i>CardioVascular and Interventional Radiology</i> , 2021, 44, 401-413.	0.9	18
1014	Prognostic nomograms and risk classifications of outcomes in very early-stage hepatocellular carcinoma patients after hepatectomy. <i>European Journal of Surgical Oncology</i> , 2021, 47, 681-689.	0.5	10
1015	Praeruptorin A reduces metastasis of human hepatocellular carcinoma cells by targeting <sup>ERK</sup>/<sup>MMP1</sup> signaling pathway. <i>Environmental Toxicology</i> , 2021, 36, 540-549.	2.1	27
1016	Tumor Necrosis Impacts Prognosis of Patients Undergoing Curative-Intent Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 797-805.	0.7	28
1017	Balloon-occluded chemoembolization for hepatocellular carcinoma: a prospective study of safety, feasibility and outcomes. <i>Hepatic Oncology</i> , 2021, 8, HEP31.	4.2	4
1018	Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast?. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103167.	2.0	30

#	ARTICLE	IF	CITATIONS
1019	Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells. <i>Cellular and Molecular Immunology</i> , 2021, 18, 112-127.	4.8	159
1020	The PGC1 $\beta$ /NRF1-MPC1 axis suppresses tumor progression and enhances the sensitivity to sorafenib/doxorubicin treatment in hepatocellular carcinoma. <i>Free Radical Biology and Medicine</i> , 2021, 163, 141-152.	1.3	23
1021	The changing scenario of hepatocellular carcinoma in Italy: an update. <i>Liver International</i> , 2021, 41, 585-597.	1.9	69
1022	Prediction model for recurrence of hepatocellular carcinoma after resection by using neighbor2vec based algorithms. <i>Wiley Interdisciplinary Reviews: Data Mining and Knowledge Discovery</i> , 2021, 11, e1390.	4.6	1
1023	Comprehensive analysis of partial epithelial mesenchymal transition-related genes in hepatocellular carcinoma. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 448-462.	1.6	23
1024	Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1317-1325.	1.4	22
1025	Late recurrence of hepatocellular carcinoma after radiofrequency ablation: a multicenter study of risk factors, patterns, and survival. <i>European Radiology</i> , 2021, 31, 3053-3064.	2.3	32
1026	A prediction model for overall survival after transarterial chemoembolization for hepatocellular carcinoma invading the hepatic vein or inferior vena cava. <i>European Radiology</i> , 2021, 31, 4232-4242.	2.3	13
1027	Combination of canstatin and arsenic trioxide suppresses the development of hepatocellular carcinoma. <i>Drug Development Research</i> , 2021, 82, 430-439.	1.4	4
1028	The 14-3-3 $\beta$ protein promotes HCC anoikis resistance by inhibiting EGFR degradation and thereby activating the EGFR-dependent ERK1/2 signaling pathway. <i>Theranostics</i> , 2021, 11, 996-1015.	4.6	43
1029	Therapeutic Ultrasound Parameter Optimization for Drug Delivery Applied to a Murine Model of Hepatocellular Carcinoma. <i>Ultrasound in Medicine and Biology</i> , 2021, 47, 309-322.	0.7	10
1030	Sophoridine suppresses lenvatinib-resistant hepatocellular carcinoma growth by inhibiting RAS/MEK/ERK axis via decreasing VEGFR2 expression. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 549-560.	1.6	41
1031	Detection of circulating tumour cells enables early recurrence prediction in hepatocellular carcinoma patients undergoing liver transplantation. <i>Liver International</i> , 2021, 41, 562-573.	1.9	32
1032	Radiomics Analysis Based on Multiparametric $\text{^1H}$ MRI for Predicting Early Recurrence in Hepatocellular Carcinoma After Partial Hepatectomy. <i>Journal of Magnetic Resonance Imaging</i> , 2021, 53, 1066-1079.	1.9	49
1033	Huge hepatocellular carcinoma with extrahepatic collateral arteries successfully treated by multidisciplinary treatment including laparoscopic devascularization: a case report. <i>Clinical Journal of Gastroenterology</i> , 2021, 14, 251-257.	0.4	1
1035	Impact of Brazilian expanded criteria for liver transplantation in patients with hepatocellular carcinoma: a multicenter study. <i>Annals of Hepatology</i> , 2021, 22, 100294.	0.6	6
1036	Hepatocellular carcinoma in patients with chronic renal disease: Challenges of interventional treatment. <i>Surgical Oncology</i> , 2021, 36, 42-50.	0.8	7
1037	Upregulated lncRNA DLX6-AS1 underpins hepatocellular carcinoma progression via the miR-513c/Cul4A/ANXA10 axis. <i>Cancer Gene Therapy</i> , 2021, 28, 486-501.	2.2	20

#	ARTICLE	IF	CITATIONS
1038	Australian recommendations for the management of hepatocellular carcinoma: a consensus statement. <i>Medical Journal of Australia</i> , 2021, 214, 475-483.	0.8	36
1039	Transarterial chemoembolisation enhances programmed death-1 and programmed death-ligand 1 expression in hepatocellular carcinoma. <i>Histopathology</i> , 2021, 79, 36-46.	1.6	49
1040	CMTM6 Stabilizes PD-1 Expression and Is a New Prognostic Impact Factor in Hepatocellular Carcinoma. <i>Hepatology Communications</i> , 2021, 5, 334-348.	2.0	24
1041	Comparison of PET imaging of activated fibroblasts and 18F-FDG for diagnosis of primary hepatic tumours: a prospective pilot study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1593-1603.	3.3	87
1042	Irreversible Electroporation For Hepatocellular Carcinoma: Longer-Term Outcomes At A Single Centre. <i>CardioVascular and Interventional Radiology</i> , 2021, 44, 247-253.	0.9	14
1043	Fluorescence sensing strategy based on aptamer recognition and mismatched catalytic hairpin assembly for highly sensitive detection of alpha-fetoprotein. <i>Analytica Chimica Acta</i> , 2021, 1141, 21-27.	2.6	36
1044	Therapeutic efficacy of ramucirumab after lenvatinib for post-progression treatment of unresectable hepatocellular carcinoma. <i>Gastroenterology Report</i> , 2021, 9, 133-138.	0.6	21
1045	Extracellular-vesicles delivered tumor-specific sequential nanocatalysts can be used for MRI-informed nanocatalytic Therapy of hepatocellular carcinoma. <i>Theranostics</i> , 2021, 11, 64-78.	4.6	17
1046	Predictive factors of severe abdominal pain during and after transarterial chemoembolization for hepatocellular carcinoma. <i>European Radiology</i> , 2021, 31, 3267-3275.	2.3	9
1047	Guidelines Adaptation to the COVID-19 Outbreak for the Management of Hepatocellular Carcinoma. <i>Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A</i> , 2021, 31, 266-272.	0.5	9
1048	Prognosis Nomogram for Hepatocellular Carcinoma Patients with Portal Vein Invasion Undergoing Transarterial Chemoembolization Plus Sorafenib Treatment: A Retrospective Multicentre Study. <i>CardioVascular and Interventional Radiology</i> , 2021, 44, 63-72.	0.9	5
1049	Three-dimensional bio-printing of primary human hepatocellular carcinoma for personalized medicine. <i>Biomaterials</i> , 2021, 265, 120416.	5.7	74
1050	RSK2-inactivating mutations potentiate MAPK signaling and support cholesterol metabolism in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2021, 74, 360-371.	1.8	30
1051	Endpoints and design of clinical trials in patients with decompensated cirrhosis: Position paper of the LiverHope Consortium. <i>Journal of Hepatology</i> , 2021, 74, 200-219.	1.8	16
1052	TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms. <i>Gut</i> , 2021, 70, 1345-1361.	6.1	59
1053	Integrating baseline MR imaging biomarkers into BCLC and CLIP improves overall survival prediction of patients with hepatocellular carcinoma (HCC). <i>European Radiology</i> , 2021, 31, 1630-1641.	2.3	8
1054	A Healthy Liver After SVR: Food for Thought. <i>Digestive Diseases and Sciences</i> , 2021, 66, 1778-1779.	1.1	0
1055	Preoperative controlling nutritional status (CONUT) score predicts long-term outcomes in patients with non-B non-C hepatocellular carcinoma after curative hepatic resection. <i>Langenbeck's Archives of Surgery</i> , 2021, 406, 99-107.	0.8	10

#	ARTICLE	IF	CITATIONS
1056	An overview of hepatocellular carcinoma with atypical enhancement pattern: spectrum of magnetic resonance imaging findings with pathologic correlation. <i>Radiology and Oncology</i> , 2021, 55, 130-143.	0.6	8
1057	Rutin attenuates Sorafenib-induced Chemoresistance and Autophagy in Hepatocellular Carcinoma by regulating BANC/miRNA-590-5P/OLR1 Axis. <i>International Journal of Biological Sciences</i> , 2021, 17, 3595-3607.	2.6	33
1058	CLINICAL UTILITY OF LIVER AND TUMOR STIFFNESS MEASURED BY ULTRASOUND SHEAR WAVE ELASTOGRAPHY IN PATIENTS WITH HEPATOCELLULAR CARCINOMA TREATED BY THERMAL ABLATION.., 2021,, 63-65.		0
1059	Hepatocellular Carcinoma Misdiagnosed as a Liver Abscess – A Story of Misdiagnosis and Long-Term Malignant Disease Control. <i>Cureus</i> , 2021, 13, e12636.	0.2	1
1060	A polymeric nanoformulation improves the bioavailability and efficacy of sorafenib for hepatocellular carcinoma therapy. <i>Biomaterials Science</i> , 2021, 9, 2508-2518.	2.6	5
1061	Prognostic Value of Alpha-Fetoprotein in Patients Who Achieve a Complete Response to Transarterial Chemoembolization for Hepatocellular Carcinoma. <i>Yonsei Medical Journal</i> , 2021, 62, 12.	0.9	6
1062	Association Between Curative Treatment after Transarterial Radioembolization and Better Survival Outcomes in Patients with Hepatocellular Carcinoma. <i>Cancer Investigation</i> , 2021, 39, 274-283.	0.6	1
1063	Withaferin A Acts as a Novel Regulator of Liver X Receptor- $\beta$ in HCC. <i>Frontiers in Oncology</i> , 2020, 10, 628506.	1.3	18
1064	Estradiol is significantly associated with prognosis in non-surgical liver cancer patients: from bench to bedside. <i>Aging</i> , 2021, 13, 3483-3500.	1.4	5
1065	Subsequent Ultrasound Vascular Targeting Therapy of Hepatocellular Carcinoma Improves the Treatment Efficacy. <i>Biology</i> , 2021, 10, 79.	1.3	8
1066	Prognosis after Curative Resection of Single Hepatocellular Carcinoma with A Focus on LI-RADS Targetoid Appearance on Preoperative Gadoteric Acid-Enhanced MRI. <i>Korean Journal of Radiology</i> , 2021, 22, 1786.	1.5	16
1067	Impact of Early Lenvatinib Administration on Survival in Patients with Intermediate-Stage Hepatocellular Carcinoma: A Multicenter, Inverse Probability Weighting Analysis. <i>Oncology</i> , 2021, 99, 518-527.	0.9	5
1068	Preoperative classification of primary and metastatic liver cancer via machine learning-based ultrasound radiomics. <i>European Radiology</i> , 2021, 31, 4576-4586.	2.3	50
1069	TDO2 Promotes the EMT of Hepatocellular Carcinoma Through Kyn-AhR Pathway. <i>Frontiers in Oncology</i> , 2020, 10, 562823.	1.3	25
1070	Oral administration of EGCG solution equivalent to daily achievable dosages of regular tea drinkers effectively suppresses miR483-3p induced metastasis of hepatocellular carcinoma cells in mice. <i>Food and Function</i> , 2021, 12, 3381-3392.	2.1	16
1071	Transcriptional and epigenetic landscape of Ca <sup>2+</sup> -signaling genes in hepatocellular carcinoma. <i>Journal of Cell Communication and Signaling</i> , 2021, 15, 433-445.	1.8	3
1072	CircCAMSAP1 promotes hepatocellular carcinoma progression through miR-1294/GRAMD1A pathway. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 3793-3802.	1.6	28
1073	Role of long non-coding RNA H19 in therapy resistance of digestive system cancers. <i>Molecular Medicine</i> , 2021, 27, 1.	1.9	42

#	ARTICLE	IF	CITATIONS
1074	Alternating Lenvatinib and Trans-Arterial Therapy Prolongs Overall Survival in Patients with Inter-Mediate Stage HepatoCellular Carcinoma: A Propensity Score Matching Study. <i>Cancers</i> , 2021, 13, 160.	1.7	38
1075	Molecular phenotypes reveal heterogeneous engraftments of patient-derived hepatocellular carcinoma xenografts. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2021, 33, 470-479.	0.7	8
1076	Preoperative transarterial chemoembolization for laparoscopic liver resection in Child A cirrhotic patients with hepatocellular carcinoma. <i>Langenbeck's Archives of Surgery</i> , 2021, 406, 763-771.	0.8	6
1077	Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma. <i>Cancer Treatment and Research Communications</i> , 2021, 27, 100328.	0.7	70
1078	Nomograms based on clinicopathological factors and inflammatory indicators for prediction of early and late recurrence of hepatocellular carcinoma after surgical resection for patients with chronic hepatitis B. <i>Annals of Translational Medicine</i> , 2021, 9, 12-12.	0.7	6
1079	<sup>1</sup> H-NMR metabolomics reveals a multitarget action of <i>Crithmum maritimum</i> ethyl acetate extract in inhibiting hepatocellular carcinoma cell growth. <i>Scientific Reports</i> , 2021, 11, 1259.	1.6	19
1080	Advanced intra-tumoural structural characterisation of hepatocellular carcinoma utilising FDG-PET/CT: a comparative study of radiomics and metabolic features in 3D and 2D. <i>Polish Journal of Radiology</i> , 2021, 86, 64-73.	0.5	6
1081	Complete Pathological Response of Hepatocellular Carcinoma with Portal Vein Thrombosis Treated with Sorafenib—Report of a Case. <i>Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical)</i> Tj ETQq1 1 0.784314 rgBT /Overlo	0.7	14
1082	Berberine-10-hydroxy camptothecine-loaded lipid microsphere for the synergistic treatment of liver cancer by inhibiting topoisomerase and HIF-1 $\alpha$ . <i>Drug Delivery</i> , 2021, 28, 171-182.	2.5	6
1083	An approach to grossing of hepatectomy specimens. <i>Indian Journal of Pathology and Microbiology</i> , 2021, 64, 121.	0.1	1
1084	Liver resection versus radiofrequency ablation for recurrent hepatocellular carcinoma: a systematic review and meta-analysis. <i>International Journal of Hyperthermia</i> , 2021, 38, 875-886.	1.1	17
1085	Propensity score matching study of 325 patients with spontaneous rupture of hepatocellular carcinoma. <i>Hepatobiliary Surgery and Nutrition</i> , 2022, 11, 808-821.	0.7	6
1086	$\beta$ 2-Trcp and CK1 $\beta$ -mediated degradation of LZTS2 activates PI3K/AKT signaling to drive tumorigenesis and metastasis in hepatocellular carcinoma. <i>Oncogene</i> , 2021, 40, 1269-1283.	2.6	17
1087	Role of Multidisciplinary Care in the Management of Hepatocellular Carcinoma. <i>Seminars in Liver Disease</i> , 2021, 41, 001-008.	1.8	14
1088	Folic acid modified TPGS as a novel nano-micelle for delivery of nitidine chloride to improve apoptosis induction in Huh7 human hepatocellular carcinoma. <i>BMC Pharmacology &amp; Toxicology</i> , 2021, 22, 1.	1.0	33
1089	A Practical Model is Equivalent to the BALAD or BALAD-2 Score in Predicting Long-term Survival after Hepatectomy in Chinese Patients with Hepatocellular Carcinoma. <i>Journal of Cancer</i> , 2021, 12, 1474-1482.	1.2	0
1090	Liver Cancer (Current Therapies). , 2022, , 112-125.		1
1091	A narrative review of near-infrared fluorescence imaging in hepatectomy for hepatocellular carcinoma. <i>Annals of Translational Medicine</i> , 2021, 9, 171-171.	0.7	19

#	ARTICLE	IF	CITATIONS
1092	Meningioma-associated protein 30 accelerates the proliferation and invasion of hepatocellular carcinoma by modulating Wnt/GSK-3 $\beta$ / $\beta$ -catenin signaling. <i>Journal of Bioenergetics and Biomembranes</i> , 2021, 53, 73-83.	1.0	5
1093	Machine Learning Model Based on Electronic Health Records for Predicting Recurrence after Microwave Ablation of Hepatocellular Carcinoma. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1094	Silver Nanocolloids Loaded with Betulinic Acid with Enhanced Antitumor Potential: Physicochemical Characterization and In Vitro Evaluation. <i>Nanomaterials</i> , 2021, 11, 152.	1.9	7
1095	Optimizing the Combination of Immunotherapy and Trans-Arterial Locoregional Therapy for Stages B and C Hepatocellular Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 1499-1510.	0.7	3
1096	Predicting hyperprogressive disease in patients with advanced hepatocellular carcinoma treated with anti-programmed cell death 1 therapy. <i>EClinicalMedicine</i> , 2021, 31, 100673.	3.2	23
1097	Recent updates on chimeric antigen receptor T cell therapy for hepatocellular carcinoma. <i>Cancer Gene Therapy</i> , 2021, 28, 1075-1087.	2.2	23
1098	LETM1 Knockdown Promotes Autophagy and Apoptosis Through AMP-Activated Protein Kinase Phosphorylation-Mediated Beclin-1/Bcl-2 Complex Dissociation in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 606790.	1.3	7
1099	Radiomic analysis of MRI to Predict Sustained Complete Response after Radiofrequency Ablation in Patients with Hepatocellular Carcinoma - A Pilot Study. <i>Clinics</i> , 2021, 76, e2888.	0.6	9
1100	Systemic characterization of the SLC family genes reveals SLC26A6 as a novel oncogene in hepatocellular carcinoma. <i>Translational Cancer Research</i> , 2021, 10, 2882-2894.	0.4	6
1101	IL6 plays a crucial role in epithelial-mesenchymal transition and pro-metastasis induced by sorafenib in liver cancer. <i>Oncology Reports</i> , 2021, 45, 1105-1117.	1.2	10
1102	Efficacy and Safety of Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma. <i>Oncology</i> , 2021, 99, 507-517.	0.9	38
1103	Effects of hypoxia-inducible factor-1 $\alpha$ and hypoxia-inducible factor-2 $\alpha$ overexpression on hepatocellular carcinoma survival: A systematic review with meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1487-1496.	1.4	6
1104	Astrocyte elevated gene-1 (AEG-1): A key driver of hepatocellular carcinoma (HCC). <i>Advances in Cancer Research</i> , 2021, 152, 329-381.	1.9	3
1105	Identification of Hub Genes Associated with Hepatocellular Carcinoma Prognosis by Bioinformatics Analysis. <i>Journal of Cancer Therapy</i> , 2021, 12, 186-207.	0.1	6
1106	Low applicability of the six-and-twelve score in hepatocellular carcinoma treated with drug-eluting beads transarterial chemoembolization. <i>Revista Espanola De Enfermedades Digestivas</i> , 2021, , .	0.1	2
1107	Gene expression evaluation of antioxidant enzymes in patients with hepatocellular carcinoma: RT-qPCR and bioinformatic analyses. <i>Genetics and Molecular Biology</i> , 2021, 44, e20190373.	0.6	9
1108	The value of preoperative systemic immune-inflammation index in predicting vascular invasion of hepatocellular carcinoma: a meta-analysis. <i>Brazilian Journal of Medical and Biological Research</i> , 2021, 54, e10273.	0.7	7
1109	Age, Gender and Geographic Differences in Global Health Burden of Cirrhosis and Liver Cancer due to Nonalcoholic Steatohepatitis. <i>Journal of Cancer</i> , 2021, 12, 2855-2865.	1.2	9

#	ARTICLE	IF	CITATIONS
1111	Is the Barcelona Clinic Liver Cancer guideline for treating intermediate to advanced staged hepatocellular carcinoma still appropriate?. <i>Annals of Translational Medicine</i> , 2021, 9, 1-1.	0.7	9
1112	Immunohistochemical Signature Add Prognostic Value in Patients With Early and Intermediate Hepatocellular Carcinoma Underwent Curative Liver Resection. <i>Frontiers in Oncology</i> , 2020, 10, 616263.	1.3	2
1113	Safety and efficacy study: Short-term application of radiofrequency ablation and stereotactic body radiotherapy for Barcelona Clinical Liver Cancer stage Oâ€“B1 hepatocellular carcinoma. <i>PLoS ONE</i> , 2021, 16, e0245076.	1.1	2
1114	Construction and validation of a three-microRNA signature as prognostic biomarker in patients with hepatocellular carcinoma. <i>International Journal of Medical Sciences</i> , 2021, 18, 984-999.	1.1	11
1115	Long non-coding RNA TTN antisense RNA 1 facilitates hepatocellular carcinoma progression via regulating miR-139-5p/SPOCK1 axis. <i>Bioengineered</i> , 2021, 12, 578-588.	1.4	22
1116	A Marine Terpenoid, Heteronemin, Induces Both the Apoptosis and Ferroptosis of Hepatocellular Carcinoma Cells and Involves the ROS and MAPK Pathways. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-12.	1.9	79
1117	DEAH-box polypeptide 32 promotes hepatocellular carcinoma progression via activating the Î²-catenin pathway. <i>Annals of Medicine</i> , 2021, 53, 437-447.	1.5	9
1118	Diagnostic value of 5 serum biomarkers for hepatocellular carcinoma with different epidemiological backgrounds: A large-scale, retrospective study. <i>Cancer Biology and Medicine</i> , 2021, 18, 256-270.	1.4	13
1119	Lidocaine Inhibits Hepatocellular Carcinoma Development by Modulating circ_ITCH/miR-421/CPEB3 Axis. <i>Digestive Diseases and Sciences</i> , 2021, 66, 4384-4397.	1.1	22
1120	The Dark Side of the Force: When the Immune System Is the Fuel of Tumor Onset. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1224.	1.8	9
1121	NIR-absorbing Prussian blue nanoparticles for transarterial infusion photothermal therapy of VX2 tumors implanted in rabbits. <i>Nanoscale</i> , 2021, 13, 8490-8497.	2.8	12
1122	Circulating Cell-Free DNA Combined to Magnetic Resonance Imaging for Early Detection of HCC in Patients with Liver Cirrhosis. <i>Cancers</i> , 2021, 13, 521.	1.7	5
1123	Rhamnetin decelerates the elimination and enhances the antitumor effect of the molecular-targeting agent sorafenib in hepatocellular carcinoma cells <i>via</i> the miR-148a/PXR axis. <i>Food and Function</i> , 2021, 12, 2404-2417.	2.1	48
1124	A review of cutting-edge therapies for hepatocellular carcinoma (HCC): Perspectives from patents. <i>International Journal of Medical Sciences</i> , 2021, 18, 3066-3081.	1.1	12
1125	MST4 negatively regulates the EMT, invasion and metastasis of HCC cells by inactivating PI3K/AKT/Snail1 axis. <i>Journal of Cancer</i> , 2021, 12, 4463-4477.	1.2	19
1126	Activated Lymphocytes and Increased Risk of Dermatologic Adverse Events during Sorafenib Therapy for Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 426.	1.7	4
1127	Rationalizing heptadecaphobia: T<sub>H</sub>17 cells and associated cytokines in cancer and metastasis. <i>FEBS Journal</i> , 2021, 288, 6942-6971.	2.2	7
1128	Definitive Radiotherapy for Locally Advanced Hepatocellular Carcinoma. , 2021, , 191-207.		0

#	ARTICLE	IF	CITATIONS
1129	What Can Be Done to Solve the Unmet Clinical Need of Hepatocellular Carcinoma Patients following Lenvatinib Failure?. <i>Liver Cancer</i> , 2021, 10, 115-125.	4.2	12
1130	Transarterial chemoembolization with or without sorafenib for hepatocellular carcinoma: A real-world propensity score-matched study. <i>Tzu Chi Medical Journal</i> , 2022, 34, 219.	0.4	3
1131	Time-Varying mHAP-III Is the Most Accurate Predictor of Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. <i>Liver Cancer</i> , 2021, 10, 126-136.	4.2	6
1132	What Is Different Between Pediatric and Adult Liver Transplantation?. , 2021, , 8-13.		0
1133	The E-Twenty-Six Family in Hepatocellular Carcinoma: Moving into the Spotlight. <i>Frontiers in Oncology</i> , 2020, 10, 620352.	1.3	0
1134	TRPM5 rs886277 Polymorphism Predicts Hepatic Fibrosis Progression in Non-Cirrhotic HCV-Infected Patients. <i>Journal of Clinical Medicine</i> , 2021, 10, 483.	1.0	1
1135	HOPMCLDA: predicting lncRNA-disease associations based on high-order proximity and matrix completion. <i>Molecular Omics</i> , 2021, 17, 760-768.	1.4	1
1136	ICAM-1 Activates Platelets and Promotes Endothelial Permeability through VE-Cadherin after Insufficient Radiofrequency Ablation. <i>Advanced Science</i> , 2021, 8, 2002228.	5.6	22
1137	Four types of tumor progression after microwave ablation of single hepatocellular carcinoma of 5cm: incidence, risk factors and clinical significance. <i>International Journal of Hyperthermia</i> , 2021, 38, 1164-1173.	1.1	7
1138	Green synthesis of gold nanoparticles from <i>Dendrobium officinale</i> and its anticancer effect on liver cancer. <i>Drug Delivery</i> , 2021, 28, 985-994.	2.5	19
1139	Cytosolic Delivery of Thiolated Neoantigen NanoVaccine Combined with Immune Checkpoint Blockade to Boost Anti-Cancer T Cell Immunity. <i>Advanced Science</i> , 2021, 8, 2003504.	5.6	34
1140	Long Non-Coding RNAs: Potential Biomarkers and Targets for Hepatocellular Carcinoma Therapy and Diagnosis. <i>International Journal of Biological Sciences</i> , 2021, 17, 220-235.	2.6	27
1141	Early recurrence after radiofrequency ablation for hepatocellular carcinoma: a multicenter retrospective study on definition, patterns and risk factors. <i>International Journal of Hyperthermia</i> , 2021, 38, 437-446.	1.1	11
1142	Identification of Hub Genes Associated With Immune Infiltration and Predict Prognosis in Hepatocellular Carcinoma via Bioinformatics Approaches. <i>Frontiers in Genetics</i> , 2020, 11, 575762.	1.1	22
1143	Epigenetic mechanisms of hepatocellular carcinoma progression: Potential therapeutic opportunities. , 2021, , 279-296.		0
1144	Pseudogene Annexin A2 Pseudogene 1 Contributes to Hepatocellular Carcinoma Progression by Modulating Its Parental Gene ANXA2 via miRNA-376a-3p. <i>Digestive Diseases and Sciences</i> , 2021, 66, 3903-3915.	1.1	4
1145	Deep learning predicts postsurgical recurrence of hepatocellular carcinoma from digital histopathologic images. <i>Scientific Reports</i> , 2021, 11, 2047.	1.6	33
1146	Safflower yellow reduces DEN-induced hepatocellular carcinoma by enhancing liver immune infiltration through promotion of collagen degradation and modulation of gut microbiota. <i>Food and Function</i> , 2021, 12, 10632-10643.	2.1	13



#	ARTICLE	IF	CITATIONS
1147	Inflammatory microenvironment of fibrotic liver promotes hepatocellular carcinoma growth, metastasis and sorafenib resistance through STAT3 activation. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 1568-1582.	1.6	21
1148	Gut Microbiome and Liver Cancer. <i>Physiology in Health and Disease</i> , 2021, , 199-255.	0.2	0
1149	Radiomics analysis of [18F]FDG PET/CT for microvascular invasion and prognosis prediction in very-early- and early-stage hepatocellular carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2599-2614.	3.3	59
1150	UHRF2 promotes Hepatocellular Carcinoma Progression by Upregulating ErbB3/Ras/Raf Signaling Pathway. <i>International Journal of Medical Sciences</i> , 2021, 18, 3097-3105.	1.1	6
1151	One- versus two-stage partial hepatectomy for large resectable solitary hepatocellular carcinomas determined preoperatively to have a narrow resection margin: a propensity score matching analysis. <i>Hepatobiliary Surgery and Nutrition</i> , 2022, 11, 662-674.	0.7	1
1152	Comparison of intrahepatic progression patterns of hepatocellular carcinoma and colorectal liver metastases following CT-guided high dose-rate brachytherapy. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110423.	1.4	1
1154	Determining novel candidate anti-hepatocellular carcinoma drugs using interaction networks and molecular docking between drug targets and natural compounds of SiNiSan. <i>PeerJ</i> , 2021, 9, e10745.	0.9	3
1155	COCH predicts survival and adjuvant TACE response in patients with HCC. <i>Oncology Letters</i> , 2021, 21, 275.	0.8	4
1156	A nomogram combining PPAR $\gamma$ expression profiles and clinical factors predicts survival in patients with hepatocellular carcinoma. <i>Oncology Letters</i> , 2021, 21, 319.	0.8	3
1157	Clinical Benefit of Antiviral Agents for Hepatocellular Carcinoma Patients With Low Preoperative HBV-DNA Loads Undergoing Curative Resection: A Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 605648.	1.3	12
1158	Curcumin inhibits the growth of liver cancer by impairing myeloid-derived suppressor cells in murine tumor tissues. <i>Oncology Letters</i> , 2021, 21, 286.	0.8	29
1159	Carbon ion radiotherapy for patients with hepatocellular carcinoma in the caudate lobe. <i>Hepatology Research</i> , 2021, 51, 303-312.	1.8	4
1160	Homoharringtonine Exerts Anti-tumor Effects in Hepatocellular Carcinoma Through Activation of the Hippo Pathway. <i>Frontiers in Pharmacology</i> , 2021, 12, 592071.	1.6	7
1161	Silencing the Expression of Cyclin G1 Enhances the Radiosensitivity of Hepatocellular Carcinoma In Vitro and In Vivo by Inducing Apoptosis. <i>Radiation Research</i> , 2021, 195, 378-384.	0.7	1
1162	Preoperative transarterial chemoembolization for barcelona clinic liver cancer stage A/B hepatocellular carcinoma beyond the milan criteria: a propensity score matching analysis. <i>Hpb</i> , 2021, 23, 1427-1438.	0.1	6
1163	RSPO4-CRISPR alleviates liver injury and restores gut microbiota in a rat model of liver fibrosis. <i>Communications Biology</i> , 2021, 4, 230.	2.0	15
1164	Liver resection versus transarterial chemoembolization for huge hepatocellular carcinoma: a propensity score matched analysis. <i>Scientific Reports</i> , 2021, 11, 4493.	1.6	11
1165	Percutaneous liquid ablation agent for tumor treatment and drug delivery. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	25

#	ARTICLE	IF	CITATIONS
1166	Prediction of Patient Survival Following Hepatic Resection in Early-Stage Hepatocellular Carcinoma with Indexed Ratios of Aspartate Aminotransferase to Platelets: A Retrospective Cohort Study. <i>Cancer Management and Research</i> , 2021, Volume 13, 1733-1746.	0.9	5
1167	PSMC2 Regulates Cell Cycle Progression Through the p21/Cyclin D1 Pathway and Predicts a Poor Prognosis in Human Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 607021.	1.3	9
1168	The lymphocyte-C-reactive protein ratio as the optimal inflammation-based score in patients with hepatocellular carcinoma underwent TACE. <i>Aging</i> , 2021, 13, 5358-5368.	1.4	19
1169	Hepatocellular carcinoma in patients coinfecting with hepatitis B or C and HIV: more aggressive tumor behavior?. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, 583-588.	0.8	6
1170	Metabolic Alteration in Hepatocellular Carcinoma: Mechanism of Lipid Accumulation in Well-Differentiated Hepatocellular Carcinoma. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2021, 2021, 1-13.	0.8	11
1171	Expanding Indications of Liver Transplantation in Spain: Consensus Statement and Recommendations by the Spanish Society of Liver Transplantation. <i>Transplantation</i> , 2021, 105, 602-607.	0.5	24
1172	Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma. <i>JAMA Network Open</i> , 2021, 4, e210037.	2.8	81
1173	Clinical utility of serum biomarkers for hepatocellular carcinoma. <i>Biomarkers in Medicine</i> , 2021, 15, 151-155.	0.6	3
1174	DNA primase subunit 1 deteriorated progression of hepatocellular carcinoma by activating AKT/mTOR signaling and UBE2C-mediated P53 ubiquitination. <i>Cell and Bioscience</i> , 2021, 11, 42.	2.1	30
1175	Irbesartan inhibits metastasis by interrupting the adherence of tumor cell to endothelial cell induced by angiotensin II in hepatocellular carcinoma. <i>Annals of Translational Medicine</i> , 2021, 9, 207-207.	0.7	10
1176	PIWIL1 governs the crosstalk of cancer cell metabolism and immunosuppressive microenvironment in hepatocellular carcinoma. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 86.	7.1	25
1177	A thermochromic tissue-mimicking phantom model for verification of ablation plans in thermal ablation. <i>Annals of Translational Medicine</i> , 2021, 9, 354-354.	0.7	6
1178	Elevated soluble urokinase plasminogen activator receptor serum levels indicate poor survival following transarterial chemoembolization therapy for hepatic malignancies: An exploratory analysis. <i>JGH Open</i> , 2021, 5, 356-363.	0.7	0
1179	Is the Rationale of Anatomical Liver Resection for Hepatocellular Carcinoma Universally Adoptable? A Hypothesis-Driven Review. <i>Medicina (Lithuania)</i> , 2021, 57, 131.	0.8	3
1180	RNA binding protein DAZAP1 promotes HCC progression and regulates ferroptosis by interacting with SLC7A11 mRNA. <i>Experimental Cell Research</i> , 2021, 399, 112453.	1.2	56
1181	A radiomics nomogram based on contrast-enhanced MRI for preoperative prediction of macrotrabecular-massive hepatocellular carcinoma. <i>Abdominal Radiology</i> , 2021, 46, 3139-3148.	1.0	25
1182	Development and Validation of a Machine Learning Prognostic Model for Hepatocellular Carcinoma Recurrence After Surgical Resection. <i>Frontiers in Oncology</i> , 2020, 10, 593741.	1.3	14
1183	Pterostilbene Nanoparticles Downregulate Hypoxia-Inducible Factors in Hepatoma Cells Under Hypoxic Conditions. <i>International Journal of Nanomedicine</i> , 2021, Volume 16, 867-879.	3.3	14

#	ARTICLE	IF	CITATIONS
1184	The Outcome of Primary Hepatic Carcinoid Tumor: A Retrospective Study Based on Propensity Score Matched Survival Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 609397.	1.3	1
1185	Comparison of Trans-Arterial Chemoembolization and Bland Embolization for the Treatment of Hepatocellular Carcinoma: A Propensity Score Analysis. <i>Cancers</i> , 2021, 13, 812.	1.7	10
1186	P21-activated kinase 5 potentiates the chemoresistant phenotype of liver cancer. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 47.	7.1	5
1187	Value of KPNA4 as a diagnostic and prognostic biomarker for hepatocellular carcinoma. <i>Aging</i> , 2021, 13, 5263-5283.	1.4	10
1188	A comparison of factors associated with the temporal improvement in the overall survival of BCLC stage 0 hepatocellular carcinoma patients. <i>Digestive and Liver Disease</i> , 2021, 53, 210-215.	0.4	2
1189	From Liver Cirrhosis to Cancer: The Role of Micro-RNAs in Hepatocarcinogenesis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1492.	1.8	16
1190	Serum Inc34a is a potential prediction biomarker for bone metastasis in hepatocellular carcinoma patients. <i>BMC Cancer</i> , 2021, 21, 161.	1.1	8
1191	Prevalence and profiles of ramucirumab-associated severe ascites in patients with hepatocellular carcinoma. <i>Molecular and Clinical Oncology</i> , 2021, 14, 79.	0.4	8
1192	Mannose-Derived Carbon Dots Amplify Microwave Ablation-Induced Antitumor Immune Responses by Capturing and Transferring "Danger Signals" to Dendritic Cells. <i>ACS Nano</i> , 2021, 15, 2920-2932.	7.3	52
1193	High expression of aldolase A is associated with tumor progression and poor prognosis in hepatocellular carcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 174-183.	0.6	12
1194	The Space of Disse: The Liver Hub in Health and Disease. <i>Livers</i> , 2021, 1, 3-26.	0.8	23
1195	Cooperative Role of Thrombopoietin and Vascular Endothelial Growth Factor-A in the Progression of Liver Cirrhosis to Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1818.	1.8	6
1196	Kaempferol exhibits a synergistic effect with doxorubicin to inhibit proliferation, migration, and invasion of liver cancer. <i>Oncology Reports</i> , 2021, 45, .	1.2	21
1197	Elastin-specific MRI of extracellular matrix-remodelling following hepatic radiofrequency-ablation in a VX2 liver tumor model. <i>Scientific Reports</i> , 2021, 11, 6814.	1.6	1
1198	Elevated TEFM expression promotes growth and metastasis through activation of ROS/ERK signaling in hepatocellular carcinoma. <i>Cell Death and Disease</i> , 2021, 12, 325.	2.7	14
1199	Identification and validation of a glycolysis-associated multiomics prognostic model for hepatocellular carcinoma. <i>Aging</i> , 2021, 13, 7481-7498.	1.4	5
1200	Role of bFGF in Acquired Resistance upon Anti-VEGF Therapy in Cancer. <i>Cancers</i> , 2021, 13, 1422.	1.7	31
1201	The Clinical Role of Serum Epidermal Growth Factor Receptor 3 in Hepatitis C Virus-Infected Patients with Early Hepatocellular Carcinoma. <i>Biology</i> , 2021, 10, 215.	1.3	4

#	ARTICLE	IF	CITATIONS
1202	Percutaneous ablation versus surgical ablation and resection of liver tumors: medicare volume and physician reimbursement trends from 2010 to 2018. <i>Abdominal Radiology</i> , 2021, 46, 4056-4061.	1.0	1
1203	Inter-reader agreement of CEUS LI-RADS among radiologists with different levels of experience. <i>European Radiology</i> , 2021, 31, 6758-6767.	2.3	13
1204	The dual functions of the long noncoding RNA CASC15 in malignancy. <i>Biomedicine and Pharmacotherapy</i> , 2021, 135, 111212.	2.5	18
1205	Network Pharmacology and Pharmacological Evaluation Reveals the Mechanism of the Sanguisorba Officinalis in Suppressing Hepatocellular Carcinoma. <i>Frontiers in Pharmacology</i> , 2021, 12, 618522.	1.6	19
1206	Silencing CDCA8 Suppresses Hepatocellular Carcinoma Growth and Stemness via Restoration of ATF3 Tumor Suppressor and Inactivation of AKT/ $\beta$ -Catenin Signaling. <i>Cancers</i> , 2021, 13, 1055.	1.7	33
1207	Diagnostic performance of MRI using extracellular contrast agents versus gadoteric acid for hepatocellular carcinoma: A systematic review and meta-analysis. <i>Liver International</i> , 2021, 41, 1117-1128.	1.9	15
1208	Lessons From Immune Checkpoint Inhibitor Trials in Hepatocellular Carcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 652172.	2.2	21
1209	Hepatitis B-Induced IL8 Promotes Hepatocellular Carcinoma Venous Metastasis and Intrahepatic Treg Accumulation. <i>Cancer Research</i> , 2021, 81, 2386-2398.	0.4	31
1210	Response Prediction in Immune Checkpoint Inhibitor Immunotherapy for Advanced Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 1607.	1.7	19
1211	NEDD4 Induces K48-Linked Degradative Ubiquitination of Hepatitis B Virus X Protein and Inhibits HBV-Associated HCC Progression. <i>Frontiers in Oncology</i> , 2021, 11, 625169.	1.3	7
1212	Chlorogenic acid inhibits proliferation in human hepatoma cells by suppressing noncanonical NF- $\kappa$ B signaling pathway and triggering mitochondrial apoptosis. <i>Molecular Biology Reports</i> , 2021, 48, 2351-2364.	1.0	17
1213	Randomized controlled study to examine the efficacy of hepatic arterial infusion chemotherapy with cisplatin before radiofrequency ablation for hepatocellular carcinoma. <i>Hepatology Research</i> , 2021, 51, 694-701.	1.8	9
1214	Six genes involved in prognosis of hepatocellular carcinoma identified by Cox hazard regression. <i>BMC Bioinformatics</i> , 2021, 22, 167.	1.2	6
1215	Comparing the Safety and Efficacy of Microwave Ablation Using Thermosphere™ Technology versus Radiofrequency Ablation for Hepatocellular Carcinoma: A Propensity Score-Matched Analysis. <i>Cancers</i> , 2021, 13, 1295.	1.7	11
1216	Risk Signature Related to Immunotherapy Reaction of Hepatocellular Carcinoma Based on the Immune-Related Genes Associated With CD8+ T Cell Infiltration. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 602227.	1.6	3
1217	SPARC inhibition accelerates NAFLD-associated hepatocellular carcinoma development by dysregulating hepatic lipid metabolism. <i>Liver International</i> , 2021, 41, 1677-1693.	1.9	17
1218	Segmentation and Registration of the Liver in Dynamic Contrast-Enhanced Computed Tomography Images. <i>Journal of Medical Imaging and Health Informatics</i> , 2021, 11, 773-780.	0.2	0
1219	Albumin platelet product as a novel score for liver fibrosis stage and prognosis. <i>Scientific Reports</i> , 2021, 11, 5345.	1.6	4

#	ARTICLE	IF	CITATIONS
1220	miR-186 Inhibits Liver Cancer Stem Cells Expansion via Targeting PTPN11. <i>Frontiers in Oncology</i> , 2021, 11, 632976.	1.3	16
1221	Autophagy, an accomplice or antagonist of drug resistance in HCC?. <i>Cell Death and Disease</i> , 2021, 12, 266.	2.7	31
1222	Current Trends and Characteristics of Hepatocellular Carcinoma in Patients with Autoimmune Liver Diseases. <i>Cancers</i> , 2021, 13, 1023.	1.7	20
1223	An epithelial-mesenchymal transition-related 5-gene signature predicting the prognosis of hepatocellular carcinoma patients. <i>Cancer Cell International</i> , 2021, 21, 166.	1.8	12
1224	Immune-based combinations for advanced hepatocellular carcinoma: shaping the direction of first-line therapy. <i>Future Oncology</i> , 2021, 17, 755-757.	1.1	60
1225	Indication of Liver Transplantation for Hepatocellular Carcinoma Should Be Reconsidered in Case of Microvascular Invasion and Multilocular Tumor Occurrence. <i>Journal of Clinical Medicine</i> , 2021, 10, 1155.	1.0	7
1226	High Expression of LINC01268 is Positively Associated with Hepatocellular Carcinoma Progression via Regulating MAP3K7. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 1753-1769.	1.0	1
1227	Does access to care play a role in liver cancer survival? The ten-year (2006–2015) experience from a population-based cancer registry in Southern Italy. <i>BMC Cancer</i> , 2021, 21, 307.	1.1	0
1228	High-intensity focused ultrasound alone or combined with transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with unsuitable indications for hepatectomy and radiofrequency ablation: a phase II clinical trial. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2022, 36, 1857-1867.	1.3	9
1229	CXCL5 Has Potential to Be a Marker for Hepatocellular Carcinoma Prognosis and Was Correlating With Immune Infiltrates. <i>Frontiers in Oncology</i> , 2021, 11, 637023.	1.3	9
1230	Shedding more light on the role of Midkine in hepatocellular carcinoma: New perspectives on diagnosis and therapy. <i>IUBMB Life</i> , 2021, 73, 659-669.	1.5	22
1231	Novel biomarker for hepatocellular carcinoma: high tumoral PLK-4 expression is associated with better prognosis in patients without microvascular invasion. <i>Hpb</i> , 2021, 23, 359-366.	0.1	2
1232	Current updates in machine learning in the prediction of therapeutic outcome of hepatocellular carcinoma: what should we know?. <i>Insights Into Imaging</i> , 2021, 12, 31.	1.6	18
1233	Retrospective European Multicentric Evaluation of Selective Transarterial Chemoembolisation with and without Balloon-Occlusion in Patients with Hepatocellular Carcinoma: A Propensity Score Matched Analysis. <i>CardioVascular and Interventional Radiology</i> , 2021, 44, 1048-1059.	0.9	14
1234	Development of TACE Refractoriness Scores in Hepatocellular Carcinoma. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 615133.	1.6	5
1235	GPER-Induced ERK Signaling Decreases Cell Viability of Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 638171.	1.3	11
1236	Extracellular HMGB1 promotes CD44 expression in hepatocellular carcinoma via regulating miR-21. <i>Aging</i> , 2021, 13, 8380-8395.	1.4	8
1237	The GNAQ T96S Mutation Affects Cell Signaling and Enhances the Oncogenic Properties of Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3284.	1.8	5

#	ARTICLE	IF	CITATIONS
1238	Adherence to the modified Barcelona Clinic Liver Cancer guidelines: Results from a high-volume liver surgery center in East Asias. PLoS ONE, 2021, 16, e0249194.	1.1	11
1239	Exosomal Non-Coding RNAs: Regulatory and Therapeutic Target of Hepatocellular Carcinoma. Frontiers in Oncology, 2021, 11, 653846.	1.3	2
1240	miR-206-G6PD axis regulates lipogenesis and cell growth in hepatocellular carcinoma cell. Anti-Cancer Drugs, 2021, 32, 508-516.	0.7	11
1241	Advances in pharmacotherapeutics for hepatocellular carcinoma. Expert Opinion on Pharmacotherapy, 2021, 22, 1343-1354.	0.9	5
1242	Targeting CALM2 Inhibits Hepatocellular Carcinoma Growth and Metastasis by Suppressing E2F5-mediated Cell Cycle Progression. Anticancer Research, 2021, 41, 1315-1325.	0.5	6
1243	Impact of Metabolic Activity in Hepatocellular Carcinoma: Association With Immune Status and Vascular Formation. Hepatology Communications, 2021, 5, 1278-1289.	2.0	23
1244	Immunomodulatory Treatment Strategies of Hepatocellular Carcinoma: From Checkpoint Inhibitors Now to an Integrated Approach in the Future. Cancers, 2021, 13, 1558.	1.7	8
1245	Stereotactic body radiation therapy for hepatocellular carcinoma with Macrovascular invasion. Radiotherapy and Oncology, 2021, 156, 120-126.	0.3	19
1246	Stachydrine inhibits TGF- $\beta$ 1-induced epithelial-mesenchymal transition in hepatocellular carcinoma cells through the TGF- $\beta$ 2/Smad and PI3K/Akt/mTOR signaling pathways. Anti-Cancer Drugs, 2021, 32, 786-792.	0.7	9
1247	4-methylumbelliferone-mediated polarization of M1 macrophages correlate with decreased hepatocellular carcinoma aggressiveness in mice. Scientific Reports, 2021, 11, 6310.	1.6	13
1248	Pyroptosis: mechanisms and diseases. Signal Transduction and Targeted Therapy, 2021, 6, 128.	7.1	821
1249	Targeting Hedgehog signalling in CD133-positive hepatocellular carcinoma: improving Lenvatinib therapeutic efficiency. Medical Oncology, 2021, 38, 41.	1.2	4
1250	Ras Mitogen-activated Protein Kinase Signaling and Kinase Suppressor of Ras as Therapeutic Targets for Hepatocellular Carcinoma. Journal of Liver Cancer, 2021, 21, 1-11.	0.3	4
1251	AMD1 upregulates hepatocellular carcinoma cells stemness by FTO mediated mRNA demethylation. Clinical and Translational Medicine, 2021, 11, e352.	1.7	42
1252	Stroke and Liver Cirrhosis: A Brief Review of Current Evidence. , 0, , .		0
1253	Blood reelin in the progression of chronic liver disease. Advances in Medical Sciences, 2021, 66, 148-154.	0.9	4
1254	The antitumor role of a newly discovered $\beta$ -d-glucan from Holotrichia diomphalia Bates as a selective blocker of aldolase A. Carbohydrate Polymers, 2021, 255, 117532.	5.1	9
1255	A Prognostic Scoring System for Predicting Overall Survival of Patients with the TNM 8th Edition Stage I and II Hepatocellular Carcinoma After Surgery: A Population-Based Study. Cancer Management and Research, 2021, Volume 13, 2131-2142.	0.9	2

#	ARTICLE	IF	CITATIONS
1256	Effect of Yttrium-90 transarterial radioembolization in patients with non-surgical hepatocellular carcinoma: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2021, 16, e0247958.	1.1	7
1257	EPS364, a Novel Deep-Sea Bacterial Exopolysaccharide, Inhibits Liver Cancer Cell Growth and Adhesion. <i>Marine Drugs</i> , 2021, 19, 171.	2.2	19
1258	Advanced Techniques in the Percutaneous Ablation of Liver Tumours. <i>Diagnostics</i> , 2021, 11, 585.	1.3	16
1259	Identification of immune-related lncRNA signature for predicting immune checkpoint blockade and prognosis in hepatocellular carcinoma. <i>International Immunopharmacology</i> , 2021, 92, 107333.	1.7	62
1260	Individual or combined transcatheter arterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma: a time-to-event meta-analysis. <i>World Journal of Surgical Oncology</i> , 2021, 19, 81.	0.8	31
1261	Feasibility of SBRT for hepatocellular carcinoma in Brazil – a prospective pilot study. <i>Reports of Practical Oncology and Radiotherapy</i> , 2021, 26, 226-236.	0.3	1
1262	Rare Histological Variants of Liver Cancer and Their Management: A Single-Institution Experience. <i>Case Reports in Hepatology</i> , 2021, 2021, 1-7.	0.4	1
1263	Comprehensive analysis of genomic and immunological profiles in Chinese and Western hepatocellular carcinoma populations. <i>Aging</i> , 2021, 13, 11564-11594.	1.4	5
1264	Hypoxia-dependent expression of MAP17 coordinates the Warburg effect to tumor growth in hepatocellular carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 121.	3.5	10
1265	Urea as a By-Product of Ammonia Metabolism Can Be a Potential Serum Biomarker of Hepatocellular Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 650748.	1.8	17
1266	Circular ribonucleic acid neilike deoxyribonucleic acid glycosylase $\beta$ governs the microribonucleic acid $\beta$ 150 $\beta$ /laminin subunit $\gamma$ 1 network to partially promote the development of hepatocellular carcinoma. <i>Hepatology Research</i> , 2021, 51, 702-714.	1.8	5
1267	Systemic immune-inflammation index predicts postoperative acute kidney injury in hepatocellular carcinoma patients after hepatectomy. <i>Medicine (United States)</i> , 2021, 100, e25335.	0.4	8
1268	Re-evaluating Transarterial Chemoembolization Failure/Refractoriness: A Survey by Chinese College of Interventionalists. <i>Journal of Clinical and Translational Hepatology</i> , 2021, 000, 000-000.	0.7	14
1269	Therapeutic Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma Recurrence After Liver Transplantation: A Systematic Review and Meta-Analysis. <i>Turkish Journal of Gastroenterology</i> , 2021, 32, 30-41.	0.4	5
1270	Isoliensinine: A Natural Compound with “Drug-Like” Potential. <i>Frontiers in Pharmacology</i> , 2021, 12, 630385.	1.6	17
1271	Correlation Between Portal Pressure and Indocyanine Green Retention Rate is Unaffected by the Cause of Cirrhosis: A Prospective Study. <i>World Journal of Surgery</i> , 2021, 45, 2546-2555.	0.8	3
1272	Locoregional Combined With Systemic Therapies for Advanced Hepatocellular Carcinoma: An Inevitable Trend of Rapid Development. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 635243.	1.6	22
1273	Therapies for hepatocellular carcinoma: overview, clinical indications, and comparative outcome evaluation – part one: curative intention. <i>Abdominal Radiology</i> , 2021, 46, 3528-3539.	1.0	6

#	ARTICLE	IF	CITATIONS
1274	LncRNA ZEB1-AS1 regulates hepatocellular carcinoma progression by targeting miR-23c. <i>World Journal of Surgical Oncology</i> , 2021, 19, 121.	0.8	11
1275	Dual Role of TNF and LT $\alpha$ in Carcinogenesis as Implicated by Studies in Mice. <i>Cancers</i> , 2021, 13, 1775.	1.7	12
1276	Circular RNA hsa_circ_0013958 Functions as an Oncogenic Gene Through Modulating miR-532-3p/WEE1 Axis in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 585172.	1.3	1
1277	Proteomics-based identification of TMED9 is linked to vascular invasion and poor prognoses in patients with hepatocellular carcinoma. <i>Journal of Biomedical Science</i> , 2021, 28, 29.	2.6	11
1278	Integrated profiling identifies ITGB3BP as prognostic biomarker for hepatocellular carcinoma. <i>Bosnian Journal of Basic Medical Sciences</i> , 2021, 21, 712-723.	0.6	2
1279	Does splenectomy significantly improve the prognosis of hepatocellular carcinoma patients with hypersplenism? A systematic review and meta-analysis. <i>Annals of Translational Medicine</i> , 2021, 9, 641-641.	0.7	3
1280	Robustness of radiomic features in CT images with different slice thickness, comparing liver tumour and muscle. <i>Scientific Reports</i> , 2021, 11, 8262.	1.6	28
1281	The good and the bad about separation anxiety: roles of IL-22 and IL-22BP in liver pathologies. <i>Seminars in Immunopathology</i> , 2021, 43, 591-607.	2.8	16
1282	Irreversible electroporation induces CD8+ T cell immune response against post-ablation hepatocellular carcinoma growth. <i>Cancer Letters</i> , 2021, 503, 1-10.	3.2	40
1283	Preoperative prediction of pathologic grade of HCC on gadobenate dimeglumine-enhanced dynamic MRI. <i>European Radiology</i> , 2021, 31, 7584-7593.	2.3	13
1284	Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study. <i>Hepatology International</i> , 2021, 15, 663-675.	1.9	96
1285	The deficiency of FKBP-5 inhibited hepatocellular progression by increasing the infiltration of distinct immune cells and inhibiting obesity-associated gut microbial metabolite. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 711-721.	0.6	4
1286	The cGAS-STING Pathway: Novel Perspectives in Liver Diseases. <i>Frontiers in Immunology</i> , 2021, 12, 682736.	2.2	26
1287	Attenuation of diethyl nitrosamine-induced hepatocellular carcinoma by taxifolin and/or alogliptin: The interplay between toll-like receptor 4, transforming growth factor beta-1, and apoptosis. <i>Human and Experimental Toxicology</i> , 2021, 40, 1710-1720.	1.1	5
1288	Comprehensive analyses of competing endogenous RNA networks reveal potential biomarkers for predicting hepatocellular carcinoma recurrence. <i>BMC Cancer</i> , 2021, 21, 436.	1.1	3
1289	Optimizing the management of intermediate-stage hepatocellular carcinoma: Current trends and prospects. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 236-245.	4.5	38
1290	Apatinib suppresses the migration, invasion and angiogenesis of hepatocellular carcinoma cells by blocking VEGF and PI3K/AKT signaling pathways. <i>Molecular Medicine Reports</i> , 2021, 23, .	1.1	16
1291	Vandetanib-eluting radiopaque beads for chemoembolization: physicochemical evaluation and biological activity of vandetanib in hypoxia. <i>Anti-Cancer Drugs</i> , 2021, 32, 897-908.	0.7	0



#	ARTICLE	IF	CITATIONS
1292	Stereotactic body radiotherapy in the management of hepatocellular carcinoma: An Australian multi-institutional patterns of practice review. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2021, 65, 365-373.	0.9	7
1293	SPECT Imaging of Hepatocellular Carcinoma Detection by the GPC3 Receptor. <i>Molecular Pharmaceutics</i> , 2021, 18, 2082-2090.	2.3	4
1294	A Comparison of Lenvatinib versus Sorafenib in the First-Line Treatment of Unresectable Hepatocellular Carcinoma: Selection Criteria to Guide Physician's Choice in a New Therapeutic Scenario. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 241-251.	1.8	12
1295	circ-PRKCI targets miR-1294 and miR-186-5p by downregulating FOXK1 expression to suppress glycolysis in hepatocellular carcinoma. <i>Molecular Medicine Reports</i> , 2021, 23, .	1.1	23
1296	Cerium Oxide Nanoparticles: A New Therapeutic Tool in Liver Diseases. <i>Antioxidants</i> , 2021, 10, 660.	2.2	41
1297	An FDG PET/CT metabolic parameter-based nomogram for predicting the early recurrence of hepatocellular carcinoma after liver transplantation. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3656-3665.	3.3	5
1298	LncRNA SNHG6 promotes G1/S-phase transition in hepatocellular carcinoma by impairing miR-204-5p-mediated inhibition of E2F1. <i>Oncogene</i> , 2021, 40, 3217-3230.	2.6	19
1299	Contrast-enhanced ultrasound (CEUS) in HCC diagnosis and assessment of tumor response to locoregional therapies. <i>Abdominal Radiology</i> , 2021, 46, 3579-3595.	1.0	28
1300	Abdominal ultrasound and alpha-fetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. <i>The Cochrane Library</i> , 2021, 2021, CD013346.	1.5	24
1301	microRNA-145-5p Inhibits Migration, Invasion, and Metastasis in Hepatocellular Carcinoma by Inhibiting ARF6. <i>Cancer Management and Research</i> , 2021, Volume 13, 3473-3484.	0.9	13
1302	Repeated transarterial chemoembolization with epirubicin-loaded superabsorbent polymer microspheres vs. conventional transarterial chemoembolization for hepatocellular carcinoma. <i>Molecular and Clinical Oncology</i> , 2021, 14, 119.	0.4	1
1303	MicroRNA-4325 Suppresses Cell Progression in Hepatocellular Carcinoma via GATA-Binding Protein 6. <i>BioMed Research International</i> , 2021, 2021, 1-9.	0.9	2
1304	Hepatobiliary contrast agents in MR: Where we stand and future perspectives. <i>Liver International</i> , 2021, 41, 888-890.	1.9	0
1305	Comparison of Surgical Resection and Systemic Treatment for Hepatocellular Carcinoma with Vascular Invasion: National Cancer Database Analysis. <i>Liver Cancer</i> , 2021, 10, 407-418.	4.2	17
1306	GTSE1 promotes SNAIL1 degradation by facilitating its nuclear export in hepatocellular carcinoma cells. <i>Molecular Medicine Reports</i> , 2021, 23, .	1.1	4
1307	The long noncoding RNA of RMRP is downregulated by PERK, which induces apoptosis in hepatocellular carcinoma cells. <i>Scientific Reports</i> , 2021, 11, 7926.	1.6	4
1308	Therapeutic Role of Bone Marrow-Derived Mesenchymal Stem Cells in Controlling Prognosis of Hepatocellular Carcinoma in a Murine Model. <i>Experimental and Clinical Transplantation</i> , 2021, , .	0.2	0
1309	The Impact of Sorafenib in Combination with Transarterial Chemoembolization on the Outcomes of Intermediate-Stage Hepatocellular Carcinoma. <i>Asian Pacific Journal of Cancer Prevention</i> , 2021, 22, 1217-1224.	0.5	8

#	ARTICLE	IF	CITATIONS
1310	Downstaging treatment for patients with hepatocellular carcinoma before transplantation. <i>Transplantation Reviews</i> , 2021, 35, 100606.	1.2	6
1311	Measuring fucosylated alpha-fetoprotein in hepatocellular carcinoma: A comparison of $\hat{1}/4$ TAS and parallel reaction monitoring. <i>Proteomics - Clinical Applications</i> , 2021, 15, 2000096.	0.8	2
1312	Value of perfusion parameters and histogram analysis of triphasic computed tomography in pre-operative prediction of histological grade of hepatocellular carcinoma. <i>Chinese Medical Journal</i> , 2021, 134, 1181-1190.	0.9	4
1313	NET1 promotes HCC growth and metastasis in vitro and in vivo via activating the Akt signaling pathway. <i>Aging</i> , 2021, 13, 10672-10687.	1.4	5
1314	Incidence and risk factors for sustained hepatic function toxicity 6 months after radioembolization: analysis of the radiation-emitting sir-spheres in non-resectable liver tumor (RESIN) registry. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 639-657.	0.6	6
1315	KDM5B promotes self-renewal of hepatocellular carcinoma cells through the microRNA-448-mediated YTHDF3/ITGA6 axis. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 5949-5962.	1.6	21
1316	DPP9: Comprehensive In Silico Analyses of Loss of Function Gene Variants and Associated Gene Expression Signatures in Human Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 1637.	1.7	9
1317	Micronvasive behaviour of single small hepatocellular carcinoma: which treatment?. <i>Updates in Surgery</i> , 2021, 73, 1359-1369.	0.9	9
1318	Actual long-term survival in hepatocellular carcinoma patients with microvascular invasion: a multicenter study from China. <i>Hepatology International</i> , 2021, 15, 642-650.	1.9	24
1319	Exploratory Study Using Urinary Volatile Organic Compounds for the Detection of Hepatocellular Carcinoma. <i>Molecules</i> , 2021, 26, 2447.	1.7	26
1320	pH-Responsive Pluronic F127-Lenvatinib-Encapsulated Halogenated Boron-Dipyrromethene Nanoparticles for Combined Photodynamic Therapy and Chemotherapy of Liver Cancer. <i>ACS Omega</i> , 2021, 6, 12331-12342.	1.6	23
1321	Current status of ctDNA in precision oncology for hepatocellular carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 140.	3.5	15
1322	Tumor suppressive role of mitochondrial sirtuin 4 in induction of G2/M cell cycle arrest and apoptosis in hepatitis B virus-related hepatocellular carcinoma. <i>Cell Death Discovery</i> , 2021, 7, 88.	2.0	15
1323	Sequential transarterial chemoembolization and early radiofrequency ablation improves clinical outcomes for early-intermediate hepatocellular carcinoma in a 10-year single-center comparative study. <i>BMC Gastroenterology</i> , 2021, 21, 182.	0.8	10
1324	Serum Levels of ITGBL1 as an Early Diagnostic Biomarker for Hepatocellular Carcinoma with Hepatitis B Virus Infection. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 285-300.	1.8	3
1325	Percutaneous Microwave Ablation of Liver Lesions: Differences on the Sphericity Index of the Ablation Zone between Cirrhotic and Healthy Liver Parenchyma. <i>Diagnostics</i> , 2021, 11, 655.	1.3	3
1326	Current status of radical laparoscopy for treating hepatocellular carcinoma with portal hypertension. <i>World Journal of Clinical Cases</i> , 2021, 9, 2419-2432.	0.3	6
1327	Transcatheter arterial chemoembolization of hepatocellular carcinoma on liver cirrhosis in patients awaiting liver transplantation. <i>Vestnik Khirurgii Imeni I I Grekova</i> , 2021, 179, 18-23.	0.0	0

#	ARTICLE	IF	CITATIONS
1328	Identification of Mitochondrial-Related Prognostic Biomarkers Associated With Primary Bile Acid Biosynthesis and Tumor Microenvironment of Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 587479.	1.3	21
1329	The diagnostic and prognostic value of H2AFY in hepatocellular carcinoma. <i>BMC Cancer</i> , 2021, 21, 418.	1.1	13
1330	Immunological significance of prognostic alternative splicing signature in hepatocellular carcinoma. <i>Cancer Cell International</i> , 2021, 21, 190.	1.8	15
1331	Prognostic factors of nivolumab in advanced hepatocellular carcinoma: a systematic review and meta-analysis. <i>Panminerva Medica</i> , 2021, , .	0.2	2
1332	Surgical Resection vs. Percutaneous Ablation for Single Hepatocellular Carcinoma: Exploring the Impact of Li-RADS Classification on Oncological Outcomes. <i>Cancers</i> , 2021, 13, 1671.	1.7	18
1333	Irreversible electroporation versus radiofrequency ablation for hepatocellular carcinoma: a single centre propensity-matched comparison. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 942-947.	0.6	9
1334	Cell-Free DNA Analysis by Whole-Exome Sequencing for Hepatocellular Carcinoma: A Pilot Study in Thailand. <i>Cancers</i> , 2021, 13, 2229.	1.7	13
1335	LncRNA-CCDC144NL-AS1 Promotes the Development of Hepatocellular Carcinoma by Inducing WDR5 Expression via Sponging miR-940. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 333-348.	1.8	15
1336	Co-administration of combretastatin A4 nanoparticles and anti-PD-L1 for synergistic therapy of hepatocellular carcinoma. <i>Journal of Nanobiotechnology</i> , 2021, 19, 124.	4.2	12
1337	An excellent nomogram predicts microvascular invasion that cannot independently stratify outcomes of small hepatocellular carcinoma. <i>Annals of Translational Medicine</i> , 2021, 9, 757-757.	0.7	4
1338	eIF4E-eIF4G complex inhibition synergistically enhances the effect of sorafenib in hepatocellular carcinoma. <i>Anti-Cancer Drugs</i> , 2021, 32, 822-828.	0.7	7
1339	CD74+ macrophages are associated with favorable prognosis and immune contexture in hepatocellular carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 57-69.	2.0	15
1340	A Systematic Review and Narrative Synthesis of Health Economic Evaluations of Hepatocellular Carcinoma Screening Strategies. <i>Value in Health</i> , 2021, 24, 733-743.	0.1	6
1341	LncRNA ILF3-AS1 promotes cell migration, invasion and EMT process in hepatocellular carcinoma via the miR-628â€“5p/MEIS2 axis to activate the Notch pathway. <i>Digestive and Liver Disease</i> , 2022, 54, 125-135.	0.4	8
1342	Centromere protein N may be a novel malignant prognostic biomarker for hepatocellular carcinoma. <i>PeerJ</i> , 2021, 9, e11342.	0.9	7
1343	Combined hepatocellular-cholangiocarcinoma: An update. <i>Journal of Hepatology</i> , 2021, 74, 1212-1224.	1.8	94
1345	Multigene Panel Testing in Individuals With Hepatocellular Carcinoma Identifies Pathogenic Germline Variants. <i>JCO Precision Oncology</i> , 2021, 5, 988-1000.	1.5	10
1346	Skeletal Muscle Volume Is an Independent Predictor of Survival after Sorafenib Treatment Failure for Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 2247.	1.7	8

#	ARTICLE	IF	CITATIONS
1347	Treatment of liver cancer cells with ethyl acetate extract of <i>Crithmum maritimum</i> permits reducing sorafenib dose and toxicity maintaining its efficacy. <i>Journal of Pharmacy and Pharmacology</i> , 2021, 73, 1369-1376.	1.2	16
1348	TNF $\alpha$ /NF $\kappa$ B signaling epigenetically represses PSD4 transcription to promote alcohol-related hepatocellular carcinoma progression. <i>Cancer Medicine</i> , 2021, 10, 3346-3357.	1.3	5
1349	NEAT1/hsa-miR-372 <sup>3p</sup> axis participates in rapamycin-induced lipid metabolic disorder. <i>Free Radical Biology and Medicine</i> , 2021, 167, 1-11.	1.3	7
1350	Multicomponent thermosensitive lipid complexes enhance desmoplastic tumor therapy through boosting anti-angiogenesis and synergistic strategy. <i>International Journal of Pharmaceutics</i> , 2021, 601, 120533.	2.6	10
1351	Autophagy-Related Gene Pairs Signature for the Prognosis of Hepatocellular Carcinoma. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 670241.	1.6	5
1352	Antitumor Effects of Triterpenes in Hepatocellular Carcinoma. <i>Current Medicinal Chemistry</i> , 2021, 28, 2465-2484.	1.2	7
1353	Change in the Recurrence Pattern and Predictors over Time after Complete Cure of Hepatocellular Carcinoma. <i>Gut and Liver</i> , 2021, 15, 420-429.	1.4	11
1354	Functions of CXC chemokines as biomarkers and potential therapeutic targets in the hepatocellular carcinoma microenvironment. <i>Translational Cancer Research</i> , 2021, 10, 2169-2187.	0.4	9
1355	A comparative study of portal vein embolization versus radiation lobectomy with Yttrium-90 micropheres in preparation for liver resection for initially unresectable hepatocellular carcinoma. <i>Surgery</i> , 2021, 169, 1044-1051.	1.0	18
1356	Artificial intelligence assists identifying malignant <i>versus</i> benign liver lesions using contrast-enhanced ultrasound. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2875-2883.	1.4	30
1357	Impact of COVID-19 Pandemic on Intervals and Outcomes of Repeated Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 602700.	1.3	6
1358	Hepatocellular carcinoma progression in hepatitis B virus-related cirrhosis patients receiving nucleoside (acid) analogs therapy: A retrospective cross-sectional study. <i>World Journal of Gastroenterology</i> , 2021, 27, 2025-2038.	1.4	3
1359	Prediction models for development of hepatocellular carcinoma in chronic hepatitis B patients. <i>World Journal of Clinical Cases</i> , 2021, 9, 3238-3251.	0.3	4
1360	Salivary metabolites are promising non-invasive biomarkers of hepatocellular carcinoma and chronic liver disease. <i>Liver Cancer International</i> , 2021, 2, 33-44.	0.2	14
1361	STMN2 mediates nuclear translocation of Smad2/3 and enhances TGF $\beta$ 2 signaling by destabilizing microtubules to promote epithelial-mesenchymal transition in hepatocellular carcinoma. <i>Cancer Letters</i> , 2021, 506, 128-141.	3.2	11
1362	Serum levels of soluble programmed death-ligand 1 (sPD-L1): A possible biomarker in predicting post-treatment outcomes in patients with early hepatocellular carcinoma. <i>International Immunopharmacology</i> , 2021, 94, 107467.	1.7	18
1363	A novel five-gene signature predicts overall survival of patients with hepatocellular carcinoma. <i>Cancer Medicine</i> , 2021, 10, 3808-3821.	1.3	26
1364	Lenvatinib Plus Camrelizumab versus Lenvatinib Monotherapy as Post-Progression Treatment for Advanced Hepatocellular Carcinoma: A Short-Term Prognostic Study. <i>Cancer Management and Research</i> , 2021, Volume 13, 4233-4240.	0.9	17

#	ARTICLE	IF	CITATIONS
1365	Resubclassification and clinical management for Barcelona Clinic Liver Cancer Stage C hepatocellular carcinoma. <i>Hepatology International</i> , 2021, 15, 946-956.	1.9	8
1366	LncRNA XIST promotes liver cancer progression by acting as a molecular sponge of miR-200b-3p to regulate ZEB1/2 expression. <i>Journal of International Medical Research</i> , 2021, 49, 030006052110162.	0.4	13
1367	Identification of BHLHE40 expression in peripheral blood mononuclear cells as a novel biomarker for diagnosis and prognosis of hepatocellular carcinoma. <i>Scientific Reports</i> , 2021, 11, 11201.	1.6	4
1368	Nomogram Based on Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio to Predict Recurrence in Patients with Hepatocellular Carcinoma after Radiofrequency Ablation. <i>CardioVascular and Interventional Radiology</i> , 2021, 44, 1551-1560.	0.9	13
1369	Immune-related adverse events predict responses to PD-1 blockade immunotherapy in hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2021, 149, 959-966.	2.3	15
1370	Hepatocellular Carcinoma: An Overview of the Changing Landscape of Treatment Options. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 387-401.	1.8	62
1371	NEIL3 Prevents Senescence in Hepatocellular Carcinoma by Repairing Oxidative Lesions at Telomeres during Mitosis. <i>Cancer Research</i> , 2021, 81, 4079-4093.	0.4	19
1372	Exosomal microRNAs as Biomarkers and Therapeutic Targets for Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4997.	1.8	33
1373	Random Survival Forests to Predict Disease Control for Hepatocellular Carcinoma Treated With Transarterial Chemoembolization Combined With Sorafenib. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 618050.	1.6	6
1374	Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Predictors of Outcomes in Patients With Unresectable Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Plus Sorafenib. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 624366.	1.6	8
1375	Predictors and patterns of recurrence after radiofrequency ablation for hepatocellular carcinoma within up-to-seven criteria: A multicenter retrospective study. <i>European Journal of Radiology</i> , 2021, 138, 109623.	1.2	16
1376	A prognostic model based on seven immune-related genes predicts the overall survival of patients with hepatocellular carcinoma. <i>BioData Mining</i> , 2021, 14, 29.	2.2	7
1377	miR-93 regulates liver tumor initiating cells expansion and predicts chemotherapeutic response of patients. <i>Archives of Biochemistry and Biophysics</i> , 2021, 703, 108871.	1.4	6
1378	Prediction of Microvascular Invasion in Hepatocellular Carcinoma via Deep Learning: A Multi-Center and Prospective Validation Study. <i>Cancers</i> , 2021, 13, 2368.	1.7	36
1379	Current Strategies to Identify Patients That Will Benefit from TACE Treatment and Future Directions a Practical Step-by-Step Guide. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 403-419.	1.8	25
1380	The therapeutic landscape of hepatocellular carcinoma. <i>Med</i> , 2021, 2, 505-552.	2.2	20
1381	Multi-Institutional Development and External Validation of a Nomogram for Prediction of Extrahepatic Recurrence After Curative-Intent Resection for Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 7624-7633.	0.7	4
1382	Anti-miR-518d-5p overcomes liver tumor cell death resistance through mitochondrial activity. <i>Cell Death and Disease</i> , 2021, 12, 555.	2.7	10

#	ARTICLE	IF	CITATIONS
1383	Comprehensive analysis of the competing endogenous circRNA-lncRNA-miRNA-mRNA network and identification of a novel potential biomarker for hepatocellular carcinoma. <i>Aging</i> , 2021, 13, 15990-16008.	1.4	34
1384	The impact of portal vein tumor thrombosis on survival in patients with hepatocellular carcinoma treated with different therapies: A cohort study. <i>PLoS ONE</i> , 2021, 16, e0249426.	1.1	11
1385	Magnetic resonance imaging for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. <i>The Cochrane Library</i> , 0, .	1.5	2
1386	PNO1 regulates autophagy and apoptosis of hepatocellular carcinoma via the MAPK signaling pathway. <i>Cell Death and Disease</i> , 2021, 12, 552.	2.7	28
1387	Anticancer Effects of Tacrolimus on Induced Hepatocellular Carcinoma in Mice. <i>Current Molecular Pharmacology</i> , 2021, 14, .	0.7	0
1388	Uni-, Bi- or Trifocal Hepatocellular Carcinoma in Western Patients: Recurrence and Survival after Percutaneous Thermal Ablation. <i>Cancers</i> , 2021, 13, 2700.	1.7	6
1389	Therapeutic efficacy of lenvatinib as third-line treatment after regorafenib for unresectable hepatocellular carcinoma progression. <i>Hepatology Research</i> , 2021, 51, 880-889.	1.8	15
1390	Probabilistic ratiocination of hepatocellular carcinoma after resection: evaluation of expected to be promising approaches. <i>Annals of Translational Medicine</i> , 2021, 9, 778-778.	0.7	0
1391	The Association between Prognostic Nutritional Index (PNI) and Intraoperative Transfusion in Patients Undergoing Hepatectomy for Hepatocellular Carcinoma: A Retrospective Cohort Study. <i>Cancers</i> , 2021, 13, 2508.	1.7	11
1392	Quantitative dual-energy CT for evaluating hepatocellular carcinoma after transarterial chemoembolization. <i>Scientific Reports</i> , 2021, 11, 11127.	1.6	11
1393	Immunological Significance of Prognostic DNA Methylation Sites in Hepatocellular Carcinoma. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 683240.	1.6	14
1394	Advances in systemic therapy for the first-line treatment of unresectable HCC. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 621-628.	1.1	11
1395	Antiviral therapy in the palliative setting of HCC (BCLC-B and -C). <i>Journal of Hepatology</i> , 2021, 74, 1225-1233.	1.8	42
1396	The Role of the Microbiome in Liver Cancer. <i>Cancers</i> , 2021, 13, 2330.	1.7	16
1397	Comparison of liver exposure in CT-guided high-dose rate (HDR) interstitial brachytherapy versus SBRT in hepatocellular carcinoma. <i>Radiation Oncology</i> , 2021, 16, 86.	1.2	11
1398	Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. <i>Medicina Clínica (English Edition)</i> , 2021, 156, 463.e1-463.e30.	0.1	16
1399	Structure-Based and Rational Design of a Hepatitis C Virus Vaccine. <i>Viruses</i> , 2021, 13, 837.	1.5	7
1400	Clinical significance of LARGE1 in progression of liver cancer and the underlying mechanism. <i>Gene</i> , 2021, 779, 145493.	1.0	2

#	ARTICLE	IF	CITATIONS
1401	Loss of PGRMC1 Delays the Progression of Hepatocellular Carcinoma via Suppression of Pro-Inflammatory Immune Responses. <i>Cancers</i> , 2021, 13, 2438.	1.7	11
1402	Liver resection for hepatocellular carcinoma larger than 10 cm: A multi-institution long-term observational study. <i>World Journal of Gastrointestinal Surgery</i> , 2021, 13, 476-492.	0.8	8
1403	Selection of first-line systemic therapies for advanced hepatocellular carcinoma: A network meta-analysis of randomized controlled trials. <i>World Journal of Gastroenterology</i> , 2021, 27, 2415-2433.	1.4	16
1404	Tamoxifen for hepatocellular carcinoma. <i>The Cochrane Library</i> , 0, , .	1.5	0
1405	Correlation Between Contrast-enhanced Ultrasound and Immune Response of Distant Hepatocellular Carcinoma After Radiofrequency Ablation in a Murine Model. <i>Journal of Ultrasound in Medicine</i> , 2022, 41, 713-723.	0.8	4
1406	The novel immune-related genes predict the prognosis of patients with hepatocellular carcinoma. <i>Scientific Reports</i> , 2021, 11, 10728.	1.6	3
1407	Successful management of the hepatocellular carcinoma with inferior vena cava tumor thrombus. <i>Medicine (United States)</i> , 2021, 100, e26081.	0.4	0
1408	Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update. <i>Liver Cancer</i> , 2021, 10, 181-223.	4.2	307
1409	The role of a ceRNA regulatory network based on lncRNA MALAT1 site in cancer progression. <i>Biomedicine and Pharmacotherapy</i> , 2021, 137, 111389.	2.5	61
1410	The two facets of gp130 signalling in liver tumorigenesis. <i>Seminars in Immunopathology</i> , 2021, 43, 609-624.	2.8	7
1411	Phase I Trial on Arterial Embolization with Hypoxia Activated Tirapazamine for Unresectable Hepatocellular Carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 421-434.	1.8	15
1412	Building consensus on definition and nomenclature of hepatic, pancreatic, and biliary organoids. <i>Cell Stem Cell</i> , 2021, 28, 816-832.	5.2	133
1413	Epigenetic reprogramming promotes the antiviral action of IFN $\beta$ in HBV-infected cells. <i>Cell Death Discovery</i> , 2021, 7, 130.	2.0	2
1414	Immunonutritive Scoring in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Prognostic Nutritional Index or Controlling Nutritional Status Score?. <i>Frontiers in Oncology</i> , 2021, 11, 696183.	1.3	17
1415	Hypoxia-induced RNASEH2A limits activation of cGAS-STING signaling in HCC and predicts poor prognosis. <i>Tumori</i> , 2022, 108, 63-76.	0.6	3
1416	Bioengineered Liver Models for Investigating Disease Pathogenesis and Regenerative Medicine. <i>Seminars in Liver Disease</i> , 2021, 41, 368-392.	1.8	2
1417	The expression of microRNA-331-3p and microRNA-23b3 in Egyptian patients with early-stage hepatocellular carcinoma in hepatitis C-related liver cirrhosis. <i>Egyptian Liver Journal</i> , 2021, 11, .	0.3	0
1418	Downregulation of snoRNA SNORA52 and Its Clinical Significance in Hepatocellular Carcinoma. <i>BioMed Research International</i> , 2021, 2021, 1-7.	0.9	11

#	ARTICLE	IF	CITATIONS
1419	Significance of liver resection for intermediate stage hepatocellular carcinoma according to subclassification. <i>BMC Cancer</i> , 2021, 21, 668.	1.1	6
1420	Expression and Diagnostic Value of miR-497 and miR-1246 in Hepatocellular Carcinoma. <i>Frontiers in Genetics</i> , 2021, 12, 666306.	1.1	15
1421	Systemic Treatment for Older Patients with Unresectable Hepatocellular Carcinoma. <i>Drugs and Aging</i> , 2021, 38, 579-591.	1.3	5
1422	Natural killer cell activity is a risk factor for the recurrence risk after curative treatment of hepatocellular carcinoma. <i>BMC Gastroenterology</i> , 2021, 21, 258.	0.8	14
1423	Knockdown of MUC16 (CA125) Enhances the Migration and Invasion of Hepatocellular Carcinoma Cells. <i>Frontiers in Oncology</i> , 2021, 11, 667669.	1.3	6
1424	A Simple Prognostic Scoring System for Hepatocellular Carcinoma Treated with Selective Internal Radiation Therapy. <i>Digestive Diseases</i> , 2022, 40, 322-334.	0.8	3
1425	Correlation analysis of tumor mutation burden of hepatocellular carcinoma based on data mining. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 1117-1131.	0.6	7
1426	Discovery of an Orally Efficacious MYC Inhibitor for Liver Cancer Using a GNMT-Based High-Throughput Screening System and Structure-Activity Relationship Analysis. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 8992-9009.	2.9	5
1427	Peritumoral Dilation Radiomics of Gadoxetate Disodium-Enhanced MRI Excellently Predicts Early Recurrence of Hepatocellular Carcinoma without Macrovascular Invasion After Hepatectomy. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 545-563.	1.8	26
1428	H-ferritin suppression and pronounced mitochondrial respiration make Hepatocellular Carcinoma cells sensitive to RSL3-induced ferroptosis. <i>Free Radical Biology and Medicine</i> , 2021, 169, 294-303.	1.3	34
1429	High HBV Load Weakens Predictive Effect of Serum miR-122 on Response to Sorafenib in Hepatocellular Carcinoma Patients. <i>Journal of Oncology</i> , 2021, 2021, 1-8.	0.6	2
1430	CASK Silence Overcomes Sorafenib Resistance of Hepatocellular Carcinoma Through Activating Apoptosis and Autophagic Cell Death. <i>Frontiers in Oncology</i> , 2021, 11, 681683.	1.3	7
1431	Impact of Postoperative Complications on Long-Term Survival After Resection of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. <i>Annals of Surgical Oncology</i> , 2021, 28, 8221-8233.	0.7	18
1432	Prognostic Value of the Preoperative Lymphocyte-C-Reactive Protein Ratio in Hepatocellular Carcinoma Patients Treated with Curative Intent: A Large-Scale Multicentre Study. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 2483-2495.	1.6	9
1433	Quantitative Ultrasound Elastography Methods in Focal Liver Lesions Including Hepatocellular Carcinoma. <i>Ultrasound Quarterly</i> , 2021, 37, 90-96.	0.3	1
1434	LGR5/R-Spo1/Wnt3a axis promotes stemness and aggressive phenotype in hepatoblast-like hepatocellular carcinoma cell lines. <i>Cellular Signalling</i> , 2021, 82, 109972.	1.7	7
1435	Periodic mesoporous organosilica-coated magnetite nanoparticles combined with lipiodol for transcatheter arterial chemoembolization to inhibit the progression of liver cancer. <i>Journal of Colloid and Interface Science</i> , 2021, 591, 211-220.	5.0	15
1436	The multidisciplinary management of hepatocellular carcinoma with portal vein tumor thrombus. <i>BioScience Trends</i> , 2021, 15, 148-154.	1.1	14



#	ARTICLE	IF	CITATIONS
1437	IRF2 regulates cellular survival and Lenvatinib-sensitivity of hepatocellular carcinoma (HCC) through regulating $\beta$ -catenin. <i>Translational Oncology</i> , 2021, 14, 101059.	1.7	26
1438	The effects of stereotactic body radiotherapy on peripheral natural killer and CD3+CD56+ NKT-like cells in patients with hepatocellular carcinoma. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2021, 20, 240-250.	0.6	11
1439	The Phenomenon of Gene Rearrangement is Frequently Associated with TP53 Mutations and Poor Disease-Free Survival in Hepatocellular Carcinoma. <i>Pharmacogenomics and Personalized Medicine</i> , 2021, Volume 14, 723-736.	0.4	2
1440	Urine miR-93-5p is a promising biomarker for early detection of HBV-related hepatocellular carcinoma. <i>European Journal of Surgical Oncology</i> , 2022, 48, 95-102.	0.5	8
1441	Targeting Long Non-Coding RNAs in Hepatocellular Carcinoma: Progress and Prospects. <i>Frontiers in Oncology</i> , 2021, 11, 670838.	1.3	6
1442	MicroRNA-1178-3p suppresses the growth of hepatocellular carcinoma by regulating transducin (beta)-like 1 X-linked receptor 1. <i>Human Cell</i> , 2021, 34, 1466-1477.	1.2	7
1443	Analysis of Medical Use and Treatment Costs of Hepatocellular Carcinoma Patients Using National Patient Sample Data. <i>Korean Journal of Clinical Pharmacy</i> , 2021, 31, 153-159.	0.0	0
1444	A genetic variant in toll-like receptor 5 is linked to chemokine levels and hepatocellular carcinoma in steatohepatitis. <i>Liver International</i> , 2021, 41, 2139-2148.	1.9	6
1445	An Integrative Transcriptomic and Methylation Approach for Identifying Differentially Expressed Circular RNAs Associated with DNA Methylation Change. <i>Biomedicines</i> , 2021, 9, 657.	1.4	6
1446	Ataxia telangiectasia mutated inhibitor-loaded copper sulfide nanoparticles for low-temperature photothermal therapy of hepatocellular carcinoma. <i>Acta Biomaterialia</i> , 2021, 127, 276-286.	4.1	37
1447	Phenotypic Characterization by Single-Cell Mass Cytometry of Human Intrahepatic and Peripheral NK Cells in Patients with Hepatocellular Carcinoma. <i>Cells</i> , 2021, 10, 1495.	1.8	7
1448	Easy albumin-bilirubin score as a new prognostic predictor in hepatocellular carcinoma. <i>Hepatology Research</i> , 2021, 51, 1129-1138.	1.8	17
1449	Limited tumour progression beyond Milan criteria while on the waiting list does not result in unacceptable impairment of survival. <i>Journal of Hepatology</i> , 2021, 75, 1154-1163.	1.8	9
1450	Interference with circRNA DOCK1 inhibits hepatocellular carcinoma cell proliferation, invasion and migration by regulating the miR-654-5p/SMAD2 axis. <i>Molecular Medicine Reports</i> , 2021, 24, .	1.1	4
1451	Surgical treatment of hepatocellular carcinoma. <i>BioScience Trends</i> , 2021, 15, 138-141.	1.1	63
1452	Atezolizumab and bevacizumab-induced encephalitis in advanced hepatocellular carcinoma. <i>Medicine (United States)</i> , 2021, 100, e26377.	0.4	10
1453	Urolithins: The Gut Based Polyphenol Metabolites of Ellagitannins in Cancer Prevention, a Review. <i>Frontiers in Nutrition</i> , 2021, 8, 647582.	1.6	57
1454	I125 irradiation stent for treatment of hepatocellular carcinoma with portal vein thrombosis: A meta-analysis. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2021, 25, 340-349.	0.6	11

#	ARTICLE	IF	CITATIONS
1455	Effect of Hepatocellular Carcinoma Surveillance Programmes on Overall Survival in a Mixed Cirrhotic UK Population: A Prospective, Longitudinal Cohort Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 2770.	1.0	8
1456	Exosomes in hepatocellular carcinoma microenvironment and their potential clinical application value. <i>Biomedicine and Pharmacotherapy</i> , 2021, 138, 111529.	2.5	16
1457	Efficacy of combined transarterial radioembolization and sorafenib in the treatment of hepatocarcinoma: A meta-analysis. <i>Digestive and Liver Disease</i> , 2022, 54, 316-323.	0.4	4
1458	Clinical Utility of Protein Induced by Vitamin K Absence-II in Patients with Hepatocellular Carcinoma. <i>Asian Pacific Journal of Cancer Prevention</i> , 2021, 22, 1731-1736.	0.5	1
1459	Isolated cancer stem cells from human liver cancer: morphological and functional characteristics in primary culture. <i>Clinical and Translational Oncology</i> , 2021, , 1.	1.2	1
1460	A Fully Automated and Integrated Microfluidic System for Efficient CTC Detection and Its Application in Hepatocellular Carcinoma Screening and Prognosis. <i>ACS Applied Materials &amp; Interfaces</i> , 2021, 13, 30174-30186.	4.0	20
1461	Atezolizumab and Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Pharmacokinetic and Safety Assessments Based on Hepatic Impairment Status and Geographic Region. <i>Liver Cancer</i> , 2021, 10, 485-499.	4.2	8
1462	Liver transplantation: would it be the best and last chance of cure for hepatocellular carcinoma with major venous invasion?. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 10, 308-314.	0.7	9
1463	Multimodal treatment involving molecular targeted agents and onâ€demand transcatheter arterial chemoembolization for advanced hepatocellular carcinoma: A case report. <i>Molecular and Clinical Oncology</i> , 2021, 15, 154.	0.4	3
1464	International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2021, 160, 2572-2584.	0.6	91
1465	Blocking siglec-10hi tumor-associated macrophages improves anti-tumor immunity and enhances immunotherapy for hepatocellular carcinoma. <i>Experimental Hematology and Oncology</i> , 2021, 10, 36.	2.0	36
1466	miR-760 mediated the proliferation and metastasis of hepatocellular carcinoma cells by regulating HMGA2. <i>Pathology Research and Practice</i> , 2021, 222, 153420.	1.0	1
1467	EVA1A Plays an Important Role by Regulating Autophagy in Physiological and Pathological Processes. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6181.	1.8	8
1468	Serum level of cytokeratin 19 as a diagnostic and prognostic marker in patients with HCV-related hepatocellular carcinoma. <i>Egyptian Liver Journal</i> , 2021, 11, .	0.3	2
1469	The therapeutic effect of IL-21 combined with IFN- $\gamma$ inducing CD4+CXCR5+CD57+T cells differentiation on hepatocellular carcinoma. <i>Journal of Advanced Research</i> , 2021, 36, 89-99.	4.4	3
1470	ATE1 Inhibits Liver Cancer Progression through RGS5-Mediated Suppression of Wnt/ $\beta$ -Catenin Signaling. <i>Molecular Cancer Research</i> , 2021, 19, 1441-1453.	1.5	10
1471	Inclusive Quantification Assay of Serum Desâ€Carboxyprothrombin Proteoforms for Hepatocellular Carcinoma Surveillance by Targeted Mass Spectrometry. <i>Hepatology Communications</i> , 2021, 5, 1767-1783.	2.0	4
1472	Berberine Sensitizes Human Hepatoma Cells to Regorafenib via Modulating Expression of Circular RNAs. <i>Frontiers in Pharmacology</i> , 2021, 12, 632201.	1.6	4

#	ARTICLE	IF	CITATIONS
1473	Multi-functionalized dendrimers for targeted co-delivery of sorafenib and paclitaxel in liver cancers. <i>Journal of Drug Delivery Science and Technology</i> , 2021, 63, 102493.	1.4	13
1474	Pristimerin synergistically sensitizes conditionally reprogrammed patient derived-primary hepatocellular carcinoma cells to sorafenib through endoplasmic reticulum stress and ROS generation by modulating Akt/FoxO1/p27kip1 signaling pathway. <i>Phytomedicine</i> , 2021, 86, 153563.	2.3	14
1475	Homogeneous Visual and Fluorescence Detection of Circulating Tumor Cells in Clinical Samples via Selective Recognition Reaction and Enzyme-Free Amplification. <i>ACS Nano</i> , 2021, 15, 11634-11643.	7.3	81
1476	CT texture analysis of abdominal lesions – Part I.: Liver lesions. <i>Imaging</i> , 2021, 13, 13-24.	0.3	1
1477	High SGO2 Expression Predicts Poor Overall Survival: A Potential Therapeutic Target for Hepatocellular Carcinoma. <i>Genes</i> , 2021, 12, 876.	1.0	2
1478	USP1-dependent RPS16 protein stability drives growth and metastasis of human hepatocellular carcinoma cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 201.	3.5	27
1479	Cancer incidence and mortality trends in France over 1990–2018 for solid tumors: the sex gap is narrowing. <i>BMC Cancer</i> , 2021, 21, 726.	1.1	38
1480	CDCA2 protects against oxidative stress by promoting BRCA1–NRF2 signaling in hepatocellular carcinoma. <i>Oncogene</i> , 2021, 40, 4368-4383.	2.6	12
1481	STARD1 promotes NASH-driven HCC by sustaining the generation of bile acids through the alternative mitochondrial pathway. <i>Journal of Hepatology</i> , 2021, 74, 1429-1441.	1.8	34
1482	Intratumoral Administration of Thermosensitive Hydrogel Co-Loaded with Norcantharidin Nanoparticles and Doxorubicin for the Treatment of Hepatocellular Carcinoma. <i>International Journal of Nanomedicine</i> , 2021, Volume 16, 4073-4085.	3.3	39
1483	PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 4350-4368.	3.3	62
1484	<sup>68</sup> Ga-FAPI-04 Versus <sup>18</sup> F-FDG PET/CT in the Detection of Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 693640.	1.3	55
1485	AFP and eGFR are related to early and late recurrence of HCC following antiviral therapy. <i>BMC Cancer</i> , 2021, 21, 699.	1.1	10
1486	m6A RNA Methylation Regulators Elicit Malignant Progression and Predict Clinical Outcome in Hepatocellular Carcinoma. <i>Disease Markers</i> , 2021, 2021, 1-12.	0.6	4
1487	Complete response of a hepatocellular carcinoma with complex macrovascular invasion after combined treatment with chemoembolization and immunotherapy: a case report. <i>Acta Gastro-Enterologica Belgica</i> , 2021, 84, 371-374.	0.4	2
1488	Prospects and Challenges for T Cell-Based Therapies of HCC. <i>Cells</i> , 2021, 10, 1651.	1.8	13
1489	Identification of genes predicting unfavorable prognosis in hepatitis B virus-associated hepatocellular carcinoma. <i>Annals of Translational Medicine</i> , 2021, 9, 975-975.	0.7	5
1490	Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma?. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 371-378.	1.9	65

#	ARTICLE	IF	CITATIONS
1491	Identifying the biomarkers and pathways associated with hepatocellular carcinoma based on an integrated analysis approach. <i>Liver International</i> , 2021, 41, 2485-2498.	1.9	2
1492	Hepatocellular carcinoma in viral and autoimmune liver diseases: Role of CD4+ CD25+ Foxp3+ regulatory T cells in the immune microenvironment. <i>World Journal of Gastroenterology</i> , 2021, 27, 2994-3009.	1.4	103
1493	DNA methylation biomarkers for diagnosis of primary liver cancer and distinguishing hepatocellular carcinoma from intrahepatic cholangiocarcinoma. <i>Aging</i> , 2021, 13, 17592-17606.	1.4	8
1494	Identification of SRGAP2 as a potential oncogene and a prognostic biomarker in hepatocellular carcinoma. <i>Life Sciences</i> , 2021, 277, 119592.	2.0	9
1495	MELD-Sarcopenia is Better than ALBI and MELD Score in Patients with Hepatocellular Carcinoma Awaiting Liver Transplantation. <i>Asian Pacific Journal of Cancer Prevention</i> , 2021, 22, 2005-2009.	0.5	9
1496	Hepatocellular carcinoma in patients with renal dysfunction: Pathophysiology, prognosis, and treatment challenges. <i>World Journal of Gastroenterology</i> , 2021, 27, 4104-4142.	1.4	15
1497	No-Touch Radio Frequency Ablation for a Subcapsular Hepatocellular Carcinoma: A Case Report and Review of Literature. <i>Journal of Clinical Interventional Radiology ISVIR</i> , 0, , .	0.0	0
1498	Advanced Deep Learning Approach to Automatically Segment Malignant Tumors and Ablation Zone in the Liver With Contrast-Enhanced CT. <i>Frontiers in Oncology</i> , 2021, 11, 669437.	1.3	10
1499	Successful multimodality treatment for advanced hepatocellular carcinoma with tumor thrombosis of the main portal trunk: a case study. <i>Clinical Journal of Gastroenterology</i> , 2021, 14, 1517-1524.	0.4	0
1500	Novel small molecular inhibitor of Pit-Oct-Unc transcription factor 1 suppresses hepatocellular carcinoma cell proliferation. <i>Life Sciences</i> , 2021, 277, 119521.	2.0	15
1501	Preoperative CT for Characterization of Aggressive Macrotrabecular-Massive Subtype and Vessels That Encapsulate Tumor Clusters Pattern in Hepatocellular Carcinoma. <i>Radiology</i> , 2021, 300, 219-229.	3.6	53
1502	Impact of chemotherapy on prognosis of resectable pathological T3N0M0 esophageal cancer patients: a population-based study. <i>Future Oncology</i> , 2021, 17, 3925-3940.	1.1	1
1503	Metallomic profile in non-cirrhotic hepatocellular carcinoma supports a phenomenon of metal metabolism adaptation in tumor cells. <i>Scientific Reports</i> , 2021, 11, 14195.	1.6	5
1504	Using the aMAP Risk Score to Predict Late Recurrence Following Radiofrequency Ablation for Hepatocellular Carcinoma in Chinese Population: A Multicenter Study. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 837-850.	1.8	2
1505	Experimental Models of Hepatocellular Carcinoma—A Preclinical Perspective. <i>Cancers</i> , 2021, 13, 3651.	1.7	26
1506	MiR-424 Acts as a Novel Biomarker in the Diagnosis of Patients with Hepatocellular Carcinoma. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2023, 38, 670-673.	0.7	4
1507	Involvement and Targeted Intervention of Mortalin-Regulated Proteome Phosphorylated-Modification in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 687871.	1.3	6
1508	Prognostic Impact of Lymphocyte—C-Reactive Protein Ratio in Patients Who Underwent Surgical Resection for Hepatocellular Carcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2022, 26, 104-112.	0.9	12

#	ARTICLE	IF	CITATIONS
1509	Metal-organic framework IRMOFs coated with a temperature-sensitive gel delivering norcantharidin to treat liver cancer. <i>World Journal of Gastroenterology</i> , 2021, 27, 4203-4215.	1.4	1
1510	Metal-organic framework IRMOFs coated with a temperature-sensitive gel delivering norcantharidin to treat liver cancer. <i>World Journal of Gastroenterology</i> , 2021, 27, 4208-4220.	1.4	14
1511	Role of circulating microRNAs to predict hepatocellular carcinoma recurrence in patients treated with radiofrequency ablation or surgery. <i>Hpb</i> , 2022, 24, 244-254.	0.1	4
1512	Early Versus Late Hepatocellular Carcinoma Recurrence After Transplantation: Predictive Factors, Patterns, and Long-term Outcome. <i>Transplantation</i> , 2021, 105, 1778-1790.	0.5	15
1513	Plasma extracellular vesicle microRNA-491-5p as diagnostic and prognostic marker for head and neck squamous cell carcinoma. <i>Cancer Science</i> , 2021, 112, 4257-4269.	1.7	18
1514	Multi-omics analysis reveals prognostic value of tumor mutation burden in hepatocellular carcinoma. <i>Cancer Cell International</i> , 2021, 21, 342.	1.8	27
1515	Setting the Frame or Framing Practice: The Never-Ending Guidelines Paradox. <i>CardioVascular and Interventional Radiology</i> , 2021, 44, 1683-1684.	0.9	0
1516	Optimal Timing of Administration of Direct-acting Antivirals for Patients With Hepatitis C-associated Hepatocellular Carcinoma Undergoing Liver Transplantation. <i>Annals of Surgery</i> , 2021, 274, 613-620.	2.1	3
1517	Circular RNA circ_ABCB10 in cancer. <i>Clinica Chimica Acta</i> , 2021, 518, 93-100.	0.5	7
1518	Predictors of Successful Yttrium-90 Radioembolization Bridging or Downstaging in Patients with Hepatocellular Carcinoma. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2021, 2021, 1-14.	0.8	2
1519	A Novel Five-Gene Signature for Prognosis Prediction in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 642563.	1.3	14
1520	Hepatic Arterial Infusion Chemotherapy Is a Feasible Treatment Option for Hepatocellular Carcinoma: A New Update. <i>Gastrointestinal Tumors</i> , 2021, 8, 145-152.	0.3	6
1521	Topological analysis of hepatocellular carcinoma tumour microenvironment based on imaging mass cytometry reveals cellular neighbourhood regulated reversely by macrophages with different ontogeny. <i>Gut</i> , 2022, 71, 1176-1191.	6.1	52
1522	Plasmonic-doped melanin-mimic for CXCR4-targeted NIR-II photoacoustic computed tomography-guided photothermal ablation of orthotopic hepatocellular carcinoma. <i>Acta Biomaterialia</i> , 2021, 129, 245-257.	4.1	15
1523	Dynamic Contrast-Enhanced and Intravoxel Incoherent Motion MRI Biomarkers Are Correlated to Survival Outcome in Advanced Hepatocellular Carcinoma. <i>Diagnostics</i> , 2021, 11, 1340.	1.3	6
1524	Lenvatinib: established and promising drug for the treatment of advanced hepatocellular carcinoma. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 1353-1365.	1.3	6
1525	A Novel Expression Signature from the Perspective of Mesenchymal-Epithelial Transition for Hepatocellular Carcinoma with Regard to Prognosis, Clinicopathological Features, Immune Cell Infiltration, Chemotherapeutic Efficacy, and Immunosuppressive Molecules. <i>Journal of Oncology</i> , 2021, 2021, 1-14.	0.6	3
1526	Recent advances in immunotherapy for hepatocellular carcinoma. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2021, 20, 511-520.	0.6	29

#	ARTICLE	IF	CITATIONS
1527	Hsa-miR-4277 Decelerates the Metabolism or Clearance of Sorafenib in HCC Cells and Enhances the Sensitivity of HCC Cells to Sorafenib by Targeting cyp3a4. <i>Frontiers in Oncology</i> , 2021, 11, 735447.	1.3	12
1529	Association between the HGF/c-MET signaling pathway and tumorigenesis, progression and prognosis of hepatocellular carcinoma (Review). <i>Oncology Reports</i> , 2021, 46, .	1.2	4
1530	miR-100 Suppresses the Proliferation, Invasion, and Migration of Hepatocellular Carcinoma Cells via Targeting CXCR7. <i>Journal of Immunology Research</i> , 2021, 2021, 1-11.	0.9	3
1531	Pathophysiological Implications of Urinary Peptides in Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 3786.	1.7	7
1532	Myofibroblast-specific Msi2 Knockout Inhibits HCC Progression in a Mouse Model. <i>Hepatology</i> , 2021, 74, 458-473.	3.6	15
1533	Hepatic Arterial Infusion Chemotherapy Followed by Lipiodol Infusion for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Single-Center Experience. <i>Medicina (Lithuania)</i> , 2021, 57, 779.	0.8	2
1534	m6A Regulator-Associated Modification Patterns and Immune Infiltration of the Tumor Microenvironment in Hepatocarcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 687756.	1.8	17
1535	Identification of a new TRAF6 inhibitor for the treatment of hepatocellular carcinoma. <i>International Journal of Biological Macromolecules</i> , 2021, 182, 910-920.	3.6	4
1536	Low efficiency of leucocyte plugging-based drug delivery to cancer in mice. <i>Drug Delivery and Translational Research</i> , 2022, 12, 1475-1487.	3.0	0
1537	Bisegmentectomy 7-8 for Small-for-Size Remnant Liver for Cirrhotic Patients Under Right Hemi-hepatectomy With Hepatocellular Carcinoma: A Case-Matched Comparative Study. <i>Frontiers in Surgery</i> , 2021, 8, 675666.	0.6	1
1538	The APAC Score: A Novel and Highly Performant Serological Tool for Early Diagnosis of Hepatocellular Carcinoma in Patients with Liver Cirrhosis. <i>Journal of Clinical Medicine</i> , 2021, 10, 3392.	1.0	14
1539	Screening and identification of angiogenesis-related genes as potential novel prognostic biomarkers of hepatocellular carcinoma through bioinformatics analysis. <i>Aging</i> , 2021, 13, 17707-17733.	1.4	6
1540	Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 559-568.	3.7	121
1541	Impact of metformin use on risk and mortality of hepatocellular carcinoma in diabetes mellitus. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2022, 46, 101781.	0.7	13
1542	Intra-procedural cone-beam CT with parenchymal blood volume assessment for transarterial chemoembolization guidance: Impact on the effectiveness of the individual TACE sessions compared to DSA guidance alone. <i>European Journal of Radiology</i> , 2021, 140, 109768.	1.2	3
1543	Radioembolization for Hepatocellular Carcinoma. <i>Digestive Disease Interventions</i> , 2021, 05, 268-276.	0.3	0
1544	Macrophage migration inhibitory factor predicts an unfavorable outcome after transarterial chemoembolization for hepatic malignancies. <i>Clinical and Translational Science</i> , 2021, 14, 1853-1863.	1.5	6
1545	CircRNA UBAP2 serves as a sponge of miR-1294 to increase tumorigenesis in hepatocellular carcinoma through regulating c-Myc expression. <i>Carcinogenesis</i> , 2021, 42, 1293-1303.	1.3	16

#	ARTICLE	IF	CITATIONS
1546	Liver Imaging Reporting and Data System: Review of Pros and Cons. <i>Seminars in Liver Disease</i> , 2022, 42, 104-111.	1.8	2
1547	Advances of Targeted Therapy for Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 719896.	1.3	23
1548	Risk Factors for Beyond Milan Recurrence After Hepatic Resection for Single Hepatocellular Carcinoma No Larger Than 5 Centimeters. <i>Liver Transplantation</i> , 2021, 27, 1116-1129.	1.3	3
1549	Long-Term Surgical Outcomes of Liver Resection for Hepatocellular Carcinoma in Patients With HBV and HCV Co-Infection: A Multicenter Observational Study. <i>Frontiers in Oncology</i> , 2021, 11, 700228.	1.3	6
1550	Current Trends in Non-Invasive Imaging of Interactions in the Liver Tumor Microenvironment Mediated by Tumor Metabolism. <i>Cancers</i> , 2021, 13, 3645.	1.7	2
1551	Reductions in AFP and PIVKA-II can predict the efficiency of anti-PD-1 immunotherapy in HCC patients. <i>BMC Cancer</i> , 2021, 21, 775.	1.1	28
1552	Pharmacological Mechanisms Underlying the Hepatoprotective Effects of Ecliptae herba on Hepatocellular Carcinoma. <i>Evidence-based Complementary and Alternative Medicine</i> , 2021, 2021, 1-17.	0.5	11
1553	Identification of Multiple Hub Genes and Pathways in Hepatocellular Carcinoma: A Bioinformatics Analysis. <i>BioMed Research International</i> , 2021, 2021, 1-11.	0.9	8
1554	C1orf61 promotes hepatocellular carcinoma metastasis and increases the therapeutic response to sorafenib. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2021, 1868, 119048.	1.9	4
1555	Y-box binding protein 1 augments sorafenib resistance <i>via</i> the PI3K/Akt signaling pathway in hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2021, 27, 4667-4686.	1.4	7
1556	TACE plus PD-1 inhibitor (Camrelizumab) treatment for bridging to tumor resection in HCC: case reports. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 46, 101777.	0.7	7
1557	Combination of natural killer cell-based immunotherapy and irreversible electroporation for the treatment of hepatocellular carcinoma. <i>Annals of Translational Medicine</i> , 2021, 9, 1089-1089.	0.7	5
1558	Impact of modified albuminâ€bilirubin grade on survival in patients with HCC who received lenvatinib. <i>Scientific Reports</i> , 2021, 11, 14474.	1.6	13
1559	Antifungal agent Terbinafine restrains tumor growth in preclinical models of hepatocellular carcinoma via AMPK-mTOR axis. <i>Oncogene</i> , 2021, 40, 5302-5313.	2.6	11
1560	Construction of an Immune-Related Six-lncRNA Signature to Predict the Outcomes, Immune Cell Infiltration, and Immunotherapy Response in Patients With Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 661758.	1.3	41
1561	<sc>Contrast-Enhanced</sc> Ultrasound for Differentiation Between Poorly Differentiated Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. <i>Journal of Ultrasound in Medicine</i> , 2022, 41, 1213-1225.	0.8	11
1562	Long non-coding RNA LINC00630 facilitates hepatocellular carcinoma progression through recruiting transcription factor E2F1 to up-regulate cyclin-dependent kinase 2 expression. <i>Human and Experimental Toxicology</i> , 2021, 40, S257-S268.	1.1	6
1563	Bidirectional deep neural networks to integrate RNA and DNA data for predicting outcome for patients with hepatocellular carcinoma. <i>Future Oncology</i> , 2021, 17, 4481-4495.	1.1	9

#	ARTICLE	IF	CITATIONS
1564	Landscape of Prognostic m6A RNA Methylation Regulators in Hepatocellular Carcinoma to Aid Immunotherapy. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 669145.	1.8	8
1565	MRI-Radiomics Prediction for Cytokeratin 19-Positive Hepatocellular Carcinoma: A Multicenter Study. <i>Frontiers in Oncology</i> , 2021, 11, 672126.	1.3	18
1566	The Putative Role of Natural Killer Cells in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma. <i>Asian Pacific Journal of Cancer Prevention</i> , 2021, 22, 2559-2567.	0.5	5
1567	Surveillance Strategy after Complete Ablation of Initial Recurrent Hepatocellular Carcinoma: A Risk-Based Machine Learning Study. <i>Journal of Vascular and Interventional Radiology</i> , 2021, 32, 1548-1557.e2.	0.2	3
1568	A Novel Oxygen Carrier (M101) Attenuates Ischemia-Reperfusion Injuries during Static Cold Storage in Steatotic Livers. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8542.	1.8	12
1569	Liquid Biopsy in Hepatocellular Carcinoma: Opportunities and Challenges for Immunotherapy. <i>Cancers</i> , 2021, 13, 4334.	1.7	20
1570	Immediate risk of non-cancer deaths after a cancer diagnosis. <i>BMC Cancer</i> , 2021, 21, 963.	1.1	10
1571	A prognostic model for hepatocellular carcinoma patients based on signature ferroptosis-related genes. <i>Hepatology International</i> , 2022, 16, 112-124.	1.9	31
1572	CDKN2A is a prognostic biomarker and correlated with immune infiltrates in hepatocellular carcinoma. <i>Bioscience Reports</i> , 2021, 41, .	1.1	33
1573	The State of Immunotherapy in Hepatobiliary Cancers. <i>Cells</i> , 2021, 10, 2096.	1.8	18
1574	Identification of PAFAH1B3 as Candidate Prognosis Marker and Potential Therapeutic Target for Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 700700.	1.3	5
1575	XRCC2 repairs mitochondrial DNA damage and fuels malignant behavior in hepatocellular carcinoma. <i>Cancer Letters</i> , 2021, 512, 1-14.	3.2	14
1576	PD-1 Blockade for Hepatocellular Carcinoma: Current Research and Future Prospects. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 887-897.	1.8	17
1577	Refining Prognosis in Chemoembolization for Hepatocellular Carcinoma: Immunonutrition and Liver Function. <i>Cancers</i> , 2021, 13, 3961.	1.7	7
1578	Transarterial chemoembolization plus sorafenib versus sorafenib for intermediate-advanced hepatocellular carcinoma. <i>Medicine (United States)</i> , 2021, 100, e26958.	0.4	3
1579	Spleen Radiomics Signature: A Potential Biomarker for Prediction of Early and Late Recurrences of Hepatocellular Carcinoma After Resection. <i>Frontiers in Oncology</i> , 2021, 11, 716849.	1.3	5
1580	EHMT2 promotes the pathogenesis of hepatocellular carcinoma by epigenetically silencing APC expression. <i>Cell and Bioscience</i> , 2021, 11, 152.	2.1	12
1581	Mild chronic hypoxia-induced HIF-2 $\beta$ interacts with c-MYC through competition with HIF-1 $\beta$ to induce hepatocellular carcinoma cell proliferation. <i>Cellular Oncology (Dordrecht)</i> , 2021, 44, 1151-1166.	2.1	9



#	ARTICLE	IF	CITATIONS
1582	Decreased risk of liver and intrahepatic cancer in non-H. pylori-infected perforated peptic ulcer patients with truncal vagotomy: a nationwide study. <i>Scientific Reports</i> , 2021, 11, 15594.	1.6	1
1583	Dietary and Genetic Cholesterol Loading Rather Than Steatosis Promotes Liver Tumorigenesis and NASH-Driven HCC. <i>Cancers</i> , 2021, 13, 4091.	1.7	14
1584	Synergistic efficacy of curcumin and anti-programmed cell death-1 in hepatocellular carcinoma. <i>Life Sciences</i> , 2021, 279, 119359.	2.0	30
1585	First-line immune checkpoint inhibitor-based combinations in unresectable hepatocellular carcinoma: current management and future challenges. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 1245-1251.	1.4	75
1586	The effect of the TP53 and RB1 mutations on the survival of hepatocellular carcinoma patients with different racial backgrounds. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 1786-1796.	0.6	5
1587	Risk characteristics with seven epithelial-mesenchymal transition-related genes are used to predict the prognosis of patients with hepatocellular carcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 1884-1894.	0.6	0
1588	Early Tumor Response and Safety of Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma in Real-World Practice. <i>Cancers</i> , 2021, 13, 3958.	1.7	29
1589	HHLA2 Expression is Associated with Poor Survival in Patients with Hepatocellular Carcinoma. <i>Biologics: Targets and Therapy</i> , 2021, Volume 15, 329-341.	3.0	5
1590	Traditional Chinese medicine for prevention and treatment of hepatocellular carcinoma: A focus on epithelial-mesenchymal transition. <i>Journal of Integrative Medicine</i> , 2021, 19, 469-477.	1.4	33
1591	Dihydrotanshinone I inhibits the growth of hepatoma cells by direct inhibition of Src. <i>Phytomedicine</i> , 2022, 95, 153705.	2.3	5
1592	ATF2-Induced Overexpression of lncRNA LINC00882, as a Novel Therapeutic Target, Accelerates Hepatocellular Carcinoma Progression via Sponging miR-214-3p to Upregulate CENPM. <i>Frontiers in Oncology</i> , 2021, 11, 714264.	1.3	6
1593	TDO2 Was Downregulated in Hepatocellular Carcinoma and Inhibited Cell Proliferation by Upregulating the Expression of p21 and p27. <i>BioMed Research International</i> , 2021, 2021, 1-10.	0.9	7
1594	State-of-the-art surgery for hepatocellular carcinoma. <i>Langenbeck's Archives of Surgery</i> , 2021, 406, 2151-2162.	0.8	12
1595	lncRNA MAGI2-AS3 Exerts Antioncogenic Roles in Hepatocellular Carcinoma via Regulating the miR-519c-3p/TXNIP Axis. <i>Journal of Oncology</i> , 2021, 2021, 1-11.	0.6	5
1596	Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study.. <i>Digestive and Liver Disease</i> , 2021, 53, 1011-1019.	0.4	7
1597	Surveillance Strategy for Barcelona Clinic Liver Cancer B Hepatocellular Carcinoma Achieving Complete Response: An Individualized Risk-Based Machine Learning Study. <i>Frontiers in Bioengineering and Biotechnology</i> , 2021, 9, 667641.	2.0	1
1598	FAPI PET/CT research progress in digestive system tumours. <i>Digestive and Liver Disease</i> , 2022, 54, 164-169.	0.4	13
1599	IL-1 $\beta$ -Induced Elevation of Solute Carrier Family 7 Member 11 Promotes Hepatocellular Carcinoma Metastasis Through Upregulating Programmed Death Ligand 1 and Colony-Stimulating Factor 1. <i>Hepatology</i> , 2021, 74, 3174-3193.	3.6	64

#	ARTICLE	IF	CITATIONS
1600	External validation of different difficulty scoring systems of laparoscopic liver resection for hepatocellular carcinoma. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2022, 36, 3732-3749.	1.3	7
1601	ABL1 Is a Prognostic Marker and Associated with Immune Infiltration in Hepatocellular Carcinoma. <i>Journal of Oncology</i> , 2021, 2021, 1-12.	0.6	2
1602	LncRNA CRNDE Promotes ATG4B-Mediated Autophagy and Alleviates the Sensitivity of Sorafenib in Hepatocellular Carcinoma Cells. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 687524.	1.8	16
1603	Super-Resolution Ultrasound Localization Microscopy on a Rabbit Liver VX2 Tumor Model: An Initial Feasibility Study. <i>Ultrasound in Medicine and Biology</i> , 2021, 47, 2416-2429.	0.7	20
1604	SMG9 Serves as an Oncogene to Promote the Tumor Progression via EMT and Wnt/ $\beta$ -Catenin Signaling Pathway in Hepatocellular Carcinoma. <i>Frontiers in Pharmacology</i> , 2021, 12, 701454.	1.6	5
1605	Significance of hepatocyte atypia in liver fine needle aspiration. <i>Diagnostic Cytopathology</i> , 2021, , .	0.5	2
1606	Muscle-Invasive Bladder Cancer in Patients with Liver Cirrhosis: A Review of Pertinent Considerations. <i>Bladder Cancer</i> , 2021, 7, 261-278.	0.2	1
1607	Antioxidants Threaten Multikinase Inhibitor Efficacy against Liver Cancer by Blocking Mitochondrial Reactive Oxygen Species. <i>Antioxidants</i> , 2021, 10, 1336.	2.2	11
1608	Cooperation between liver-specific mutations of pten and tp53 genetically induces hepatocarcinogenesis in zebrafish. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 262.	3.5	2
1609	Cancer-Associated Fibroblasts Promote Vascular Invasion of Hepatocellular Carcinoma via Downregulating Decorin-integrin $\beta$ 1 Signaling. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 678670.	1.8	7
1610	Liver Transplantation in Patients with Hepatocellular Carcinoma beyond the Milan Criteria: A Comprehensive Review. <i>Journal of Clinical Medicine</i> , 2021, 10, 3932.	1.0	13
1611	Combined DNA Methylation and Transcriptomic Assessments to Determine a Prognostic Model for PD-1-Negative Hepatocellular Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 708819.	1.8	4
1612	KIF18B as a regulator in tumor microenvironment accelerates tumor progression and triggers poor outcome in hepatocellular carcinoma. <i>International Journal of Biochemistry and Cell Biology</i> , 2021, 137, 106037.	1.2	3
1613	Impact of alcohol abstinence on survival after hepatic resection for hepatocellular carcinoma in patients with alcohol-related liver disease. <i>Annals of Medicine and Surgery</i> , 2021, 68, 102644.	0.5	4
1614	Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 927-939.	1.1	9
1615	Magnetic mesoporous embolic microspheres in transcatheter arterial chemoembolization for liver cancer. <i>Acta Biomaterialia</i> , 2021, 130, 374-384.	4.1	13
1616	Liver Stiffness Measured by Two-Dimensional Shear Wave Elastography for Predicting Symptomatic Post-hepatectomy Liver Failure in Patients with Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2022, 29, 327-336.	0.7	7
1617	RAB27A-dependent release of exosomes by liver cancer stem cells induces Nanog expression in their differentiated progenies and confers regorafenib resistance. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 3429-3437.	1.4	19

#	ARTICLE	IF	CITATIONS
1618	Clinical application of mask region-based convolutional neural network for the automatic detection and segmentation of abnormal liver density based on hepatocellular carcinoma computed tomography datasets. <i>PLoS ONE</i> , 2021, 16, e0255605.	1.1	6
1619	Association between socioeconomic status and survival in patients with hepatocellular carcinoma. <i>Cancer Medicine</i> , 2021, 10, 7347-7359.	1.3	8
1620	Hepatic sexual dimorphism â€™ implications for non-alcoholic fatty liver disease. <i>Nature Reviews Endocrinology</i> , 2021, 17, 662-670.	4.3	41
1621	Neutrophil Lymphocyte Ratio to Albumin Ratio and White Blood Cell to Hemoglobin Ratio as Prognostic Markers for Hepatocellular Carcinoma Patients Who Underwent Curative Hepatectomy. <i>International Journal of General Medicine</i> , 2021, Volume 14, 5029-5038.	0.8	5
1622	Immunological Value of Prognostic Signature Based on Cancer Stem Cell Characteristics in Hepatocellular Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 710207.	1.8	14
1623	Tumor size may influence the prognosis of solitary hepatocellular carcinoma patients with cirrhosis and without macrovascular invasion after hepatectomy. <i>Scientific Reports</i> , 2021, 11, 16343.	1.6	20
1624	Immune suppressive checkpoint interactions in the tumour microenvironment of primary liver cancers. <i>British Journal of Cancer</i> , 2021, , .	2.9	12
1625	ASO Author Reflections: Liver Stiffness by Ultrasonic Elastographyâ€™A Role in Surgical Resection for Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2022, 29, 337-338.	0.7	0
1626	Key features of the environment promoting liver cancer in the absence of cirrhosis. <i>Scientific Reports</i> , 2021, 11, 16727.	1.6	12
1627	Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study. <i>Scientific Reports</i> , 2021, 11, 16663.	1.6	30
1628	The Expression of Circulating miR-497 and Metadherin in Hepatocellular Carcinoma: Relation to the Tumor Characteristics and Patientsâ€™ Survival. <i>Medicina (Lithuania)</i> , 2021, 57, 866.	0.8	2
1629	Development and validation of LRP1B mutation-associated prognostic model for hepatocellular carcinoma. <i>Bioscience Reports</i> , 2021, 41, .	1.1	4
1630	A novel immune signature to predict the prognosis of patients with hepatocellular carcinoma. <i>Medicine (United States)</i> , 2021, 100, e26948.	0.4	1
1631	DTYMK promote hepatocellular carcinoma proliferation by regulating cell cycle. <i>Cell Cycle</i> , 2021, 20, 1681-1691.	1.3	15
1632	Validation of a Novel Multitarget Blood Test Shows High Sensitivity to Detect Early Stage Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 173-182.e7.	2.4	62
1633	PD-L1, TMB, and other potential predictors of response to immunotherapy for hepatocellular carcinoma: how can they assist drug clinical trials?. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 415-423.	1.9	78
1634	Novel Microcrystal Formulations of Sorafenib Facilitate a Long-Acting Antitumor Effect and Relieve Treatment Side Effects as Observed With Fundus Microcirculation Imaging. <i>Frontiers in Oncology</i> , 2021, 11, 743055.	1.3	9
1635	E2F1-Induced lncRNA BAIAP2-AS1 Overexpression Contributes to the Malignant Progression of Hepatocellular Carcinoma via miR-361-3p/SOX4 Axis. <i>Disease Markers</i> , 2021, 2021, 1-18.	0.6	11

#	ARTICLE	IF	CITATIONS
1636	One-step preparation of photoclick method for embolic microsphere synthesis and assessment for transcatheter arterial embolization. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2021, 166, 94-102.	2.0	10
1637	Signalling pathways and transcriptional regulators orchestrating liver development and cancer. <i>Development (Cambridge)</i> , 2021, 148, .	1.2	9
1638	Transcatheter Arterial Embolization Containing Donafenib Induces Anti-Angiogenesis and Tumoricidal CD8+ T-Cell Infiltration in Rabbit VX2 Liver Tumor. <i>Cancer Management and Research</i> , 2021, Volume 13, 6943-6952.	0.9	4
1639	Preoperative Prediction of Microvascular Invasion in Patients With Hepatocellular Carcinoma Based on Radiomics Nomogram Using Contrast-Enhanced Ultrasound. <i>Frontiers in Oncology</i> , 2021, 11, 709339.	1.3	22
1640	AGTRAP Is a Prognostic Biomarker Correlated With Immune Infiltration in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 713017.	1.3	5
1641	Impact of Hypothyroidism on Patients with Hepatocellular Carcinoma Undergoing Liver Transplantation. <i>International Journal of General Medicine</i> , 2021, Volume 14, 5711-5718.	0.8	2
1642	Development and validation of prognostic nomograms for single large and huge hepatocellular carcinoma after curative resection. <i>European Journal of Cancer</i> , 2021, 155, 85-96.	1.3	19
1643	The photodynamic and intrinsic effects of Azure B on mitochondrial bioenergetics and the consequences of its intrinsic effects on hepatic energy metabolism. <i>Photodiagnosis and Photodynamic Therapy</i> , 2021, 35, 102446.	1.3	1
1644	Portal Vein Tumor Thrombosis and Hepatocellular Carcinoma – The Changing Tides. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 1089-1115.	1.8	28
1645	A Novel Prognostic Biomarker LPAR6 in Hepatocellular Carcinoma via Associating with Immune Infiltrates. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 10, 90-103.	0.7	9
1646	Liver cirrhosis. <i>Lancet, The</i> , 2021, 398, 1359-1376.	6.3	515
1647	Preparation of Near-Infrared/Photoacoustic Dual-Mode Imaging and Photothermal/Chemo Synergistic Theranostic Nanoparticles and Their Imaging and Treating of Hepatic Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 750807.	1.3	4
1648	Hedyotis diffusa Willd. Suppresses Hepatocellular Carcinoma via Downregulating AKT/mTOR Pathways. <i>Evidence-based Complementary and Alternative Medicine</i> , 2021, 2021, 1-9.	0.5	5
1649	Prognostic Role of ceRNA Network in Immune Infiltration of Hepatocellular Carcinoma. <i>Frontiers in Genetics</i> , 2021, 12, 739975.	1.1	7
1650	Elevated LINC01232 is associated with poor prognosis and HBV infection in hepatocellular carcinoma patients and contributes to tumor progression in vitro. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 46, 101813.	0.7	6
1651	Gut microbiome in cirrhotic hepatitis C virus patients with and without hepatocellular carcinoma. <i>Egyptian Liver Journal</i> , 2021, 11, .	0.3	2
1652	Bromodomain-containing protein 9 promotes hepatocellular carcinoma progression via activating the Wnt/ $\beta$ -catenin signaling pathway. <i>Experimental Cell Research</i> , 2021, 406, 112727.	1.2	5
1653	The Neutrophil-to-Lymphocyte Ratio (NLR) Predicts the Prognosis of Unresectable Intermediate and Advanced Hepatocellular Carcinoma Treated with Apatinib. <i>Cancer Management and Research</i> , 2021, Volume 13, 6989-6998.	0.9	5

#	ARTICLE	IF	CITATIONS
1654	Identification and Validation of a Nine-Gene Amino Acid Metabolism-Related Risk Signature in HCC. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 731790.	1.8	40
1655	ASIC1a promotes acidic microenvironment-induced HCC cells migration and invasion by inducing autophagy. <i>European Journal of Pharmacology</i> , 2021, 907, 174252.	1.7	14
1656	iRGD Peptide-Mediated Liposomal Nanoparticles with Photoacoustic/Ultrasound Dual-Modality Imaging for Precision Theranostics Against Hepatocellular Carcinoma. <i>International Journal of Nanomedicine</i> , 2021, Volume 16, 6455-6475.	3.3	17
1657	Travel distance and overall survival in hepatocellular cancer care. <i>American Journal of Surgery</i> , 2021, 222, 584-593.	0.9	5
1658	High Visceral Adipose Tissue Density Correlates With Unfavorable Outcomes in Patients With Intermediate-Stage Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 710104.	1.8	6
1659	Multimolecular-Targeted Agents for Intermediate-Stage Hepatocellular Carcinoma Influence Time to Stage Progression and Overall Survival. <i>Oncology</i> , 2021, 99, 756-765.	0.9	4
1660	Nondegradable Collagen Increases Liver Fibrosis but Not Hepatocellular Carcinoma in Mice. <i>American Journal of Pathology</i> , 2021, 191, 1564-1579.	1.9	10
1661	Early evaluation of treatment response to transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The role of dynamic three-dimensional contrast-enhanced ultrasound. <i>Clinical Hemorheology and Microcirculation</i> , 2021, 78, 365-377.	0.9	4
1662	Chest Wall Swelling in a Baby Boomer: An Unusual Presentation of Primary Hepatocellular Carcinoma. <i>Cureus</i> , 2021, 13, e18163.	0.2	0
1663	Novel small molecule inhibitors of the transcription factor ETS-1 and their antitumor activity against hepatocellular carcinoma. <i>European Journal of Pharmacology</i> , 2021, 906, 174214.	1.7	16
1664	Hepatic arterial infusion chemotherapy in the treatment of advanced hepatocellular carcinoma with portal vein thrombosis: a caseâ€“control study. <i>Clinical Radiology</i> , 2021, 76, 709.e1-709.e6.	0.5	5
1665	Hepatic Cancer Stem Cells: Molecular Mechanisms, Therapeutic Implications, and Circulating Biomarkers. <i>Cancers</i> , 2021, 13, 4550.	1.7	6
1666	Preoperative assessment of microvascular invasion of hepatocellular carcinoma using non-Gaussian diffusion-weighted imaging with a fractional order calculus model: A pilot study. <i>Magnetic Resonance Imaging</i> , 2023, 95, 110-117.	1.0	10
1667	Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 558-580.	5.7	181
1668	The Role of Long Non-Coding RNA and microRNA Networks in Hepatocellular Carcinoma and Its Tumor Microenvironment. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10630.	1.8	14
1669	Biomarkers and Future Perspectives for Hepatocellular Carcinoma Immunotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 716844.	1.3	12
1670	Hepatic Artery Injection of <sup>131</sup> I-Metuximab Combined with Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Prospective Nonrandomized, Multicenter Clinical Trial. <i>Journal of Nuclear Medicine</i> , 2022, 63, 556-559.	2.8	9
1671	Peptide-Based Vaccines for Hepatocellular Carcinoma: A Review of Recent Advances. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 1035-1054.	1.8	17

#	ARTICLE	IF	CITATIONS
1672	A Radiomics Approach to Predict the Emergence of New Hepatocellular Carcinoma in Computed Tomography for High-Risk Patients with Liver Cirrhosis. <i>Diagnostics</i> , 2021, 11, 1650.	1.3	1
1673	Metformin suppresses interleukin-22 induced hepatocellular carcinoma by upregulating Hippo signaling pathway. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 3469-3476.	1.4	13
1674	Minimally Invasive versus Open Liver Resection for Stage I/II Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 4800.	1.7	7
1675	Sepsis caused by <i>Anaerococcus nagsyae</i> after transarterial-chemoembolization for hepatocellular carcinoma: Case report and literature review. <i>Anaerobe</i> , 2021, 72, 102464.	1.0	3
1676	Systematic Characterization of Novel Immune Gene Signatures Predicts Prognostic Factors in Hepatocellular Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 686664.	1.8	5
1677	Efficacy of Combined Therapy with Drug-Eluting Beads-Transcatheter Arterial Chemoembolization Followed by Conventional Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multi-Center Study. <i>Cancers</i> , 2021, 13, 4605.	1.7	3
1678	Global DNA 5hmC and CK195hmC+ Contents: A Promising Biomarker for Predicting Prognosis in Small Hepatocellular Carcinoma. <i>Current Oncology</i> , 2021, 28, 3758-3770.	0.9	4
1679	SNHG16 promotes hepatocellular carcinoma development via activating ECM receptor interaction pathway. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2022, 21, 41-49.	0.6	17
1680	Bi/Se-Based Nanotherapeutics Sensitize CT Image-Guided Stereotactic Body Radiotherapy through Reprogramming the Microenvironment of Hepatocellular Carcinoma. <i>ACS Applied Materials &amp; Interfaces</i> , 2021, 13, 42473-42485.	4.0	18
1681	Comparison of Hepatic Resection with Percutaneous Ablation for Hepatocellular Carcinoma in the Caudate Lobe Within Milan Criteria. <i>Journal of Gastrointestinal Surgery</i> , 2022, 26, 323-332.	0.9	1
1682	Tumor-derived extracellular vesicles containing long noncoding RNA PART1 exert oncogenic effect in hepatocellular carcinoma by polarizing macrophages into M2. <i>Digestive and Liver Disease</i> , 2022, 54, 543-553.	0.4	14
1683	BEX2 is required for maintaining dormant cancer stem cell in hepatocellular carcinoma. <i>Cancer Science</i> , 2021, 112, 4580-4592.	1.7	8
1684	Long non-coding RNA SNHG16 as a potential biomarker in hepatocellular carcinoma. <i>Medicine (United States)</i> 100, 045005	0.45	5
1685	LncRNA DiGeorge syndrome critical region gene 5: A crucial regulator in malignant tumors. <i>Biomedicine and Pharmacotherapy</i> , 2021, 141, 111889.	2.5	4
1686	Effects of surgery, chemotherapy, and radiation on hepatocellular carcinoma patients: A SEER-based study. <i>Annals of Medicine and Surgery</i> , 2021, 69, 102782.	0.5	1
1687	Consensus Guidelines for the Definition of Time-to-Event End Points in Image-guided Tumor Ablation: Results of the SIO and DATECAN Initiative. <i>Radiology</i> , 2021, 301, 533-540.	3.6	72
1688	Clinical Application Value of Circulating Cell-free DNA in Hepatocellular Carcinoma. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 736330.	1.6	10
1689	Antibody-drug conjugate as targeted therapeutics against hepatocellular carcinoma: preclinical studies and clinical relevance. <i>Clinical and Translational Oncology</i> , 2022, 24, 407-431.	1.2	6

#	ARTICLE	IF	CITATIONS
1690	Programmed cell death 10 promotes metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma via PP2Ac-mediated YAP activation. <i>Cell Death and Disease</i> , 2021, 12, 849.	2.7	15
1691	Dysregulated N6-methyladenosine (m6A) processing in hepatocellular carcinoma. <i>Annals of Hepatology</i> , 2021, 25, 100538.	0.6	9
1692	Drug-eluting bead transarterial chemoembolization (TACE) exhibits superior efficacy and equal tolerance to conventional TACE in hepatocellular carcinoma patients with conventional TACE history. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2022, 46, 101814.	0.7	4
1693	MicroRNA-199: A Potential Therapeutic Tool for Hepatocellular Carcinoma in an Experimental Model. <i>Asian Pacific Journal of Cancer Prevention</i> , 2021, 22, 2771-2779.	0.5	3
1694	Nrf2 signaling promotes cancer stemness, migration, and expression of ABC transporter genes in sorafenib-resistant hepatocellular carcinoma cells. <i>PLoS ONE</i> , 2021, 16, e0256755.	1.1	19
1696	Development of pre and postoperative nomograms to predict individual survival for ideal liver resection candidates with hepatocellular carcinoma. <i>Liver International</i> , 2021, 41, 2974-2985.	1.9	6
1697	Upregulation of MicroRNA-937 Predicts a Poor Prognosis and Promotes Hepatocellular Carcinoma Cell Proliferation, Migration, and Invasion. <i>Molecular Biotechnology</i> , 2022, 64, 33-41.	1.3	2
1698	ASPM promotes hepatocellular carcinoma progression by activating Wnt/ $\beta$ -catenin signaling through antagonizing autophagy-mediated Dvl2 degradation. <i>FEBS Open Bio</i> , 2021, 11, 2784-2799.	1.0	22
1699	Long non-coding RNA TMCC1-AS1 predicts poor prognosis and accelerates epithelial-mesenchymal transition in liver cancer. <i>Oncology Letters</i> , 2021, 22, 773.	0.8	13
1700	Trends of rapamycin in survival benefits of liver transplantation for hepatocellular carcinoma. <i>World Journal of Gastrointestinal Surgery</i> , 2021, 13, 953-966.	0.8	4
1701	Decitabine-Loaded Gold Nanocages for Photothermal Cancer Therapy via DNA Hypermethylation Reversal. <i>ACS Applied Nano Materials</i> , 2021, 4, 10556-10564.	2.4	7
1702	Effect of transjugular intrahepatic portosystemic shunt on transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis. , 2021, 27, 671-676.		3
1703	Immunological Markers, Prognostic Factors and Challenges Following Curative Treatments for Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10271.	1.8	14
1704	The Progress in the Treatment of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus. <i>Frontiers in Oncology</i> , 2021, 11, 635731.	1.3	26
1705	Nucleolar protein 6 promotes cell proliferation and acts as a potential novel prognostic marker for hepatocellular carcinoma. <i>Chinese Medical Journal</i> , 2021, 134, 2611-2618.	0.9	3
1706	Outcomes of Hepatic Resection for Hepatocellular Carcinoma Associated with Portal Vein Invasion. <i>Journal of Surgical Research</i> , 2021, 266, 269-283.	0.8	5
1707	The HSP90 inhibitor, XL888, enhanced cell apoptosis via downregulating STAT3 after insufficient radiofrequency ablation in hepatocellular carcinoma. <i>Life Sciences</i> , 2021, 282, 119762.	2.0	13
1708	Current pharmacological treatment of hepatocellular carcinoma. <i>Current Opinion in Pharmacology</i> , 2021, 60, 141-148.	1.7	12

#	ARTICLE	IF	CITATIONS
1709	Exploration and time-serial validation of logistic regression models composed of multiple laboratory tests for early detection of HCV-associated hepatocellular carcinoma. <i>Clinica Chimica Acta</i> , 2021, 521, 137-143.	0.5	1
1710	A Broad Range High-Throughput Assay for Lenvatinib Using Ultra-High Performance Liquid Chromatography Coupled to Tandem Mass Spectrometry With Clinical Application in Patients With Hepatocellular Carcinoma. <i>Therapeutic Drug Monitoring</i> , 2021, 43, 664-671.	1.0	5
1711	Marine bacterial exopolysaccharide EPS11 inhibits migration and invasion of liver cancer cells by directly targeting collagen I. <i>Journal of Biological Chemistry</i> , 2021, 297, 101133.	1.6	16
1712	Systemic treatment of hepatocellular carcinoma: An EASL position paper. <i>Journal of Hepatology</i> , 2021, 75, 960-974.	1.8	217
1713	Combination of transcatheter arterial chemoembolization and portal vein embolization for patients with hepatocellular carcinoma: a review. <i>World Journal of Surgical Oncology</i> , 2021, 19, 293.	0.8	8
1714	Molecular mechanisms and therapeutic implications of dihydromyricetin in liver disease. <i>Biomedicine and Pharmacotherapy</i> , 2021, 142, 111927.	2.5	25
1715	ALBI grade: Evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma. <i>JHEP Reports</i> , 2021, 3, 100347.	2.6	57
1716	Extremely high titer of hepatitis B surface antigen antibodies in a primary hepatocellular carcinoma patient: A case report. <i>World Journal of Clinical Cases</i> , 2021, 9, 8492-8497.	0.3	0
1717	Bovine Serum Albumin Nanoparticle-Mediated Delivery of Sorafenib for Improving Hepatocellular Carcinoma Therapy. <i>Journal of Nanoscience and Nanotechnology</i> , 2021, 21, 5075-5082.	0.9	2
1718	Development and Verification of an Immune-Related Gene Pairs Prognostic Signature in Hepatocellular Carcinoma. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 715728.	1.6	4
1719	Evolution of Radioembolization in Treatment of Hepatocellular Carcinoma: A Pictorial Review. <i>Radiographics</i> , 2021, 41, 1802-1818.	1.4	33
1720	Conversion surgery for hepatocellular carcinoma after multidisciplinary treatment including lenvatinib. <i>Hepatology Research</i> , 2021, 51, 1029-1030.	1.8	2
1721	Viral infections and the efficacy of PD-(L)1 inhibitors in virus-related cancers: Head and neck squamous cell carcinoma and hepatocellular carcinoma. <i>International Immunopharmacology</i> , 2021, 100, 108128.	1.7	13
1722	Protein arginine methyltransferases and hepatocellular carcinoma: A review. <i>Translational Oncology</i> , 2021, 14, 101194.	1.7	7
1723	Global analysis of DNA methylation in hepatocellular carcinoma via a whole-genome bisulfite sequencing approach. <i>Genomics</i> , 2021, 113, 3618-3634.	1.3	4
1724	Diagnosis and prognosis models for hepatocellular carcinoma patient's management based on tumor mutation burden. <i>Journal of Advanced Research</i> , 2021, 33, 153-165.	4.4	49
1725	Construction of a novel radiomics nomogram for the prediction of aggressive intrasegmental recurrence of HCC after radiofrequency ablation. <i>European Journal of Radiology</i> , 2021, 144, 109955.	1.2	7
1726	Arterial chemoembolisation with cisplatin versus epirubicin for hepatocellular carcinoma (ACE 500) Tj ETQq1 1 0.784314 rgBT /Overlock 373-382.	1.3	9



#	ARTICLE	IF	CITATIONS
1727	A preoperative model for predicting microvascular invasion and assisting in prognostic stratification in liver transplantation for HCC regarding empirical criteria. <i>Translational Oncology</i> , 2021, 14, 101200.	1.7	6
1728	Evaluation of Threshold Dose of Damaged Hepatic Tissue After Carbon-Ion Radiation Therapy Using Gd-EOB-DTPA-enhanced Magnetic Resonance Imaging. <i>Advances in Radiation Oncology</i> , 2021, 6, 100775.	0.6	0
1729	Preferentially released miR-122 from cyclodextrin-based star copolymer nanoparticle enhances hepatoma chemotherapy by apoptosis induction and cytotoxic efflux inhibition. <i>Bioactive Materials</i> , 2021, 6, 3744-3755.	8.6	18
1730	Persistent mTORC1 activation via Depdc5 deletion results in spontaneous hepatocellular carcinoma but does not exacerbate carcinogen- and high-fat diet-induced hepatic carcinogenesis in mice. <i>Biochemical and Biophysical Research Communications</i> , 2021, 578, 142-149.	1.0	3
1731	Lipid response of hepatocellular carcinoma cells to anticancer drug detected on nanostructure-assisted LDI-MS platform. <i>Talanta</i> , 2021, 235, 122817.	2.9	1
1732	Plasmacytoid dendritic cells recruited by HIF-1 $\alpha$ /eADO/ADORA1 signaling induce immunosuppression in hepatocellular carcinoma. <i>Cancer Letters</i> , 2021, 522, 80-92.	3.2	37
1733	A cascaded copper-based nanocatalyst by modulating glutathione and cyclooxygenase-2 for hepatocellular carcinoma therapy. <i>Journal of Colloid and Interface Science</i> , 2022, 607, 1516-1526.	5.0	41
1734	Changes in the Mean Intrahepatic Target Computed Tomography Attenuation Value During Treatment May be a Useful New Predictor of the Post-progression Survival Associated with Lenvatinib Treatment. <i>Internal Medicine</i> , 2022, , .	0.3	0
1735	Upregulating <i>KTN1</i> promotes Hepatocellular Carcinoma progression. <i>Journal of Cancer</i> , 2021, 12, 4791-4809.	1.2	4
1736	Impact of regulatory T cells on the prognosis of hepatocellular carcinoma. <i>Medicine (United States)</i> , 2021, 100, e23957.	0.4	2
1737	miR-369 inhibits Liver Cancer progression by targeting ZEB1 pathway and predicts the prognosis of HCC patients. <i>Journal of Cancer</i> , 2021, 12, 3067-3076.	1.2	13
1738	A multifunctional targeted nanoprobe with high NIR-II PAI/MRI performance for precise theranostics of orthotopic early-stage hepatocellular carcinoma. <i>Journal of Materials Chemistry B</i> , 2021, 9, 8779-8792.	2.9	15
1739	NAFLD Indirectly Impairs Antigen Specific CD8 <sup>+</sup> T Cell Immunity Against Liver Cancer in Mice. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1740	Intra-arterial Chemotherapy and Transarterial Chemoembolization in Hepatocellular Carcinoma. , 2021, , 171-187.		0
1741	Body Composition Changes in Hepatocellular Carcinoma: Prediction of Survival to Transcatheter Arterial Chemoembolization in Combination With Clinical Prognostic Factors. <i>Cancer Control</i> , 2021, 28, 1073274821110384.	0.7	9
1742	Immunotherapy for targeting cancer stem cells in hepatocellular carcinoma. <i>Theranostics</i> , 2021, 11, 3489-3501.	4.6	35
1743	Characteristics and outcome of incidental hepatocellular carcinoma after liver transplantation: a cohort study. <i>Revista Espanola De Enfermedades Digestivas</i> , 2021, , .	0.1	1
1744	Exosomes in Hepatocellular Carcinoma: an update. <i>Journal of Cancer</i> , 2021, 12, 2526-2536.	1.2	23

#	ARTICLE	IF	CITATIONS
1745	Value of alpha-fetoprotein in hepatocellular carcinoma. <i>Translational Gastroenterology and Hepatology</i> , 2021, 6, 0-0.	1.5	3
1746	A Novel Epigenetic Machine Learning Model to Define Risk of Progression for Hepatocellular Carcinoma Patients. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1075.	1.8	6
1747	SAV1, regulated by HERC4, inhibits the proliferation, migration, and invasion of hepatocellular carcinoma. <i>Translational Cancer Research</i> , 2021, 10, 349-360.	0.4	2
1748	BRD7 inhibits tumor progression by positively regulating the p53 pathway in hepatocellular carcinoma. <i>Journal of Cancer</i> , 2021, 12, 1507-1519.	1.2	8
1749	Albumin-to-alkaline phosphatase ratio as a predictor of tumor recurrence and prognosis in patients with early-stage hepatocellular carcinoma undergoing radiofrequency ablation as initial therapy. <i>International Journal of Hyperthermia</i> , 2021, 38, 1-10.	1.1	16
1750	Magnetic liquid metal loaded nano-in-micro spheres as fully flexible theranostic agents for SMART embolization. <i>Nanoscale</i> , 2021, 13, 8817-8836.	2.8	39
1751	Designer exosomes for targeted and efficient ferroptosis induction in cancer via chemo-photodynamic therapy. <i>Theranostics</i> , 2021, 11, 8185-8196.	4.6	105
1752	Multi-scale and multi-parametric radiomics of gadoxetate disodium-enhanced MRI predicts microvascular invasion and outcome in patients with solitary hepatocellular carcinoma $\leq$ 5 cm. <i>European Radiology</i> , 2021, 31, 4824-4838.	2.3	106
1753	Characteristics and etiologies of hepatocellular carcinoma in patients without cirrhosis: When East meets West. <i>PLoS ONE</i> , 2021, 16, e0244939.	1.1	22
1754	Checkpoint Inhibitors and Hepatotoxicity. <i>Biomedicines</i> , 2021, 9, 101.	1.4	17
1755	Prognostic value of liver stiffness measurement in patients with hepatocellular carcinoma (HCC) treated by radiofrequency ablation: a meta-analysis. <i>International Journal of Hyperthermia</i> , 2021, 38, 1052-1059.	1.1	6
1756	NR2F1-AS1/miR-140/HK2 Axis Regulates Hypoxia-Induced Glycolysis and Migration in Hepatocellular Carcinoma. <i>Cancer Management and Research</i> , 2021, Volume 13, 427-437.	0.9	24
1757	Systematic Construction and Validation of an RNA-Binding Protein-Associated Model for Prognosis Prediction in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 597996.	1.3	4
1758	Enhanced penetrative siRNA delivery by a nanodiamond drug delivery platform against hepatocellular carcinoma 3D models. <i>Nanoscale</i> , 2021, 13, 16131-16145.	2.8	15
1759	Hepatic Arterial Infusion Chemotherapy Combined with Radiation Therapy for Advanced Hepatocellular Carcinoma with Tumor Thrombosis of the Main Trunk or Bilobar of the Portal Vein. <i>Liver Cancer</i> , 2021, 10, 151-160.	4.2	20
1760	Risk factors for early and late recurrence in hepatocellular carcinoma after liver transplantation. <i>Journal of Medical Sciences (Taiwan)</i> , 2021, .	0.1	0
1761	Membrane protein-chimeric liposome-mediated delivery of triptolide for targeted hepatocellular carcinoma therapy. <i>Drug Delivery</i> , 2021, 28, 2033-2043.	2.5	11
1762	A Pre-TACE Radiomics Model to Predict HCC Progression and Recurrence in Liver Transplantation: A Pilot Study on a Novel Biomarker. <i>Transplantation</i> , 2021, 105, 2435-2444.	0.5	20

#	ARTICLE	IF	CITATIONS
1763	Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2). <i>Liver Cancer</i> , 2021, 10, 451-460.	4.2	5
1764	A high-throughput imaging platform to characterize extracellular pH in organotypic three-dimensional in vitro models of liver cancer. <i>NMR in Biomedicine</i> , 2021, 34, e4465.	1.6	3
1765	Multimodal Priors Guided Segmentation of Liver Lesions in MRI Using Mutual Information Based Graph Co-Attention Networks. <i>Lecture Notes in Computer Science</i> , 2020, , 429-438.	1.0	9
1766	LncRNA RHPN1-AS1 accelerates proliferation, migration, and invasion via regulating miR-485-5p/BSG axis in hepatocellular carcinoma. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2020, 393, 2543-2551.	1.4	8
1767	Oligometastatic Colorectal Cancer Management: A Survey of the Italian College of Interventional Radiology. <i>CardioVascular and Interventional Radiology</i> , 2020, 43, 1474-1483.	0.9	6
1768	Using the Controlling Nutritional Status (CONUT) Score for Evaluating Patients with Early-Stage Hepatocellular Carcinoma After Radiofrequency Ablation: A Two-Center Retrospective Study. <i>CardioVascular and Interventional Radiology</i> , 2020, 43, 1294-1304.	0.9	10
1769	The Clinical Value of Postoperative Transarterial Chemoembolization for Resectable Patients with Intermediate Hepatocellular Carcinoma After Radical Hepatectomy: a Propensity Score-Matching Study. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 1172-1183.	0.9	7
1770	Risk Factors for Hypervascularization in Hepatobiliary Phase Hypointense Nodules without Arterial Phase Hyperenhancement: A Systematic Review and Meta-analysis. <i>Academic Radiology</i> , 2022, 29, 198-210.	1.3	5
1771	FOX transcription factor family in hepatocellular carcinoma. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2020, 1874, 188376.	3.3	29
1772	Riesgo de recurrencia del carcinoma hepatocelular en pacientes tratados con antivirales libres de interferón. <i>Gastroenterología Y Hepatología</i> , 2019, 42, 502-511.	0.2	7
1773	Sequential transcatheter arterial chemoembolization and portal vein embolization before right hemihepatectomy in patients with hepatocellular carcinoma. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2020, 19, 244-251.	0.6	12
1774	miR-552 Regulates Liver Tumor-Initiating Cell Expansion and Sorafenib Resistance. <i>Molecular Therapy - Nucleic Acids</i> , 2020, 19, 1073-1085.	2.3	31
1775	m6A RNA methylation-mediated HNF3 $\beta$ reduction renders hepatocellular carcinoma dedifferentiation and sorafenib resistance. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 296.	7.1	72
1776	Involvement of CDK11B-mediated SPDEF ubiquitination and SPDEF-mediated microRNA-448 activation in the oncogenicity and self-renewal of hepatocellular carcinoma stem cells. <i>Cancer Gene Therapy</i> , 2021, 28, 1136-1149.	2.2	10
1777	Comparison of diagnostic accuracy of Midkine and AFP for detecting hepatocellular carcinoma: a systematic review and meta-analysis. <i>Bioscience Reports</i> , 2020, 40, .	1.1	23
1778	Long noncoding RNA FAM83A-AS1 facilitates hepatocellular carcinoma progression by binding with NOP58 to enhance the mRNA stability of FAM83A. <i>Bioscience Reports</i> , 2019, 39, .	1.1	39
1779	Statin use and the prognosis of patients with hepatocellular carcinoma: a meta-analysis. <i>Bioscience Reports</i> , 2020, 40, .	1.1	13
1780	Identification of prognostic biomarkers and correlations with immune infiltrates among cGAS-STING in hepatocellular carcinoma. <i>Bioscience Reports</i> , 2020, 40, .	1.1	42

#	ARTICLE	IF	CITATIONS
1781	Chemokines in hepatocellular carcinoma: a meta-analysis. <i>Carcinogenesis</i> , 2020, 41, 1682-1694.	1.3	12
1782	Co-expression of KIAA1199 and hypoxia-inducible factor 1 $\alpha$ is a biomarker for an unfavorable prognosis in hepatocellular carcinoma. <i>Medicine (United States)</i> , 2020, 99, e23369.	0.4	5
1783	Platelet-lymphocyte ratio predicts survival in patients with hepatocellular carcinoma who receive lenvatinib: an inverse probability weighting analysis. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 32, 261-268.	0.8	9
1784	Transjugular intrahepatic portosystemic shunt versus endoscopic therapy for prevention of variceal rebleeding in patients with hepatocellular carcinoma meeting the Milan criteria. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, 436-442.	0.8	3
1785	Development and Validation of a Nomogram to Preoperatively Estimate Post-hepatectomy Liver Dysfunction Risk and Long-term Survival in Patients With Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2021, 274, e1209-e1217.	2.1	45
1788	A clinical trial with valproic acid and hydralazine in combination with gemcitabine and cisplatin followed by doxorubicin and dacarbazine for advanced hepatocellular carcinoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2022, 18, 19-27.	0.7	2
1789	Bioinformatic analysis of RHO family of GTPases identifies RAC1 pharmacological inhibition as a new therapeutic strategy for hepatocellular carcinoma. <i>Gut</i> , 2021, 70, 1362-1374.	6.1	21
1790	MicroRNA-361-5p Inhibits Tumorigenesis and the EMT of HCC by Targeting Twist1. <i>BioMed Research International</i> , 2020, 2020, 1-14.	0.9	16
1791	Augmentation of IFN- $\gamma$ + CD8+ T cell responses correlates with survival of HCC patients on sorafenib therapy. <i>JCI Insight</i> , 2019, 4, .	2.3	52
1792	Myeloid signature reveals immune contexture and predicts the prognosis of hepatocellular carcinoma. <i>Journal of Clinical Investigation</i> , 2020, 130, 4679-4693.	3.9	42
1793	The role of RICTOR amplification in targeted therapy and drug resistance. <i>Molecular Medicine</i> , 2020, 26, 20.	1.9	18
1794	Hedgehog signaling promotes sorafenib resistance in hepatocellular carcinoma patient-derived organoids. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 22.	3.5	50
1796	Long Stress Induced Non-Coding Transcripts 5 (LSINCT5) Promotes Hepatocellular Carcinoma Progression Through Interaction with High-Mobility Group AT-hook 2 and MiR-4516. <i>Medical Science Monitor</i> , 2018, 24, 8510-8523.	0.5	18
1797	Clinical Significance of TRMT6 in Hepatocellular Carcinoma: A Bioinformatics-Based Study. <i>Medical Science Monitor</i> , 2019, 25, 3894-3901.	0.5	20
1798	Increased Expression of Serine Hydroxymethyltransferase 2 (SHMT2) is a Negative Prognostic Marker in Patients with Hepatocellular Carcinoma and is Associated with Proliferation of HepG2 Cells. <i>Medical Science Monitor</i> , 2019, 25, 5823-5832.	0.5	22
1799	An Individualized Immune Prognostic Index is a Superior Predictor of Survival of Hepatocellular Carcinoma. <i>Medical Science Monitor</i> , 2020, 26, e921786.	0.5	8
1800	Bioinformatics Analysis of Prognostic Tumor Microenvironment-Related Genes in the Tumor Microenvironment of Hepatocellular Carcinoma. <i>Medical Science Monitor</i> , 2020, 26, e922159.	0.5	7
1801	Measurement of Cyclin D2 (CCND2) Gene Promoter Methylation in Plasma and Peripheral Blood Mononuclear Cells and Alpha-Fetoprotein Levels in Patients with Hepatitis B Virus-Associated Hepatocellular Carcinoma. <i>Medical Science Monitor</i> , 2020, 26, e927444.	0.5	6

#	ARTICLE	IF	CITATIONS
1802	End-stage liver disease score and future liver remnant volume predict post-hepatectomy liver failure in hepatocellular carcinoma. <i>World Journal of Clinical Cases</i> , 2019, 7, 3734-3741.	0.3	23
1803	Treatment patterns and survival in hepatocellular carcinoma in the United States and Taiwan. <i>PLoS ONE</i> , 2020, 15, e0240542.	1.1	11
1804	Gene and protein expression of mTOR and LC3 in hepatocellular carcinoma, colorectal liver metastasis and "normal" liver tissues. <i>PLoS ONE</i> , 2020, 15, e0244356.	1.1	3
1805	Role of Locoregional Therapies in Patients With Hepatocellular Cancer Awaiting Liver Transplantation. <i>American Journal of Gastroenterology</i> , 2021, 116, 57-67.	0.2	12
1806	Cellular Origin of Hepatocellular Carcinoma. , 0, , 1-28.		5
1807	Mouse Models of Hepatocellular Carcinoma. , 0, , 69-94.		8
1809	Puerarin inhibits hepatocellular carcinoma invasion and metastasis through miR-21-mediated PTEN/AKT signaling to suppress the epithelial-mesenchymal transition. <i>Brazilian Journal of Medical and Biological Research</i> , 2020, 53, e8882.	0.7	25
1810	A poor prognosis in human hepatocellular carcinoma is associated with low expression of DPP4. <i>Brazilian Journal of Medical and Biological Research</i> , 2020, 53, e9114.	0.7	5
1811	BRAZILIAN SOCIETY OF HEPATOLOGY UPDATED RECOMMENDATIONS FOR DIAGNOSIS AND TREATMENT OF HEPATOCELLULAR CARCINOMA. <i>Arquivos De Gastroenterologia</i> , 2020, 57, 1-20.	0.3	22
1812	Metabolic syndrome, non-alcoholic fatty liver disease and hepatocarcinoma. <i>Revista Espanola De Enfermedades Digestivas</i> , 2020, 112, 133-138.	0.1	7
1813	Recent Advances and Future Directions in Immunotherapeutics for Hepatocellular Carcinoma. <i>Journal of Liver Cancer</i> , 2019, 19, 1-11.	0.3	4
1814	Ubiquitin-speciĳ-c protease 4 promotes metastasis of hepatocellular carcinoma by increasing TGF-ĳ <sup>2</sup> signaling-induced epithelial-mesenchymal transition. <i>Aging</i> , 2018, 10, 2783-2799.	1.4	29
1815	Tumor-suppressive miR-3650 inhibits tumor metastasis by directly targeting NFASC in hepatocellular carcinoma. <i>Aging</i> , 2019, 11, 3432-3444.	1.4	16
1816	Tree-based classification system incorporating the HVTT-PVTT score for personalized management of hepatocellular carcinoma patients with macroscopic vascular invasion. <i>Aging</i> , 2019, 11, 9544-9555.	1.4	8
1817	Large-scale analyses identify a cluster of novel long noncoding RNAs as potential competitive endogenous RNAs in progression of hepatocellular carcinoma. <i>Aging</i> , 2019, 11, 10422-10453.	1.4	31
1818	Obg-like ATPase 1 (OLA1) overexpression predicts poor prognosis and promotes tumor progression by regulating P21/CDK2 in hepatocellular carcinoma. <i>Aging</i> , 2020, 12, 3025-3041.	1.4	19
1819	Elevated systemic inflammatory responses, factors associated with physical and mental quality of life, and prognosis of hepatocellular carcinoma. <i>Aging</i> , 2020, 12, 4357-4370.	1.4	9
1820	Identification and validation of the angiogenic genes for constructing diagnostic, prognostic, and recurrence models for hepatocellular carcinoma. <i>Aging</i> , 2020, 12, 7848-7873.	1.4	9

#	ARTICLE	IF	CITATIONS
1821	Androgen receptor affects the response to immune checkpoint therapy by suppressing PD-L1 in hepatocellular carcinoma. <i>Aging</i> , 2020, 12, 11466-11484.	1.4	27
1822	A novel molecular-clinicopathologic nomogram to improve prognosis prediction of hepatocellular carcinoma. <i>Aging</i> , 2020, 12, 12896-12920.	1.4	7
1823	RP11-295G20.2 facilitates hepatocellular carcinoma progression via the miR-6884-3p/CCNB1 pathway. <i>Aging</i> , 2020, 12, 14918-14932.	1.4	8
1824	Prognostic roles of metabolic reprogramming-associated genes in patients with hepatocellular carcinoma. <i>Aging</i> , 2020, 12, 22199-22219.	1.4	14
1825	Isoquercitrin induces apoptosis and autophagy in hepatocellular carcinoma cells via AMPK/mTOR/p70S6K signaling pathway. <i>Aging</i> , 2020, 12, 24318-24332.	1.4	37
1826	Integrated bioinformatic analysis of RNA binding proteins in hepatocellular carcinoma. <i>Aging</i> , 2021, 13, 2480-2505.	1.4	18
1827	Combined locoregional and systemic therapy for advanced hepatocellular carcinoma: finally, the future is obscure. <i>Annals of Translational Medicine</i> , 2020, 8, 1700-1700.	0.7	6
1828	Camrelizumab targeting a novel PD-1 epitope to treat hepatocellular carcinoma. <i>Annals of Translational Medicine</i> , 2020, 8, 1614-1614.	0.7	2
1829	Does microvascular invasion in Barcelona Clinic Liver Cancer stage A multinodular hepatocellular carcinoma indicate early-stage behavior?. <i>Annals of Translational Medicine</i> , 2019, 7, 428-428.	0.7	15
1830	Renin-angiotensin inhibitors were associated with improving outcomes of hepatocellular carcinoma with primary hypertension after hepatectomy. <i>Annals of Translational Medicine</i> , 2019, 7, 739-739.	0.7	6
1831	Comparison of liver function and safety in hepatocellular cancer patients treated with DEB-TACE and cTACE: a multi-center, retrospective cohort study. <i>Translational Cancer Research</i> , 2019, 8, 1950-1964.	0.4	6
1832	KIF14 and KIF23 Promote Cell Proliferation and Chemoresistance in HCC Cells, and Predict Worse Prognosis of Patients with HCC. <i>Cancer Management and Research</i> , 2020, Volume 12, 13241-13257.	0.9	19
1833	Tumor-Linked Macrophages Promote HCC Development by Mediating the CCAT1/Let-7b/HMGA2 Signaling Pathway. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 12829-12843.	1.0	12
1834	Bioinformatics Analysis based on Multiple Databases Identifies Hub Genes Associated with Hepatocellular Carcinoma. <i>Current Genomics</i> , 2019, 20, 349-361.	0.7	34
1835	Insights into Nanotherapeutic Strategies as an Impending Approach to Liver Cancer Treatment. <i>Current Topics in Medicinal Chemistry</i> , 2020, 20, 1839-1854.	1.0	7
1836	Alcoholic liver fibrosis: detection and treatment. <i>Minerva Medica</i> , 2018, 109, 457-471.	0.3	37
1837	DNA Methyltransferases as Potential Biomarkers for HCV Related Hepatocellular Carcinoma. <i>Asian Pacific Journal of Cancer Prevention</i> , 2020, 21, 3357-3363.	0.5	5
1838	Risk Scoring System based on lncRNA Expression for Predicting Survival in Hepatocellular Carcinoma with Cirrhosis. <i>Asian Pacific Journal of Cancer Prevention</i> , 2020, 21, 1787-1795.	0.5	15

#	ARTICLE	IF	CITATIONS
1839	The diagnostic performance of contrast-enhanced ultrasound (CEUS) for evaluating hepatocellular carcinoma (HCC) juxtaposed to MRI findings; a retrospective single-center analysis of 292 patients. <i>Clinical Hemorheology and Microcirculation</i> , 2020, 76, 155-160.	0.9	12
1840	Switching to systemic therapy after locoregional treatment failure: Definition and best timing. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 155-162.	4.5	44
1841	Serological Biomarkers for Early Detection of Hepatocellular Carcinoma: A Focus on Autoantibodies against Tumor-Associated Antigens Encoded by Cancer Driver Genes. <i>Cancers</i> , 2020, 12, 1271.	1.7	16
1842	Molecular Mechanisms Regulating Obesity-Associated Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 1290.	1.7	20
1843	Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: An Overview. <i>Pharmaceuticals</i> , 2021, 14, 3.	1.7	16
1844	Emergence of immunotherapy as a novel way to treat hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2018, 24, 1839-1858.	1.4	30
1845	Hepatocellular carcinoma in Latin America: Diagnosis and treatment challenges. <i>World Journal of Gastroenterology</i> , 2018, 24, 4224-4229.	1.4	19
1846	Management of sub-centimeter recurrent hepatocellular carcinoma after curative treatment: Current status and future. <i>World Journal of Gastroenterology</i> , 2018, 24, 5215-5222.	1.4	22
1847	Six-long non-coding RNA signature predicts recurrence-free survival in hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2019, 25, 220-232.	1.4	114
1848	Immunotherapy with dendritic cells and cytokine-induced killer cells for hepatocellular carcinoma: A meta-analysis. <i>World Journal of Gastroenterology</i> , 2019, 25, 3649-3663.	1.4	36
1849	Treatment of hepatocellular carcinoma in patients with portal vein tumor thrombosis: Beyond the known frontiers. <i>World Journal of Gastroenterology</i> , 2019, 25, 4360-4382.	1.4	83
1850	Locoregional treatments for hepatocellular carcinoma: Current evidence and future directions. <i>World Journal of Gastroenterology</i> , 2019, 25, 4614-4628.	1.4	77
1851	CARMA3/NF- $\kappa$ B signaling contributes to tumorigenesis of hepatocellular carcinoma and is inhibited by sodium aescinate. <i>World Journal of Gastroenterology</i> , 2019, 25, 5483-5493.	1.4	12
1852	Post-transplant infection improves outcome of hepatocellular carcinoma patients after orthotopic liver transplantation. <i>World Journal of Gastroenterology</i> , 2019, 25, 5630-5640.	1.4	4
1853	Role of liver biopsy in hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2019, 25, 6041-6052.	1.4	92
1854	Effect of adipose-derived mesenchymal stem cells on hepatocellular carcinoma: <i>In vitro</i> inhibition of carcinogenesis. <i>World Journal of Gastroenterology</i> , 2019, 25, 567-583.	1.4	28
1855	Validation of the six-and-twelve criteria among patients with hepatocellular carcinoma and performance score 1 receiving transarterial chemoembolization. <i>World Journal of Gastroenterology</i> , 2020, 26, 1805-1818.	1.4	4
1856	Radiofrequency combined with immunomodulation for hepatocellular carcinoma: State of the art and innovations. <i>World Journal of Gastroenterology</i> , 2020, 26, 2040-2048.	1.4	13

#	ARTICLE	IF	CITATIONS
1857	Recent progress in pulsed electric field ablation for liver cancer. <i>World Journal of Gastroenterology</i> , 2020, 26, 3421-3431.	1.4	14
1858	Tumor microenvironment in primary liver tumors: A challenging role of natural killer cells. <i>World Journal of Gastroenterology</i> , 2020, 26, 4900-4918.	1.4	19
1859	Application of artificial intelligence in the diagnosis and treatment of hepatocellular carcinoma: A review. <i>World Journal of Gastroenterology</i> , 2020, 26, 5617-5628.	1.4	40
1860	Validation and evaluation of clinical prediction systems for first and repeated transarterial chemoembolization in unresectable hepatocellular carcinoma: A Chinese multicenter retrospective study. <i>World Journal of Gastroenterology</i> , 2020, 26, 657-669.	1.4	8
1861	Modified Child-Pugh grade <i>vs</i> albumin-bilirubin grade for predicting prognosis of hepatocellular carcinoma patients after hepatectomy. <i>World Journal of Gastroenterology</i> , 2020, 26, 749-758.	1.4	12
1862	Anti-angiogenic and anti-proliferative effects of Benja-ummarit extract in rats with hepatocellular carcinoma. <i>Biomedical Reports</i> , 2020, 12, 109-120.	0.9	6
1863	Extracellular vesicles from senescent hepatic stellate cells promote cell viability of hepatoma cells through increasing EGF secretion from differentiated THP-1 cells. <i>Biomedical Reports</i> , 2020, 12, 163-170.	0.9	13
1864	Efficacy and safety of drug-eluting beads for transarterial chemoembolization in patients with advanced hepatocellular carcinoma. <i>Experimental and Therapeutic Medicine</i> , 2019, 18, 4625-4630.	0.8	5
1865	Bioinformatics analysis reveals meaningful markers and outcome predictors in HBV-associated hepatocellular carcinoma. <i>Experimental and Therapeutic Medicine</i> , 2020, 20, 427-435.	0.8	6
1866	The role of long noncoding RNA SNHG7 in human cancers (Review). <i>Molecular and Clinical Oncology</i> , 2020, 13, 1-1.	0.4	13
1867	Impact of cancer rehabilitation on the prognosis of patients with hepatocellular carcinoma. <i>Oncology Letters</i> , 2020, 19, 2355-2367.	0.8	20
1868	Indication of suitable transarterial chemoembolization and multikinase inhibitors for intermediate stage hepatocellular carcinoma. <i>Oncology Letters</i> , 2020, 19, 2667-2676.	0.8	7
1869	BUB1 promotes proliferation of liver cancer cells by activating SMAD2 phosphorylation. <i>Oncology Letters</i> , 2020, 19, 3506-3512.	0.8	35
1870	Exosomes derived from endoplasmic reticulum-stressed liver cancer cells enhance the expression of cytokines in macrophages via the STAT3 signaling pathway. <i>Oncology Letters</i> , 2020, 20, 589-600.	0.8	30
1871	Genomic DNA methylation profiling indicates immune response following thermal ablation treatment for HBV-associated hepatocellular carcinoma. <i>Oncology Letters</i> , 2020, 20, 677-684.	0.8	3
1872	Identification of hub genes involved in the occurrence and development of hepatocellular carcinoma via bioinformatics analysis. <i>Oncology Letters</i> , 2020, 20, 1695-1708.	0.8	8
1873	Lenvatinib prolongs the progression-free survival time of patients with intermediate-stage hepatocellular carcinoma refractory to transarterial chemoembolization: A multicenter cohort study using data mining analysis. <i>Oncology Letters</i> , 2020, 20, 2257-2265.	0.8	44
1874	Identification of the association between HMMR expression and progression of hepatocellular carcinoma via construction of a co-expression network. <i>Oncology Letters</i> , 2020, 20, 2645-2654.	0.8	10



#	ARTICLE	IF	CITATIONS
1875	MicroRNAâ€²12â€²3p inhibits paclitaxel resistance through regulating epithelialâ€²mesenchymal transition, migration and invasion by targeting ZEB2 in human hepatocellular carcinoma. <i>Oncology Letters</i> , 2020, 20, 23.	0.8	12
1876	Risk scoring based on expression of long nonâ€²coding RNAs can effectively predict survival in hepatocellular carcinoma patients with or without fibrosis. <i>Oncology Reports</i> , 2020, 43, 1451-1466.	1.2	21
1877	Selecting the first line treatment in non-metastatic hepatocellular carcinoma - comparing clinical practice guidelines. <i>Oncology Reviews</i> , 2020, 14, 515.	0.8	5
1878	Microwave ablation versus other interventions for hepatocellular carcinoma: A systematic review and meta-analysis. <i>Journal of Cancer Research and Therapeutics</i> , 2020, 16, 379.	0.3	9
1879	Abnormal CD44 activation of hepatocytes with nonalcoholic fatty accumulation in rat hepatocarcinogenesis. <i>World Journal of Gastrointestinal Oncology</i> , 2020, 12, 66-76.	0.8	9
1880	Sorafenib combined with embolization plus hepatic arterial infusion chemotherapy for inoperable hepatocellular carcinoma. <i>World Journal of Gastrointestinal Oncology</i> , 2020, 12, 663-676.	0.8	13
1881	Cirrhotic patients and older people. <i>World Journal of Hepatology</i> , 2019, 11, 678-688.	0.8	22
1882	Hepatocellular carcinoma staging systems: Hong Kong liver cancer <i>vs</i> Barcelona clinic liver cancer in a Western population. <i>World Journal of Hepatology</i> , 2019, 11, 689-700.	0.8	8
1883	Imaging response predictors following drug eluting beads chemoembolization in the neoadjuvant liver transplant treatment of hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2020, 12, 21-33.	0.8	8
1884	Clinical characteristics and treatment outcomes in patients with liver cirrhosis and lymphoma. <i>World Journal of Hepatology</i> , 2020, 12, 34-45.	0.8	4
1885	Biomarkers for hepatocellular cancer. <i>World Journal of Hepatology</i> , 2020, 12, 558-573.	0.8	30
1886	Cost-Effectiveness of Cabozantinib in the Second-Line Treatment of Advanced Hepatocellular Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 669-675.	2.3	29
1887	Management of Hepatocellular Carcinoma during the COVID-19 Pandemic - SÃ£o Paulo ClÃ¢nicas Liver Cancer Group Multidisciplinary Consensus Statement. <i>Clinics</i> , 2020, 75, e2192.	0.6	11
1888	Second-line treatment options in hepatocellular carcinoma. <i>Drugs in Context</i> , 2019, 8, 1-13.	1.0	32
1889	Identification of Flap endonuclease 1 as a potential core gene in hepatocellular carcinoma by integrated bioinformatics analysis. <i>PeerJ</i> , 2019, 7, e7619.	0.9	11
1890	A genomic-clinical nomogram predicting recurrence-free survival for patients diagnosed with hepatocellular carcinoma. <i>PeerJ</i> , 2019, 7, e7942.	0.9	8
1891	LINC00844 promotes proliferation and migration of hepatocellular carcinoma by regulating NDRG1 expression. <i>PeerJ</i> , 2020, 8, e8394.	0.9	13
1892	Transcriptome analysis revealed key prognostic genes and microRNAs in hepatocellular carcinoma. <i>PeerJ</i> , 2020, 8, e8930.	0.9	26

#	ARTICLE	IF	CITATIONS
1893	Diagnosis and Evaluation of Hepatocellular Carcinoma. , 2021, , 1-22.		0
1894	Hepatocellular Cancer. UNIPA Springer Series, 2021, , 689-706.	0.1	2
1895	Circular RNA hsa_circ_0001306 Functions as a Competing Endogenous RNA to Regulate FBXW7 Expression by Sponging miR-527 in Hepatocellular Carcinoma. Journal of Cancer, 2021, 12, 6531-6542.	1.2	6
1896	Histogram peritumoral enhanced features on MRI arterial phase with extracellular contrast agent can improve prediction of microvascular invasion of hepatocellular carcinoma. Quantitative Imaging in Medicine and Surgery, 2022, 12, 1372-1384.	1.1	4
1897	Methylene tetrahydrofolate reductase (MTHFR) and vascular endothelial growth factor (VEGF) polymorphisms in Brazilian patients with Hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC). Clinics, 2021, 76, e2881.	0.6	4
1898	Microwave ablation vs. surgical resection for treatment naïve hepatocellular carcinoma within the Milan criteria: a follow-up of at least 5 years. Cancer Biology and Medicine, 2021, 19, 1078-1088.	1.4	4
1899	Diosmetin inhibits cell growth and proliferation by regulating the cell cycle and lipid metabolism pathway in hepatocellular carcinoma. Food and Function, 2021, 12, 12036-12046.	2.1	15
1900	The Toronto Postliver Transplantation Hepatocellular Carcinoma Recurrence Calculator: A Machine Learning Approach. Liver Transplantation, 2022, 28, 593-602.	1.3	28
1901	Comparison Between Portal Vein Perfusion Chemotherapy and Neoadjuvant Hepatic Arterial Infusion Chemotherapy for Resectable Intermediate to Advanced Stage Hepatocellular Carcinoma. Annals of Surgical Oncology, 2022, 29, 2016-2029.	0.7	7
1902	Thermal ablation and immunotherapy for hepatocellular carcinoma: Recent advances and future directions. World Journal of Gastrointestinal Oncology, 2021, 13, 1397-1411.	0.8	9
1903	In the Era of Systemic Therapy for Hepatocellular Carcinoma Is Transarterial Chemoembolization Still a Card to Play?. Cancers, 2021, 13, 5129.	1.7	2
1904	Role of N6-Methyladenosine (m6A) Methylation Regulators in Hepatocellular Carcinoma. Frontiers in Oncology, 2021, 11, 755206.	1.3	16
1905	Circulating Tumor Cell Is a Clinical Indicator of Pretransplant Radiofrequency Ablation for Patients with Hepatocellular Carcinoma. Journal of Oncology, 2021, 2021, 1-10.	0.6	4
1906	Predictors of residual hepatic reserve and hepatic decompensation in cirrhotic patients after ablated hepatocellular carcinoma treated by DDAs or systemic therapy. Egyptian Liver Journal, 2021, 11, .	0.3	0
1907	Does Neutrophil to Lymphocyte Ratio Have a Role in Identifying Cytokeratin 19-Expressing Hepatocellular Carcinoma?. Journal of Personalized Medicine, 2021, 11, 1078.	1.1	3
1908	A novel tumor doubling time-related immune gene signature for prognosis prediction in hepatocellular carcinoma. Cancer Cell International, 2021, 21, 522.	1.8	6
1909	Gene expression signature as a surrogate marker of microvascular invasion on routine hepatocellular carcinoma biopsies. Journal of Hepatology, 2022, 76, 343-352.	1.8	30
1910	MRI-based Nomogram Predicts the Risk of Progression of Unresectable Hepatocellular Carcinoma After Combined Lenvatinib and anti-PD-1 Antibody Therapy. Academic Radiology, 2022, 29, 819-829.	1.3	8

#	ARTICLE	IF	CITATIONS
1911	Long-read sequencing reveals the structural complexity of genomic integration of HBV DNA in hepatocellular carcinoma. <i>Npj Genomic Medicine</i> , 2021, 6, 84.	1.7	10
1912	Preoperative Serum Prealbumin Level and Adverse Prognosis in Patients With Hepatocellular Carcinoma After Hepatectomy: A Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 775425.	1.3	6
1913	Treatment of microvascular invasion in hepatocellular carcinoma with drug-loaded nanocomposite platform under synergistic effect of magnetic field/near-infrared light. <i>Journal of Biomedical Materials Research - Part B Applied Biomaterials</i> , 2021, , .	1.6	1
1914	Early Prediction of Objective Response of Fibrinogen in a Real-World Cohort of Hepatocellular Carcinoma Cases Treated by Programmed Cell Death Receptor-1 and Lenvatinib. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 5019-5026.	1.0	4
1915	A novel m6A-related prognostic signature for predicting the overall survival of hepatocellular carcinoma patients. <i>IET Systems Biology</i> , 2022, 16, 1-17.	0.8	5
1916	MiR-122 radiosensitize hepatocellular carcinoma cells by suppressing cyclin G1. <i>International Journal of Radiation Biology</i> , 2022, 98, 11-17.	1.0	5
1917	CT-based radiomics to predict development of macrovascular invasion in hepatocellular carcinoma: A multicenter study. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2022, 21, 325-333.	0.6	5
1918	Exploring the clinical value of preoperative serum gamma-glutamyl transferase levels in the management of patients with hepatocellular carcinoma receiving postoperative adjuvant transarterial chemoembolization. <i>BMC Cancer</i> , 2021, 21, 1117.	1.1	0
1919	Hsa_circ_0001806 promotes glycolysis and cell progression in hepatocellular carcinoma through miR-125b/HK2. <i>Journal of Clinical Laboratory Analysis</i> , 2021, 35, e23991.	0.9	10
1920	The difference in prolonged continuous and intermittent Pringle maneuver during complex hepatectomy for hepatocellular carcinoma patients with chronic liver disease: A retrospective cohort study. <i>Cancer Medicine</i> , 2021, 10, 8507-8517.	1.3	4
1921	Therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma. <i>JGH Open</i> , 2021, 5, 1275-1283.	0.7	12
1922	circSLC30A7 Inhibits Hepatocellular Carcinoma Cell Proliferation via the miR-767-5p/FBXW7/NOTCH1 Axis. <i>Journal of Oncology</i> , 2021, 2021, 1-15.	0.6	1
1923	Upregulation of Nei-Like DNA Glycosylase 3 Predicts Poor Prognosis in Hepatocellular Carcinoma. <i>Journal of Oncology</i> , 2021, 2021, 1-11.	0.6	4
1924	Translational Regulation in Hepatocellular Carcinogenesis. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 4359-4369.	2.0	3
1925	ERK5 signalling pathway is a novel target of sorafenib: Implication in EGF biology. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 10591-10603.	1.6	7
1926	Outcomes of reduction hepatectomy combined with postoperative multidisciplinary therapy for advanced hepatocellular carcinoma. <i>World Journal of Gastrointestinal Surgery</i> , 2021, 13, 1245-1257.	0.8	2
1927	The impact of particulate matter 2.5 on the risk of hepatocellular carcinoma: a meta-analysis. <i>International Archives of Occupational and Environmental Health</i> , 2022, 95, 677-683.	1.1	9
1928	GP73-mediated secretion of AFP and GP73 promotes proliferation and metastasis of hepatocellular carcinoma cells. <i>Oncogenesis</i> , 2021, 10, 69.	2.1	8

#	ARTICLE	IF	CITATIONS
1929	Role of radiotherapy in Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma treated with sorafenib. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 387-394.	1.4	10
1930	CCL23 in Balancing the Act of Endoplasmic Reticulum Stress and Antitumor Immunity in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 727583.	1.3	5
1931	Maximum Plasma Concentration of Lenvatinib Is Useful for Predicting Thrombocytopenia in Patients Treated for Hepatocellular Carcinoma. <i>World Journal of Oncology</i> , 2021, 12, 165-172.	0.6	2
1932	Identification of Gene-Set Signature in Early-Stage Hepatocellular Carcinoma and Relevant Immune Characteristics. <i>Frontiers in Oncology</i> , 2021, 11, 740484.	1.3	2
1933	Thermal ablation combined with transarterial chemoembolization for hepatocellular carcinoma: What is the right treatment sequence?. <i>European Journal of Radiology</i> , 2021, 144, 110006.	1.2	6
1934	GNA14's interaction with RACK1 inhibits hepatocellular carcinoma progression through reducing MAPK/JNK and PI3K/AKT signaling pathway. <i>Carcinogenesis</i> , 2021, 42, 1357-1369.	1.3	12
1935	Regorafenib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: a real-world study. <i>BMC Gastroenterology</i> , 2021, 21, 393.	0.8	18
1936	Impact of aging on primary liver cancer: epidemiology, pathogenesis and therapeutics. <i>Aging</i> , 2021, 13, 23416-23434.	1.4	17
1937	Alpelisib combination treatment as novel targeted therapy against hepatocellular carcinoma. <i>Cell Death and Disease</i> , 2021, 12, 920.	2.7	13
1938	Ferritinophagy-Mediated ROS Production Contributed to Proliferation Inhibition, Apoptosis, and Ferroptosis Induction in Action of Mechanism of 2-Pyridylhydrazone Dithiocarbamate Acetate. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-17.	1.9	8
1939	Lobar Radioembolization for Intermediate and Advanced Hepatocellular Carcinoma: Retrospective and Prospective Data. <i>Seminars in Interventional Radiology</i> , 2021, 38, 412-418.	0.3	1
1940	Implementing a robotic liver resection program does not always require prior laparoscopic experience. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2022, 36, 3317-3322.	1.3	9
1941	Association between Time to Local Tumor Control and Treatment Outcomes Following Repeated Loco-Regional Treatment Session in Patients with Hepatocellular Carcinoma: A Retrospective, Single-Center Study. <i>Life</i> , 2021, 11, 1062.	1.1	0
1942	Targeting the complex I and III of mitochondrial electron transport chain as a potentially viable option in liver cancer management. <i>Cell Death Discovery</i> , 2021, 7, 293.	2.0	4
1943	Improving Outcomes of Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma: New Data and Ongoing Trials. <i>Frontiers in Oncology</i> , 2021, 11, 752725.	1.3	28
1944	Engineering nanotheranostic strategies for liver cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 1213-1228.	0.8	7
1945	Integrated bioinformatics analyses of key genes involved in hepatocellular carcinoma immunosuppression. <i>Oncology Letters</i> , 2021, 22, 830.	0.8	10
1946	Circular RNA Circ-0003006 Promotes Hepatocellular Carcinoma Proliferation and Metastasis Through Sponging miR-542-3p and Regulating HIF-1A. <i>Cancer Management and Research</i> , 2021, Volume 13, 7859-7870.	0.9	4

#	ARTICLE	IF	CITATIONS
1947	Long Non-coding RNA DANCR in Cancer: Roles, Mechanisms, and Implications. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 753706.	1.8	17
1948	Immunonutritive Scoring for Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Evaluation of the CALLY Index. <i>Cancers</i> , 2021, 13, 5018.	1.7	16
1949	Cyclin-dependent kinase 1 as a potential target for lycorine against hepatocellular carcinoma. <i>Biochemical Pharmacology</i> , 2021, 193, 114806.	2.0	14
1950	Targeted delivery of Bi2Se3 Nanoflowers to orthotopic liver tumor via transarterial infusion for enhanced microwave ablation sensibilization. <i>Nano Today</i> , 2021, 41, 101314.	6.2	10
1951	Optimizing outcomes in HCC: Comment on "Optimal timing of combining sorafenib with trans-arterial chemoembolization in patients with hepatocellular carcinoma: A meta-analysis" by Jiang et al.. <i>Translational Oncology</i> , 2021, 14, 101246.	1.7	0
1952	Hepatocellular cancer and liver transplantation: necessity to go from chaos to order. <i>Almanah Klinicheskoj Mediciny</i> , 2018, 46, 552-559.	0.2	1
1953	Recent advances in the systemic treatment of gastrointestinal malignancy. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2019, 40, 336.	0.1	0
1954	Alcohol Intake and Cancer Risk. <i>Food Chemistry, Function and Analysis</i> , 2019, , 108-127.	0.1	0
1955	Efficacy and Safety of Transarterial Chemoembolization Combined with Apatinib Mesylate in Patients with Advanced Hepatocellular Carcinoma. <i>Advances in Clinical Medicine</i> , 2019, 09, 1339-1345.	0.0	0
1956	A case of hepatocellular carcinoma diagnosis using direct oral anticoagulants. <i>Acta Hepatologica Japonica</i> , 2019, 60, 39-45.	0.0	1
1957	Characteristics and survival of hepatocellular carcinoma in non-cirrhotic liver.. <i>Revista Espanola De Enfermedades Digestivas</i> , 2019, 111, 760-766.	0.1	3
1958	Altered expression of COX-2 and TNF-a in patients with hepatocellular carcinoma. <i>Revista Espanola De Enfermedades Digestivas</i> , 2019, 111, 364-370.	0.1	3
1959	Advances in Research on Immunological Checkpoint Inhibitors in Immunotherapy of Liver Cancer. <i>International Journal of Clinical Medicine</i> , 2019, 10, 62-69.	0.1	0
1960	The future is now: beyond first line systemic therapy in hepatocellular carcinoma. <i>Translational Cancer Research</i> , 2019, 8, S261-S274.	0.4	5
1961	The combination of transcatheter arterial chemoembolisation (TACE) and thermal ablation versus TACE alone for hepatocellular carcinoma. <i>The Cochrane Library</i> , 0, , .	1.5	1
1962	ĐžĐ   Đ†ĐĐšĐ•Đ•Đ—ĐŸĐ•ĐšĐĐžĐ;ĐĐ† Đ’ĐĐłĐĐĐ†Đ’ĐĐ—ĐžĐŸĐ•ĐšĐ†ĐĐšĐžĐ’ĐžĐ“Đž Đ’Đ’Đ•Đ”Đ•ĐĐĐˆ 10%ĐĐžĐ—ĐšĐĐĐĐ		
1963	Extrahepatic Vascular Parasitization by a Hepatocellular Carcinoma. <i>Cureus</i> , 2019, 11, e5807.	0.2	0
1964	Microvascular invasion in hepatocellular carcinoma: is it predictable with quantitative computed tomography parameters?. <i>Radiologia Brasileira</i> , 2019, 52, 287-292.	0.3	8

#	ARTICLE	IF	CITATIONS
1965	Systemic inflammatory response predicts poor prognoses in Barcelona Clinic Liver Cancer stage B/C hepatocellular carcinoma with transarterial chemoembolization: a prospective study. <i>Translational Cancer Research</i> , 2019, 8, 2552-2563.	0.4	3
1966	Improved outcomes with surgery compared to radiofrequency ablation in the treatment of resectable hepatocellular carcinoma. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 1397-1402.	0.8	0
1968	Liver Carcinoma. , 2020, , 131-143.		0
1969	A Transposon-Based Mouse Model of Hepatocellular Carcinoma via Hydrodynamic Tail Vein Injection. <i>Methods in Molecular Biology</i> , 2020, 2164, 129-143.	0.4	1
1970	Emerging Roles of Phytochemicals in Hepatocellular Carcinoma. , 2020, , 287-302.		0
1973	Differences in Survival Between First-Line Radiofrequency Ablation versus Surgery for Early-Stage Hepatocellular Carcinoma: A Population Study Using the Surveillance, Epidemiology, and End Results Database. <i>Medical Science Monitor</i> , 2020, 26, e921782.	0.5	2
1974	Serum Levels of Granulocyte-Macrophage-colony-stimulating Factor and Stem-cell Factor During Liver Regeneration after Partial Hepatectomy in Humans. <i>Reviews on Recent Clinical Trials</i> , 2020, 15, 131-136.	0.4	0
1975	Efficacy of combining electricâ€field and coronalâ€plane imaging to obtain ultrasoundâ€ultrasound fusion images in monopolar radiofrequency ablation for patients with liver cancer. <i>Hepatology Research</i> , 2020, 50, 985-995.	1.8	4
1976	Development and validation of a risk score for predicting mortality after resection of primary hepatocellular carcinoma. <i>Aging</i> , 2020, 12, 11878-11892.	1.4	0
1977	STAT3 Inhibition by Centipede Scolopendra Extract in Liver Cancer HepG2 Cells and Orthotopic Mouse Models of Hepatocellular Carcinoma. <i>Digital Chinese Medicine</i> , 2020, 3, 67-79.	0.5	1
1978	Modern principles of hepatocellular carcinoma treatment. <i>Annals of HPB Surgery</i> , 2020, 25, 15-26.	0.1	1
1979	Hepatitis B virus X protein boosts hepatocellular carcinoma progression by downregulating microRNA-137. <i>Pathology Research and Practice</i> , 2020, 216, 152981.	1.0	9
1980	FOXK2 downregulation suppresses EMT in hepatocellular carcinoma. <i>Open Medicine (Poland)</i> , 2020, 15, 702-708.	0.6	5
1981	&lt;em&gt;NT5DC2&lt;/em&gt; is a novel prognostic marker in human hepatocellular carcinoma. <i>Oncology Letters</i> , 2020, 20, 70.	0.8	7
1983	â€Six-and-twelveâ€score for outcome prediction of hepatocellular carcinoma following transarterial chemoembolization. In-depth analysis from a multicenter French cohort. <i>World Journal of Hepatology</i> , 2020, 12, 525-532.	0.8	3
1984	Value of surgical resection compared to transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein tumor thrombus: A meta-analysis of hazard ratios from five observational studies. <i>Annals of Hepato-biliary-pancreatic Surgery</i> , 2020, 24, 243-251.	0.1	2
1985	MicroRNAâ€875â€5p inhibits tumor growth and metastasis of hepatocellular carcinoma by targeting eukaryotic translation initiation factor 3 subunit a. <i>Oncology Reports</i> , 2020, 44, 2067-2079.	1.2	8
1986	Neutrophil-mediated clinical nanodrug for treatment of residual tumor after focused ultrasound ablation. <i>Journal of Nanobiotechnology</i> , 2021, 19, 345.	4.2	10

#	ARTICLE	IF	CITATIONS
1987	Chemo-photodynamic therapy with light-triggered disassembly of theranostic nanoplatform in combination with checkpoint blockade for immunotherapy of hepatocellular carcinoma. <i>Journal of Nanobiotechnology</i> , 2021, 19, 355.	4.2	33
1989	Superselective Transarterial Chemoembolization for Unresectable or "Ablation Unsuitable" Hepatocellular Carcinoma in the Caudate Lobe: A Real World, Single-Center Retrospective Study. <i>Frontiers in Oncology</i> , 2021, 11, 678847.	1.3	1
1990	Development of a novel prognostic nomogram for the early recurrence of liver cancer after curative hepatectomy. <i>Annals of Translational Medicine</i> , 2021, 9, 1541-1541.	0.7	6
1991	Association of FOXO3 Expression with Tumor Pathogenesis, Prognosis and Clinicopathological Features in Hepatocellular Carcinoma: A Systematic Review with Meta-Analysis. <i>Cancers</i> , 2021, 13, 5349.	1.7	9
1992	In vitro evaluation of anti-proliferative activity of protein from Litchi chinensis honey against human cervical cancer cell line (HeLa). <i>Journal of Herbal Medicine</i> , 2021, 31, 100518.	1.0	1
1993	Optimal application of stereotactic body radiotherapy and radiofrequency ablation treatment for different multifocal hepatocellular carcinoma lesions in patients with Barcelona Clinic Liver Cancer stage A4-B1: a pilot study. <i>BMC Cancer</i> , 2021, 21, 1169.	1.1	2
1994	Molecular alterations that precede the establishment of the hallmarks of cancer: An approach on the prevention of hepatocarcinogenesis. <i>Biochemical Pharmacology</i> , 2021, 194, 114818.	2.0	3
1995	Artificial neural network for prediction of acute kidney injury after liver transplantation for cirrhosis and hepatocellular carcinoma. <i>Artificial Intelligence in Cancer</i> , 2021, 2, 51-59.	1.1	0
1996	Transradial Access for Interventional Oncology: Chemoembolization and Radioembolization Applications. , 2022, , 57-61.		0
1997	CTNNB1 Alternation Is a Potential Biomarker for Immunotherapy Prognosis in Patients With Hepatocellular Carcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 759565.	2.2	29
1998	Breath-Taking Perspectives and Preliminary Data toward Early Detection of Chronic Liver Diseases. <i>Biomedicines</i> , 2021, 9, 1563.	1.4	9
1999	Identification of SLITRK6 as a Novel Biomarker in hepatocellular carcinoma by comprehensive bioinformatic analysis. <i>Biochemistry and Biophysics Reports</i> , 2021, 28, 101157.	0.7	2
2000	Immunotherapeutic treatments in hepatocellular carcinoma; achievements, challenges and future prospects. <i>International Immunopharmacology</i> , 2021, 101, 108322.	1.7	18
2001	HNRNPU promotes the progression of hepatocellular carcinoma by enhancing CDK2 transcription. <i>Experimental Cell Research</i> , 2021, 409, 112898.	1.2	13
2002	Constructing the Logical Regression Model to Predict the Target of Jianpi Jiedu Decoction in the Treatment of Hepatocellular Carcinoma. <i>Evidence-based Complementary and Alternative Medicine</i> , 2020, 2020, 1-12.	0.5	1
2003	Connective Tissue Growth Factor in Digestive System Cancers: A Review and Meta-Analysis. <i>BioMed Research International</i> , 2020, 2020, 1-10.	0.9	2
2004	Hepatocellular carcinoma: update on treatment guidelines. <i>Gastrointestinal Nursing</i> , 2020, 18, S18-S26.	0.0	1
2005	Locoregional Therapy: Cancer Interventions with and Without Radionuclides. , 2021, , 89-109.		0

#	ARTICLE	IF	CITATIONS
2006	Three new 3-formyl-2-arylbenzofurans from <i>Itea yunnanensis</i> and their anti-hepatocellular carcinoma effects. <i>Natural Product Research</i> , 2022, 36, 1205-1214.	1.0	8
2007	Propofol versus midazolam for sedation during radiofrequency ablation in patients with hepatocellular carcinoma. <i>JGH Open</i> , 2021, 5, 273-279.	0.7	4
2008	Selection of patients with esophageal varices for liver resection of hepatocellular carcinoma. <i>BioScience Trends</i> , 2020, 14, 436-442.	1.1	1
2009	Isolated right ventricular metastasis of hepatocellular carcinoma induced by epithelial-mesenchymal transition: a case report. <i>European Heart Journal - Case Reports</i> , 2021, 5, ytaa517.	0.3	0
2010	Radiolabeled Peptide Probes for Liver Cancer Imaging. <i>Current Medicinal Chemistry</i> , 2020, 27, 6968-6986.	1.2	8
2012	Indian Council of Medical Research consensus document on hepatocellular carcinoma. <i>Indian Journal of Medical Research</i> , 2020, 152, 468.	0.4	9
2014	Saudi Association for the Study of Liver diseases and Transplantation practice guidelines on the diagnosis and management of hepatocellular carcinoma. <i>Saudi Journal of Gastroenterology</i> , 2020, 26, 1.	0.5	13
2015	New Immunological Approaches in Hepatocellular Carcinoma: Glypican-3 (GPC-3) Opportunities and Challenges. <i>Journal of Cancer Therapy</i> , 2020, 11, 647-659.	0.1	0
2016	Liver Cancer. , 2020, , 341-368.		0
2017	Development and Validation of a Tool to Assess Hepatocellular Carcinoma Knowledge among Hepatocellular Carcinoma Patients in Taiwan. <i>Open Journal of Nursing</i> , 2020, 10, 341-352.	0.2	0
2018	Hepatocellular Carcinoma: Western Experience. , 2020, , 81-118.		0
2019	Hepatobiliary Cancers and Immunology. , 2020, , 505-524.		0
2020	Comparative Analysis of Image Quality and Adverse Events between Iopamidol 250 and Ioversol 320 in Hepatic Angiography for Transcatheter Arterial Chemoembolization. <i>Journal of the Korean Society of Radiology</i> , 2020, 81, 166.	0.1	0
2021	Development and Validation of Prognostic Nomograms for BCLC A Stage Hepatocellular Carcinoma Beyond Milan Criteria after Curative Resection. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
2022	Long non-coding RNA GACAT3 promotes liver cancer progression by regulating the proliferation, apoptosis and migration of tumor cells. <i>Experimental and Therapeutic Medicine</i> , 2020, 19, 3377-3383.	0.8	3
2023	LINC00978 promotes hepatocellular carcinoma carcinogenesis partly via activating the MAPK/ERK pathway. <i>Bioscience Reports</i> , 2020, 40, .	1.1	9
2024	A combination of the preoperative neutrophil-to-lymphocyte and lymphocyte-to-monocyte ratios as a useful predictor of survival outcomes following the transarterial chemoembolization of huge hepatocellular carcinoma. <i>Journal of King Abdulaziz University, Islamic Economics</i> , 2020, 41, 376-382.	0.5	4
2025	Androgen Receptors Act as a Tumor Suppressor Gene to Suppress Hepatocellular Carcinoma Cells Progression via miR-122-5p/RABL6 Signaling. <i>Frontiers in Oncology</i> , 2021, 11, 756779.	1.3	5



#	ARTICLE	IF	CITATIONS
2026	Thyroid Disease and Hepatocellular Carcinoma Survival: A Danish Nationwide Cohort Study. <i>Gastrointestinal Tumors</i> , 2022, 9, 37-42.	0.3	0
2027	Mac-2-Binding Protein Glycosylation Isomer as a Novel Predictor of Hepatocellular Carcinoma Recurrence in Patients with Hepatitis C Virus Eradication. <i>Annals of Surgical Oncology</i> , 2022, 29, 2711-2719.	0.7	2
2028	Hepatocellular Carcinoma in 2021: An Exhaustive Update. <i>Cureus</i> , 2021, 13, e19274.	0.2	32
2029	The Potential Application of Chinese Medicine in Liver Diseases: A New Opportunity. <i>Frontiers in Pharmacology</i> , 2021, 12, 771459.	1.6	16
2030	Substrate Stiffness Drives Epithelial to Mesenchymal Transition and Proliferation through the NEAT1-Wnt/ $\beta^2$ -Catenin Pathway in Liver Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12066.	1.8	27
2031	Black race is independently associated with underutilization of transplantation for clinical T1 hepatocellular carcinoma. <i>Hpb</i> , 2022, 24, 925-932.	0.1	1
2032	Recent Advances in Local Thermal Ablation Therapy for Hepatocellular Carcinoma. <i>American Surgeon</i> , 2023, 89, 1966-1973.	0.4	4
2033	In Vivo and In Vitro Models of Hepatocellular Carcinoma: Current Strategies for Translational Modeling. <i>Cancers</i> , 2021, 13, 5583.	1.7	18
2034	Remote Ischemic Preconditioning in a Cirrhotic Patient Undergoing Major Hepatectomy. <i>Cureus</i> , 2020, 12, e9056.	0.2	1
2036	Bioinformatics analysis to reveal key biomarkers for early and late hepatocellular carcinoma. <i>Translational Cancer Research</i> , 2020, 9, 4070-4079.	0.4	1
2037	Weighted correlation gene network analysis reveals a new stemness index-related survival model for prognostic prediction in hepatocellular carcinoma. <i>Aging</i> , 2020, 12, 13502-13517.	1.4	14
2038	Biology of Liver Tumors and Outcomes of Liver Surgery. , 2021, , 303-313.		0
2039	Transarterial Chemoembolisation and Combined Therapy. <i>Medical Radiology</i> , 2021, , 283-317.	0.0	0
2040	Transarterial $^{90}\text{Y}$ trium Radioembolisation. <i>Medical Radiology</i> , 2021, , 319-347.	0.0	0
2041	Experience of Hepatocellular Cancer Therapy with Multikinase Inhibitors in the Republic of Bashkortostan. <i>KreativnaĀ HirurgiĀ I OnkologiĀ</i> , 2020, 10, 183-189.	0.1	0
2042	Effect of menopausal status on the survival and recurrence of sex-classified hepatocellular carcinoma after liver resection: a case-matched study with propensity score matching. <i>Aging</i> , 2020, 12, 25895-25915.	1.4	6
2043	Development of a Tetravalent T-Cell Engaging Bispecific Antibody Against Glypican-3 for Hepatocellular Carcinoma. <i>Journal of Immunotherapy</i> , 2021, 44, 106-113.	1.2	6
2044	Update on HCC Management and Review of the New EASL Guidelines. <i>Gastroenterology and Hepatology</i> , 2018, 14, 384-386.	0.2	7

#	ARTICLE	IF	CITATIONS
2045	EYA1 promotes cell migration and tumor metastasis in hepatocellular carcinoma. American Journal of Translational Research (discontinued), 2019, 11, 2328-2338.	0.0	5
2046	Anti-metastasis traditional Chinese medicine monomer screening system based on perinucleolar compartment analysis in hepatocellular carcinoma cells. American Journal of Translational Research (discontinued), 2019, 11, 3555-3566.	0.0	1
2047	Factors impacting technical success rate of image-guided intra-arterial therapy in rat orthotopic liver tumor model. American Journal of Translational Research (discontinued), 2019, 11, 3761-3770.	0.0	7
2048	New insights into autophagy in hepatocellular carcinoma: mechanisms and therapeutic strategies. American Journal of Cancer Research, 2019, 9, 1329-1353.	1.4	25
2050	Effects of microbubble-enhanced ultrasound combined with prothrombin on microwave ablation in rabbit VX2 liver tumor. American Journal of Translational Research (discontinued), 2019, 11, 5764-5775.	0.0	0
2052	SPP1 functions as an enhancer of cell growth in hepatocellular carcinoma targeted by miR-181c. American Journal of Translational Research (discontinued), 2019, 11, 6924-6937.	0.0	20
2053	Clinical proteomics: a driving force for cancer therapeutic target discovery and precision medicine. Cancer Biology and Medicine, 2019, 16, 623-629.	1.4	0
2054	Comparison of treatment efficacy and safety between drug-eluting bead transarterial chemoembolization with CalliSpheres microspheres and conventional transarterial chemoembolization as first-line treatment in hepatocellular carcinoma patients. American Journal of Translational Research (discontinued), 2019, 11, 7456-7470.	0.0	14
2055	Identifying TF-miRNA-mRNA regulatory modules in nitidine chloride treated HCC xenograft of nude mice. American Journal of Translational Research (discontinued), 2019, 11, 7503-7522.	0.0	7
2056	Exogenous OGF enhances the anti-tumor activity of cisplatin on hepatocellular carcinoma. International Journal of Clinical and Experimental Pathology, 2019, 12, 590-598.	0.5	0
2057	Drug-eluting bead transarterial chemoembolization is efficient and well-tolerated in treating elderly Chinese hepatocellular carcinoma patients. International Journal of Clinical and Experimental Pathology, 2018, 11, 4867-4878.	0.5	4
2058	Increased expression of osteopontin indicates poor prognosis in hepatocellular carcinoma. International Journal of Clinical and Experimental Pathology, 2018, 11, 5916-5922.	0.5	6
2060	Dedifferentiation of hepatocellular carcinoma: molecular mechanisms and therapeutic implications. American Journal of Translational Research (discontinued), 2020, 12, 2099-2109.	0.0	15
2061	Expression levels of lncRNAs are prognostic for hepatocellular carcinoma overall survival. American Journal of Translational Research (discontinued), 2020, 12, 1873-1883.	0.0	7
2062	Prognostic value of combined preoperative gamma-glutamyl transpeptidase to platelet ratio and fibrinogen in patients with HBV-related hepatocellular carcinoma after hepatectomy. American Journal of Translational Research (discontinued), 2020, 12, 2984-2997.	0.0	6
2063	MicroRNA-125a-5p regulates liver cancer cell growth, migration and invasion and EMT by targeting HAX1. International Journal of Molecular Medicine, 2020, 46, 1849-1861.	1.8	1
2064	Distinct 5-methylcytosine profiles of circular RNA in human hepatocellular carcinoma. American Journal of Translational Research (discontinued), 2020, 12, 5719-5729.	0.0	11
2065	Landscape of active enhancers developed de novo in cirrhosis and conserved in hepatocellular carcinoma. American Journal of Cancer Research, 2020, 10, 3157-3178.	1.4	8

#	ARTICLE	IF	CITATIONS
2066	Inhibitor for protein disulfide-isomerase family A member 3 enhances the antiproliferative effect of inhibitor for mechanistic target of rapamycin in liver cancer: An study on combination treatment with everolimus and 16F16. <i>Oncology Letters</i> , 2021, 21, 28.	0.8	2
2067	Abnormal expression of HNRNPA3 in multistep hepatocarcinogenesis. <i>Oncology Letters</i> , 2021, 21, 46.	0.8	1
2068	Construction of ceRNA network and identification of two differentially expressed circRNAs in hepatocellular carcinoma by bioinformatic analysis. <i>International Journal of Clinical and Experimental Pathology</i> , 2020, 13, 2727-2737.	0.5	1
2069	Epigenetically silenced linc00261 contributes to the metastasis of hepatocellular carcinoma via inducing the deficiency of FOXA2 transcription. <i>American Journal of Cancer Research</i> , 2021, 11, 277-296.	1.4	4
2070	Deep learning radiomics model accurately predicts hepatocellular carcinoma occurrence in chronic hepatitis B patients: a five-year follow-up. <i>American Journal of Cancer Research</i> , 2021, 11, 576-589.	1.4	2
2071	Adamantane-linked isothioureia derivatives suppress the growth of experimental hepatocellular carcinoma inhibition of TLR4-MyD88-NF- $\kappa$ B signaling. <i>American Journal of Cancer Research</i> , 2021, 11, 350-369.	1.4	4
2072	LncRNA RUSC1-AS1 contributes to the progression of hepatocellular carcinoma cells by modulating miR-340-5p/CREB1 axis. <i>American Journal of Translational Research (discontinued)</i> , 2021, 13, 1022-1036.	0.0	2
2073	BRCA1-associated protein 1 serves as a tumor suppressor in hepatocellular carcinoma by deubiquitinating and stabilizing PTEN. <i>American Journal of Cancer Research</i> , 2021, 11, 2044-2061.	1.4	0
2074	Inhibition of mu-opioid receptor suppresses proliferation of hepatocellular carcinoma cells via CD147-p53-MAPK cascade signaling pathway. <i>American Journal of Translational Research (discontinued)</i> , 2021, 13, 3967-3986.	0.0	1
2076	The emerging landscape of long non-coding RNAs in hepatocellular carcinoma. <i>International Journal of Clinical and Experimental Pathology</i> , 2021, 14, 920-937.	0.5	0
2077	Associations between methylenetetrahydrofolate reductase polymorphisms and hepatocellular carcinoma risk: An update meta-analysis and trial sequential analysis. <i>Medicine (United States)</i> , 2021, 100, e27527.	0.4	0
2078	Screening of a novel autophagy-related prognostic signature and therapeutic targets in hepatocellular carcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 2985-2998.	0.6	5
2079	TACE Combined with HIFU Versus Surgical Resection for Single Hepatocellular Carcinoma with Child-Pugh B Cirrhosis in Overall Survival and Progression-Free Survival: A Retrospective Study. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382110601.	0.8	3
2080	SLPI suppresses hepatocellular carcinoma progression via endoplasmic reticulum stress induced apoptosis. <i>International Journal of Biological Sciences</i> , 2022, 18, 140-153.	2.6	4
2081	Identification and Validation of a Prognostic Model Based on Three MVI-Related Genes in Hepatocellular Carcinoma. <i>International Journal of Biological Sciences</i> , 2022, 18, 261-275.	2.6	25
2082	Silybum marianum total extract, silymarin and silibinin abate hepatocarcinogenesis and hepatocellular carcinoma growth via modulation of the HGF/c-Met, Wnt/ $\beta$ -catenin, and PI3K/Akt/mTOR signaling pathways. <i>Biomedicine and Pharmacotherapy</i> , 2022, 145, 112409.	2.5	27
2083	Associations between methylenetetrahydrofolate reductase polymorphisms and hepatocellular carcinoma risk. <i>Medicine (United States)</i> , 2021, 100, e27527.	0.4	3
2084	The Construction of a Prognostic Model Based on a Peptidyl Prolyl Cis-Trans Isomerase Gene Signature in Hepatocellular Carcinoma. <i>Frontiers in Genetics</i> , 2021, 12, 730141.	1.1	0

#	ARTICLE	IF	CITATIONS
2085	A validation study of combined resection and ablation therapy for multiple hepatocellular carcinoma. <i>Clinical Radiology</i> , 2021, , .	0.5	1
2086	The best predictive model for hepatocellular carcinoma in patients with chronic hepatitis B infection. <i>Clinical and Molecular Hepatology</i> , 2022, 28, 351-361.	4.5	17
2087	Emerging roles of circular RNAs in liver cancer. <i>JHEP Reports</i> , 2022, 4, 100413.	2.6	10
2088	Roles and mechanisms of exosomal non-coding RNAs in human health and diseases. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 383.	7.1	143
2089	Mitochondrial Plasticity Promotes Resistance to Sorafenib and Vulnerability to STAT3 Inhibition in Human Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 6029.	1.7	2
2090	Long Noncoding RNA SNHG1 Regulates LMNB2 Expression by Sponging miR-326 and Promotes Cancer Growth in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 784067.	1.3	5
2091	Inhibition of DTYMK significantly restrains the growth of HCC and increases sensitivity to oxaliplatin. <i>Cell Death and Disease</i> , 2021, 12, 1093.	2.7	9
2092	Integrated Bioinformatics Analysis Identifies Heat Shock Factor 2 as a Prognostic Biomarker Associated With Immune Cell Infiltration in Hepatocellular Carcinoma. <i>Frontiers in Genetics</i> , 2021, 12, 668516.	1.1	1
2093	The role of complement in the clinical course of hepatocellular carcinoma. <i>Immunity, Inflammation and Disease</i> , 2022, 10, .	1.3	8
2094	LAGE3 promoted cell proliferation, migration, and invasion and inhibited cell apoptosis of hepatocellular carcinoma by facilitating the JNK and ERK signaling pathway. <i>Cellular and Molecular Biology Letters</i> , 2021, 26, 49.	2.7	14
2095	Fatty acid transport protein-5 (FATP5) deficiency enhances hepatocellular carcinoma progression and metastasis by reprogramming cellular energy metabolism and regulating the AMPK-mTOR signaling pathway. <i>Oncogenesis</i> , 2021, 10, 74.	2.1	12
2096	GRAMD4 inhibits tumour metastasis by recruiting the E3 ligase ITCH to target TAK1 for degradation in hepatocellular carcinoma. <i>Clinical and Translational Medicine</i> , 2021, 11, e635.	1.7	6
2097	Glycosylated 4â€methylumbelliferone as a targeted therapy for hepatocellular carcinoma. <i>Liver International</i> , 2022, 42, 444-457.	1.9	3
2098	LDH and GGT/ALT Ratio as Novel Prognostic Biomarkers in Hepatocellular Carcinoma Patients after Liver Transplantation. <i>Computational and Mathematical Methods in Medicine</i> , 2021, 2021, 1-8.	0.7	5
2099	Inhibition of matrix stiffness relating integrin $\beta$ 1 signaling pathway inhibits tumor growth in vitro and in hepatocellular cancer xenografts. <i>BMC Cancer</i> , 2021, 21, 1276.	1.1	13
2100	LncSNHG3 promotes hepatocellular carcinoma epithelial mesenchymal transition progression through the miR-152-3p/JAK1 pathway. <i>Genes and Genomics</i> , 2021, , 1.	0.5	1
2101	Surgical Conversion for Initially Unresectable Locally Advanced Hepatocellular Carcinoma Using a Triple Combination of Angiogenesis Inhibitors, Anti-PD-1 Antibodies, and Hepatic Arterial Infusion Chemotherapy: A Retrospective Study. <i>Frontiers in Oncology</i> , 2021, 11, 729764.	1.3	28
2102	Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors. <i>Cancers</i> , 2021, 13, 5665.	1.7	5

#	ARTICLE	IF	CITATIONS
2103	UBE2S promotes cell chemoresistance through PTEN-AKT signaling in hepatocellular carcinoma. <i>Cell Death Discovery</i> , 2021, 7, 357.	2.0	14
2104	Hepatitis B Before and After Hepatocellular Carcinoma. <i>Journal of Gastrointestinal Cancer</i> , 2021, 52, 1206-1210.	0.6	7
2105	Evaluating the Effectiveness of Yttrium-90 Glass Microspheres in the Treatment of Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, and Metastatic Colorectal Cancer in Practice: Protocol for the Prospective PROACTIF Phase IV Registry Study in France. <i>CardioVascular and Interventional Radiology</i> , 2022, 45, 1-11.	0.9	3
2106	Combination therapies plus transarterial chemoembolization in hepatocellular carcinoma: a snapshot of clinical trial progress. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 379-391.	1.9	5
2107	Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodules. <i>Journal of Hepatology</i> , 2022, 76, 874-882.	1.8	17
2108	BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. <i>Journal of Hepatology</i> , 2022, 76, 681-693.	1.8	1,495
2109	Optimal subsequent treatments for patients with hepatocellular carcinoma resistant to anti-PD-1 treatment. <i>Immunotherapy</i> , 2021, , .	1.0	0
2110	Virological breakthrough after immune checkpoint inhibitor and nucleos(t)ide analog treatment in patients with hepatitis B surface antigen positive hepatocellular carcinoma: a real-world study. , 2021, 9, e003195.		3
2111	Development of a DNA Aptamer against Multidrug-Resistant Hepatocellular Carcinoma for <i>In Vivo</i> Imaging. <i>ACS Applied Materials &amp; Interfaces</i> , 2021, 13, 54656-54664.	4.0	11
2112	Exploring the Prognostic Value, Immune Implication and Biological Function of H2AFY Gene in Hepatocellular Carcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 723293.	2.2	3
2114	Role of mammalian target of rapamycin complex 2 in primary and secondary liver cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 1632-1647.	0.8	5
2115	Lenvatinib Plus Immune Checkpoint Inhibitors Improve Survival in Advanced Hepatocellular Carcinoma: A Retrospective Study. <i>Frontiers in Oncology</i> , 2021, 11, 751159.	1.3	16
2116	Identifying a Hypoxia-Related Long Non-Coding RNAs Signature to Improve the Prediction of Prognosis and Immunotherapy Response in Hepatocellular Carcinoma. <i>Frontiers in Genetics</i> , 2021, 12, 785185.	1.1	13
2117	Inositol 1,4,5-trisphosphate receptor type 3 is involved in resistance to apoptosis and maintenance of human hepatocellular carcinoma. <i>Oncology Letters</i> , 2021, 23, 32.	0.8	1
2118	A Novel Nine-Gene Signature Associated With Immune Infiltration for Predicting Prognosis in Hepatocellular Carcinoma. <i>Frontiers in Genetics</i> , 2021, 12, 730732.	1.1	2
2119	The Hepatic Sinusoid in Chronic Liver Disease: The Optimal Milieu for Cancer. <i>Cancers</i> , 2021, 13, 5719.	1.7	14
2120	Increased Serum Pentraxin 3 Levels are Associated with Poor Prognosis of Hepatitis B Virus-Related Hepatocellular Carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 1367-1373.	1.8	2
2121	TRAF7 contributes to tumor progression by promoting ubiquitin-proteasome mediated degradation of P53 in hepatocellular carcinoma. <i>Cell Death Discovery</i> , 2021, 7, 352.	2.0	14

#	ARTICLE	IF	CITATIONS
2122	Interventional Radiology Image-Guided Locoregional Therapies (LRTs) and Immunotherapy for the Treatment of HCC. <i>Cancers</i> , 2021, 13, 5797.	1.7	13
2123	HBV HBx-Downregulated lncRNA LINC01010 Attenuates Cell Proliferation by Interacting with Vimentin. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12497.	1.8	5
2124	A scoring model based on ferroptosis genes for prognosis and immunotherapy response prediction and tumor microenvironment evaluation in liver hepatocellular carcinoma. <i>Aging</i> , 2021, 13, 24866-24881.	1.4	4
2125	Repeated loco-regional therapies for hepatocellular carcinoma is associated with inferior outcome after living donor liver transplantation in cirrhotic patients. <i>Journal of the Chinese Medical Association</i> , 2022, 85, 317-323.	0.6	3
2126	Construction of an HCC recurrence model based on the investigation of immune-related lncRNAs and related mechanisms. <i>Molecular Therapy - Nucleic Acids</i> , 2021, 26, 1387-1400.	2.3	6
2127	Role of CD5L and SRD5A2 as Prognostic Biomarkers for Hepatocellular Carcinoma. <i>International Journal of General Medicine</i> , 2021, Volume 14, 9247-9260.	0.8	4
2128	Centromere protein F promotes progression of hepatocellular carcinoma through ERK and cell cycle-associated pathways. <i>Cancer Gene Therapy</i> , 2021, , .	2.2	9
2129	Novel Nanocrystal Injection of Insoluble Drug Anlotinib and Its Antitumor Effects on Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 777356.	1.3	3
2130	Fluorescence lifetime needle optical biopsy discriminates hepatocellular carcinoma. <i>Biomedical Optics Express</i> , 2022, 13, 633.	1.5	8
2131	Patterns, treatments, and prognosis of tumor recurrence after resection for hepatocellular carcinoma with microvascular invasion: a multicenter study from China. <i>Hpb</i> , 2022, 24, 1063-1073.	0.1	8
2132	The EASLâ€œLancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. <i>Lancet</i> , The, 2022, 399, 61-116.	6.3	257
2133	Potential of antiviral drug oseltamivir for the treatment of liver cancer. <i>International Journal of Oncology</i> , 2021, 59, .	1.4	10
2134	LINC00852 Regulates Cell Proliferation, Invasion, Migration and Apoptosis in Hepatocellular Carcinoma Via the miR-625/E2F1 Axis. <i>Cellular and Molecular Bioengineering</i> , 2022, 15, 207-217.	1.0	3
2135	PRRC2A Promotes Hepatocellular Carcinoma Progression and Associates with Immune Infiltration. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 1495-1511.	1.8	15
2136	Leukocytes infiltration correlates intratumoral microvessel density and influence overall and late-phase disease-free survival in hepatocellular carcinoma. <i>Medicine (United States)</i> , 2021, 100, e28135.	0.4	2
2137	Differential expression of long noncoding RNA in hepatocellular carcinoma on top of chronic HCV and HBV infections. <i>Clinical and Experimental Hepatology</i> , 2021, 7, 337-350.	0.6	4
2138	Toripalimab Combined With Hepatic Arterial Infusion Chemotherapy Versus Lenvatinib for Advanced Hepatocellular Carcinoma. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382110638.	0.8	10
2139	DEAD-box Helicase 27 Promotes Hepatocellular Carcinoma Progression Through ERK Signaling. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382110559.	0.8	5

#	ARTICLE	IF	CITATIONS
2140	Success is not final, failure is not fatal: The changing landscape of systemic therapy for advanced hepatocellular carcinoma. <i>Journal of Cancer Research and Practice</i> , 2021, 8, 127.	0.2	2
2141	Gambogenic Acid Inhibits Basal Autophagy of Drug-Resistant Hepatoma Cells and Improves Its Sensitivity to Adriamycin. <i>Biological and Pharmaceutical Bulletin</i> , 2022, 45, 63-70.	0.6	6
2142	Comprehensive kinomic study via a chemical proteomic approach reveals kinome reprogramming in hepatocellular carcinoma tissues. <i>Proteomics</i> , 2021, , 2100141.	1.3	0
2143	Prognosis of patients with hepatocellular carcinoma and portal vein tumor thrombus treated with combination of transarterial chemoembolization and palliative thermal ablation. <i>International Journal of Hyperthermia</i> , 2022, 39, 97-107.	1.1	1
2144	Long non-coding RNAs in gastrointestinal cancers: Implications for protein phosphorylation. <i>Biochemical Pharmacology</i> , 2022, 197, 114907.	2.0	5
2145	Exosomes as potential diagnosis and treatment for liver cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2022, 14, 334-347.	0.8	8
2146	Analysis of Survival and Response to Lenvatinib in Unresectable Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 320.	1.7	8
2147	Effect of Lipopolysaccharides on Liver Tumor Metastasis of twist1a/krasV12 Double Transgenic Zebrafish. <i>Biomedicines</i> , 2022, 10, 95.	1.4	1
2148	CRISPR screens uncover protective effect of PSTK as a regulator of chemotherapy-induced ferroptosis in hepatocellular carcinoma. <i>Molecular Cancer</i> , 2022, 21, 11.	7.9	46
2149	Do changes in inflammatory markers predict hepatocellular carcinoma recurrence and survival after liver transplantation?. <i>Annals of Hepato-biliary-pancreatic Surgery</i> , 2022, 26, 40-46.	0.1	3
2150	PERK Regulates the Sensitivity of Hepatocellular Carcinoma Cells to High-LET Carbon Ions via either Apoptosis or Ferroptosis. <i>Journal of Cancer</i> , 2022, 13, 669-680.	1.2	20
2151	The role of BCL9 genetic variation as a biomarker for hepatitis C-related hepatocellular carcinoma in Egyptian patients. <i>Journal of Genetic Engineering and Biotechnology</i> , 2022, 20, 4.	1.5	1
2152	Single-Cell RNA Sequencing Reveals the Role of Phosphorylation-Related Genes in Hepatocellular Carcinoma Stem Cells. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 734287.	1.8	11
2153	MiR-369-5p inhibits the proliferation and migration of hepatocellular carcinoma cells by down-regulating HOXA13 expression. <i>Tissue and Cell</i> , 2022, 74, 101721.	1.0	0
2154	Stability of a high-concentrated aqueous solution of idarubicin stored in a polypropylene syringe for transarterial chemoembolization. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2022, 210, 114543.	1.4	2
2155	Pre-mRNA processing factor 19 functions in DNA damage repair and radioresistance by modulating cyclin D1 in hepatocellular carcinoma. <i>Molecular Therapy - Nucleic Acids</i> , 2022, 27, 390-403.	2.3	6
2156	Use the Chinese herbal compound regulatory network to verify the relationship between the Jun, Chen, Zuo, and Shi of Xiaochaihu Decoction in treating hepatitis. <i>Pharmacological Research Modern Chinese Medicine</i> , 2022, 2, 100023.	0.5	4
2157	GST-Perfringolysin O production for the localization and quantification of membrane cholesterol in human and mouse brain and liver. <i>STAR Protocols</i> , 2022, 3, 101068.	0.5	0

#	ARTICLE	IF	CITATIONS
2158	The role of FUNDC1 in mitophagy, mitochondrial dynamics and human diseases. <i>Biochemical Pharmacology</i> , 2022, 197, 114891.	2.0	27
2159	Pleiotropic roles of FXR in liver and colorectal cancers. <i>Molecular and Cellular Endocrinology</i> , 2022, 543, 111543.	1.6	5
2160	All-in-one hollow nanoformulations enabled imaging-guided Mn-amplified chemophototherapy against hepatocellular carcinoma. <i>Nano Today</i> , 2022, 43, 101382.	6.2	7
2161	MicroRNA-125a-5p regulates liver cancer cell growth, migration and invasion and EMT by targeting HAX1. <i>International Journal of Molecular Medicine</i> , 2020, 46, 1849-1861.	1.8	3
2162	Inhibitor for protein disulfide isomerase family A member-3 enhances the antiproliferative effect of inhibitor for mechanistic target of rapamycin in liver cancer: An <i>in vitro</i> study on combination treatment with everolimus and 16F16. <i>Oncology Letters</i> , 2020, 21, 28.	0.8	5
2163	Predictive factors for long-term survival in patients with advanced hepatocellular carcinoma treated with sorafenib. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, e114-e120.	0.8	2
2164	Abnormal expression of HNRNPA3 in multistep hepatocarcinogenesis. <i>Oncology Letters</i> , 2020, 21, 46.	0.8	2
2165	PD-1 blockade improves the anti-tumor potency of exhausted CD3 <sup>+</sup> CD56 <sup>+</sup> NKT-like cells in patients with primary hepatocellular carcinoma. <i>Oncolimmunology</i> , 2021, 10, 2002068.	2.1	27
2166	Dynamics of endothelial progenitor cells in patients with advanced hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2021, , .	0.4	0
2167	Construction of a novel immune-related lncRNA signature and its potential to predict the immune status of patients with hepatocellular carcinoma. <i>BMC Cancer</i> , 2021, 21, 1347.	1.1	3
2168	CircRPN2 Inhibits Aerobic Glycolysis and Metastasis in Hepatocellular Carcinoma. <i>Cancer Research</i> , 2022, 82, 1055-1069.	0.4	57
2169	Study of Stability, Cytotoxic and Antimicrobial Activity of Chios Mastic Gum Fractions (Neutral,) Tj ETQq1 1 0.784314 rgBT /Qoverlock 10	1.9	6
2170	Period-Dependent Survival Benefit of Percutaneous Microwave Ablation for Hepatocellular Carcinoma: A 12-Year Real-World, Multicentric Experience. <i>Liver Cancer</i> , 2022, 11, 341-353.	4.2	11
2171	Liver-Directed Treatment Options Following Liver Tumor Recurrence: A Review of the Literature. <i>Frontiers in Oncology</i> , 2022, 12, 832405.	1.3	7
2172	Transarterial Chemoembolization (TACE) Plus Sorafenib Compared to TACE Alone in Transplant Recipients with Hepatocellular Carcinoma: An Institution Experience. <i>Cancers</i> , 2022, 14, 650.	1.7	17
2173	Surgical Strategy for Resecting Hepatocellular Carcinoma in the Caudate Lobe: Isolated or Combined Lobectomy? A Single-Center Study and Meta-Analysis. <i>Journal of Hepatocellular Carcinoma</i> , 2022, Volume 9, 13-25.	1.8	1
2174	Comparison of Treatment Response, Survival Profiles, as Well as Safety Profiles Between CalliSpheres® Microsphere Transarterial Chemoembolization and Conventional Transarterial Chemoembolization in Huge Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 793581.	1.3	9
2175	Medical Treatment for Hepatocellular Carcinoma in Japan. <i>Journal of Nippon Medical School</i> , 2022, , .	0.3	1



#	ARTICLE	IF	CITATIONS
2176	Antitumor Effect of Regorafenib on MicroRNA Expression in Hepatocellular Carcinoma Cell Lines. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1667.	1.8	2
2177	Non-alcoholic fatty liver disease and hepatocellular carcinoma: Clinical challenges of an intriguing link. <i>World Journal of Gastroenterology</i> , 2022, 28, 310-331.	1.4	29
2178	Cabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma: shedding light on the preclinical rationale and clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 401-413.	1.9	9
2179	Hepatocellular Carcinoma: Molecular Pathogenesis and Therapeutic Advances. <i>Cancers</i> , 2022, 14, 621.	1.7	34
2180	A painful mass in the jaw. <i>Cleveland Clinic Journal of Medicine</i> , 2022, 89, 27-35.	0.6	0
2181	The combination of transcatheter arterial chemoembolisation (TACE) and thermal ablation versus TACE alone for hepatocellular carcinoma. <i>The Cochrane Library</i> , 2022, 2022, CD013345.	1.5	8
2182	Occupational dose and associated factors during transarterial chemoembolization of hepatocellular carcinoma using real-time dosimetry. <i>Medicine (United States)</i> , 2022, 101, e28744.	0.4	0
2183	Development and Validation of Genome Instability-Associated lncRNAs to Predict Prognosis and Immunotherapy of Patients With Hepatocellular Carcinoma. <i>Frontiers in Genetics</i> , 2021, 12, 763281.	1.1	2
2184	Bioinformatics analysis and experimental verification of five metabolism-related lncRNAs as prognostic models for hepatocellular carcinoma. <i>Medicine (United States)</i> , 2022, 101, e28694.	0.4	3
2185	RNF135 Promoter Methylation Is Associated With Immune Infiltration and Prognosis in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 752511.	1.3	6
2186	Treatment and the prognosis of hepatocellular carcinoma in Asia. <i>Liver International</i> , 2022, 42, 2042-2054.	1.9	49
2187	Gene signature to predict prognostic survival of hepatocellular carcinoma. <i>Open Medicine (Poland)</i> , 2022, 17, 135-150.	0.6	7
2188	Rab31 promotes activation of hepatic stellate cells by accelerating TGF- $\beta$ 2 receptor II complex endocytosis. <i>International Journal of Biochemistry and Cell Biology</i> , 2022, 144, 106170.	1.2	4
2189	The Landscape Of Alpha Fetoprotein In Hepatocellular Carcinoma: Where Are We?. <i>International Journal of Biological Sciences</i> , 2022, 18, 536-551.	2.6	54
2190	A super-stable homogeneous Lipiodol-hydrophilic chemodrug formulation for treatment of hepatocellular carcinoma. <i>Theranostics</i> , 2022, 12, 1769-1782.	4.6	33
2191	Inhibitory effect of CC chemokine ligand 23 (CCL23)/ transcription factor activating enhancer binding protein 4 (TFAP4) on cell proliferation, invasion and angiogenesis in hepatocellular carcinoma. <i>Bioengineered</i> , 2022, 13, 1626-1636.	1.4	5
2192	Non-Alcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma: Immunohistochemical Assessment of Markers of Cancer Cell Metabolism. <i>Pathobiology</i> , 2022, 89, 157-165.	1.9	1
2193	Application value of mixed reality in hepatectomy for hepatocellular carcinoma. <i>World Journal of Gastrointestinal Surgery</i> , 2022, 14, 36-45.	0.8	6

#	ARTICLE	IF	CITATIONS
2194	ATF2 accelerates the invasion and metastasis of hepatocellular carcinoma through targeting the miR-548p/TUFT1 axis. <i>Hepatology Research</i> , 2021, .	1.8	1
2195	RNA-Seq Explores the Mechanism of Oxygen-Boosted Sonodynamic Therapy Based on All-in-One Nanobubbles to Enhance Ferroptosis for the Treatment of HCC. <i>International Journal of Nanomedicine</i> , 2022, Volume 17, 105-123.	3.3	24
2196	BRD4 inhibition induces synthetic lethality in ARID2-deficient hepatocellular carcinoma by increasing DNA damage. <i>Oncogene</i> , 2022, 41, 1397-1409.	2.6	7
2197	Quantitative washout in patients with hepatocellular carcinoma undergoing TACE: an imaging biomarker for predicting prognosis?. <i>Cancer Imaging</i> , 2022, 22, 5.	1.2	3
2198	PP-10 induces apoptosis via JNK/SPAK activation and STAT3 inhibition in Hepatocarcinoma cells in vitro. <i>Food Science and Technology</i> , 0, .	0.8	0
2199	Prognostic Biomarker DDOST and Its Correlation With Immune Infiltrates in Hepatocellular Carcinoma. <i>Frontiers in Genetics</i> , 2021, 12, 819520.	1.1	10
2200	A novel combined prognostic nutritional index and aspartate aminotransferase-to-platelet ratio index-based score can predict the survival of patients with hepatocellular carcinoma who undergo hepatic resection. <i>Surgery Today</i> , 2022, 52, 1096-1108.	0.7	4
2201	SHC4 promotes tumor proliferation and metastasis by activating STAT3 signaling in hepatocellular carcinoma. <i>Cancer Cell International</i> , 2022, 22, 24.	1.8	6
2202	Golgi phosphoprotein 3 promotes angiogenesis and sorafenib resistance in hepatocellular carcinoma via upregulating exosomal miR-494-3p. <i>Cancer Cell International</i> , 2022, 22, 35.	1.8	13
2203	Histone Acetylation Regulator-Mediated Acetylation Patterns Define Tumor Malignant Pathways and Tumor Microenvironment in Hepatocellular Carcinoma. <i>Frontiers in Immunology</i> , 2022, 13, 761046.	2.2	19
2204	PAK3 promotes the metastasis of hepatocellular carcinoma by regulating EMT process. <i>Journal of Cancer</i> , 2022, 13, 153-161.	1.2	10
2205	Microwave versus radiofrequency ablation for the treatment of liver malignancies: a randomized controlled phase 2 trial. <i>Scientific Reports</i> , 2022, 12, 316.	1.6	34
2206	Recent advances in systemic therapy for hepatocellular carcinoma. <i>Biomarker Research</i> , 2022, 10, 3.	2.8	94
2207	Downregulation of Methionine Cycle Genes MAT1A and GNMT Enriches Protein-Associated Translation Process and Worsens Hepatocellular Carcinoma Prognosis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 481.	1.8	8
2208	Knowledge Mapping of Immunotherapy for Hepatocellular Carcinoma: A Bibliometric Study. <i>Frontiers in Immunology</i> , 2022, 13, 815575.	2.2	63
2209	Somatic Mutation Profiles Revealed by Next Generation Sequencing (NGS) in 39 Chinese Hepatocellular Carcinoma Patients. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 800679.	1.6	2
2210	Drug-eluting bead transarterial chemoembolization followed by apatinib is effective and safe in treating hepatocellular carcinoma patients with BCLC stage C. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2022, , 101859.	0.7	2
2211	Sox9/CXCL5 axis facilitates tumour cell growth and invasion in hepatocellular carcinoma. <i>FEBS Journal</i> , 2022, 289, 3535-3549.	2.2	13

#	ARTICLE	IF	CITATIONS
2212	Extracellular Vesicle-Encapsulated MicroRNA-375 from Bone Marrow-Derived Mesenchymal Stem Cells Inhibits Hepatocellular Carcinoma Progression through Regulating HOXB3-Mediated Wnt/ $\beta^2$ -Catenin Pathway. <i>Analytical Cellular Pathology</i> , 2022, 2022, 1-19.	0.7	4
2213	Experiences of Symptoms and Impact on Daily Life and Health in Hepatocellular Carcinoma Patients. <i>Cancer Nursing</i> , 2022, 45, 430-437.	0.7	7
2214	Associations of Multimodal Analgesia With Postoperative Pain Trajectories and Morphine Consumption After Hepatic Cancer Surgery. <i>Frontiers in Medicine</i> , 2021, 8, 777369.	1.2	3
2215	A hepatocellularis carcinoma komplex kezel�se.. <i>Orvosi Hetilap</i> , 2022, 162, 2-31.	0.1	1
2216	Preoperative Microvascular Invasion Prediction to Assist in Surgical Plan for Single Hepatocellular Carcinoma: Better Together with Radiomics. <i>Annals of Surgical Oncology</i> , 2022, 29, 2960-2970.	0.7	11
2217	Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: cancer and beyond. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 2844-2868.	3.3	43
2218	A Novel Lactate Metabolism-Related Gene Signature for Predicting Clinical Outcome and Tumor Microenvironment in Hepatocellular Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 801959.	1.8	23
2219	Subsequent Treatment after Transarterial Chemoembolization Failure/Refractoriness: A Review Based on Published Evidence. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 10, 740-747.	0.7	7
2220	Molecular mechanisms of Tanshinone IIA in Hepatocellular carcinoma therapy via WGCNA-based network pharmacology analysis. <i>Biocell</i> , 2022, 46, 1245-1259.	0.4	6
2221	Metabolic Reprogramming and Risk Stratification of Hepatocellular Carcinoma Studied by Using Gas Chromatography�Mass Spectrometry-Based Metabolomics. <i>Cancers</i> , 2022, 14, 231.	1.7	5
2222	MiR-25 enhances autophagy and promotes sorafenib resistance of hepatocellular carcinoma via targeting FBXW7. <i>International Journal of Medical Sciences</i> , 2022, 19, 257-266.	1.1	24
2223	Precision Medicine for Hepatocellular Carcinoma: Clinical Perspective. <i>Journal of Personalized Medicine</i> , 2022, 12, 149.	1.1	14
2224	From LI-RADS Classification to HCC Pathology: A Retrospective Single-Institution Analysis of Clinico-Pathological Features Affecting Oncological Outcomes after Curative Surgery. <i>Diagnostics</i> , 2022, 12, 160.	1.3	19
2225	Risk factors for recurrence beyond Milan criteria after radiofrequency ablation in transplantable small hepatocellular carcinoma. <i>Revista Espanola De Enfermedades Digestivas</i> , 2022, , .	0.1	2
2227	Cancer Genomic Alterations Can Be Potential Biomarkers Predicting Microvascular Invasion and Early Recurrence of Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2022, 12, 783109.	1.3	3
2228	Impact of acute decompensation on the prognosis of patients with hepatocellular carcinoma. <i>PLoS ONE</i> , 2022, 17, e0261619.	1.1	4
2229	HCC-neuroendocrine transition: Tumor plasticity under immunotherapy. <i>Gastroenterolog�a Y Hepatolog�a</i> , 2022, , .	0.2	1
2230	Metabolic Risks Are Increasing in Non-B Non-C Early-Stage Hepatocellular Carcinoma: A 10-Year Follow-Up Study. <i>Frontiers in Oncology</i> , 2022, 12, 816472.	1.3	7

#	ARTICLE	IF	CITATIONS
2231	NAFLD indirectly impairs antigen-specific CD8+ T cell immunity against liver cancer in mice. <i>IScience</i> , 2022, 25, 103847.	1.9	12
2232	Single-cell multiomics reveals heterogeneous cell states linked to metastatic potential in liver cancer cell lines. <i>IScience</i> , 2022, 25, 103857.	1.9	11
2233	Targeting the PDGF/PDGFR signaling pathway for cancer therapy: A review. <i>International Journal of Biological Macromolecules</i> , 2022, 202, 539-557.	3.6	55
2234	Homogeneous two-dimensional visual and fluorescence analysis of circulating tumor cells in clinical samples via steric hindrance regulated enzymes recognition cleavage and elongation. <i>Biosensors and Bioelectronics</i> , 2022, 202, 114009.	5.3	15
2235	Fabrication of programmed photosensitizer-conjugated nanoassemblies by dual supramolecular self-assembly for photodynamic therapy of orthotopic hepatoma. <i>Chemical Engineering Journal</i> , 2022, 435, 134930.	6.6	8
2236	Role of SLC39A6 in the development and progression of liver cancer. <i>Oncology Letters</i> , 2022, 23, 77.	0.8	5
2237	Monitoring Clinical Pathological Grading of Hepatocellular Carcinoma Using MicroRNA-Guided Semiconducting Polymer Dots. <i>ACS Applied Materials &amp; Interfaces</i> , 2022, 14, 7717-7730.	4.0	5
2238	The pyroptosis-related gene signature predicts prognosis and indicates immune activity in hepatocellular carcinoma. <i>Molecular Medicine</i> , 2022, 28, 16.	1.9	37
2239	Proglumide Reverses Nonalcoholic Steatohepatitis by Interaction with the Farnesoid X Receptor and Altering the Microbiome. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1899.	1.8	5
2240	Gadoxetic Acid-Enhanced MRI Features for Predicting Treatment Outcomes of Early Hepatocellular Carcinoma (<math>\leq 3\text{ cm}</math>) After Transarterial Chemoembolization. <i>Academic Radiology</i> , 2022, 29, e178-e188.	1.3	4
2241	Successful conversion therapy and radical resection for huge Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma: A case report. <i>World Chinese Journal of Digestology</i> , 2022, 30, 164-168.	0.0	0
2242	A predictive model integrating deep and radiomics features based on gadobenate dimeglumine-enhanced MRI for postoperative early recurrence of hepatocellular carcinoma. <i>Radiologia Medica</i> , 2022, 127, 259-271.	4.7	24
2243	PIGR-enriched circulating vesicles contributes to hepatocellular carcinoma aggressiveness. <i>Journal of Hepatology</i> , 2022, 76, 768-770.	1.8	1
2244	Hyaluronated and PEGylated Liposomes as a Potential Drug-Delivery Strategy to Specifically Target Liver Cancer and Inflammatory Cells. <i>Molecules</i> , 2022, 27, 1062.	1.7	14
2245	T-Cell Subsets as Potential Biomarkers for Hepatobiliary Cancers and Selection of Immunotherapy Regimens as a Treatment Strategy. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 203-214.	2.3	1
2246	Current Perspective of Traditional Chinese Medicines and Active Ingredients in the Therapy of Hepatocellular Carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 2022, Volume 9, 41-56.	1.8	10
2247	The Nrf2 Pathway in Liver Diseases. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 826204.	1.8	51
2248	Doxorubicin-Loaded UiO-66/Bi <sub>2</sub> S <sub>3</sub> Nanocomposite-Enhanced Synergistic Transarterial Chemoembolization and Photothermal Therapy against Hepatocellular Carcinoma. <i>ACS Applied Materials &amp; Interfaces</i> , 2022, 14, 7579-7591.	4.0	18

#	ARTICLE	IF	CITATIONS
2249	GPC3-targeted immunoPET imaging of hepatocellular carcinomas. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 2682-2692.	3.3	23
2250	Acute-Phase Serum Amyloid A May Predict Microvascular Invasion and Early Tumor Recurrence in Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma Undergoing Liver Resection. <i>Journal of Investigative Surgery</i> , 2022, , 1-9.	0.6	1
2251	Identification of a glycolysis-related gene signature for predicting prognosis in patients with hepatocellular carcinoma. <i>BMC Cancer</i> , 2022, 22, 142.	1.1	9
2252	Optimizing systemic therapy for advanced hepatocellular carcinoma: the key role of liver function. <i>Digestive and Liver Disease</i> , 2022, 54, 452-460.	0.4	38
2253	Evaluation of Safety-Related Outcomes of One-Segment and More-Than-One-Segment High-Level Hepatectomy in Hepatocellular Carcinoma Based on the Japanese Board Certification System. <i>World Journal of Surgery</i> , 2022, 46, 1141-1150.	0.8	0
2254	AXL and MET in Hepatocellular Carcinoma: A Systematic Literature Review. <i>Liver Cancer</i> , 2022, 11, 94-112.	4.2	10
2255	Multiplex imaging reveals the architecture of the tumor immune microenvironment. <i>Cancer Biology and Medicine</i> , 2021, 18, 949-954.	1.4	3
2256	Immunotherapies for hepatocellular carcinoma. <i>Cancer Medicine</i> , 2022, 11, 571-591.	1.3	29
2257	Construction and Comprehensive Analysis of a Stratification System Based on AGTRAP in Patients with Hepatocellular Carcinoma. <i>Disease Markers</i> , 2021, 2021, 1-18.	0.6	4
2258	The first two cases of posterior reversible encephalopathy syndrome (PRES) secondary to conventional transcatheter arterial chemoembolization of hepatocellular carcinoma. <i>BMC Gastroenterology</i> , 2021, 21, 492.	0.8	2
2260	Single-Cell Sequencing of Hepatocellular Carcinoma Reveals Cell Interactions and Cell Heterogeneity in the Microenvironment. <i>International Journal of General Medicine</i> , 2021, Volume 14, 10141-10153.	0.8	6
2261	The Efficacy of TACE Combined With Lenvatinib Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study. <i>Frontiers in Oncology</i> , 2021, 11, 783480.	1.3	42
2262	The past, present and future of conversion therapy for liver cancer. <i>American Journal of Cancer Research</i> , 2021, 11, 4711-4724.	1.4	2
2263	The Role of Hepatic Arterial Infusion Chemotherapy in the Combination Therapy of Advanced Hepatocellular Carcinoma. <i>Advances in Clinical Medicine</i> , 2022, 12, 1881-1887.	0.0	0
2264	Enhanced fluorescence/magnetic resonance dual imaging and gene therapy of liver cancer using cationized amylose nanoprobe. <i>Materials Today Bio</i> , 2022, 13, 100220.	2.6	10
2265	Rehmanniae Radix-Induced apoptosis via inhibition of PI3K/AKT/mTOR signaling pathways in human hepatocellular carcinoma cell lines SMMC-7721. <i>Pharmacognosy Magazine</i> , 2022, 18, 4.	0.3	1
2266	Establishment and Validation of a Peroxisome-related Gene Signature for Prognostic Prediction and Immune Distinction in Hepatocellular Carcinoma. <i>Journal of Cancer</i> , 2022, 13, 1418-1435.	1.2	1
2267	Metabolic pathway-based target therapy to hepatocellular carcinoma: a computational approach. , 2022, , 83-103.		0

#	ARTICLE	IF	CITATIONS
2268	Updates on the staging and treatment of hepatocellular carcinoma. , 2022, , 307-319.		0
2269	Predictive Value of Platelet-Related Measures in Patients with Hepatocellular Carcinoma. Technology in Cancer Research and Treatment, 2022, 21, 153303382110644.	0.8	2
2270	Hepatoprotective potential of bioflavonoids. Studies in Natural Products Chemistry, 2022, , 259-285.	0.8	8
2271	Dynamic Nomogram for Predicting Macrovascular Invasion of Patients with Unresectable Hepatocellular Carcinoma after Transarterial Chemoembolization. Journal of Cancer, 2022, 13, 1914-1922.	1.2	2
2272	Mitochondrial metabolism in progression of liver cancer. , 2022, , 153-165.		0
2273	ENKUR expression induced by chemically synthesized cinobufotalin suppresses malignant activities of hepatocellular carcinoma by modulating $\beta^2$ -catenin/c-Jun/MYH9/USP7/c-Myc axis. International Journal of Biological Sciences, 2022, 18, 2553-2567.	2.6	16
2274	Predictive value of collagen in cancer. Advances in Cancer Research, 2022, 154, 15-45.	1.9	11
2275	High Expression of Ferritinophagy-Related RRM2 Gene in Relation to Unfavorable Outcome and Immune Cells Infiltration in Hepatocellular Carcinoma. SSRN Electronic Journal, 0, , .	0.4	0
2276	Hepatocellular carcinoma surveillance: current practice and future directions. Hepatoma Research, 0, , .	0.6	9
2277	Distance Matters: Correlation of Hepatocellular Carcinoma Nodule Distance to Overall Survival. Digestive Diseases, 2023, 41, 107-114.	0.8	0
2278	Clinical implications and molecular mechanisms of Cyclin-dependent kinases 4 for patients with hepatocellular carcinoma. BMC Gastroenterology, 2022, 22, 77.	0.8	2
2279	A novel qualitative signature based on lncRNA pairs for prognosis prediction in hepatocellular carcinoma. Cancer Cell International, 2022, 22, 95.	1.8	8
2280	Characterization of Cisplatin Effects in Lenvatinib-resistant Hepatocellular Carcinoma Cells. Anticancer Research, 2022, 42, 1263-1275.	0.5	2
2281	Diffusion MRI signal cumulants and hepatocyte microstructure at fixed diffusion time: Insights from simulations, 9.4T imaging, and histology. Magnetic Resonance in Medicine, 2022, 88, 365-379.	1.9	5
2282	Patients Benefit from Liver Transplantation for Hepatocellular Carcinoma beyond Milan Criteria without Harming the Health Care System. Cancers, 2022, 14, 1136.	1.7	1
2283	Two cases of rapid progression of esophageal varices after atezolizumab“bevacizumab treatment for hepatocellular carcinoma. Clinical Journal of Gastroenterology, 2022, 15, 451-459.	0.4	8
2284	Tryptophan-sorbitol based carbon quantum dots for theranostics against hepatocellular carcinoma. Journal of Nanobiotechnology, 2022, 20, 78.	4.2	18
2285	The synergistic antitumor effect of IL-6 neutralization with NVP-BEZ235 in hepatocellular carcinoma. Cell Death and Disease, 2022, 13, 146.	2.7	11

#	ARTICLE	IF	CITATIONS
2286	ECM Depletion Is Required to Improve the Intratumoral Uptake of Iron Oxide Nanoparticles in Poorly Perfused Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2022, 12, 837234.	1.3	3
2287	Stereotactic body radiation therapy as a salvage treatment for single viable hepatocellular carcinoma at the site of incomplete transarterial chemoembolization: a retrospective analysis of 302 patients. <i>BMC Cancer</i> , 2022, 22, 175.	1.1	4
2288	Long noncoding RNA LINC01234 promotes hepatocellular carcinoma progression through orchestrating aspartate metabolic reprogramming. <i>Molecular Therapy</i> , 2022, 30, 2354-2369.	3.7	35
2289	LncRNA THEMIS2, a tumor-originated circulating exosomal biomarker, promotes the growth and metastasis of hepatocellular carcinoma by functioning as a competing endogenous RNA. <i>FASEB Journal</i> , 2022, 36, e22238.	0.2	16
2290	Barcelona Clinic Liver Cancer 2022 update: Linking prognosis prediction and evidence-based treatment recommendation with multidisciplinary clinical decision-making. <i>Liver International</i> , 2022, 42, 488-491.	1.9	8
2291	Glypican-3: A Novel and Promising Target for the Treatment of Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2022, 12, 824208.	1.3	28
2292	Identification of the Expression Patterns and Potential Prognostic Role of 5-Methylcytosine Regulators in Hepatocellular Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 842220.	1.8	8
2293	microRNA-378a-3p regulates the progression of hepatocellular carcinoma by regulating PD-L1 and STAT3. <i>Bioengineered</i> , 2022, 13, 4730-4743.	1.4	13
2295	The novel circular RNA HIPK3 accelerates the proliferation and invasion of hepatocellular carcinoma cells by sponging the micro RNA-124 or micro RNA-506/pyruvate dehydrogenase kinase 2 axis. <i>Bioengineered</i> , 2022, 13, 4717-4729.	1.4	9
2296	Tumor Burden in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Head-to-Head Comparison of Current Scoring Systems. <i>Frontiers in Oncology</i> , 2022, 12, 850454.	1.3	7
2297	DNTTIP1 is a Prognostic Biomarker Correlated With Immune Infiltrates in Hepatocellular Carcinoma: A Study Based on The Cancer Genome Atlas Data. <i>Frontiers in Genetics</i> , 2021, 12, 767834.	1.1	1
2298	ASARA, a prediction model based on Child-Pugh class in hepatocellular carcinoma patients undergoing transarterial chemoembolization. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2022, , .	0.6	3
2299	Comparison of Clinical Efficacy and Safety between 70-150 $\mu$ m and 100-300 $\mu$ m Doxorubicin Drug-Eluting Bead Transarterial Chemoembolization for Hepatocellular Carcinoma. <i>Life</i> , 2022, 12, 297.	1.1	3
2300	The circular RNA hsa_circ_0001394 promotes hepatocellular carcinoma progression by targeting the miR-527/LUBE2A axis. <i>Cell Death Discovery</i> , 2022, 8, 81.	2.0	5
2301	The dual checkpoint blockade in unresectable hepatocellular carcinoma: opportunities emerging in clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 425-435.	1.9	3
2302	Classification of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma Based on Radiomic Analysis. <i>Computational and Mathematical Methods in Medicine</i> , 2022, 2022, 1-9.	0.7	17
2303	Innate and Adaptive Immunopathogenesis in Viral Hepatitis; Crucial Determinants of Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 1255.	1.7	24
2304	Determining the Prognostic Value of Spliceosome-Related Genes in Hepatocellular Carcinoma Patients. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 759792.	1.6	4

#	ARTICLE	IF	CITATIONS
2306	Discovery of Novel Indazoles as Potent and Selective PI3K $\beta$ Inhibitors with High Efficacy for Treatment of Hepatocellular Carcinoma. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 3849-3865.	2.9	9
2307	Scoring systems for the management of oncological hepato-pancreato-biliary patients. <i>Annals of Hepato-biliary-pancreatic Surgery</i> , 2022, 26, 17-30.	0.1	3
2308	Selumetinib: a selective MEK1 inhibitor for solid tumor treatment. <i>Clinical and Experimental Medicine</i> , 2023, 23, 229-244.	1.9	10
2309	Intratumoral Microbiome of Human Primary Liver Cancer. <i>Hepatology Communications</i> , 2022, 6, 1741-1752.	2.0	18
2310	Differences Between Sorafenib and Lenvatinib Treatment from Genetic and Clinical Perspectives for Patients with Hepatocellular Carcinoma. <i>Medical Science Monitor</i> , 2022, 28, e934936.	0.5	2
2311	Physical & Chemical Microwave Ablation (MWA) Enabled by Nonionic MWA Nanosensitizers Repress Incomplete MWA-Arised Liver Tumor Recurrence. <i>ACS Nano</i> , 2022, 16, 5704-5718.	7.3	27
2312	Ablation of high-mobility group box 1 in the liver reduces hepatocellular carcinoma but causes hyperbilirubinemia in Hippo signaling-deficient mice. <i>Hepatology Communications</i> , 2022, 6, 2155-2169.	2.0	3
2313	Radiation Segmentectomy for the Treatment of Solitary Hepatocellular Carcinoma: Outcomes Compared with Those of Surgical Resection. <i>Journal of Vascular and Interventional Radiology</i> , 2022, 33, 775-785.e2.	0.2	9
2314	Real-world efficiency of lenvatinib plus PD-1 blockades in advanced hepatocellular carcinoma: an exploration for expanded indications. <i>BMC Cancer</i> , 2022, 22, 293.	1.1	18
2315	Long non-coding RNA H19 as a biomarker for hepatocellular carcinoma. <i>Liver International</i> , 2022, 42, 1410-1422.	1.9	14
2316	Overexpression of SLC25A51 promotes hepatocellular carcinoma progression by driving aerobic glycolysis through activation of SIRT5. <i>Free Radical Biology and Medicine</i> , 2022, 182, 11-22.	1.3	13
2317	Successful Transcatheter Arterial Radioembolization of Hepatocellular Carcinoma Via Left Internal Mammary Artery: A Case Report. <i>Cureus</i> , 2022, 14, e22954.	0.2	0
2318	Alcohol-related hepatocellular carcinoma is a heterogenous condition: Lessons from a latent class analysis. <i>Liver International</i> , 2022, 42, 1638-1647.	1.9	2
2319	Tumour endothelial cells for translational research and therapeutics. <i>Clinical and Translational Discovery</i> , 2022, 2, .	0.2	0
2320	Preparation of layering-structured magnetic fluorescent liposomes and labeling of HepG2 cells. <i>Bio-Medical Materials and Engineering</i> , 2022, 33, 147-158.	0.4	0
2321	Efficacy of Lenvatinib and Sorafenib in the Real-World First-Line Treatment of Advanced-Stage Hepatocellular Carcinoma in a Taiwanese Population. <i>Journal of Clinical Medicine</i> , 2022, 11, 1444.	1.0	12
2322	Roles of lncRNAs Mediating Wnt/ $\beta$ -Catenin Signaling in HCC. <i>Frontiers in Oncology</i> , 2022, 12, 831366.	1.3	6
2323	The Oncogenic and Diagnostic Potential of Stanniocalcin 2 in Hepatocellular Carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 2022, Volume 9, 141-155.	1.8	10



#	ARTICLE	IF	CITATIONS
2324	Characteristics and Clinical Significance of T-Cell Receptor Repertoire in Hepatocellular Carcinoma. <i>Frontiers in Immunology</i> , 2022, 13, 847263.	2.2	1
2325	Transarterial Chemoembolization for Hepatocellular Carcinoma: Why, When, How?. <i>Journal of Personalized Medicine</i> , 2022, 12, 436.	1.1	16
2326	Role of Preoperational Imaging Traits for Guiding Treatment in Single Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2022, , 1.	0.7	2
2327	Periodontitis, chronic liver diseases, and the emerging oral-gut-liver axis. <i>Periodontology 2000</i> , 2022, 89, 125-141.	6.3	40
2328	POLYETHYLENE-GLYCOL DRUG-ELUTING EMBOLIC MICROSPHERES LOADED WITH DOXORUBICIN FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA: FEASIBILITY, SAFETY AND PHARMACOKINETIC STUDY. <i>Journal of Vascular and Interventional Radiology</i> , 2022, , .	0.2	2
2329	Aspirin in hepatocellular carcinoma: Is it an out-of-date or promising treatment?. , 2022, 1, 55-64.		1
2330	Involvement of NF- $\kappa$ B/PI3K/AKT signaling pathway in the protective effect of prunetin against a diethylnitrosamine induced hepatocellular carcinogenesis in rats. <i>Journal of Biochemical and Molecular Toxicology</i> , 2022, 36, e23016.	1.4	9
2331	Serum TERT C228T is an important predictor of non-viral liver cancer with fatty liver disease. <i>Hepatology International</i> , 2022, 16, 412-422.	1.9	2
2332	Risk Factors for Brain Metastasis of Hepatocellular Carcinoma. <i>Journal of Healthcare Engineering</i> , 2022, 2022, 1-5.	1.1	3
2333	Prognostic Role of Albumin-Bilirubin Grade in Hepatocellular Carcinoma After Ultrasound-guided Percutaneous Radiofrequency Ablation. <i>Surgical Laparoscopy, Endoscopy and Percutaneous Techniques</i> , 2022, Publish Ahead of Print, .	0.4	1
2334	Prognostic role of multiparameter MRI and radiomics in progression of advanced unresectable hepatocellular carcinoma following combined transcatheter arterial chemoembolization and lenvatinib therapy. <i>BMC Gastroenterology</i> , 2022, 22, 108.	0.8	7
2335	The Emerging Role of PRMT6 in Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 841381.	1.3	22
2336	NLRP6-Dependent Pyroptosis-Related lncRNAs Predict the Prognosis of Hepatocellular Carcinoma. <i>Frontiers in Medicine</i> , 2022, 9, 760722.	1.2	5
2337	Use of miRNA Sequencing to Reveal Hub miRNAs and the Effect of miR-582-3p/SMAD2 in the Progression of Hepatocellular Carcinoma. <i>Frontiers in Genetics</i> , 2022, 13, 819553.	1.1	0
2338	Targeted-detection and sequential-treatment of small hepatocellular carcinoma in the complex liver environment by GPC-3-targeted nanoparticles. <i>Journal of Nanobiotechnology</i> , 2022, 20, 156.	4.2	9
2339	TACE with portal vein radioactive seeds for HCC with portal vein tumor thrombus: a meta-analysis. <i>Minimally Invasive Therapy and Allied Technologies</i> , 2022, , 1-9.	0.6	3
2340	Multi-phase contrast-enhanced magnetic resonance image-based radiomics-combined machine learning reveals microscopic ultra-early hepatocellular carcinoma lesions. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 2917-2928.	3.3	9
2341	Clotrimazole Inhibits HCC Migration and Invasion by Modulating the ERK-p65 Signaling Pathway. <i>Drug Design, Development and Therapy</i> , 2022, Volume 16, 863-871.	2.0	4

#	ARTICLE	IF	CITATIONS
2342	Is multidisciplinary treatment effective for hepatocellular carcinoma with portal vein tumor thrombus?. <i>Journal of Liver Cancer</i> , 2022, 22, 1-3.	0.3	2
2343	Prognostic Analysis of Postoperative Survival for Ruptured Hepatocellular Carcinoma with or without Cirrhosis. <i>Journal of Oncology</i> , 2022, 2022, 1-15.	0.6	2
2344	New Insights Into a Classification-Based Microvascular Invasion Prediction Model in Hepatocellular Carcinoma: A Multicenter Study. <i>Frontiers in Oncology</i> , 2022, 12, 796311.	1.3	1
2345	Human Papillomavirus Infection Is Associated with Decreased Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Patients: Taiwan Nationwide Matched Cohort Study. <i>Cancers</i> , 2022, 14, 1289.	1.7	5
2346	Radiofrequency ablation, radiation therapy, transarterial chemoembolization, and yttrium 90: no differences for local treatment of liver cancer?. <i>Acta Oncologica</i> , 2022, 61, 730-730.	0.8	1
2347	LR-3 and LR-4 Lesions Are More Likely to Be Hepatocellular Carcinoma in Transplant Patients with LR-5 or LR-TR Lesions. <i>Digestive Diseases and Sciences</i> , 2022, , 1.	1.1	1
2348	Surveillance for hepatocellular carcinoma: current status and future perspectives for improvement. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 371-381.	1.1	6
2349	Dynamic risk profiling of HCC recurrence after curative intent liver resection. <i>Hepatology</i> , 2022, 76, 1291-1301.	3.6	21
2350	Risk of intra-abdominal seeding after laparoscopic-assisted thermal ablation of exophytic hepatocellular carcinoma tumors. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2022, 36, 7569-7576.	1.3	2
2351	An intelligent serological SERS test toward early-stage hepatocellular carcinoma diagnosis through ultrasensitive nanobiosensing. <i>Nano Research</i> , 2022, 15, 5331-5339.	5.8	8
2352	The clinical relevance of epithelial-mesenchymal transition and its correlations with tumorigenic immune infiltrates in hepatocellular carcinoma. <i>Immunology</i> , 2022, 166, 185-196.	2.0	6
2353	Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition). <i>Hepatobiliary Surgery and Nutrition</i> , 2022, 11, 227-252.	0.7	55
2354	Green synthesis and characterization of gold nanoparticles from <i>Pholiota adiposa</i> and their anticancer effects on hepatic carcinoma. <i>Drug Delivery</i> , 2022, 29, 997-1006.	2.5	10
2355	Acute-phase serum amyloid A for early detection of hepatocellular carcinoma in cirrhotic patients with low AFP level. <i>Scientific Reports</i> , 2022, 12, 5799.	1.6	6
2356	Development and Validation of a Prediction Model for Predicting the Prognosis of Postoperative Patients with Hepatocellular Carcinoma. <i>International Journal of General Medicine</i> , 2022, Volume 15, 3625-3637.	0.8	1
2357	Context in medical imaging: the case of focal liver lesion classification. , 2022, , .		4
2358	Circular RNA CircITCH (has-circ-0001141) suppresses hepatocellular carcinoma (HCC) progression by sponging miR-184. <i>Cell Cycle</i> , 2022, 21, 1557-1577.	1.3	9
2359	A novel peptide encoded by N6-methyladenosine modified circMAP3K4 prevents apoptosis in hepatocellular carcinoma. <i>Molecular Cancer</i> , 2022, 21, 93.	7.9	62

#	ARTICLE	IF	CITATIONS
2360	LncRNA FGD5â€AS1 enhances the proliferation and stemness of hepatocellular carcinoma cells through targeting miRâ€223 and regulating the expression of ECT2 and FAT1. <i>Hepatology Research</i> , 2022, 52, 614-629.	1.8	5
2361	A Potential Prognostic Marker for Recognizing VEGF-Positive Hepatocellular Carcinoma Based on Magnetic Resonance Radiomics Signature. <i>Frontiers in Oncology</i> , 2022, 12, 857715.	1.3	6
2362	Fully automated AI-based splenic segmentation for predicting survival and estimating the risk of hepatic decompensation in TACE patients with HCC. <i>European Radiology</i> , 2022, 32, 6302-6313.	2.3	13
2363	Encouraging specific biomarkers-based therapeutic strategies for hepatocellular carcinoma. <i>World Journal of Clinical Cases</i> , 2022, 10, 3321-3333.	0.3	1
2364	Downregulation of Low-density lipoprotein receptor-related protein 1B (LRP1B) inhibits the progression of hepatocellular carcinoma cells by activating the endoplasmic reticulum stress signaling pathway. <i>Bioengineered</i> , 2022, 13, 9467-9481.	1.4	4
2365	Physical activity improves outcomes of combined lenvatinib plus anti-PD-1 therapy in unresectable hepatocellular carcinoma: a retrospective study and mouse model. <i>Experimental Hematology and Oncology</i> , 2022, 11, 20.	2.0	6
2366	Preoperative prediction of microvascular invasion in hepatocellular carcinoma: a radiomic nomogram based on MRI. <i>Clinical Radiology</i> , 2022, 77, e269-e279.	0.5	6
2367	Activating transcription factor 2 promotes the progression of hepatocellular carcinoma by inducing the activation of the <scp>WHSC1</scp>â€mediated <scp>TOP2A</scp>/<scp>PI3K</scp>/<scp>AKT</scp> axis. <i>Kaohsiung Journal of Medical Sciences</i> , 2022, 38, 662-674.	0.8	2
2368	Dynamic changes in liver volume calculated using a threeâ€dimensional visualisation system after microwave ablation of hepatocellular carcinomas. <i>Medical Physics</i> , 2022, 49, 4613-4621.	1.6	1
2369	Deep Segmentation Feature-Based Radiomics Improves Recurrence Prediction of Hepatocellular Carcinoma. <i>BME Frontiers</i> , 2022, 2022, .	2.2	3
2370	Inhibitory effect of aptamer-carbon dot nanomaterial-siRNA complex on the metastasis of hepatocellular carcinoma cells by interfering with FMRP. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2022, 174, 47-55.	2.0	9
2371	Differentiating Cytokeratin 19 expression of hepatocellular carcinoma by using multi-b-value diffusion-weighted MR imaging with mono-exponential, stretched exponential, intravoxel incoherent motion, diffusion kurtosis imaging and fractional order calculus models. <i>European Journal of Radiology</i> , 2022, 150, 110237.	1.2	12
2372	DNA N6-Adenine methylation in HBV-related hepatocellular carcinoma. <i>Gene</i> , 2022, 822, 146353.	1.0	6
2373	Cinobufotalin inhibits the epithelial-mesenchymal transition of hepatocellular carcinoma cells through down-regulate Î²-catenin in vitro and in vivo. <i>European Journal of Pharmacology</i> , 2022, 922, 174886.	1.7	6
2374	The value of liver stiffness measured by two-dimensional shear wave elastography for predicting symptomatic posthepatectomy liver failure in patients with hepatocellular carcinoma. <i>European Journal of Radiology</i> , 2022, 150, 110248.	1.2	1
2375	HIF-2Î±-targeted interventional chemoembolization multifunctional microspheres for effective elimination of hepatocellular carcinoma. <i>Biomaterials</i> , 2022, 284, 121512.	5.7	21
2376	Understanding initiation and progression of hepatocellular carcinoma through single cell sequencing. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2022, 1877, 188720.	3.3	26
2377	Multi-material basis and multi-mechanisms of the Dahuang Zhechong pill for regulating Treg/Th1 balance in hepatocellular carcinoma. <i>Phytomedicine</i> , 2022, 100, 154055.	2.3	10

#	ARTICLE	IF	CITATIONS
2378	Exosomal LncRNAs and hepatocellular Carcinoma: From basic research to clinical practice. <i>Biochemical Pharmacology</i> , 2022, 200, 115032.	2.0	6
2379	A nomogram based on multi-modal ultrasound for prediction of microvascular invasion and recurrence of hepatocellular carcinoma. <i>European Journal of Radiology</i> , 2022, 151, 110281.	1.2	8
2380	Hepatic and biliary tumours. , 2021, , 114-127.		0
2381	Multi-scale patches convolutional neural network predicting the histological grade of hepatocellular carcinoma. , 2021, 2021, 2584-2587.		4
2382	Combined analysis of imaging tumor capsule with imaging tumor size guides the width of resection margin for solitary hepatocellular carcinoma. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2022, 21, 551-558.	0.6	4
2383	Mulberry fruit polysaccharides alleviate diethylnitrosamine/phenobarbital-induced hepatocarcinogenesis in vivo: the roles of cell apoptosis and inflammation. <i>Bioengineered</i> , 2021, 12, 11599-11611.	1.4	5
2384	GDI2 is a novel diagnostic and prognostic biomarker in hepatocellular carcinoma. <i>Aging</i> , 2021, 13, 25304-25324.	1.4	11
2385	Aqueous extracts from <i>Tenebrio molitor</i> larval and pupal stages inhibit early hepatocarcinogenesis in vivo. <i>Journal of Zhejiang University: Science B</i> , 2021, 22, 1045-1052.	1.3	5
2386	IL-6/STAT3 Is a Promising Therapeutic Target for Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 760971.	1.3	86
2387	Evolution of Survival Impact of Molecular Target Agents in Patients with Advanced Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2022, 11, 48-60.	4.2	25
2388	Meta-Analysis of Postoperative Adjuvant Hepatic Artery Infusion Chemotherapy Versus Surgical Resection Alone for Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 720079.	1.3	9
2389	Identification of Therapeutic Targets and Prognostic Biomarkers Among Chemokine (C-C Motif) Ligands in the Liver Hepatocellular Carcinoma Microenvironment. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 748269.	1.8	5
2390	Laparoscopic versus open hepatectomy for hepatocellular carcinoma with cirrhosis: a single-center propensity score matching analysis. <i>Annals of Translational Medicine</i> , 2021, 9, 1733-1733.	0.7	1
2391	Early Differentiation of Irreversible Electroporation Ablation Regions With Radiomics Features of Conventional MRI. <i>Academic Radiology</i> , 2022, 29, 1378-1386.	1.3	3
2392	Prediction of late recurrence after radiofrequency ablation of HBV-related hepatocellular carcinoma with the age-male-albumin-bilirubin-platelets (aMAP) risk score: a multicenter study. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 2930-2942.	0.6	6
2393	Circulating Tumor Cells in Hepatocellular Carcinoma: A Comprehensive Review and Critical Appraisal. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13073.	1.8	10
2394	Anti-tumor effect of ginkgetin on human hepatocellular carcinoma cell lines by inducing cell cycle arrest and promoting cell apoptosis. <i>Cell Cycle</i> , 2022, 21, 74-85.	1.3	11
2395	Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?. <i>Frontiers in Oncology</i> , 2021, 11, 803133.	1.3	83

#	ARTICLE	IF	CITATIONS
2396	Conversion Surgery for Hepatocellular Carcinoma Following Molecular Therapy. <i>Anticancer Research</i> , 2022, 42, 35-44.	0.5	8
2397	A systematic review and meta-analysis: the diagnostic accuracy of methylated <i>SEPTIN9</i> for the detection of hepatocellular carcinoma and the clinical evaluation of its use in combination with other surveillance modalities. <i>Scandinavian Journal of Gastroenterology</i> , 2022, 57, 473-480.	0.6	2
2398	Cell Death in Hepatocellular Carcinoma: Pathogenesis and Therapeutic Opportunities. <i>Cancers</i> , 2022, 14, 48.	1.7	30
2399	Comparative study between sorafenib and lenvatinib as the first-line therapy in the sequential treatment of unresectable hepatocellular carcinoma in a real-world setting. <i>JGH Open</i> , 2022, 6, 29-35.	0.7	6
2400	Abnormal Expression of Centromere Protein U Is Associated with Hepatocellular Cancer Progression. <i>BioMed Research International</i> , 2021, 2021, 1-14.	0.9	3
2401	Development of a Prognostic Nomogram in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus Following Trans-Arterial Chemoembolization with Drug-Eluting Beads. <i>Cancer Management and Research</i> , 2021, Volume 13, 9367-9377.	0.9	2
2402	Combination of squamous cell carcinoma antigen immunocomplex and alpha-fetoprotein in mid- and long-term prediction of hepatocellular carcinoma among cirrhotic patients. <i>World Journal of Gastroenterology</i> , 2021, 27, 8343-8356.	1.4	1
2403	Nomograms including the controlling nutritional status score in patients with hepatocellular carcinoma undergoing transarterial chemoembolisation for prediction survival: a retrospective analysis. <i>British Journal of Nutrition</i> , 2022, 128, 1966-1974.	1.2	2
2404	Comparison of local recurrence in transcatheter arterial chemoembolization of hepatocellular carcinoma with or without accumulation of iodized oil beyond corona enhancement area: Short-term results. <i>Radiology and Oncology</i> , 2021, 56, 69-75.	0.6	3
2405	Unique situation of hepatocellular carcinoma in Egypt: A review of epidemiology and control measures. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 1919-1938.	0.8	15
2406	Surgery for hepatocellular carcinoma with tumor thrombosis in inferior vena cava: A case report. <i>World Journal of Clinical Cases</i> , 2021, 9, 11495-11503.	0.3	0
2407	18Î²-Glycyrrhetic Acid Inhibits TGF-Î²-Induced Epithelial-to-Mesenchymal Transition and Metastasis of Hepatocellular Carcinoma by Targeting STAT3. <i>The American Journal of Chinese Medicine</i> , 2022, 50, 313-332.	1.5	9
2408	Molecular mechanism of CK19 involved in the regulation of postoperative recurrence of HBV-associated primary hepatocellular carcinoma in Guangxi. <i>Annals of Translational Medicine</i> , 2021, 9, 1780-1780.	0.7	4
2409	Editorial: the role for PIVKA-III measurement after HCV elimination by direct-acting anti-virals in terms of prediction of hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 122-123.	1.9	1
2410	Hepatocellular carcinoma surveillance and quantile regression for determinants of underutilisation in at-risk Australian patients. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 2149-2160.	0.8	2
2411	Disease control and failure patterns of unresectable hepatocellular carcinoma following transarterial radioembolization with yttrium-90 microspheres and with/without sorafenib. <i>World Journal of Gastroenterology</i> , 2021, 27, 8166-8181.	1.4	1
2412	Hepatocellular Carcinoma With Portal Vein Tumor Thrombus Treated With Transarterial Chemoembolization and Sorafenib vs. 125Iodine Implantation. <i>Frontiers in Oncology</i> , 2021, 11, 806907.	1.3	14
2413	Current status of laparoscopic hepatectomy for the treatment of hepatocellular carcinoma. <i>Medicine (United States)</i> , 2021, 100, e27826.	0.4	9

#	ARTICLE	IF	CITATIONS
2414	Current status of first-line therapy, anti-angiogenic therapy and its combinations of other agents for unresectable hepatocellular carcinoma. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 2038-2049.	0.8	3
2415	lncRNA Expression-Based Risk Scoring System Can Predict Survival of Tumor-Positive Patients with Hepatocellular Carcinoma. <i>Asian Pacific Journal of Cancer Prevention</i> , 2021, 22, 3741-3753.	0.5	1
2416	The Disassociation of the A20/HSP90 Complex via Downregulation of HSP90 Restores the Effect of A20 Enhancing the Sensitivity of Hepatocellular Carcinoma Cells to Molecular Targeted Agents. <i>Frontiers in Oncology</i> , 2021, 11, 804412.	1.3	4
2417	Long-term outcome of novel combined surgical-injection treatment (COSIT) for large hepatocellular carcinoma: Stage 2A IDEAL prospective case series. <i>Annals of Medicine and Surgery</i> , 2021, 72, 103098.	0.5	1
2418	Delta-tocotrienol enhances the anti-tumor effects of interferon alpha through reactive oxygen species and Erk/MAPK signaling pathways in hepatocellular carcinoma cells. <i>Canadian Journal of Physiology and Pharmacology</i> , 2021, , 1-11.	0.7	1
2419	Why may citrate sodium significantly increase the effectiveness of transarterial chemoembolization in hepatocellular carcinoma?. <i>Drug Resistance Updates</i> , 2021, 59, 100790.	6.5	19
2420	hsa_circ_0003410 promotes hepatocellular carcinoma progression by increasing the ratio of M2/M1 macrophages through the miR-139a-3p/CCL5 axis. <i>Cancer Science</i> , 2022, 113, 634-647.	1.7	26
2421	Feasibility of liver stiffness measured using two-dimensional shear wave elastography in assessing preoperative liver function for patients with hepatocellular carcinoma. <i>Abdominal Radiology</i> , 2022, 47, 664-671.	1.0	2
2422	Neoadjuvant treatment strategies for hepatocellular carcinoma. <i>World Journal of Gastrointestinal Surgery</i> , 2021, 13, 1550-1566.	0.8	9
2423	HIF-1 $\alpha$ -activated long non-coding RNA KDM4A-AS1 promotes hepatocellular carcinoma progression via the miR-411-5p/KPNA2/AKT pathway. <i>Cell Death and Disease</i> , 2021, 12, 1152.	2.7	39
2424	<scp>BCL10</scp> correlates with bad prognosis and immune infiltration of tumor microenvironment in hepatocellular carcinoma. <i>IUBMB Life</i> , 2021, , .	1.5	1
2425	Ferritinophagic Flux Was a Driving Force in Determination of Status of EMT, Ferroptosis, and NDRG1 Activation in Action of Mechanism of 2-Pyridylhydrazone Dithiocarbamate S-Acetic Acid. <i>Journal of Oncology</i> , 2021, 2021, 1-12.	0.6	7
2426	MicroRNA-128-3p Mediates Lenvatinib Resistance of Hepatocellular Carcinoma Cells by Downregulating c-Met. <i>Journal of Hepatocellular Carcinoma</i> , 2022, Volume 9, 113-126.	1.8	13
2427	Niu Huang (Bovis Calculus)-Shexiang (Moschus) combination induces apoptosis and inhibits proliferation in hepatocellular carcinoma via PI3K/AKT/mTOR pathway. <i>Digital Chinese Medicine</i> , 2022, 5, 83-92.	0.5	0
2428	Targeting Wnt/ $\beta$ -Catenin Pathways in Primary Liver Tumours: From Microenvironment Signaling to Therapeutic Agents. <i>Cancers</i> , 2022, 14, 1912.	1.7	16
2429	CircSEC24A (hsa_circ_0003528) interference suppresses epithelial-mesenchymal transition of hepatocellular carcinoma cells via miR-421/MMP3 axis. <i>Bioengineered</i> , 2022, 13, 9050-9063.	1.4	6
2430	Overexpressed RING Finger 44 Correlates with Poor Prognosis in Hepatocellular Carcinoma. <i>Journal of Healthcare Engineering</i> , 2022, 2022, 1-18.	1.1	1
2431	Update on Glycosphingolipids Abundance in Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4477.	1.8	3

#	ARTICLE	IF	CITATIONS
2432	Defective Fe Metal-Organic Frameworks Enhance Metabolic Profiling for High-Accuracy Diagnosis of Human Cancers. <i>Advanced Materials</i> , 2022, 34, e2201422.	11.1	39
2433	An Efficient Nomogram for Discriminating Intrahepatic Cholangiocarcinoma From Hepatocellular Carcinoma: A Retrospective Study. <i>Frontiers in Oncology</i> , 2022, 12, 833999.	1.3	5
2434	Which role for predictors of response to immune checkpoint inhibitors in hepatocellular carcinoma?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2022, 16, 333-339.	1.4	65
2435	Development and External Validation of the Munich Sorafenib Evaluation Score for Hepatocellular Carcinoma. <i>Digestive Diseases</i> , 2023, 41, 268-281.	0.8	0
2436	Right hepatectomy with preservation of segment VI: Seven cases of preliminary experience. , 2022, 1, 122-126.		0
2437	Cleavage stimulation factor 2 promotes malignant progression of liver hepatocellular carcinoma by activating phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin pathway. <i>Bioengineered</i> , 2022, 13, 10047-10060.	1.4	5
2438	WTAP Is Correlated With Unfavorable Prognosis, Tumor Cell Proliferation, and Immune Infiltration in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2022, 12, 852000.	1.3	3
2439	Radiomics analysis of ultrasound to predict recurrence of hepatocellular carcinoma after microwave ablation. <i>International Journal of Hyperthermia</i> , 2022, 39, 595-604.	1.1	7
2440	Identification of two immune-related risk score signatures through integrated analysis of multi-omics data in hepatocellular carcinoma. <i>Gene</i> , 2022, , 146519.	1.0	0
2441	Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 2018.	1.7	15
2442	Efficacy and Safety of TACE Combined With Lenvatinib Plus PD-1 Inhibitors Compared With TACE Alone for Unresectable Hepatocellular Carcinoma Patients: A Prospective Cohort Study. <i>Frontiers in Oncology</i> , 2022, 12, 874473.	1.3	22
2443	HSPB11 is a Prognostic Biomarker Associated with Immune Infiltrates in Hepatocellular Carcinoma. <i>International Journal of General Medicine</i> , 2022, Volume 15, 4017-4027.	0.8	1
2444	Long-term outcomes of ablation, liver resection, and liver transplant as first-line treatment for solitary HCC of 3 cm or less using an intention-to-treat analysis: A retrospective cohort study. <i>Annals of Medicine and Surgery</i> , 2022, 77, .	0.5	1
2445	Major postoperative complications are associated with early recurrence of hepatocellular carcinoma following hepatectomy. <i>Langenbeck's Archives of Surgery</i> , 2022, 407, 2373-2380.	0.8	2
2515	Five-year comparative risk of hepatocellular carcinoma development under entecavir or tenofovir treatment-naïve patients with chronic hepatitis B-related compensated cirrhosis in Taiwan. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1695-1706.	1.9	14
2516	Partnering with support persons and clinicians to improve the health care experiences of patients with cirrhosis. <i>Journal of Clinical Nursing</i> , 2022, , .	1.4	1
2517	Analysis of the Heterogeneity of the Tumor Microenvironment and the Prognosis and Immunotherapy Response of Different Immune Subtypes in Hepatocellular Carcinoma. <i>Journal of Oncology</i> , 2022, 2022, 1-21.	0.6	0
2518	New and effective method to develop primary hepatocytes from liver cancer patients. <i>Experimental Biology and Medicine</i> , 2022, 247, 972-981.	1.1	1

#	ARTICLE	IF	CITATIONS
2519	Nuclear respiratory factor 1 promotes the growth of liver hepatocellular carcinoma cells via E2F1 transcriptional activation. <i>BMC Gastroenterology</i> , 2022, 22, 198.	0.8	5
2520	Piezo1 promoted hepatocellular carcinoma progression and EMT through activating TGF- $\beta$ 2 signaling by recruiting Rab5c. <i>Cancer Cell International</i> , 2022, 22, 162.	1.8	11
2523	Hepatocellular carcinoma in non-alcoholic fatty liver disease (NAFLD) - pathological evidence for a predominance of steatohepatitic inflammatory non-proliferative subtype. <i>Histology and Histopathology</i> , 2020, 35, 729-740.	0.5	2
2524	Clinical proteomics: a driving force for cancer therapeutic target discovery and precision medicine. <i>Cancer Biology and Medicine</i> , 2019, 16, 623-629.	1.4	1
2525	Effects of Stereotactic Body Radiation Therapy Plus PD-1 Inhibitors for Patients With Transarterial Chemoembolization Refractory. <i>Frontiers in Oncology</i> , 2022, 12, 839605.	1.3	8
2526	Progression of AFP SCORE is a Preoperative Predictive Factor of Microvascular Invasion in Selected Patients Meeting Liver Transplantation Criteria for Hepatocellular Carcinoma. <i>Transplant International</i> , 2022, 35, 10412.	0.8	7
2528	Clinical application of advances and innovation in radiation treatment of hepatocellular carcinoma.. <i>Journal of Clinical and Translational Research</i> , 2021, 7, 811-833.	0.3	1
2529	Construction of a ceRNA network in hepatocellular carcinoma and comprehensive analysis of immune infiltration patterns.. <i>American Journal of Translational Research (discontinued)</i> , 2021, 13, 13356-13379.	0.0	1
2530	CalliSpheres microspheres drug-eluting bead transhepatic artery chemoembolization with or without sorafenib for the treatment of large liver cancer: a multi-center retrospective study.. <i>American Journal of Translational Research (discontinued)</i> , 2021, 13, 13931-13940.	0.0	1
2531	Establishment and validation of prognostic nomograms to predict the overall and cancer-specific survival in patients with hepatic malignant vascular tumors.. <i>American Journal of Translational Research (discontinued)</i> , 2022, 14, 798-818.	0.0	0
2532	Orthotopic liver transplantation improves postoperative quality of life, survival rate and reduces recurrence rate in patients with liver cancer.. <i>American Journal of Translational Research (discontinued)</i> , 2022, 14, 990-1000.	0.0	0
2533	Research Progress of Immune Checkpoint Inhibitors in the Treatment of Primary Liver Cancer. <i>Advances in Clinical Medicine</i> , 2022, 12, 3360-3366.	0.0	0
2534	Role of phytoconstituents in the hepatocellular carcinoma management: current perspective, challenges, and future perspectives. , 2022, , 175-196.		0
2535	Management of Systemic Therapies and Hepatic Arterial Infusion Chemotherapy in Patients with Advanced Hepatocellular Carcinoma Based on Sarcopenia Assessment. <i>Liver Cancer</i> , 2022, 11, 329-340.	4.2	5
2536	Down-regulated HSA_circ_0003528 inhibits hepatocellular carcinoma aggressiveness via the miR-212-3p/<i>XIAP</i> axis. <i>Bioengineered</i> , 2022, 13, 11269-11280.	1.4	1
2537	Bronchial artery embolization for hemoptysis caused by metastatic hepatocellular carcinoma. <i>Scientific Reports</i> , 2022, 12, 6906.	1.6	4
2538	CT volumetry helps predict prognosis of large hepatocellular carcinoma after resection. <i>Clinical Radiology</i> , 2022, 77, e599-e605.	0.5	2
2539	Comprehensive Analysis of RAPGEF2 for Predicting Prognosis and Immunotherapy Response in Patients with Hepatocellular Carcinoma. <i>Journal of Oncology</i> , 2022, 2022, 1-11.	0.6	1



#	ARTICLE	IF	CITATIONS
2540	The Synergistic Cooperation between TGF- $\beta$ 2 and Hypoxia in Cancer and Fibrosis. <i>Biomolecules</i> , 2022, 12, 635.	1.8	17
2541	Serum Amino Acid Profiles Predict the Development of Hepatocellular Carcinoma in Patients with Chronic HBV Infection. <i>ACS Omega</i> , 2022, 7, 15795-15808.	1.6	7
2542	Non-Invasive Tests of Liver Fibrosis Help in Predicting the Development of Hepatocellular Carcinoma among Patients with NAFLD. <i>Journal of Clinical Medicine</i> , 2022, 11, 2466.	1.0	3
2543	Vitamin D Reverts the Exosome-Mediated Transfer of Cancer Resistance to the mTOR Inhibitor Everolimus in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2022, 12, 874091.	1.3	2
2544	Hepatocellular Carcinoma: How the Gut Microbiota Contributes to Pathogenesis, Diagnosis, and Therapy. <i>Frontiers in Microbiology</i> , 2022, 13, 873160.	1.5	13
2545	A Glycolysis-Related Gene Signature Correlates With the Characteristics of the Tumor Immune Microenvironment and Predicts Prognosis in Patients With Hepatocellular Carcinoma. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 834976.	1.6	0
2546	Comprehensive Analysis of the Correlation Between Pyroptosis-Related lncRNAs and Tumor Microenvironment, Prognosis, and Immune Infiltration in Hepatocellular Carcinoma. <i>Frontiers in Genetics</i> , 2022, 13, 867627.	1.1	12
2548	Mesenchymal Stem Cells and Their Small Extracellular Vesicles as Crucial Immunological Efficacy for Hepatic Diseases. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	9
2549	Magnetic resonance imaging for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. <i>The Cochrane Library</i> , 2022, 2022, CD014798.	1.5	10
2550	Methylation site <i>APC</i> 112043544 as a potential biomarker for post-transplant hepatocellular carcinoma recurrence. <i>Future Oncology</i> , 2022, 18, 2401-2413.	1.1	1
2551	HLA-DQB1-AS1 Promotes Cell Proliferation, Inhibits Apoptosis, and Binds with ZRANB2 Protein in Hepatocellular Carcinoma. <i>Journal of Oncology</i> , 2022, 2022, 1-10.	0.6	3
2552	MRI features of treated hepatocellular carcinoma following locoregional therapy: a pictorial review. <i>Abdominal Radiology</i> , 2022, 47, 2299-2313.	1.0	4
2553	Novel immunotherapy combinations in clinical trials for hepatocellular carcinoma: will they shape the future treatment landscape?. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 681-691.	1.9	7
2554	Optimised systematic review tool: Application to candidate biomarkers for the diagnosis of hepatocellular carcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, , .	1.1	1
2555	Short- and long-term outcomes after robotic and open liver resection for elderly patients with hepatocellular carcinoma: a propensity score-matched study. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2022, 36, 8132-8143.	1.3	8
2556	ARV-771 Acts as an Inducer of Cell Cycle Arrest and Apoptosis to Suppress Hepatocellular Carcinoma Progression. <i>Frontiers in Pharmacology</i> , 2022, 13, .	1.6	5
2557	Lipolysis-Stimulated Lipoprotein Receptor Impairs Hepatocellular Carcinoma and Inhibits the Oncogenic Activity of YAP1 via PPPY Motif. <i>Frontiers in Oncology</i> , 2022, 12, 896412.	1.3	1
2558	Integrated Analysis of the Altered lncRNA, microRNA, and mRNA Expression in HBV-Positive Hepatocellular Carcinoma. <i>Life</i> , 2022, 12, 701.	1.1	4

#	ARTICLE	IF	CITATIONS
2559	Real-time automatic prediction of treatment response to transcatheter arterial chemoembolization in patients with hepatocellular carcinoma using deep learning based on digital subtraction angiography videos. <i>Cancer Imaging</i> , 2022, 22, 23.	1.2	12
2560	U1RNP/lncRNA/Transcription Cycle Axis Promotes Tumorigenesis of Hepatocellular Carcinoma. <i>Diagnostics</i> , 2022, 12, 1133.	1.3	2
2561	The "No-touch" technique improves the survival of patients with advanced hepatocellular carcinomas treated by liver transplantation: A single-center prospective randomized controlled trial. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2022, , .	0.6	0
2562	All-Trans-Retinoic Acid Plus Oxaliplatin/Fluorouracil/Leucovorin for Advanced Hepatocellular Carcinoma with Pulmonary Metastasis: A Multicenter Retrospective Study. <i>Cancer Management and Research</i> , 2022, Volume 14, 1663-1670.	0.9	2
2563	Safety and efficacy of drug-eluting microspheres chemoembolization under cone beam computed tomography control in patients with early and intermediate stage hepatocellular carcinoma. <i>Radiology and Oncology</i> , 2022, 56, 311-318.	0.6	0
2564	DNA hypermethylation modification promotes the development of hepatocellular carcinoma by depressing the tumor suppressor gene ZNF334. <i>Cell Death and Disease</i> , 2022, 13, 446.	2.7	6
2565	Compound kushen injection in cancer treatments: Efficacy, active ingredients, and mechanisms. <i>Pharmacological Research Modern Chinese Medicine</i> , 2022, 3, 100108.	0.5	2
2566	Construction and validation of a pyroptosis-related gene signature in hepatocellular carcinoma based on RNA sequencing. <i>Translational Cancer Research</i> , 2021, .	0.4	1
2567	Chimeric antigen receptor (CAR) T cell therapy in hepatocellular carcinoma; a review of recent advances. <i>Modern Medical Laboratory Journal</i> , 2021, 4, 19-27.	0.2	0
2568	Dietary lipids and malignant tumor of the digestive system. , 2022, , 83-109.		0
2569	VCP interaction with HMGB1 promotes hepatocellular carcinoma progression by activating the PI3K/AKT/mTOR pathway. <i>Journal of Translational Medicine</i> , 2022, 20, 212.	1.8	12
2570	UDP-glucose 6-dehydrogenase lessens sorafenib sensitivity via modulating unfolded protein response. <i>Biochemical and Biophysical Research Communications</i> , 2022, 613, 207-213.	1.0	3
2571	High Expression of EZH2 Mediated by ncRNAs Correlates with Poor Prognosis and Tumor Immune Infiltration of Hepatocellular Carcinoma. <i>Genes</i> , 2022, 13, 876.	1.0	5
2572	Predictors of response for hepatocellular carcinoma immunotherapy: is there anything on the horizon?. <i>Expert Review of Precision Medicine and Drug Development</i> , 2022, 7, 50-57.	0.4	1
2573	Integrated Analysis Reveals Critical Ferroptosis Regulators and FTL Contribute to Cancer Progression in Hepatocellular Carcinoma. <i>Frontiers in Genetics</i> , 2022, 13, .	1.1	9
2574	MEG8: An Indispensable Long Non-coding RNA in Multiple Cancers. <i>Current Pharmaceutical Design</i> , 2022, 28, 1688-1694.	0.9	2
2575	Circ_0006404 enhances hepatocellular carcinoma progression by regulating miR-624. <i>Environmental Science and Pollution Research</i> , 2022, , .	2.7	1
2576	The potential, analysis and prospect of ctDNA sequencing in hepatocellular carcinoma. <i>PeerJ</i> , 0, 10, e13473.	0.9	4

#	ARTICLE	IF	CITATIONS
2577	Robotic laser position versus freehand in CT-guided percutaneous microwave ablation for single hepatocellular carcinoma (diameter <math>\leq 3\text{ cm}</math>): a preliminary study. <i>International Journal of Hyperthermia</i> , 2022, 39, 725-732.	1.1	1
2578	Experimental drug treatments for hepatocellular carcinoma: clinical trial failures 2015 to 2021. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 693-706.	1.9	2
2579	Exploring the underlying molecular mechanism of liver cancer cells under hypoxia based on RNA sequencing. <i>BMC Genomic Data</i> , 2022, 23, 38.	0.7	2
2580	E2F1-mediated GINS2 transcriptional activation promotes tumor progression through PI3K/AKT/mTOR pathway in hepatocellular carcinoma.. <i>American Journal of Cancer Research</i> , 2022, 12, 1707-1726.	1.4	0
2581	Practice guidance for the use of terlipressin for liver cirrhosis-related complications. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482210982.	1.4	8
2582	Functions of three ubiquitin-conjugating enzyme 2 genes in hepatocellular carcinoma diagnosis and prognosis. <i>World Journal of Hepatology</i> , 2022, 14, 957-972.	0.8	0
2583	Molecular characteristics of novel immune subtypes of HCC based on lncRNAs related to immune disorders. <i>Scientific Reports</i> , 2022, 12, .	1.6	0
2584	Study Protocol: Adjuvant Holmium-166 Radioembolization After Radiofrequency Ablation in Early-Stage Hepatocellular Carcinoma Patientsâ€”A Dose-Finding Study (HORA EST HCC Trial). <i>CardioVascular and Interventional Radiology</i> , 2022, 45, 1057-1063.	0.9	4
2585	Liver cancer in severe alpha-1 antitrypsin deficiency: who is at risk?. <i>European Respiratory Journal</i> , 2022, 60, 2200718.	3.1	4
2586	SPINDOC is Highly Expressed in Pan-Cancer Samples and Can Promote the Proliferation, Invasion and Migration of Hepatocellular Carcinoma Cells by Activating Wnt/ $\beta$ -Catenin Signaling Pathway. <i>OncoTargets and Therapy</i> , 0, Volume 15, 555-570.	1.0	2
2587	Network Pharmacology-Based Strategy to Investigate the Mechanisms of Lenvatinib in the Treatment of Hepatocellular Carcinoma. <i>Computational Intelligence and Neuroscience</i> , 2022, 2022, 1-14.	1.1	1
2588	Loco-regional treatment of hepatocellular carcinoma: Role of contrast-enhanced ultrasonography. <i>World Journal of Hepatology</i> , 2022, 14, 911-922.	0.8	2
2590	Effects of Berberine on Liver Cancer. <i>Natural Product Communications</i> , 2022, 17, 1934578X2211020.	0.2	1
2591	Overall Survival Signature of 5-Methylcytosine Regulators Related Long Non-Coding RNA in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	5
2592	CT-Based Radiomics for the Recurrence Prediction of Hepatocellular Carcinoma After Surgical Resection. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 9, 453-465.	1.8	4
2593	Demethylzeylasteral targets lactate by inhibiting histone lactylation to suppress the tumorigenicity of liver cancer stem cells. <i>Pharmacological Research</i> , 2022, 181, 106270.	3.1	82
2594	The Pyroptosis-Related Long Noncoding RNA Signature Predicts Prognosis and Indicates Immunotherapeutic Efficiency in Hepatocellular Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, .	1.8	13
2595	Sphingomyelin Phodiesterase Acid-Like 3A Promotes Hepatocellular Carcinoma Growth Through the Enhancer of Rudimentary Homolog. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3

#	ARTICLE	IF	CITATIONS
2596	Identification of an Endoplasmic Reticulum Stress-Related Gene Signature to Evaluate the Immune Status and Predict the Prognosis of Hepatocellular Carcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	4
2597	Functions of three ubiquitin-conjugating enzyme 2 genes in hepatocellular carcinoma diagnosis and prognosis. <i>World Journal of Hepatology</i> , 2022, 14, 956-971.	0.8	3
2598	Safety and Efficacy of Sintilimab and Anlotinib as First Line Treatment for Advanced Hepatocellular Carcinoma (KEEP-G04): A Single-Arm Phase 2 Study. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	22
2599	Efficient Delivery of Curcumin by Alginate Oligosaccharide Coated Aminated Mesoporous Silica Nanoparticles and In Vitro Anticancer Activity against Colon Cancer Cells. <i>Pharmaceutics</i> , 2022, 14, 1166.	2.0	29
2600	Hypoxia-induced HIF1A Activates DUSP18-mediated MAPK14 Dephosphorylation to Promote Hepatocellular Carcinoma Cell Migration and Invasion. <i>Pathology Research and Practice</i> , 2022, , 153955.	1.0	1
2601	Identification of a seven-gene signature predicting clinical outcome of liver cancer based on tumor mutational burden. <i>Human Cell</i> , 2022, 35, 1192-1206.	1.2	6
2602	Bufalin stimulates antitumor immune response by driving tumor-infiltrating macrophage toward M1 phenotype in hepatocellular carcinoma. , 2022, 10, e004297.		41
2603	Clinical Utility of Albumin Bilirubin Grade as a Prognostic Marker in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: a Systematic Review and Meta-analysis. <i>Journal of Gastrointestinal Cancer</i> , 2023, 54, 420-432.	0.6	8
2604	Outcome of liver cancer patients with SARS-CoV-2 infection: An International, Multicentre, Cohort Study. <i>Liver International</i> , 2022, 42, 1891-1901.	1.9	11
2605	Image-Guided Percutaneous Ablation for Primary and Metastatic Tumors. <i>Diagnostics</i> , 2022, 12, 1300.	1.3	9
2606	Combination therapy using microwave ablation and d-mannose-chelated iron oxide nanoparticles inhibits hepatocellular carcinoma progression. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 3475-3485.	5.7	15
2607	GBA1-dependent membrane glucosylceramide reprogramming promotes liver cancer metastasis via activation of the Wnt/ $\beta$ -catenin signalling pathway. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	7
2608	Combined hepatic segment color rendering technique improves the outcome of anatomical hepatectomy in patients with hepatocellular carcinoma. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2022, , .	0.6	0
2609	A Phase I Study of Locoregional High-Dose Autologous Natural Killer Cell Therapy With Hepatic Arterial Infusion Chemotherapy in Patients With Locally Advanced Hepatocellular Carcinoma. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	15
2610	miR-382-5p promotes cell invasion in hepatocellular carcinoma by targeting PTEN to activate PI3K/Akt signaling pathway. <i>World Journal of Surgical Oncology</i> , 2022, 20, .	0.8	4
2611	Paraneoplastic syndromes in hepatocellular carcinoma: a review. <i>Expert Review of Gastroenterology and Hepatology</i> , 2022, 16, 449-471.	1.4	6
2612	First-Line Targeted Therapy for Hepatocellular Carcinoma: Role of Atezolizumab/Bevacizumab Combination. <i>Biomedicines</i> , 2022, 10, 1304.	1.4	9
2613	Biliary complications and efficacy after ablation of peribiliary tumors using irreversible electroporation (IRE) or radiofrequency ablation (RFA). <i>International Journal of Hyperthermia</i> , 2022, 39, 751-757.	1.1	4

#	ARTICLE	IF	CITATIONS
2614	Tomoelastography based on multifrequency MR elastography predicts liver function reserve in patients with hepatocellular carcinoma: a prospective study. <i>Insights Into Imaging</i> , 2022, 13, .	1.6	3
2615	Combination of Radiofrequency Ablation With Resiquimod to Treat Hepatocellular Carcinoma Via Inflammation of Tumor Immune Microenvironment and Suppression of Angiogenesis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
2616	Immune Checkpoint Inhibitors Plus an Anti-VEGF Antibody as the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis and Cost-Effectiveness Analysis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	6
2617	A clinical trial of super-stable homogeneous lipiodol-nanolCG formulation-guided precise fluorescent laparoscopic hepatocellular carcinoma resection. <i>Journal of Nanobiotechnology</i> , 2022, 20, .	4.2	17
2618	Hepatobiliary carcinomas. , 2023, , 358-365.		0
2620	Effect of IL-8 on hepatocellular carcinoma-associated metastasis by targeting MMP9 in mice. <i>Translational Cancer Research</i> , 2021, .	0.4	0
2621	ZIC5 promotes human hepatocellular carcinoma cell proliferation through upregulating COL1A1. <i>Journal of Gastrointestinal Oncology</i> , 2021, .	0.6	1
2622	Study on safety and efficacy of regorafenib combined with transcatheter arterial chemoembolization in the treatment of advanced hepatocellular carcinoma after first-line targeted therapy. <i>Journal of Gastrointestinal Oncology</i> , 2022, 13, 1248-1254.	0.6	7
2624	Hepatocarcinoma: experiencia de la vida real en un centro especializado de Bogotá, Colombia. <i>Revista Colombiana De Gastroenterología</i> , 2022, 37, 163-173.	0.1	1
2625	Fat and exposure to 4-nitroquinoline-1-oxide causes histologic and inflammatory changes in murine livers. <i>PLoS ONE</i> , 2022, 17, e0268891.	1.1	0
2626	Comparison of the prognostic effect of sarcopenia on atezolizumab plus bevacizumab and lenvatinib therapy in hepatocellular carcinoma patients. <i>JGH Open</i> , 2022, 6, 477-486.	0.7	13
2627	The efficacy of transarterial chemoembolization in downstaging unresectable hepatocellular carcinoma to curative therapy: a predicted regression model. <i>Investigational New Drugs</i> , 0, , .	1.2	1
2628	Liver cancer heterogeneity modeled by in situ genome editing of hepatocytes. <i>Science Advances</i> , 2022, 8, .	4.7	15
2629	Comparison of the efficacy and safety of repeated hepatectomy and radiofrequency ablation in the treatment of primary recurrent liver cancer: a meta-analysis. <i>World Journal of Surgical Oncology</i> , 2022, 20, .	0.8	3
2630	The role of stereotactic body radiotherapy in hepatocellular carcinoma: guidelines and evidences. <i>Journal of the National Cancer Center</i> , 2022, 2, 171-182.	3.0	3
2631	Identification of ferroptosis-related genes for overall survival prediction in hepatocellular carcinoma. <i>Scientific Reports</i> , 2022, 12, .	1.6	15
2632	<scp>DNASE1L3</scp> inhibits proliferation, invasion and metastasis of hepatocellular carcinoma by interacting with ð²â€œcatenin to promote its ubiquitin degradation pathway. <i>Cell Proliferation</i> , 2022, 55, .	2.4	9
2633	Identification of CFHR4 as a Potential Prognosis Biomarker Associated With Immune Infiltrates in Hepatocellular Carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5

#	ARTICLE	IF	CITATIONS
2634	Hepatosellülüler Karsinomda A <sup>9</sup> la <sup>Ş</sup> Y <sup>4</sup> klenebilir Mikrok <sup>4</sup> reler ile Yap <sup>±</sup> lan Transarteriyel Kemoembolizasyonun Etkinli <sup>Y</sup> i: Tek Merkez Deneyimi. Duzce Universitesi Tip Fak <sup>4</sup> ltesi Dergisi, 0, , .	0.3	0
2635	Preoperative gadoteric acid-enhanced MRI predicts aggressive pathological features in LI-RADS category 5 hepatocellular carcinoma. <i>Clinical Radiology</i> , 2022, 77, 708-716.	0.5	4
2636	Novel antigens for targeted radioimmunotherapy in hepatocellular carcinoma. <i>Molecular and Cellular Biochemistry</i> , 2023, 478, 23-37.	1.4	7
2637	Novel <sup>β</sup> T cell-based prognostic signature to estimate risk and aid therapy in hepatocellular carcinoma. <i>BMC Cancer</i> , 2022, 22, .	1.1	2
2638	Long Non-Coding RNA MCM3AP-AS1: A Crucial Role in Human Malignancies. <i>Pathology and Oncology Research</i> , 0, 28, .	0.9	2
2640	A Multifunctional Vanadium-Iron-Oxide Nanoparticle Eradicates Hepatocellular Carcinoma via Targeting Tumor and Endothelial Cells. <i>ACS Applied Materials &amp; Interfaces</i> , 2022, 14, 28514-28526.	4.0	12
2641	The role of YAP1 in liver cancer stem cells: proven and potential mechanisms. <i>Biomarker Research</i> , 2022, 10, .	2.8	7
2642	Changing Epidemiological Trends of Hepatobiliary Carcinomas in Austria 2010â€“2018. <i>Cancers</i> , 2022, 14, 3093.	1.7	5
2643	Capsaicin suppresses hepatocarcinogenesis by inhibiting the stemness of hepatic progenitor cells via <sup>SIRT1</sup> / <sup>SOX2</sup> signaling pathway. <i>Cancer Medicine</i> , 2022, 11, 4283-4296.	1.3	7
2644	<sup>OGG1</sup> contributes to hepatocellular carcinoma by promoting cell cycleâ€related protein expression and enhancing <sup>DNA</sup> oxidative damage repair in tumor cells. <i>Journal of Clinical Laboratory Analysis</i> , 2022, 36, .	0.9	2
2645	circACTG1 Promotes Hepatocellular Carcinoma Progression by Regulating miR-940/RIF1 Axis and Activating AKT/mTOR Pathway. <i>Journal of Immunology Research</i> , 2022, 2022, 1-13.	0.9	2
2646	Clinical Nursing Paths Benefit Patient Outcomes Undergoing Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma. <i>Evidence-based Complementary and Alternative Medicine</i> , 2022, 2022, 1-8.	0.5	2
2647	Aggregationâ€Induced Emission (AIE) and Magnetic Resonance Imaging Characteristics for Targeted and Imageâ€Guided siRNA Therapy of Hepatocellular Carcinoma. <i>Advanced Healthcare Materials</i> , 2022, 11, .	3.9	6
2648	Long non-coding RNA LINC01793 as a potential diagnostic biomarker of hepatitis B virus-related hepatocellular carcinoma. <i>Clinical Biochemistry</i> , 2022, 108, 56-62.	0.8	5
2649	CLEC1B is a Promising Prognostic Biomarker and Correlated with Immune Infiltration in Hepatocellular Carcinoma. <i>International Journal of General Medicine</i> , 0, Volume 15, 5661-5672.	0.8	3
2650	Laparoscopic versus open liver resection for resectable HCC with BCLC stage B: a propensity score-matched analysis. <i>Updates in Surgery</i> , 2022, 74, 1291-1297.	0.9	5
2651	A risk score model based on TGF- <sup>β</sup> pathway-related genes predicts survival, tumor microenvironment and immunotherapy for liver hepatocellular carcinoma. <i>Proteome Science</i> , 2022, 20, .	0.7	4
2652	Prognostic MicroRNA Panel for HCV-Associated HCC: Integrating Computational Biology and Clinical Validation. <i>Cancers</i> , 2022, 14, 3036.	1.7	5

#	ARTICLE	IF	CITATIONS
2653	High nuclear ABCG1 expression is a poor predictor for hepatocellular carcinoma patient survival. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2022, 21, 370-377.	0.6	5
2654	Recent Insights of Metformin on Hepatocellular Carcinoma (HCC). <i>Mini-Reviews in Medicinal Chemistry</i> , 2022, 22, .	1.1	1
2655	3D printed hydrogel scaffolds combining glutathione depletion-induced ferroptosis and photothermia-augmented chemodynamic therapy for efficiently inhibiting postoperative tumor recurrence. <i>Journal of Nanobiotechnology</i> , 2022, 20, .	4.2	25
2657	Ligand-modified Nanomaterials for Specific Targeting of Hepatocellular Carcinoma. , 2022, 2, .		0
2658	Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	18
2659	Targeted glutamine-decorated chitosan nanoparticles with enhanced synergism of chemotherapeutic and natural medicine for hepatic carcinoma therapy. <i>Materials and Design</i> , 2022, 220, 110842.	3.3	2
2660	Emodin regulates the autophagy via the miR-371a-5p/PTEN axis to inhibit hepatic malignancy. <i>Biochemical and Biophysical Research Communications</i> , 2022, 619, 1-8.	1.0	6
2661	PLIN2 promotes HCC cells proliferation by inhibiting the degradation of HIF1 $\alpha$ . <i>Experimental Cell Research</i> , 2022, 418, 113244.	1.2	5
2662	The comparison between albumin-bilirubin grade and Child-Pugh grade for assessing the prognosis of hepatocellular carcinoma after thermal ablation: a propensity score-matched analysis. <i>Translational Cancer Research</i> , 2022, 11, 2523-2535.	0.4	3
2663	Effect of demethyltransferase FTO on tumor progression. <i>Biocell</i> , 2022, 46, 2387-2397.	0.4	0
2664	Combination of Targeting Mitochondrial Dynamics and Metabolism Reverses the Acquired Resistance to Sorafenib in Hepatocellular Carcinoma. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
2665	Trend Analysis and Prediction of Hepatobiliary Pancreatic Cancer Incidence and Mortality in Korea. <i>Journal of Korean Medical Science</i> , 2022, 37, .	1.1	2
2666	A Single Nucleotide Mixture Enhances the Antitumor Activity of Molecular-Targeted Drugs Against Hepatocellular Carcinoma. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
2667	Deep-learning-based analysis of preoperative MRI predicts microvascular invasion and outcome in hepatocellular carcinoma. <i>World Journal of Surgical Oncology</i> , 2022, 20, .	0.8	7
2668	COVID-19 and Liver Surgery: How the Pandemic Affected an Italian Medium-Volume HBP Center. <i>Frontiers in Surgery</i> , 0, 9, .	0.6	2
2669	Prediction Model and Nomogram of Early Recurrence of Hepatocellular Carcinoma after Radiofrequency Ablation Based on Logistic Regression Analysis. <i>Ultrasound in Medicine and Biology</i> , 2022, , .	0.7	5
2670	PET imaging of hepatocellular carcinoma by targeting tumor-associated endothelium using [68Ga]Ga-PSMA-617. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 4000-4013.	3.3	13
2671	Integrated Bioinformatics Analysis for the Screening of Hub Genes and Therapeutic Drugs in Hepatocellular Carcinoma. <i>Current Pharmaceutical Biotechnology</i> , 2023, 24, 1035-1058.	0.9	4

#	ARTICLE	IF	CITATIONS
2672	Hypoxia-inducible factor-1 $\alpha$ : A critical target for inhibiting the metastasis of hepatocellular carcinoma (Review). <i>Oncology Letters</i> , 2022, 24, .	0.8	7
2673	Clinical significance and immunogenomic landscape analysis of glycolysis-associated prognostic model to guide clinical therapy in hepatocellular carcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2022, 13, 1351-1366.	0.6	1
2674	3D-Epigenomic Regulation of Gene Transcription in Hepatocellular Carcinoma. <i>Genetics &amp; Genomics Next</i> , 2022, 3, .	0.8	1
2675	Green synthesized gold nanoparticles from <i>Pseudobulbus Cremastrae seu Pleiones</i> show efficacy against hepatic carcinoma potentially through immunoregulation. <i>Drug Delivery</i> , 2022, 29, 1983-1993.	2.5	0
2676	Development and Validation of a Novel Ferroptosis-Related Gene Signature for Prognosis and Immunotherapy in Hepatocellular Carcinoma. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	12
2677	Efficacy and safety of transcatheter arterial chemoembolization-lenvatinib sequential therapy for patients with unresectable hepatocellular carcinoma: a single-arm clinical study. <i>Journal of Gastrointestinal Oncology</i> , 2022, 13, 1367-1375.	0.6	2
2678	Targeted Proteins Reveal Cathepsin D as a Novel Biomarker in Differentiating Hepatocellular Carcinoma from Cirrhosis and Other Liver Cancers. <i>Asian Pacific Journal of Cancer Prevention</i> , 2022, 23, 2017-2025.	0.5	2
2679	Transarterial chemoembolization failure/refractoriness: A scientific concept or pseudo-proposition. <i>World Journal of Gastrointestinal Surgery</i> , 2022, 14, 528-537.	0.8	5
2680	The second Mexican consensus on hepatocellular carcinoma. Part II: Treatment. <i>Revista De GastroenterologÍa De Méjico (English Edition)</i> , 2022, , .	0.1	0
2681	Potential of Apolipoprotein A1 (ApoA1) for Detecting Liver Cirrhosis and Hepatocellular Carcinoma. <i>Asian Pacific Journal of Cancer Prevention</i> , 2022, 23, 2001-2008.	0.5	6
2682	Population Pharmacokinetic Modeling of Lenvatinib in Chinese Patients with Advanced Hepatocellular Carcinoma using Real-World Data. <i>Journal of Clinical Pharmacology</i> , 0, , .	1.0	0
2683	GLIPR1 promotes proliferation, metastasis and 5-fluorouracil resistance in hepatocellular carcinoma by activating the PI3K/PDK1/ROCK1 pathway. <i>Cancer Gene Therapy</i> , 0, , .	2.2	2
2684	Potential Diagnostic and Prognostic Values of CBX8 Expression in Liver Hepatocellular Carcinoma, Kidney Renal Clear Cell Carcinoma, and Ovarian Cancer: A Study Based on TCGA Data Mining. <i>Computational and Mathematical Methods in Medicine</i> , 2022, 2022, 1-28.	0.7	2
2685	Identification and Validation of a Novel Tumor Microenvironment-Related Prognostic Signature of Patients With Hepatocellular Carcinoma. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	6
2686	Adenine Combined with Cisplatin Promotes Anticancer Activity against Hepatocellular Cancer Cells through AMPK-Mediated p53/p21 and p38 MAPK Cascades. <i>Pharmaceuticals</i> , 2022, 15, 795.	1.7	3
2687	Mouse Models of Hepatocellular Carcinoma: Classification, Advancement, and Application. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
2688	Imbalanced gut microbiota fuels hepatocellular carcinoma development by shaping the hepatic inflammatory microenvironment. <i>Nature Communications</i> , 2022, 13, .	5.8	68
2689	Pretreatment Modified Albumin-Bilirubin Grade Is an Important Predictive Factor Associated with the Therapeutic Response and the Continuation of Atezolizumab plus Bevacizumab Combination Therapy for Patients with Unresectable Hepatocellular Carcinoma. <i>Current Oncology</i> , 2022, 29, 4799-4810.	0.9	8



#	ARTICLE	IF	CITATIONS
2690	Impact and Novel Perspective of Immune Checkpoint Inhibitors in Patients with Early and Intermediate Stage HCC. <i>Cancers</i> , 2022, 14, 3332.	1.7	11
2691	JIB-04, a Pan-Inhibitor of Histone Demethylases, Targets Histone-Lysine-Demethylase-Dependent AKT Pathway, Leading to Cell Cycle Arrest and Inhibition of Cancer Stem-Like Cell Properties in Hepatocellular Carcinoma Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7657.	1.8	3
2692	Preoperative determination of pathological grades of primary single HCC: development and validation of a scoring model. <i>Abdominal Radiology</i> , 2022, 47, 3468-3477.	1.0	2
2693	Economic evaluations of radioembolization with Itrium-90 microspheres in hepatocellular carcinoma: a systematic review. <i>BMC Gastroenterology</i> , 2022, 22, .	0.8	6
2694	Sorafenib as adjuvant therapy following radiofrequency ablation for recurrent hepatocellular carcinoma within Milan criteria: a multicenter analysis. <i>Journal of Gastroenterology</i> , 2022, 57, 684-694.	2.3	3
2695	Embolization therapy with microspheres for the treatment of liver cancer: State-of-the-art of clinical translation. <i>Acta Biomaterialia</i> , 2022, 149, 1-15.	4.1	24
2696	Laparoscopic repair of diaphragmatic hernia associating with radiofrequency ablation for hepatocellular carcinoma: A case report. <i>World Journal of Clinical Cases</i> , 2022, 10, 7020-7028.	0.3	2
2697	Prognostic Nomograms Combined Adjuvant Lenvatinib for Hepatitis B Virus-related Hepatocellular Carcinoma With Microvascular Invasion After Radical Resection. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	7
2698	Construction and Validation of an Epigenetic Regulator Signature as A Novel Biomarker For Prognosis, Immunotherapy, And Chemotherapy In Hepatocellular Carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
2699	Hepatocellular carcinoma: measures to improve the outlook in sub-Saharan Africa. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 1036-1048.	3.7	9
2700	The miR-590-3p/CFHR3/STAT3 signaling pathway promotes cell proliferation and metastasis in hepatocellular carcinoma. <i>Aging</i> , 2022, , 5783-5799.	1.4	7
2701	Role of exosomal microRNAs in cancer therapy and drug resistance mechanisms: focus on hepatocellular carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	9
2702	Association of Plasma Iron Status with Subsequent Risk of Total and Site-Specific Cancer: A Large Case Cohort Study within JPHC Study. <i>Cancer Prevention Research</i> , 2022, 15, 669-678.	0.7	1
2703	The Edible Plant <i>Crithmum maritimum</i> Shows Nutraceutical Properties by Targeting Energy Metabolism in Hepatic Cancer. <i>Plant Foods for Human Nutrition</i> , 2022, 77, 481-483.	1.4	7
2704	Ezetimibe and Cancer: Is There a Connection?. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	7
2705	VEGF-mediated tumour growth and EMT in 2D and 3D cell culture models of hepatocellular carcinoma. <i>Oncology Letters</i> , 2022, 24, .	0.8	5
2706	Sulfatase-2 from Cancer Associated Fibroblasts: An Environmental Target for Hepatocellular Carcinoma?. <i>Liver Cancer</i> , 2022, 11, 540-557.	4.2	6
2707	miR-6071 inhibits hepatocellular carcinoma progression via targeting PTPN11. <i>Archives of Biochemistry and Biophysics</i> , 2022, 727, 109345.	1.4	1

#	ARTICLE	IF	CITATIONS
2708	Emerging roles and potential clinical applications of long non-coding RNAs in hepatocellular carcinoma. <i>Biomedicine and Pharmacotherapy</i> , 2022, 153, 113327.	2.5	7
2709	A novel lncRNA RP11-386G11.10 reprograms lipid metabolism to promote hepatocellular carcinoma progression. <i>Molecular Metabolism</i> , 2022, 63, 101540.	3.0	19
2710	Association Between Socioeconomic and Insurance Status and Delayed Diagnosis of Gastrointestinal Cancers. <i>Journal of Surgical Research</i> , 2022, 279, 170-186.	0.8	6
2711	Improved anti-hepatocellular carcinoma effect by enhanced Co-delivery of Tim-3 siRNA and sorafenib via multiple pH triggered drug-eluting nanoparticles. <i>Materials Today Bio</i> , 2022, 16, 100350.	2.6	6
2712	Liver Cancer: Hepatocellular and Fibrolamellar Carcinoma. , 2023, , 109-132.		0
2713	Sema3d Restrained Hepatocellular Carcinoma Progression Through Inactivating Pi3k/Akt Signaling via Interaction With FLNA. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
2714	Fecal calprotectin level as a marker of esophageal varices in Egyptian HCV cirrhotic patients. <i>Revista De GastroenterologÃa De MÃxico (English Edition)</i> , 2023, 88, 333-340.	0.1	2
2715	Drug Discovery Using Evolutionary Similarities in Chemical Binding to Inhibit Patient-Derived Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7971.	1.8	3
2716	Efficacy Investigation of TACE Combined with Lenvatinib and Sintilimab in Intermediate-Stage Hepatocellular Carcinoma. <i>Disease Markers</i> , 2022, 2022, 1-6.	0.6	1
2717	An MMP-based risk score strongly distinguishes prognosis in hepatocellular carcinoma after resection. <i>Future Oncology</i> , 2022, 18, 2903-2917.	1.1	0
2718	A Machine Learning Model Based on Health Records for Predicting Recurrence After Microwave Ablation of Hepatocellular Carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 9, 671-684.	1.8	7
2719	Nivolumab Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	8
2720	Curcumin- and resveratrol-co-loaded nanoparticles in synergistic treatment of hepatocellular carcinoma. <i>Journal of Nanobiotechnology</i> , 2022, 20, .	4.2	25
2721	GOT2 Silencing Promotes Reprogramming of Glutamine Metabolism and Sensitizes Hepatocellular Carcinoma to Glutaminase Inhibitors. <i>Cancer Research</i> , 2022, 82, 3223-3235.	0.4	16
2722	Transfer <sc>RNA</sc>â€derived fragment 5â€2<sc>tRFâ€Gly</sc> promotes the development of hepatocellular carcinoma by direct targeting of carcinoembryonic antigenâ€related cell adhesion molecule 1. <i>Cancer Science</i> , 2022, 113, 3476-3488.	1.7	6
2724	Bilirubin inhibits the anticancer activity of sorafenib by blocking MCL-1 degradation in hepatocellular carcinoma cells. <i>Cancer Biology and Medicine</i> , 2022, 19, 1061-1077.	1.4	3
2725	The Performance of Serum Alpha-Fetoprotein for Detecting Early-Stage Hepatocellular Carcinoma Is Influenced by Antiviral Therapy and Serum Aspartate Aminotransferase: A Study in a Large Cohort of Hepatitis B Virus-Infected Patients. <i>Viruses</i> , 2022, 14, 1669.	1.5	4
2726	Stemness Analysis Uncovers That The Peroxisome Proliferator-Activated Receptor Signaling Pathway Can Mediate Fatty Acid Homeostasis In Sorafenib-Resistant Hepatocellular Carcinoma Cells. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4

#	ARTICLE	IF	CITATIONS
2727	Ultra-thin layered double hydroxide-mediated photothermal therapy combine with asynchronous blockade of PD-L1 and NR2F6 inhibit hepatocellular carcinoma. <i>Journal of Nanobiotechnology</i> , 2022, 20, .	4.2	6
2728	Hsa_circ_0008092 Contributes to Cell Proliferation and Metastasis in Hepatocellular Carcinoma via the miR-502-5p/CCND1 Axis. <i>Protein and Peptide Letters</i> , 2022, 29, 595-604.	0.4	0
2729	Glycometabolism-related gene signature of hepatocellular carcinoma predicts prognosis and guides immunotherapy. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	1
2730	Identification of the hsa_circ_0039466/miR-96-5p/FOXO1 regulatory network in hepatocellular carcinoma by whole-transcriptome analysis. <i>Annals of Translational Medicine</i> , 2022, 10, 769-769.	0.7	7
2731	Histological Severity of Cirrhosis Influences Surgical Outcomes of Hepatocellular Carcinoma After Curative Hepatectomy. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 9, 633-647.	1.8	3
2732	A novel HCC prognosis predictor PDSS1 affects the cell cycle through the STAT3 signaling pathway in HCC. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
2733	Utility of PIVKA-II and AFP in Differentiating Hepatocellular Carcinoma from Non-Malignant High-Risk Patients. <i>Medicina (Lithuania)</i> , 2022, 58, 1015.	0.8	3
2734	Comparison of the long-term outcomes of patients with hepatocellular carcinoma within the Milan criteria treated by ablation, resection, or transplantation. <i>Cancer Medicine</i> , 2023, 12, 2312-2324.	1.3	2
2735	Sirolimus increases the anti-cancer effect of Huai Er by regulating hypoxia inducible factor-1 $\alpha$ -mediated glycolysis in hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2022, 28, 4600-4619.	1.4	7
2736	Five-lipoxygenase-activating protein-mediated CYLD attenuation is a candidate driver in hepatic malignant lesion. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
2737	Comparison of Arterial Infusion Chemotherapy and Chemoembolization for Locally Advanced Hepatocellular Carcinoma: a Multicenter Retrospective Study. <i>Journal of Gastrointestinal Surgery</i> , 2022, 26, 2292-2300.	0.9	5
2738	Extending Surgical Resection for Hepatocellular Carcinoma Beyond Barcelona Clinic for Liver Cancer (BCLC) Stage A: A Novel Application of the Modified BCLC Staging System. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 9, 839-851.	1.8	7
2739	Untargeted plasma metabolomics for risk prediction of hepatocellular carcinoma: A prospective study in two Chinese cohorts. <i>International Journal of Cancer</i> , 2022, 151, 2144-2154.	2.3	12
2740	miR-3154 promotes hepatocellular carcinoma progression via suppressing HNF4 $\alpha$ . <i>Carcinogenesis</i> , 2022, 43, 1002-1014.	1.3	6
2741	MYBL1 induces transcriptional activation of ANGPT2 to promote tumor angiogenesis and confer sorafenib resistance in human hepatocellular carcinoma. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	11
2742	Epstein-Barr virus infection-associated cholangiocarcinoma: a report of one case and the review of literature. <i>Virology Journal</i> , 2022, 19, .	1.4	2
2743	A single-cell atlas of the multicellular ecosystem of primary and metastatic hepatocellular carcinoma. <i>Nature Communications</i> , 2022, 13, .	5.8	89
2744	DNA methylation regulators-related molecular patterns and tumor immune landscape in hepatocellular carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3

#	ARTICLE	IF	CITATIONS
2745	SOCS2-enhanced ubiquitination of SLC7A11 promotes ferroptosis and radiosensitization in hepatocellular carcinoma. <i>Cell Death and Differentiation</i> , 2023, 30, 137-151.	5.0	66
2746	Hepatic arterial infusion chemotherapy and sequential ablation treatment in large hepatocellular carcinoma. <i>International Journal of Hyperthermia</i> , 2022, 39, 1097-1105.	1.1	5
2747	Transarterial Chemoembolization in Hepatocellular Carcinoma: A Binational Japanese-German Study. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 9, 695-705.	1.8	0
2748	Vitamin B6 Metabolic Pathway is Involved in the Pathogenesis of Liver Diseases via Multi-Omics Analysis. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 9, 729-750.	1.8	7
2749	Optimal tumor numbers in surgical candidates for multiple hepatocellular carcinomas. <i>Surgery</i> , 2022, , .	1.0	1
2750	Collagen-binding fibroblast growth factor ameliorates liver fibrosis in murine bile duct ligation injury. <i>Journal of Biomaterials Applications</i> , 2022, 37, 918-929.	1.2	1
2751	Blockade of Tâ€cell receptor with Ig and ITIM domains elicits potent antitumor immunity in naturally occurring HBVâ€related HCC in mice. <i>Hepatology</i> , 2023, 77, 965-981.	3.6	12
2752	Initial therapeutic results of atezolizumab plus bevacizumab for unresectable advanced hepatocellular carcinoma and the importance of hepatic functional reserve. <i>Cancer Medicine</i> , 2023, 12, 2646-2657.	1.3	9
2754	Preoperative estimation of the survival of patients with unresectable hepatocellular carcinoma achieving complete response after conventional transcatheter arterial chemoembolization: assessments of clinical and LI-RADS MR features. <i>Radiologia Medica</i> , 0, , .	4.7	6
2755	CallispheresÂ® drug-eluting beads transarterial chemoembolization might be an efficient and safety down-staging therapy in unresectable liver cancer patients. <i>World Journal of Surgical Oncology</i> , 2022, 20, .	0.8	1
2756	Relationship between Intestinal Microflora and Hepatocellular Cancer Based on Gut-Liver Axis Theory. <i>Contrast Media and Molecular Imaging</i> , 2022, 2022, 1-8.	0.4	3
2757	Engineering micro oxygen factories to slow tumour progression via hyperoxic microenvironments. <i>Nature Communications</i> , 2022, 13, .	5.8	28
2758	Impact of aspartate aminotransferaseâ€toâ€platelet ratio index based score to assess posthepatectomy liver failure in patients with hepatocellular carcinoma. <i>World Journal of Surgical Oncology</i> , 2022, 20, .	0.8	1
2759	Hybrid Lipid Nanoformulations for Hepatoma Therapy: Sorafenib Loaded Nanoliposomesâ€A Preliminary Study. <i>Nanomaterials</i> , 2022, 12, 2833.	1.9	3
2760	Lenvatinib for the treatment of hepatocellular carcinomaâ€a real-world multicenter Australian cohort study. <i>Hepatology International</i> , 2022, 16, 1170-1178.	1.9	7
2761	Integrative Multi-Omics Analysis of Identified Ferroptosis-Marker RPL8 as a Candidate Oncogene Correlates with Poor Prognosis and Immune Infiltration in Liver Cancer. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2023, 26, 1298-1310.	0.6	3
2762	Lenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH). <i>Journal of Clinical Oncology</i> , 2023, 41, 117-127.	0.8	124
2763	HCC-neuroendocrine transition: Tumor plasticity under immunotherapy. <i>GastroenterologÃa Y HepatologÃa (English Edition)</i> , 2022, 45, 552-554.	0.0	0

#	ARTICLE	IF	CITATIONS
2764	Comparison of the Efficacy and Safety of Transarterial Chemoembolization with or without Lenvatinib for Unresectable Hepatocellular Carcinoma: A Retrospective Propensity Scoreâ€œMatched Analysis. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 9, 685-694.	1.8	7
2765	Clinical effectiveness of surgical treatment after lenvatinib administration for hepatocellular carcinoma. <i>International Journal of Clinical Oncology</i> , 2022, 27, 1725-1732.	1.0	5
2766	The â€œstiff rimâ€•sign of hepatocellular carcinoma on shear wave elastography: correlation with pathological features and potential prognostic value. <i>Abdominal Radiology</i> , 0, , .	1.0	1
2767	Identification of HM13 as a prognostic indicator and a predictive biomarker for immunotherapy in hepatocellular carcinoma. <i>BMC Cancer</i> , 2022, 22, .	1.1	4
2768	Radiological Features of Microvascular Invasion of Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease. <i>Gastroenterology Insights</i> , 2022, 13, 275-285.	0.7	2
2769	Role of Ultrasound Methods for the Assessment of NAFLD. <i>Journal of Clinical Medicine</i> , 2022, 11, 4581.	1.0	12
2770	Management of Acute Coronary Syndrome With a Bleeding Intra-Tumoral Hepatocellular Carcinoma: A Case Report. <i>Cureus</i> , 2022, , .	0.2	0
2771	A Ferroptosis-Related LncRNA Signature Associated with Prognosis, Tumor Immune Environment, and Genome Instability in Hepatocellular Carcinoma. <i>Computational and Mathematical Methods in Medicine</i> , 2022, 2022, 1-19.	0.7	4
2772	Multi-feature weight factor extraction and survival risk assessment of hepatocellular carcinoma based on a clinical missing dataset-independent support vector machine. , 2022, 1, 154-158.		0
2773	The role of SPARC (secreted protein acidic and rich in cysteine) in the pathogenesis of obesity, type 2 diabetes, and non-alcoholic fatty liver disease. <i>Journal of Physiology and Biochemistry</i> , 2023, 79, 815-831.	1.3	5
2774	Identification and Validation in a Novel Classification of Helicase Patterns for the Prediction of Tumor Proliferation and Prognosis. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 9, 885-900.	1.8	1
2775	Protein palmitoylation in cancer: molecular functions and therapeutic potential. <i>Molecular Oncology</i> , 2023, 17, 3-26.	2.1	23
2776	Prognostic Value of MUC16 Mutation and Its Correlation with Immunity in Hepatocellular Carcinoma Patients. <i>Evidence-based Complementary and Alternative Medicine</i> , 2022, 2022, 1-9.	0.5	2
2777	microRNA-206 prevents hepatocellular carcinoma growth and metastasis via down-regulating CREB5 and inhibiting the PI3K/AKT signaling pathway. <i>Cell Cycle</i> , 2022, 21, 2651-2663.	1.3	3
2778	Clinical applications of circulating tumor cells in hepatocellular carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
2779	Integrated Analysis of Tumor Mutation Burden and Immune Infiltrates in Hepatocellular Carcinoma. <i>Diagnostics</i> , 2022, 12, 1918.	1.3	3
2780	Radiofrequency Ablation Versus Repeat Hepatectomy for Recurrent Hepatocellular Carcinoma: A Systematic Review and Metaâ€œAnalysis. <i>World Journal of Surgery</i> , 2022, 46, 2778-2787.	0.8	3
2781	Prognostic significance and immune characteristics of CMTM4 in hepatocellular carcinoma. <i>BMC Cancer</i> , 2022, 22, .	1.1	1

#	ARTICLE	IF	CITATIONS
2782	Fucoidan inhibits EGFR redistribution and potentiates sorafenib to overcome sorafenib-resistant hepatocellular carcinoma. <i>Biomedicine and Pharmacotherapy</i> , 2022, 154, 113602.	2.5	9
2783	GSG2 promotes tumor growth through regulating cell proliferation in hepatocellular carcinoma. <i>Biochemical and Biophysical Research Communications</i> , 2022, 625, 109-115.	1.0	2
2784	The role of lifestyle factors on comorbidity of chronic liver disease and cardiometabolic disease in Chinese population: A prospective cohort study. <i>The Lancet Regional Health - Western Pacific</i> , 2022, 28, 100564.	1.3	1
2785	Atezolizumab plus bevacizumab versus nivolumab as first-line treatment for advanced or unresectable hepatocellular carcinoma: A cost-effectiveness analysis. <i>Cancer</i> , 2022, 128, 3995-4003.	2.0	9
2786	Clinical analysis of deceased donor liver transplantation in the treatment of hepatocellular carcinoma with segmental portal vein tumor thrombus: A long-term real-world study. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
2787	Transarterial Chemoembolization Combined with Apatinib for Treatment of Advanced Hepatocellular Carcinoma: Analysis of Survival and Prognostic Factors. <i>Current Medical Science</i> , 0, , .	0.7	0
2788	Safety and efficacy of lenvatinib combined with camrelizumab plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: A two-center retrospective study. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	13
2789	Novel Nanotechnology Approaches to Overcome Drug Resistance in the Treatment of Hepatocellular Carcinoma: Glypican 3 as a Useful Target for Innovative Therapies. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10038.	1.8	4
2790	Role of Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 000, 000-000.	0.7	13
2791	A comprehensive preoperative predictive score for post-hepatectomy liver failure after hepatocellular carcinoma resection based on patient comorbidities, tumor burden, and liver function: the CTF score. <i>Journal of Gastrointestinal Surgery</i> , 2022, 26, 2486-2495.	0.9	5
2792	Assessment and Monitoring of Response to Systemic Treatment in Advanced Hepatocellular Carcinoma: Current Insights. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 9, 1011-1027.	1.8	3
2793	Clinical features and prognostic factors in patients with microvascular infiltration of hepatocellular carcinoma: Development and validation of a nomogram and risk stratification based on the SEER database. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
2794	Role of m6A RNA methylation in the development of hepatitis B virus-associated hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 2039-2050.	1.4	3
2795	Decreased expression of 3-hydroxybutyrate dehydrogenase 1 is a prognostic marker and promotes tumor progression in hepatocellular carcinoma. <i>Pathology Research and Practice</i> , 2022, 238, 154111.	1.0	2
2796	The role of lncRNA just proximal to XIST (JPX) in human disease phenotypes and RNA methylation: The novel biomarker and therapeutic target potential. <i>Biomedicine and Pharmacotherapy</i> , 2022, 155, 113753.	2.5	1
2797	LncRNA AC026401.3 interacts with OCT1 to intensify sorafenib and lenvatinib resistance by activating E2F2 signaling in hepatocellular carcinoma. <i>Experimental Cell Research</i> , 2022, 420, 113335.	1.2	6
2798	CT radiomics combined with clinical variables for predicting the overall survival of hepatocellular carcinoma patients after hepatectomy. <i>Translational Oncology</i> , 2022, 26, 101536.	1.7	6
2799	Quercetin induced HepG2 cells apoptosis through ATM/JNK/STAT3 signaling pathways. <i>Biocell</i> , 2023, 47, 187-194.	0.4	0

#	ARTICLE	IF	CITATIONS
2800	Hypoxia-induced LINC00674 facilitates hepatocellular carcinoma progression by activating the NOX1/mTOR signaling pathway. <i>Journal of Cancer</i> , 2022, 13, 3177-3188.	1.2	2
2801	Polypharmacology in Clinical Applications”Anticancer Polypharmacology. , 2022, , 73-132.		0
2802	Hepatocellular carcinoma (HCC) in patients with Non-Alcoholic Fatty Liver Disease (NAFLD): screening, treatment and survival analysis in a Brazilian series. <i>Clinics</i> , 2022, 77, 100097.	0.6	0
2803	The Eph/Ephrin System in Hepatocellular Carcinoma: Functional Roles and Potential Therapeutic Targets. <i>Oncologie</i> , 2022, 24, 427-439.	0.2	5
2804	Zytostatikabeschichtete Beads. <i>Springer Reference Medizin</i> , 2022, , 1-8.	0.0	0
2805	Diagnosis and Evaluation of Hepatocellular Carcinoma. , 2022, , 27-48.		0
2806	Beyond glyco-proteomics”Understanding the role of genetics in cancer biomarkers. <i>Advances in Cancer Research</i> , 2023, , 57-81.	1.9	0
2808	Nanobubble-based anti-hepatocellular carcinoma therapy combining immune check inhibitors and sonodynamic therapy. <i>Nanoscale Advances</i> , 2022, 4, 4847-4862.	2.2	2
2809	The Role of TRAF7 in Tumorigenesis. <i>World Journal of Cancer Research</i> , 2022, 12, 188-198.	0.1	0
2810	The prominent role of miR-942 in carcinogenesis of tumors. <i>Advanced Biomedical Research</i> , 2022, 11, 63.	0.2	3
2811	Identification of a novel histone phosphorylation prognostic signature in hepatocellular carcinoma based on bulk and single-cell RNA sequencing. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	3
2812	Magnetic resonance elastography of malignant tumors. <i>Frontiers in Physics</i> , 0, 10, .	1.0	3
2813	Competitive risk analysis of the therapeutic value of liver transplantation for liver cancer in children: A population-based study. <i>Frontiers in Surgery</i> , 0, 9, .	0.6	0
2814	Hepatic stellate cell exosome-derived circWDR25 promotes the progression of hepatocellular carcinoma &lt;i>via</i> the miRNA-4474-3P-AOX-15 and EMT axes. <i>BioScience Trends</i> , 2022, 16, 267-281.	1.1	16
2815	RPNs Levels Are Prognostic and Diagnostic Markers for Hepatocellular Carcinoma. <i>Journal of Oncology</i> , 2022, 2022, 1-17.	0.6	3
2816	Targeted Multifunctional Nanoplatform for Imaging-Guided Precision Diagnosis and Photothermal/Photodynamic Therapy of Orthotopic Hepatocellular Carcinoma. <i>International Journal of Nanomedicine</i> , 0, Volume 17, 3777-3792.	3.3	4
2817	MTBP enhances the activation of transcription factor ETS-1 and promotes the proliferation of hepatocellular carcinoma cells. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
2818	The Prognostic Value of Baseline Clinical and Radiologic Imaging Features in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 9, 913-927.	1.8	3

#	ARTICLE	IF	CITATIONS
2819	RNA m6A modification in liver biology and its implication in hepatic diseases and carcinogenesis. <i>American Journal of Physiology - Cell Physiology</i> , 2022, 323, C1190-C1205.	2.1	8
2820	Multiparametric liver MRI for predicting early recurrence of hepatocellular carcinoma after microwave ablation. <i>Cancer Imaging</i> , 2022, 22, .	1.2	1
2821	Detecting Early Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Using Longitudinal Î±-Fetoprotein Screening. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 1590-1597.	2.4	4
2822	The Association between Immune Subgroups and Gene Modules for the Clinical, Cellular, and Molecular Characteristic of Hepatocellular Carcinoma. <i>Journal of Oncology</i> , 2022, 2022, 1-11.	0.6	0
2823	Efficacy of Adjuvant Transarterial Chemoembolization Combined Antiviral Therapy for HBV-Related HCC with MVI after Hepatic Resection: A Multicenter Study. <i>Asian Pacific Journal of Cancer Prevention</i> , 2022, 23, 2695-2703.	0.5	1
2824	Stemness analysis in hepatocellular carcinoma identifies an extracellular matrix gene-related signature associated with prognosis and therapy response. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	2
2825	Cuproptosis-related lncRNAs predict the clinical outcome and immune characteristics of hepatocellular carcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	7
2826	Î±-Connexin Carboxyl Terminal Peptide 1 Attenuates Ischemia-Reperfusion Injury in Liver Transplantation With Extended Cold Preservation by Stabilizing Cell Junctions in Mice. <i>Transplantation Proceedings</i> , 2022, 54, 2364-2373.	0.3	0
2827	Multifaceted Influence of Histone Deacetylases on DNA Damage Repair: Implications for Hepatocellular Carcinoma. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 000, 000-000.	0.7	2
2828	Association of hydroxysteroid 11-beta dehydrogenase 1 polymorphisms with chronic liver fibrosis and the occurrence of hepatocellular carcinoma in a Han Chinese population. <i>International Journal of Transgender Health</i> , 2022, 15, 951-959.	1.1	0
2829	Emerging roles of TRIM27 in cancer and other human diseases. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	2
2831	MEX3C-Mediated Decay of SOCS3 mRNA Promotes JAK2/STAT3 Signaling to Facilitate Metastasis in Hepatocellular Carcinoma. <i>Cancer Research</i> , 2022, 82, 4191-4205.	0.4	7
2832	Liver transplantation with simultaneous splenectomy increases risk of cancer development and mortality in hepatocellular carcinoma patients. <i>World Journal of Gastrointestinal Surgery</i> , 0, 14, 930-939.	0.8	0
2833	Lithography-based 3D printed hydrogels: From bioresin designing to biomedical application. <i>Colloids and Interface Science Communications</i> , 2022, 50, 100667.	2.0	9
2834	Contrast-enhanced ultrasound for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. <i>The Cochrane Library</i> , 2022, 2022, .	1.5	6
2835	Identification of the hub and prognostic genes in liver hepatocellular carcinoma via bioinformatics analysis. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	4
2836	Prediction of early recurrence of HCC after hepatectomy by contrast-enhanced ultrasound-based deep learning radiomics. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
2838	Cuproptosis-related lncRNAs predict the prognosis and immune response in hepatocellular carcinoma. <i>Clinical and Experimental Medicine</i> , 2023, 23, 2051-2064.	1.9	8



#	ARTICLE	IF	CITATIONS
2840	Hepatectomy versus sorafenib for advanced hepatocellular carcinoma with macroscopic portal vein tumor thrombus: A biâ€œinstitutional propensityâ€œmatched cohort study. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 0, , .	1.4	1
2841	Feasibility of hepatocellular carcinoma treatment based on the tumor microenvironment. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
2842	Impact of Interferon-Free Direct-Acting Antivirals on the Incidence of Extrahepatic Malignancies in Patients with Chronic Hepatitis C. <i>Digestive Diseases and Sciences</i> , 0, , .	1.1	0
2843	The Value of Contrast-Enhanced Magnetic Resonance Imaging Enhancement in the Differential Diagnosis of Hepatocellular Carcinoma and Combined Hepatocellular Cholangiocarcinoma. <i>Journal of Oncology</i> , 2022, 2022, 1-11.	0.6	5
2844	Overcoming Treatment Disparities for Early-Stage Hepatocellular Carcinoma in the Veteran Population: Is the MISSION Act the Solution?. <i>Annals of Surgical Oncology</i> , 0, , .	0.7	0
2845	Intrahepatic sarcomatoid cholangiocarcinoma: A case report of the youngest patient on record and a review of the condition's characteristics. <i>Frontiers in Surgery</i> , 0, 9, .	0.6	3
2846	A novel chemotherapy strategy for advanced hepatocellular carcinoma: a multicenter retrospective study. <i>Chinese Medical Journal</i> , 2022, 135, 2338-2343.	0.9	3
2847	METTL1-Mediated m7G tRNA Modification Promotes Lenvatinib Resistance in Hepatocellular Carcinoma. <i>Cancer Research</i> , 2023, 83, 89-102.	0.4	34
2848	Vessels that encapsulate tumor clusters (VETC) pattern predicts the efficacy of adjuvant TACE in hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 4163-4172.	1.2	1
2849	NIR-Triggered and ROS-Boosted Nanoplatfom for Enhanced Chemo/PDT/PTT Synergistic Therapy of Sorafenib in Hepatocellular Carcinoma. <i>Nanoscale Research Letters</i> , 2022, 17, .	3.1	8
2851	WDFY3-AS2: A Potential Prognostic Factor and Therapeutic Target Related to Cancer. <i>Current Medicinal Chemistry</i> , 2023, 30, 2814-2821.	1.2	0
2852	Sodium-glucose cotransporter 2 (SGLT2) inhibitor initiation and hepatocellular carcinoma prognosis. <i>PLoS ONE</i> , 2022, 17, e0274519.	1.1	18
2854	Is early-onset cancer an emerging global epidemic? Current evidence and future implications. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 656-673.	12.5	129
2855	Retrospective Evaluation and Significance of Neutrophil-to-Lymphocyte Ratio Prior to and 1 month Following Microwave Ablation of Hepatocellular Carcinoma. <i>CardioVascular and Interventional Radiology</i> , 2023, 46, 49-59.	0.9	2
2857	HGF-mediated elevation of ETV1 facilitates hepatocellular carcinoma metastasis through upregulating PK2 and c-MET. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	11
2858	Multi-omics data integration for hepatocellular carcinoma subtyping with multi-kernel learning. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	1
2859	Change of tumor-infiltrating lymphocyte of associating liver partition and portal vein ligation for staged hepatectomy for hepatocellular carcinoma. <i>World Journal of Gastrointestinal Surgery</i> , 0, 14, 1008-1025.	0.8	1
2860	An exploratory human study of superstable homogeneous lipiodolâ€œindocyanine green formulation for precise surgical navigation in liver cancer. <i>Bioengineering and Translational Medicine</i> , 2023, 8, .	3.9	5

#	ARTICLE	IF	CITATIONS
2861	No association of postoperative opioid usage with long-term surgery outcomes in patients with liver cancer: a population-based retrospective cohort study. <i>Pain</i> , 2022, Publish Ahead of Print, .	2.0	1
2862	<sc>Hsa-microRNA-370-3p targeting Snail and Twist1 suppresses <sc>IL-8/STAT3-driven hepatocellular carcinoma metastasis. <i>Cancer Science</i> , 2022, 113, 4120-4134.	1.7	11
2863	Individualized Approach in the Surgical Management of Hepatocellular Carcinoma: Results from a Greek Multicentre Study. <i>Cancers</i> , 2022, 14, 4387.	1.7	5
2864	Activation of the TrCP/inflammation axis limits the sensitivity of liver cancer cells to neddylation inhibition. <i>Oncology Reports</i> , 2022, 48, .	1.2	1
2865	Eupalinolide A induces autophagy via the ROS/ERK signaling pathway in hepatocellular carcinoma cells <i>in vitro</i> and <i>in vivo</i>. <i>International Journal of Oncology</i> , 2022, 61, .	1.4	3
2866	Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	16
2867	Research progress of spontaneous ruptured hepatocellular carcinoma: Systematic review and meta-analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
2868	The impact of polymorphism in PNPLA3 and TM6SF2 genes on the susceptibility and survival of hepatitis C-related hepatocellular carcinoma. <i>Egyptian Liver Journal</i> , 2022, 12, .	0.3	0
2869	Comprehensive multiomics analysis of cuproptosis-related gene characteristics in hepatocellular carcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	10
2870	Efficacy of rechallenge transcatheter arterial chemoembolization after lenvatinib treatment for advanced hepatocellular carcinoma. <i>JGH Open</i> , 2022, 6, 754-762.	0.7	1
2871	PSMD12 promotes the activation of the MEK-ERK pathway by upregulating KIF15 to promote the malignant progression of liver cancer. <i>Cancer Biology and Therapy</i> , 2022, 23, 1-11.	1.5	4
2872	Surgical Resection Is Superior to TACE in the Treatment of HCC in a Well Selected Cohort of BCLC-B Elderly Patients—A Retrospective Observational Study. <i>Cancers</i> , 2022, 14, 4422.	1.7	4
2873	Shulan Estimation Model: A New Formula for Estimation of Standard Liver Volume In Chinese Adults. <i>Transplantation Proceedings</i> , 2022, 54, 2236-2242.	0.3	0
2874	Laparoscopic repeat hepatectomy versus conventional open repeat hepatectomy for recurrent hepatocellular carcinoma: A systematic review and meta-analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
2875	Classification and Prognostic Characteristics of Hepatocellular Carcinoma Based on Glycolysis Cholesterol Synthesis Axis. <i>Journal of Oncology</i> , 2022, 2022, 1-17.	0.6	1
2876	Predicting Outcome in Combination Treatment of TACE and Camrelizumab for Advanced Hepatocellular carcinoma: Tumor Hypervascularity and Reactive Cutaneous Capillary Endothelial Proliferation. <i>Drug Design, Development and Therapy</i> , 0, Volume 16, 3421-3429.	2.0	1
2877	Dysregulation of miRISC Regulatory Network Promotes Hepatocellular Carcinoma by Targeting PI3K/Akt Signaling Pathway. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11300.	1.8	4
2878	Integrative analyses of prognosis, tumor immunity, and ceRNA network of the ferroptosis-associated gene FANCD2 in hepatocellular carcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	4

#	ARTICLE	IF	CITATIONS
2879	The updated role of exosomal proteins in the diagnosis, prognosis, and treatment of cancer. <i>Experimental and Molecular Medicine</i> , 0, , .	3.2	18
2880	OIT3 serves as a novel biomarker of hepatocellular carcinoma by mediating ferroptosis via regulating the arachidonic acid metabolism. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
2881	Characterizing PTP4A3/PRL-3 as the Potential Prognostic Marker Gene for Liver Hepatocellular Carcinoma. <i>Journal of Oncology</i> , 2022, 2022, 1-15.	0.6	1
2882	Construction and validation of a prognostic marker and risk model for HCC ultrasound therapy combined with WGCNA identification. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	2
2883	Leukocyte cell-derived chemotaxin 2 regulates epithelial-mesenchymal transition and cancer stemness in hepatocellular carcinoma. <i>Journal of Biological Chemistry</i> , 2022, 298, 102442.	1.6	2
2884	Systemic T-cell and humoral responses against cancer testis antigens in hepatocellular carcinoma patients. <i>Oncolimmunology</i> , 2022, 11, .	2.1	1
2885	A VEGFR targeting peptide-drug conjugate (PDC) suppresses tumor angiogenesis in a TACE model for hepatocellular carcinoma therapy. <i>Cell Death Discovery</i> , 2022, 8, .	2.0	3
2886	Application of systemic treatment in conversion therapy options for liver cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
2887	Clinical factors associated with early disease progression after radioembolization for hepatocellular carcinoma and feasibility of post-embolization systemic therapy. <i>Liver Cancer International</i> , 0, , .	0.2	0
2888	Local-Regional Treatment of Hepatocellular Carcinoma: A Primer for Radiologists. <i>Radiographics</i> , 2022, 42, 1670-1689.	1.4	4
2889	Engineered DBCO+PD-1 Nanovesicles Carrying 1-MT for Cancer-Targeted Immunotherapy. <i>ACS Biomaterials Science and Engineering</i> , 2022, 8, 4819-4826.	2.6	2
2890	Enhancement of dendritic cell immunotherapy by recalling antigens for hepatocellular carcinoma in mice. <i>Immunotherapy</i> , 2022, 14, 1225-1236.	1.0	1
2891	Hypoxia features as potential indicators in prognosis, immunotherapy and drug screening in Hepatocellular carcinoma patients. <i>Translational Cancer Research</i> , 2021, .	0.4	1
2892	Prognostic prediction of the platelet-to-lymphocyte ratio in hepatocellular carcinoma: a systematic review and meta-analysis. <i>Translational Cancer Research</i> , 2022, 11, 4037-4050.	0.4	4
2893	Linking GOLPH3 and Extracellular Vesicles Content as a Potential New Route in Cancer Physiopathology and a Promising Therapeutic Target is in Sight?. <i>Technology in Cancer Research and Treatment</i> , 2022, 21, 153303382211357.	0.8	0
2894	Pachymic acid inhibits growth and metastatic potential in liver cancer HepG2 and Huh7 cells. <i>Biological and Pharmaceutical Bulletin</i> , 2022, , .	0.6	0
2895	Effect of the combination of sorafenib and lenvatinib on the survival of patients with hepatocellular carcinoma: a meta-analysis. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2022, 47, 102-110.	1.1	1
2896	The Characteristics and Mortality of Chinese Herbal Medicine Users among Newly Diagnosed Inoperable Huge Hepatocellular Carcinoma (≥10 cm) Patients: A Retrospective Cohort Study with Exploration of Core Herbs. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 12480.	1.2	3

#	ARTICLE	IF	CITATIONS
2897	Immunotherapy for hepatocellular carcinoma: A promising therapeutic option for advanced disease. <i>World Journal of Hepatology</i> , 0, 14, 1862-1874.	0.8	5
2898	Analysis of Lenvatinib's Efficacy against Intermediate-Stage Unresectable Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 5066.	1.7	3
2899	Influence factors on registration of three-dimensional contrast-enhanced ultrasound fusion imaging in evaluating the ablative margin – A phantom study. <i>Clinical Hemorheology and Microcirculation</i> , 2022, , 1-12.	0.9	0
2900	Impaired Autophagy and Exosomes Release by Long-Term mTOR Pathway Activation Promotes Hepatocellular Carcinoma Occurrence and Invasion. <i>Biochemistry</i> , 0, , .	0.8	0
2901	One day versus two days of hepatic arterial infusion with oxaliplatin and fluorouracil for patients with unresectable hepatocellular carcinoma. <i>BMC Medicine</i> , 2022, 20, .	2.3	4
2902	MCM2 promotes the stemness and sorafenib resistance of hepatocellular carcinoma cells via hippo signaling. <i>Cell Death Discovery</i> , 2022, 8, .	2.0	13
2903	Perioperative and short-term outcomes of laparoscopic liver resection for recurrent hepatocellular carcinoma: A retrospective study comparing open hepatectomy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
2905	Emerging roles of mesenchymal stem cell-derived exosomes in gastrointestinal cancers. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	7
2907	Transient Cytolysis after Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma. <i>Journal of Personalized Medicine</i> , 2022, 12, 1663.	1.1	1
2908	Surveillance for Patients at Risk of Developing Hepatocellular Carcinoma. <i>Updates in Surgery Series</i> , 2023, , 183-190.	0.0	0
2909	miR-516a-3P, a potential circulating biomarker in hepatocellular carcinoma, correlated with <i>rs738409</i> polymorphism in <i>PNPLA3</i> . <i>Personalized Medicine</i> , 2022, 19, 483-493.	0.8	6
2910	Efficacy and safety of lenvatinib for preventing tumor recurrence after liver transplantation in hepatocellular carcinoma beyond the Milan criteria. <i>Annals of Translational Medicine</i> , 2022, 10, 1091-1091.	0.7	2
2911	High Level of Ubiquitin Conjugate Enzyme E2O Indicates Poor Prognosis of Patients with Hepatocellular Carcinoma. <i>Current Medical Science</i> , 0, , .	0.7	0
2912	Transarterial chemoembolization plus lenvatinib with or without programmed death-1 inhibitors for patients with unresectable hepatocellular carcinoma: A propensity score matching study. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	9
2913	Identification of Differentially Expressed Genes Associated with the Prognosis and Diagnosis of Hepatocellular Carcinoma by Integrated Bioinformatics Analysis. <i>BioMed Research International</i> , 2022, 2022, 1-12.	0.9	4
2914	Simple Predictive Markers and Clinicopathological Features of Primary Liver Cancer following HCV Clearance with Direct-Acting Antivirals. <i>Oncology</i> , 2023, 101, 79-88.	0.9	0
2915	Role of artificial intelligence in the diagnosis and treatment of hepatocellular carcinoma. <i>Artificial Intelligence in Gastroenterology</i> , 0, 3, 96-104.	0.2	0
2916	R1-Vascular Surgery for Hepatocellular Carcinoma. <i>Updates in Surgery Series</i> , 2023, , 129-138.	0.0	0

#	ARTICLE	IF	CITATIONS
2918	SNS-023 sensitizes hepatocellular carcinoma to sorafenib by inducing degradation of cancer drivers SIX1 and RPS16. <i>Acta Pharmacologica Sinica</i> , 2023, 44, 853-864.	2.8	4
2919	A mixed blessing for liver transplantation patients â€” Rapamycin. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2023, 22, 14-21.	0.6	4
2920	Prevention of variceal rebleeding in cirrhotic patients with advanced hepatocellular carcinoma receiving molecularly targeted therapy: a randomized pilot study of transjugular intrahepatic portosystemic shunt versus endoscopic plus Î²-blocker. <i>Hepatology International</i> , 2022, 16, 1379-1389.	1.9	3
2922	Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and sequential ablation in the treatment of advanced hepatocellular carcinoma. <i>Cancer Medicine</i> , 2023, 12, 5436-5449.	1.3	3
2923	Identification and validation of a tyrosine metabolism-related prognostic prediction model and characterization of the tumor microenvironment infiltration in hepatocellular carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	9
2924	Deterioration of liver function and aging disturb sequential systemic therapy for unresectable hepatocellular carcinoma. <i>Scientific Reports</i> , 2022, 12, .	1.6	5
2925	Identification of lipid metabolism-associated genes as prognostic biomarkers based on the immune microenvironment in hepatocellular carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	4
2926	Overexpression of TCERG1 as a prognostic marker in hepatocellular carcinoma: A TCGA data-based analysis. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	3
2927	Interim efficacy and safety of PD-1 inhibitors in preventing recurrence of hepatocellular carcinoma after interventional therapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	13
2928	Predictive Value of the <i>TP53</i> p.C245S Mutation Frequency for the Short-Term Recurrence of Hepatocellular Carcinoma as Detected by Pyrophosphate Sequencing. <i>Genetic Testing and Molecular Biomarkers</i> , 2022, 26, 476-484.	0.3	0
2929	Recent Advances in Hepatocellular Carcinoma Treatment with Radionuclides. <i>Pharmaceuticals</i> , 2022, 15, 1339.	1.7	2
2930	Serum SALL4 as a predictive biomarker for the prognosis of patients with hepatocellular carcinoma who underwent nonsurgical treatment. <i>Medicine (United States)</i> , 2022, 101, e31200.	0.4	1
2931	Multifunctional nanoparticles for targeting liver cancer stem cells and efficient endocytosis. <i>Chemical Papers</i> , 2023, 77, 1395-1403.	1.0	1
2932	Development and validation of a pyradiomics signature to predict initial treatment response and prognosis during transarterial chemoembolization in hepatocellular carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
2933	Systemic immune-inflammation index and the survival of hepatocellular carcinoma patients after transarterial chemoembolization: a meta-analysis. <i>Clinical and Experimental Medicine</i> , 2023, 23, 2105-2114.	1.9	4
2934	A simplified model for prophylactic transarterial chemoembolization after resection for patients with hepatocellular carcinoma. <i>PLoS ONE</i> , 2022, 17, e0276627.	1.1	0
2935	Estrogen receptor 1 inhibits the progression of hepatocellular carcinoma via positively regulating lncRNA maternally expressed gene 3 under high glucose conditions. <i>Journal of Gastrointestinal Oncology</i> , 2022, 13, 2485-2496.	0.6	4
2936	A signature based on <sc>NKG2D</sc> ligands to predict the recurrence of hepatocellular carcinoma after radical resection. <i>Cancer Medicine</i> , 0, , .	1.3	1

#	ARTICLE	IF	CITATIONS
2937	Prediction of hepatocellular carcinoma prognosis and immunotherapeutic effects based on tryptophan metabolism-related genes. <i>Cancer Cell International</i> , 2022, 22, .	1.8	3
2938	MR imaging of hepatocellular carcinoma: prospective intraindividual head-to-head comparison of the contrast agents gadoxetic acid and gadoteric acid. <i>Scientific Reports</i> , 2022, 12, .	1.6	0
2939	Long-Term Survival and Curative-Intent Treatment in Hepatitis B or C Virus-Associated Hepatocellular Carcinoma Patients Diagnosed during Screening. <i>Biology</i> , 2022, 11, 1597.	1.3	1
2940	Meta-Analysis of Repeat Hepatectomy versus Radiofrequency Ablation for Recurrence of Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 5398.	1.7	2
2941	NPRL2 downâ€regulation facilitates the growth of hepatocellular carcinoma via the mTOR pathway and autophagy suppression. <i>Hepatology Communications</i> , 2022, 6, 3563-3577.	2.0	3
2942	Comprehensive Analysis of the Expression and Prognosis for Lipid Metabolism-Related Genes in Hepatocellular Carcinoma. <i>South Asian Journal of Cancer</i> , 0, , .	0.2	0
2944	Serum BRD2 autoantibody in hepatocellular carcinoma and its detection using mimotope peptideâ€™conjugated BSA. <i>International Journal of Oncology</i> , 2022, 61, .	1.4	0
2945	Discovery of 5-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)-1H-indole-2-carboxamide derivatives as novel anti-cancer agents targeting Nur77. <i>European Journal of Medicinal Chemistry</i> , 2022, 244, 114849.	2.6	4
2946	Surgical therapy and survival in young patients with stage Iâ€™II hepatocellular carcinoma: a retrospective cohort study. <i>Translational Cancer Research</i> , 2021, .	0.4	0
2947	Serum immune biomarker levels combined with hepatitis B virus infection status predict early recurrence of early-stage hepatocellular carcinoma with microvascular invasion after liver resection. <i>Acta Chirurgica Belgica</i> , 0, , 1-7.	0.2	0
2948	Open Radiofrequency Ablation Combined with Splenectomy and Pericardial Devascularization vs. Liver Transplantation for Hepatocellular Carcinoma Patients with Portal Hypertension and Hypersplenism: A Case-Matched Comparative Study. <i>Journal of Investigative Surgery</i> , 2023, 36, 1-7.	0.6	0
2949	A rare case of unresectable, microsatellite instability-high hepatocellular carcinoma and an examination of the tumor microenvironment. <i>International Cancer Conference Journal</i> , 0, , .	0.2	1
2950	Advances in magnetic particle imaging and perspectives on liver imaging. , 2022, 1, 237-244.		4
2951	Imaging and histological features of tumor biopsy sample predict aggressive intrasegmental recurrence of hepatocellular carcinoma after radiofrequency ablation. <i>Scientific Reports</i> , 2022, 12, .	1.6	1
2952	Predictive machine learning model for microvascular invasion identification in hepatocellular carcinoma based on the LI-RADS system. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
2953	Multiscale Element-Doped Nanowire Array-Coupled Machine Learning Reveals Metabolic Fingerprints of Nonreversible Liver Diseases. <i>Analytical Chemistry</i> , 2022, 94, 16204-16212.	3.2	6
2954	Low HDL-cholesterol levels predict hepatocellular carcinoma development in individuals with liver fibrosis. <i>JHEP Reports</i> , 2023, 5, 100627.	2.6	11
2955	Well-preserved liver function enhances the clinical impact of curative-intent subsequent treatment during lenvatinib treatment for unresectable hepatocellular carcinoma. <i>Clinical Journal of Gastroenterology</i> , 2023, 16, 1-12.	0.4	2

#	ARTICLE	IF	CITATIONS
2956	IL-32 and IL-34 in hepatocellular carcinoma. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	0
2957	High expression of aurora kinase B predicts poor prognosis in hepatocellular carcinoma after curative surgery and its effects on the tumor microenvironment. <i>Annals of Translational Medicine</i> , 2022, 10, 1168-1168.	0.7	5
2958	[18F]FAPI PET/CT in the evaluation of focal liver lesions with [18F]FDG non-avidity. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2023, 50, 937-950.	3.3	12
2959	SGOL2 is a novel prognostic marker and fosters disease progression via a MAD2-mediated pathway in hepatocellular carcinoma. <i>Biomarker Research</i> , 2022, 10, .	2.8	4
2960	Clinically significant portal hypertension (CSPH) on early-stage HCC following hepatectomy: What's the impact?. <i>European Journal of Surgical Oncology</i> , 2023, 49, 771-779.	0.5	3
2962	Anticarcinogenic Effects of Isothiocyanates on Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13834.	1.8	9
2963	Radiomics nomogram based on multi-parametric magnetic resonance imaging for predicting early recurrence in small hepatocellular carcinoma after radiofrequency ablation. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
2964	Development of a novel immune-related lncRNA prognostic signature for patients with hepatocellular carcinoma. <i>BMC Gastroenterology</i> , 2022, 22, .	0.8	1
2965	Radiofrequency ablation compared with repeat hepatectomy for patients with recurrent hepatocellular carcinoma: A meta-analysis. <i>Journal of Radiation Research and Applied Sciences</i> , 2022, 15, 100478.	0.7	0
2966	Generation of a human induced pluripotent stem cell line (SYSUTFi001-A) from infiltrating cytotoxic T cells in hepatocellular carcinoma (HCC). <i>Stem Cell Research</i> , 2022, 65, 102962.	0.3	1
2967	Transarterial chemoembolization combined with radiofrequency ablation in the treatment of large hepatocellular carcinoma with stage C. <i>World Journal of Clinical Cases</i> , 0, 10, 12156-12163.	0.3	0
2968	Impact of marital status on overall survival in patients with early-stage hepatocellular carcinoma. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
2969	Exploring the mechanisms underlying the therapeutic effect of the Radix Bupleuri-Rhizoma Cyperi herb pair on hepatocellular carcinoma using multilevel data integration and molecular docking. <i>Aging</i> , 2022, 14, 9103-9127.	1.4	1
2970	DLGAP4 acts as an effective prognostic predictor for hepatocellular carcinoma and is closely related to tumour progression. <i>Scientific Reports</i> , 2022, 12, .	1.6	3
2971	LCMT1 indicates poor prognosis and is essential for cell proliferation in hepatocellular carcinoma. <i>Translational Oncology</i> , 2023, 27, 101572.	1.7	0
2972	<sc>WD</sc> repeat domain 48 promotes hepatocellular carcinoma progression by stabilizing <sc>câ€Myc</sc>. <i>Journal of Cellular and Molecular Medicine</i> , 0, , .	1.6	1
2973	Precision oncology and molecular therapies for hepatocellular carcinoma. <i>Hepatobiliary Surgery and Nutrition</i> , 2022, 11, 882-885.	0.7	0
2974	Hematological and neurological expressed 1 (HN1) activates câ€Myc signaling by inhibiting ubiquitinâ€mediated proteasomal degradation of câ€Myc in hepatocellular carcinoma. <i>Cell Biology International</i> , 2023, 47, 560-572.	1.4	5

#	ARTICLE	IF	CITATIONS
2975	LncRNA RPPH1 acts as a molecular sponge for miR-122 to regulate Wnt1/ $\beta$ -catenin signaling in hepatocellular carcinoma. <i>International Journal of Medical Sciences</i> , 2023, 20, 23-34.	1.1	1
2976	A nomogram model integrating LI-RADS features and radiomics based on contrast-enhanced magnetic resonance imaging for predicting microvascular invasion in hepatocellular carcinoma falling the Milan criteria. <i>Translational Oncology</i> , 2023, 27, 101597.	1.7	3
2977	Transarterial viroembolization improves the therapeutic efficacy of immune-excluded liver cancer: Three birds with one stone. <i>Pharmacological Research</i> , 2023, 187, 106581.	3.1	3
2978	Tumor metabolism derived from 18F-FDG PET/CT in predicting the macrotrabecular-massive subtype of hepatocellular carcinoma. <i>Quantitative Imaging in Medicine and Surgery</i> , 2023, 13, 309-319.	1.1	0
2979	An autophagy-inducing stapled peptide promotes c-MET degradation and overrides adaptive resistance to sorafenib in c-MET+ hepatocellular carcinoma. <i>Biochemistry and Biophysics Reports</i> , 2023, 33, 101412.	0.7	3
2980	CircRNAs in hepatocellular carcinoma: characteristic, functions and clinical significance. <i>International Journal of Medical Sciences</i> , 2022, 19, 2033-2043.	1.1	5
2981	The Role of Senescence in NASH-Related HCC. , 2022, , 167-191.		1
2982	An ultrasonography-based contrast-enhanced for distinguishing between benign and malignant hepatocellular carcinoma. <i>Materials Express</i> , 2022, 12, 1135-1139.	0.2	0
2983	Hepatocellular carcinoma risk-stratification based on ASGR1 in circulating epithelial cells for cancer interception. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	5
2984	Mechanisms of Hepatocarcinogenesis Development in an Acidic Microenvironment. , 0, , .		0
2985	The Association of Glycemic Index, Glycemic Load, and Daily Carbohydrates Intake with the Risk of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. <i>Nutrition and Cancer</i> , 0, , 1-9.	0.9	1
2986	Duodenal Hemorrhage Due to an Invasive Hepatocellular Carcinoma Controlled by Transarterial Embolization. <i>Cureus</i> , 2022, , .	0.2	0
2987	The roles and mechanisms of circular <sc>RNAs</sc> related to <sc>mTOR</sc> in cancers. <i>Journal of Clinical Laboratory Analysis</i> , 2022, 36, .	0.9	8
2988	Treatment-related adverse events of first-line immunotherapy versus sorafenib for advanced hepatocellular carcinoma: a meta-analysis. <i>Expert Opinion on Drug Safety</i> , 2023, 22, 323-329.	1.0	0
2989	Canonical WNT Signaling Activated by WNT7B Contributes to L-HBs-Mediated Sorafenib Resistance in Hepatocellular Carcinoma by Inhibiting Mitophagy. <i>Cancers</i> , 2022, 14, 5781.	1.7	5
2990	<sc>LncRNAâ€EWSAT1</sc> promotes hepatocellular carcinoma metastasis via activation of the <sc>Srcâ€YAP</sc> signaling axis. <i>FASEB Journal</i> , 2022, 36, .	0.2	7
2991	Irreversible electroporation: present and future in the treatment of hepatocellular carcinoma. , 2022, 45, .		0
2992	An icaritin-loaded microemulsion based on coix oil for improved pharmacokinetics and enhanced antitumor efficacy. <i>Drug Delivery</i> , 2022, 29, 3454-3466.	2.5	3



#	ARTICLE	IF	CITATIONS
2993	Preoperative differentiation of hepatocellular carcinoma with peripheral rim-like enhancement from intrahepatic mass-forming cholangiocarcinoma on contrast-enhanced MRI. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
2994	Reduced tumor stiffness quantified by tomoelastography as a predicative marker for glypican-3-positive hepatocellular carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
2995	Modulation of the p38 MAPK Pathway by Anisomycin Promotes Ferroptosis of Hepatocellular Carcinoma through Phosphorylation of H3S10. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-20.	1.9	9
2996	Preoperative identification of cytokeratin 19 status of hepatocellular carcinoma based on diffusion kurtosis imaging. <i>Abdominal Radiology</i> , 2023, 48, 579-589.	1.0	7
2997	Targeted xCTâ€mediated Ferroptosis and Protumoral Polarization of Macrophages Is Effective against HCC and Enhances the Efficacy of the Antiâ€PDâ€1/L1 Response. <i>Advanced Science</i> , 2023, 10, .	5.6	43
2998	Treatment options for unresectable hepatocellular carcinoma with hepatitis virus infection following sorafenib failure. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 1395-1403.	2.0	1
2999	NPFFR2 Contributes to the Malignancy of Hepatocellular Carcinoma Development by Activating RhoA/YAP Signaling. <i>Cancers</i> , 2022, 14, 5850.	1.7	4
3000	Ferritin Nanocaged Doxorubicin Potentiates Chemoâ€Immunotherapy against Hepatocellular Carcinoma via Immunogenic Cell Death. <i>Small Methods</i> , 2023, 7, .	4.6	10
3001	DEM-TACE as the initial treatment could improve the clinical efficacy of the hepatocellular carcinoma with portal vein tumor thrombus: a retrospective controlled study. <i>BMC Cancer</i> , 2022, 22, .	1.1	2
3002	Validation of the GALAD model and establishment of a new model for HCC detection in Chinese patients. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
3003	Construction of a prediction model for chronic HBV-associated hepatocellular carcinoma based on ultrasound radiomics. <i>Journal of Radiation Research and Applied Sciences</i> , 2022, 15, 100487.	0.7	1
3004	Clinical Effect of Lenvatinib Re-Administration after Transcatheter Arterial Chemoembolization in Patients with Intermediate Stage Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 6139.	1.7	0
3005	The Abnormal Proliferation of Hepatocytes is Associated with MC-LR and C-Terminal Truncated HBX Synergistic Disturbance of the Redox Balance. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 9, 1229-1246.	1.8	3
3006	Serum soluble DR5 predicts mortality risk in patients with HBV-related hepatocellular carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
3007	Efficacy and safety of lenvatinib versus sorafenib in first-line treatment of advanced hepatocellular carcinoma: A meta-analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	10
3008	The Novel Action of miR-193b-3p/CDK1 Signaling in HCC Proliferation and Migration: A Study Based on Bioinformatic Analysis and Experimental Investigation. <i>International Journal of Genomics</i> , 2022, 2022, 1-19.	0.8	1
3009	Minimally invasive <i>verÂsus</i> open liver resection for hepatocellular carcinoma in the elderly: international multicentre propensity score-matched study. <i>British Journal of Surgery</i> , 0, , .	0.1	1
3010	Prediction for Aggressiveness and Postoperative Recurrence of Hepatocellular Carcinoma Using Gadoxetic Acid-Enhanced Magnetic Resonance Imaging. <i>Academic Radiology</i> , 2023, 30, 841-852.	1.3	7

#	ARTICLE	IF	CITATIONS
3011	Prognostic pyroptosis-related lncRNA signature predicts the efficacy of immunotherapy in hepatocellular carcinoma. <i>Biochemistry and Biophysics Reports</i> , 2022, 32, 101389.	0.7	2
3012	Prospective Observational Study of Sorafenib in Hepatocellular Carcinoma Patients With Very High Risk of Recurrence After Surgery. <i>Anticancer Research</i> , 2022, 42, 6127-6134.	0.5	1
3013	Inflammation and Fibrosis in Patients with Non-Cirrhotic Hepatitis B Virus-Associated Hepatocellular Carcinoma: Impact on Prognosis after Hepatectomy and Mechanisms Involved. <i>Current Oncology</i> , 2023, 30, 196-218.	0.9	2
3014	An overview: Management of patients with advanced hepatocellular carcinoma. <i>BioScience Trends</i> , 2022, 16, 405-425.	1.1	7
3015	PCSK9 in Liver Cancers at the Crossroads between Lipid Metabolism and Immunity. <i>Cells</i> , 2022, 11, 4132.	1.8	5
3016	A hepatocyte-targeting nanoparticle for enhanced hepatobiliary magnetic resonance imaging. <i>Nature Biomedical Engineering</i> , 2023, 7, 221-235.	11.6	18
3017	Nanomedicine-enhancing icaritin-based immunotherapy of advanced hepatocellular carcinoma. <i>Military Medical Research</i> , 2022, 9, .	1.9	7
3018	Variations in dynamic tumor-associated antigen-specific T cell responses correlate with HCC recurrence after thermal ablation. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
3019	Regulation of Chromatin Accessibility by the Farnesoid X Receptor Is Essential for Circadian and Bile Acid Homeostasis In Vivo. <i>Cancers</i> , 2022, 14, 6191.	1.7	3
3020	CD97 serves as a novel biomarker of immune cell infiltration in hepatocellular carcinoma. <i>World Journal of Surgical Oncology</i> , 2022, 20, .	0.8	1
3022	Evaluation of short-term effects of drug-loaded microspheres and traditional transcatheter arterial chemoembolization in the treatment of advanced liver cancer. <i>World Journal of Gastrointestinal Oncology</i> , 0, 14, 2367-2379.	0.8	1
3023	A six lipid metabolism related gene signature for predicting the prognosis of hepatocellular carcinoma. <i>Scientific Reports</i> , 2022, 12, .	1.6	9
3024	Radiomics-Based Prediction of Future Portal Vein Tumor Infiltration in Patients with HCC—A Proof-of-Concept Study. <i>Cancers</i> , 2022, 14, 6036.	1.7	1
3025	Orphan Nuclear Receptor Nur77 Mediates the Lethal Endoplasmic Reticulum Stress and Therapeutic Efficacy of Cryptomeridiol in Hepatocellular Carcinoma. <i>Cells</i> , 2022, 11, 3870.	1.8	3
3026	PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	36
3027	Role of PIVKA-II in screening for malignancies at a hepatobiliary and pancreatic disease center: A large-scale real-world study. , 2022, 1, 209-216.		0
3028	Hypoxia signaling in hepatocellular carcinoma: Challenges and therapeutic opportunities. <i>Cancer and Metastasis Reviews</i> , 2023, 42, 741-764.	2.7	11
3029	Contrast-Enhanced Ultrasound with Deep Learning with Attention Mechanisms for Predicting Microvascular Invasion in Single Hepatocellular Carcinoma. <i>Academic Radiology</i> , 2023, 30, S73-S80.	1.3	5

#	ARTICLE	IF	CITATIONS
3030	Prognostic efficacy and prognostic factors of TACE plus TKI with ICIs for the treatment of unresectable hepatocellular carcinoma: A retrospective study. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	7
3031	Oxaliplatin-Resistant Hepatocellular Carcinoma Drives Immune Evasion Through PD-L1 Up-Regulation and PMN-Singular Recruitment. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2023, 15, 573-591.	2.3	4
3032	Hepatectomy After Conversion Therapy for Initially Unresectable HCC: What is the Difference?. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 9, 1353-1368.	1.8	11
3033	Transarterial chemoembolization failure in patients with hepatocellular carcinoma: Incidence, manifestation and risk factors. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2023, 47, 102071.	0.7	0
3034	A feedback loop between <a href="#">NONHSAT024276</a> and <a href="#">PTBP1</a> inhibits tumor progression and glycolysis in <a href="#">HCC</a> by increasing the <a href="#">PKM1</a> / <a href="#">PKM2</a> ratio. <i>Cancer Science</i> , 2023, 114, 1519-1540.	1.7	3
3035	Crithmum maritimum Improves Sorafenib Sensitivity by Decreasing Lactic Acid Fermentation and Inducing a Pro-Hepatocyte Marker Profile in Hepatocellular Carcinoma. <i>Plant Foods for Human Nutrition</i> , 2023, 78, 230-232.	1.4	6
3036	Comparison between PSMA PET/CT and MRI for Characterizing Hepatocellular carcinoma: A Real-World Study. <i>Tomography</i> , 2023, 9, 130-138.	0.8	1
3037	Clinical study of lenvatinib in the treatment of hepatitis virus-related hepatocellular carcinoma and antiviral therapy. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	2
3038	Human Proteome Microarray identifies autoantibodies to tumor-associated antigens as serological biomarkers for the diagnosis of hepatocellular carcinoma. <i>Molecular Oncology</i> , 2023, 17, 887-900.	2.1	4
3039	A novel fatty acid metabolism-related gene prognostic signature and candidate drugs for patients with hepatocellular carcinoma. <i>PeerJ</i> , 0, 11, e14622.	0.9	2
3040	Drug-eluting Microspheres Compared to Conventional Transarterial Chemoembolization as First Line Treatment for Unresectable Hepatocellular Carcinoma: A Single-center Retrospective Cost-utility Analysis. <i>CardioVascular and Interventional Radiology</i> , 0, , .	0.9	0
3041	Liver Cancer: Interdisciplinary Approach. , 2022, , 41-83.		0
3043	Interventional nanotheranostics in hepatocellular carcinoma. <i>Nanotheranostics</i> , 2023, 7, 128-141.	2.7	8
3044	Hepatic arterial infusion chemotherapy in hepatocellular carcinoma: A bibliometric and knowledge-map analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
3045	Crosstalk between 5-methylcytosine and N6-methyladenosine machinery defines disease progression, therapeutic response and pharmacogenomic landscape in hepatocellular carcinoma. <i>Molecular Cancer</i> , 2023, 22, .	7.9	37
3046	A Space-Dependent "Enzyme-Substrate" Type Probe based on "Carboxylesterase-Amide Group" for Ultrafast Fluorescent Imaging Orthotopic Hepatocellular Carcinoma. <i>Advanced Science</i> , 2023, 10, .	5.6	17
3047	Application of ablative therapy for intrahepatic recurrent hepatocellular carcinoma following hepatectomy. <i>World Journal of Gastrointestinal Surgery</i> , 0, 15, 9-18.	0.8	0
3048	Current status and future perspectives of radiomics in hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 0, 29, 43-60.	1.4	7

#	ARTICLE	IF	CITATIONS
3049	PNI-Based Nomograms to Predict Tumor Progression and Survival for Patients with Unresectable Hepatocellular Carcinoma Undergoing Transcatheter Arterial Chemoembolization. <i>Journal of Clinical Medicine</i> , 2023, 12, 486.	1.0	1
3050	Enhanced glypican-3-targeted identification of hepatocellular carcinoma with liver fibrosis by pre-degrading excess fibrotic collagen. <i>Acta Biomaterialia</i> , 2023, 158, 435-448.	4.1	9
3051	Clinical activity of regorafenib in elderly patients with recurrent glioblastoma. <i>Molecular and Clinical Oncology</i> , 2023, 18, .	0.4	1
3052	Comprehensive analysis of cuproptosis-related lncRNAs in immune infiltration and prognosis in hepatocellular carcinoma. <i>BMC Bioinformatics</i> , 2023, 24, .	1.2	5
3053	Association between early response of alpha-fetoprotein and treatment efficacy of systemic therapy for advanced hepatocellular carcinoma: A multicenter cohort study from China. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
3054	MECHANISM OF ACTION, SYNTHESIS, PROPERTIES AND ANALYTICAL METHODS OF CABOZANTINIB. <i>International Journal of Applied Pharmaceutics</i> , 0, , 57-65.	0.3	0
3055	Construction of HBV gene-related prognostic and diagnostic models for hepatocellular carcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	0
3056	HCC: RNA-Sequencing in Cirrhosis. <i>Biomolecules</i> , 2023, 13, 141.	1.8	1
3057	Seven centimeters as an optimal cutoff value for prognosis stratification in large monofocal hepatocellular carcinoma. <i>Langenbeck's Archives of Surgery</i> , 2023, 408, .	0.8	1
3058	Research progress of abnormal lactate metabolism and lactate modification in immunotherapy of hepatocellular carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
3059	Increased expression of TBC1D10B as a potential prognostic and immunotherapy relevant biomarker in liver hepatocellular carcinoma. <i>Scientific Reports</i> , 2023, 13, .	1.6	0
3060	Outcome of patients with HCC and liver dysfunction under immunotherapy: a systematic review and meta-analysis. <i>Hepatology</i> , 2023, 77, 1139-1149.	3.6	7
3061	The PTBP1-NCOA4 axis promotes ferroptosis in liver cancer cells. <i>Oncology Reports</i> , 2023, 49, .	1.2	8
3062	Cirrhotic and non-cirrhotic huge hepatocellular carcinoma (≥10cm): a comparative study of surgical management and follow-up treatment in a single institution. <i>Langenbeck's Archives of Surgery</i> , 2023, 408, .	0.8	0
3063	Prognostic Value of CD8+ Lymphocytes in Hepatocellular Carcinoma and Perineoplastic Parenchyma Assessed by Interface Density Profiles in Liver Resection Samples. <i>Cancers</i> , 2023, 15, 366.	1.7	4
3064	Surgical Strategies for Recurrent Hepatocellular Carcinoma after Resection: A Review of Current Evidence. <i>Cancers</i> , 2023, 15, 508.	1.7	3
3066	Midline 1 interacting protein 1 promotes cancer metastasis through FOS-like 1-mediated matrix metalloproteinase 9 signaling in HCC. <i>Hepatology</i> , 2023, 78, 1368-1383.	3.6	1
3067	Microwave ablation and synchronous transarterial chemoembolization combined with PD-1 inhibitor in patients with hepatocellular carcinoma following tyrosine kinase inhibitor intolerance. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1

#	ARTICLE	IF	CITATIONS
3068	Transradial versus transfemoral approach for TACE: a retrospective study. <i>BMC Gastroenterology</i> , 2023, 23, .	0.8	2
3069	Metabolomics in hepatocellular carcinoma: From biomarker discovery to precision medicine. <i>Frontiers in Medical Technology</i> , 0, 4, .	1.3	10
3070	Identification of a nucleotide metabolism-related signature to predict prognosis and guide patient care in hepatocellular carcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	0
3072	Gut Microbiota Modulation: Probiotics and Prebiotics in GI Cancer. , 2023, , 201-236.		1
3073	Study on the Application Value of $\hat{\pm}$ -Fetoprotein Household Test Paper (Aifupei) in a High Risk Group of Liver Cancer. <i>Advances in Clinical Medicine</i> , 2023, 13, 94-100.	0.0	0
3074	Monodisperse CaCO <sub>3</sub> -loaded gelatin microspheres for reversing lactic acid-induced chemotherapy resistance during TACE treatment. <i>International Journal of Biological Macromolecules</i> , 2023, 231, 123160.	3.6	8
3075	Deep Learning-based Risk Prediction Model for Recurrence-free Survival in Patients with Hepatocellular Carcinoma Using Multi-phase CT Image. , 2022, , .		1
3076	A Supramolecular Nanoassembly of Lenvatinib and a Green Light-Activatable NO Releaser for Combined Chemo-Phototherapy. <i>Pharmaceutics</i> , 2023, 15, 96.	2.0	1
3077	The Applications of Artificial Intelligence in Digestive System Neoplasms: A Review. <i>Health Data Science</i> , 2023, 3, .	1.1	3
3078	Prinzipien der nicht-chirurgischen lokoregionären Therapie. <i>Springer Reference Medizin</i> , 2023, , 1-10.	0.0	0
3079	New Regimen of Combining Hepatic Arterial Infusion Chemotherapy and Lipiodol Embolization in Treating Hepatocellular Carcinoma with Main Portal Vein Invasion. <i>Journal of Personalized Medicine</i> , 2023, 13, 88.	1.1	2
3080	Loss of WNK1 Suppressed the Malignant Behaviors of Hepatocellular Carcinoma Cells by Promoting Autophagy and Activating AMPK Pathway. <i>Disease Markers</i> , 2022, 2022, 1-16.	0.6	2
3081	Development and Validation of Prognostic Nomograms for Hepatocellular Carcinoma After Hepatectomy Based on Inflammatory Markers. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 9, 1403-1413.	1.8	0
3082	Efficacy and safety of radiofrequency ablation and surgery for hepatocellular carcinoma in patients with cirrhosis: A meta-analysis. <i>Medicine (United States)</i> , 2022, 101, e32470.	0.4	1
3083	ABO-Incompatible Liver Transplantation under the Desensitization Protocol with Rituximab: Effect on Biliary Microbiota and Metabolites. <i>Journal of Clinical Medicine</i> , 2023, 12, 141.	1.0	1
3084	Efficacy and safety of single- and multiple-antenna microwave ablation for the treatment of hepatocellular carcinoma and liver metastases: A systematic review and network meta-analysis. <i>Medicine (United States)</i> , 2022, 101, e32304.	0.4	3
3085	Radiotherapy of the Hepatocellular Carcinoma in Mice Has a Time-Of-Day-Dependent Impact on the Mouse Hippocampus. <i>Cells</i> , 2023, 12, 61.	1.8	0
3086	Geriatric nutritional risk index as a prognostic factor in patients with hepatocellular carcinoma following transarterial chemoembolization: A retrospective study. <i>Medicine (United States)</i> , 2022, 101, e32322.	0.4	7

#	ARTICLE	IF	CITATIONS
3087	Secular Trends of Clinical Characteristics and Survival of Hepatocellular Carcinoma in Taiwan from 2011 to 2019. <i>Viruses</i> , 2023, 15, 126.	1.5	3
3088	Boron Neutron Capture Therapy Eliminates Radioresistant Liver Cancer Cells by Targeting DNA Damage and Repair Responses. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 9, 1385-1401.	1.8	6
3089	Perspectives for novel therapeutic concepts in hepatocellular carcinoma targeting the stromal and innate immune microenvironment. <i>Liver Cancer International</i> , 0, , .	0.2	0
3090	Konjac glucomannan enhances 5-FU-induced cytotoxicity of hepatocellular carcinoma cells via TLR4/PERK/CHOP signaling to induce endoplasmic reticulum stress. <i>Oncology Research</i> , 2022, 30, 201-210.	0.6	4
3091	Prognostic analysis of RAS-related lncRNAs in liver hepatocellular carcinoma. <i>Annals of Translational Medicine</i> , 2022, 10, 1356-1356.	0.7	0
3092	Machine Learning to Predict the Response to Lenvatinib Combined with Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma. <i>Cancers</i> , 2023, 15, 625.	1.7	7
3093	Development and External Validation of a Radiomics Model Derived from Preoperative Gadoteric Acid-Enhanced MRI for Predicting Histopathologic Grade of Hepatocellular Carcinoma. <i>Diagnostics</i> , 2023, 13, 413.	1.3	3
3094	Hepatic arterial infusion chemotherapy versus sorafenib for advanced hepatocellular carcinoma with portal vein tumor thrombus: An updated meta-analysis and systematic review. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	4
3095	Poor Prognostic Biomarker KIAA1522 Is Associated with Immune Infiltrates in Hepatocellular Carcinoma. <i>Journal of Oncology</i> , 2023, 2023, 1-15.	0.6	2
3096	Tanshinone IIA and hepatocellular carcinoma: A potential therapeutic drug. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	3
3097	Mechanisms of drug resistance in HCC. <i>Hepatology</i> , 2024, 79, 926-940.	3.6	23
3098	Alkaline phosphatase combined with $\beta$ -glutamyl transferase is an independent predictor of prognosis of hepatocellular carcinoma patients receiving programmed death-1 inhibitors. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
3100	Long-term outcomes of laparoscopic liver resection versus open liver resection for hepatocellular carcinoma: A single-center 10-year experience. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1
3101	A High-Throughput Sequencing Data-Based Classifier Reveals the Metabolic Heterogeneity of Hepatocellular Carcinoma. <i>Cancers</i> , 2023, 15, 592.	1.7	2
3102	Incidental Hepatocellular Carcinoma Bony Metastasis in a Patient Listed for Liver Transplant. <i>ACG Case Reports Journal</i> , 2023, 10, e00967.	0.2	0
3103	The diagnostic performance of radiomics-based MRI in predicting microvascular invasion in hepatocellular carcinoma: A meta-analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
3104	Real-World Effectiveness of Sorafenib versus Lenvatinib Combined with PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma. <i>Cancers</i> , 2023, 15, 854.	1.7	2
3105	Outcomes of the Sequential Treatment of Unresectable Hepatocellular Carcinoma Using Lenvatinib. <i>Anticancer Research</i> , 2023, 43, 911-918.	0.5	0

#	ARTICLE	IF	CITATIONS
3106	E2F1 combined with LINC01004 super-enhancer to promote hepatocellular carcinoma cell proliferation and metastasis. <i>Clinical Epigenetics</i> , 2023, 15, .	1.8	6
3107	Dahuang Zhechong pill attenuates hepatic sinusoidal capillarization in liver cirrhosis and hepatocellular carcinoma rat model via the MK/integrin signaling pathway. <i>Journal of Ethnopharmacology</i> , 2023, 308, 116191.	2.0	3
3108	Oncolytic virus-based hepatocellular carcinoma treatment: Current status, intravenous delivery strategies, and emerging combination therapeutic solutions. <i>Asian Journal of Pharmaceutical Sciences</i> , 2023, 18, 100771.	4.3	6
3109	Short- and Long-Term Outcomes in Laparoscopic Versus Open Hepatectomy for Hepatocellular Carcinoma in Elderly Patients: A Systematic Review and Meta-Analysis. <i>Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A</i> , 0, , .	0.5	1
3110	The Role of PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma Metabolism. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2652.	1.8	30
3111	Local tumor control of intermediate and advanced stage hepatocellular carcinoma after local ablative treatment with image-guided interstitial high-dose-rate brachytherapy: A subgroup analysis of 286 HCC nodules. <i>Brachytherapy</i> , 2023, , .	0.2	0
3112	PRPF8 increases the aggressiveness of hepatocellular carcinoma by regulating FAK/AKT pathway via fibronectin 1 splicing. <i>Experimental and Molecular Medicine</i> , 2023, 55, 132-142.	3.2	5
3113	Age independent survival benefit for patients with small hepatocellular carcinoma undergoing percutaneous cryoablation: A propensity scores matching study. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
3114	Changes in Presentation, Treatment, and Survival of Patients with Hepatocellular Carcinoma in Damietta, Egypt, 2007-2019: A Retrospective Monocentric Cohort Study. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 10, 99-111.	1.8	1
3115	Attach importance to antiviral therapy in patients with hepatocellular carcinoma caused by hepatitis virus. , 2023, 1, 5-10.		0
3116	Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy. <i>Journal of Hepatology</i> , 2023, 78, 770-782.	1.8	96
3117	S100A11 Promotes Metastasis via AKT and ERK Signaling Pathways and Has a Diagnostic Role in Hepatocellular Carcinoma. <i>International Journal of Medical Sciences</i> , 2023, 20, 318-328.	1.1	1
3118	Hypo-osmolarity induces apoptosis resistance via TRPV2-mediated AKT-Bcl-2 pathway. <i>American Journal of Physiology - Renal Physiology</i> , 0, , .	1.6	0
3120	Neuropilins as potential biomarkers in hepatocellular carcinoma: a systematic review of basic and clinical implications. <i>Clinical and Molecular Hepatology</i> , 2023, 29, 293-319.	4.5	3
3121	Circular RNA circ_0003028 regulates cell development through modulating miR-498/ornithine decarboxylase 1 axis in hepatocellular carcinoma. <i>Anti-Cancer Drugs</i> , 2023, 34, 507-518.	0.7	2
3122	Novel Nomograms Based on Gamma-Glutamyl Transpeptidase-to-Lymphocyte Ratio Predict Prognosis of Hepatocellular Carcinoma Patients After Hepatectomy. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 10, 217-230.	1.8	1
3123	Inflammation-Related Marker NrLR Predicts Prognosis in AFP-Negative HCC Patients After Curative Resection. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 10, 193-202.	1.8	1
3124	<sc>ASPP2</sc> suppresses tumour growth and stemness characteristics in <sc>HCC</sc> by inhibiting Warburg effect via <sc>WNT</sc>/ $\beta$ 2-catenin/<sc>HK2</sc> axis. <i>Journal of Cellular and Molecular Medicine</i> , 2023, 27, 659-671.	1.6	3

#	ARTICLE	IF	CITATIONS
3125	Research into the characteristic molecules significantly affecting liver cancer immunotherapy. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	3
3126	TKIs in combination with immunotherapy for hepatocellular carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2023, 23, 279-291.	1.1	29
3127	Differential expression and significance of 5-hydroxymethylcytosine modification in hepatitis B virus carriers and patients with liver cirrhosis and liver cancer. <i>World Journal of Gastrointestinal Surgery</i> , 0, 15, 346-361.	0.8	0
3128	Impact of skeletal muscle volume on patients with <scp>BCLC stageâ€B</scp> hepatocellular carcinoma undergoing sorafenib therapy. <i>Cancer Medicine</i> , 0, , .	1.3	1
3129	Targeting a novel circITCH/miR-421/BTG1 axis is effective to suppress the malignant phenotypes in hepatocellular carcinoma (HCC) cells. <i>Cytotechnology</i> , 0, , .	0.7	0
3130	Efficacy and safety of HAIC alone vs. HAIC combined with lenvatinib for treatment of advanced hepatocellular carcinoma. , 2023, 40, .		2
3131	Role of SIRT5 in cancer. Friend or Foe?. <i>Biochimie</i> , 2023, 209, 131-141.	1.3	2
3132	A meta-analysis of short-term and long-term effects of indocyanine green fluorescence imaging in hepatectomy for liver cancer. <i>Photodiagnosis and Photodynamic Therapy</i> , 2023, 42, 103497.	1.3	2
3133	Stratifin promotes the growth and proliferation of hepatocellular carcinoma. <i>Tissue and Cell</i> , 2023, 82, 102080.	1.0	1
3134	The role of lamin B2 in human diseases. <i>Gene</i> , 2023, 870, 147423.	1.0	0
3138	Synergistic efficacy of telomerase-specific oncolytic adenoviral therapy and histone deacetylase inhibition in human hepatocellular carcinoma. <i>Cancer Letters</i> , 2023, 556, 216063.	3.2	2
3139	Gold Nanorodâ€™mesoporous silica core shell nanocomposites for NIR-II photothermal ablation and dual PD-L1/VEGF blockade therapy in hepatocellular carcinoma. <i>Chemical Engineering Journal</i> , 2023, 459, 141426.	6.6	11
3140	Advances in biomarker discovery using circulating cellâ€™free <scp>DNA</scp> for early detection of hepatocellular carcinoma. <i>WIREs Mechanisms of Disease</i> , 2023, 15, .	1.5	2
3141	Efficacy of dexamethasone and N-acetylcysteine combination in preventing post-embolization syndrome after transarterial chemoembolization in hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 0, 29, 890-903.	1.4	1
3142	Stat3 shRNA delivery with folate receptor-modified multi-functionalized graphene oxide particles for combined infrared radiation and gene therapy in hepatocellular carcinoma. <i>Anti-Cancer Drugs</i> , 2023, 34, 715-724.	0.7	1
3143	Neutrophil-to-lymphocyte ratio predicts therapy outcomes of transarterial chemoembolization combined with tyrosine kinase inhibitors plus programmed cell death ligand 1 antibody for unresectable hepatocellular carcinoma. <i>Anti-Cancer Drugs</i> , 0, Publish Ahead of Print, .	0.7	2
3145	Development and Validation of a Vascular Endothelial Growth Factor A-associated Prognostic Model for Unresectable Hepatocellular Carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 10, 139-156.	1.8	0
3146	Impact of Transarterial Chemoembolization or Hepatic Artery Infusion Chemotherapy on Liver Function after Hepatocellular Carcinoma Resection: An Observational Study. <i>Digestion</i> , 2023, 104, 291-298.	1.2	1



#	ARTICLE	IF	CITATIONS
3148	The role of miR-155 on liver diseases by modulating immunity, inflammation and tumorigenesis. <i>International Immunopharmacology</i> , 2023, 116, 109775.	1.7	2
3149	Preoperative Evaluation of Hepatocellular Carcinoma Differentiation Using Contrast-Enhanced Ultrasound-Based Deep-Learning Radiomics Model. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 10, 157-168.	1.8	3
3150	Inhibition of lysophosphatidic acid receptor 6 upregulated by the choline-deficient amino acid-defined diet prevents hepatocarcinogenesis in mice. <i>Molecular Carcinogenesis</i> , 2023, 62, 577-582.	1.3	5
3151	Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001). <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	44
3152	HBV Enhances Sorafenib Resistance in Hepatocellular Carcinoma by Reducing Ferroptosis via SRSF2-Mediated Abnormal PCLAF Splicing. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3263.	1.8	10
3153	Preoperative sintilimab plus transarterial chemoembolization for hepatocellular carcinoma exceeding the Milan criteria: A phase II trial. <i>Hepatology Communications</i> , 2023, 7, e0054-e0054.	2.0	2
3154	Non-alcoholic fatty liver disease-related hepatocellular carcinoma. <i>Journal of Liver Cancer</i> , 2023, 23, 127-142.	0.3	5
3155	An integrative analysis revealing cuproptosis-related lncRNAs signature as a novel prognostic biomarker in hepatocellular carcinoma. <i>Frontiers in Genetics</i> , 0, 14, .	1.1	3
3156	Comprehensive analysis of the correlation of the pan-cancer gene HAUS5 with prognosis and immune infiltration in liver cancer. <i>Scientific Reports</i> , 2023, 13, .	1.6	1
3157	Hydroxymethylation and Epigenetic Drugs: New Insights into the Diagnosis and Treatment in Epigenetics of Hepatocellular Carcinoma. <i>Journal of Oncology</i> , 2023, 2023, 1-8.	0.6	1
3158	Transarterial Chemoembolization with Anthracyclines-Loaded Polyethylene Glycol Drug Eluting Microspheres for the Treatment of Hepatocellular Carcinoma: A Pooled Multicentric Analysis of Survival in 580 Patients. <i>CardioVascular and Interventional Radiology</i> , 2023, 46, 436-446.	0.9	2
3159	Discovery of canine drug toceranib phosphate as a repurposed agent against human hepatocellular carcinoma. <i>Liver International</i> , 2023, 43, 928-944.	1.9	0
3160	The Prognostic Role of VEGFR-2 Gene Amplification in Relation to Serum AFP Levels Among Liver-Transplanted Patients with Hepatocellular Carcinoma. <i>Journal of Current Oncology</i> , 2022, 5, 85-93.	0.2	1
3161	Metabolism as a New Avenue for Hepatocellular Carcinoma Therapy. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3710.	1.8	12
3162	Radioembolization for Intermediate-Stage Hepatocellular Carcinoma Maintains Liver Function and Permits Systemic Therapy at Progression. <i>Journal of Vascular and Interventional Radiology</i> , 2023, 34, 968-975.	0.2	8
3163	Short Half-Life of Des-Î³-Carboxy Prothrombin Is a Superior Factor for Early Prediction of Outcomes of Hepatocellular Carcinoma Treated with Radiofrequency Ablation. <i>Diagnostics</i> , 2023, 13, 696.	1.3	1
3164	Association between HMGA1 and immunosuppression in hepatocellular carcinoma: A comprehensive bioinformatics analysis. <i>Medicine (United States)</i> , 2023, 102, e32707.	0.4	1
3165	lncRNA FRMD6-AS1 promotes hepatocellular carcinoma cell migration and stemness by regulating SENP1/HIF-1Î± axis. <i>Pathology Research and Practice</i> , 2023, 243, 154377.	1.0	3

#	ARTICLE	IF	CITATIONS
3166	Updates on Organoid Model for the Study of Liver Cancer. <i>Technology in Cancer Research and Treatment</i> , 2023, 22, 153303382311540.	0.8	0
3167	Targeting tumor-associated macrophages in hepatocellular carcinoma: biology, strategy, and immunotherapy. <i>Cell Death Discovery</i> , 2023, 9, .	2.0	18
3168	Function of TRPC1 in modulating hepatocellular carcinoma progression. , 2023, 40, .		2
3170	Efficacy and Safety of TACE Combined with Regorafenib Plus PD-1 Inhibitor in the Treatment of Hepatocellular Carcinoma After Sorafenib Resistance. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 10, 267-279.	1.8	1
3171	Prediction of early treatment response to the combination therapy of TACE plus lenvatinib and anti-PD-1 antibody immunotherapy for unresectable hepatocellular carcinoma: Multicenter retrospective study. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	3
3172	Development of Prognostic Features of Hepatocellular Carcinoma Based on Metabolic Gene Classification and Immune and Oxidative Stress Characteristic Analysis. <i>Oxidative Medicine and Cellular Longevity</i> , 2023, 2023, 1-29.	1.9	1
3173	Efficacy of treatment based on TKIs in combination with PD-1 inhibitors for unresectable recurrent hepatocellular carcinoma. <i>World Journal of Surgical Oncology</i> , 2023, 21, .	0.8	0
3174	Identification of G protein subunit alpha i2 as a promising therapeutic target of hepatocellular carcinoma. <i>Cell Death and Disease</i> , 2023, 14, .	2.7	1
3175	Non-Parenchymal Cells and the Extracellular Matrix in Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease. <i>Cancers</i> , 2023, 15, 1308.	1.7	3
3176	Decreased DIO3OS Expression Predicts Poor Prognosis in Hepatocellular Carcinoma and is Associated with Immune Infiltration. <i>Biochemical Genetics</i> , 2023, 61, 1791-1806.	0.8	1
3177	Diagnostic Performance of Extrahepatic Protein Induced by Vitamin K Absence in the Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. <i>Diagnostics</i> , 2023, 13, 816.	1.3	3
3178	Classification molecular subtypes of hepatocellular carcinoma based on PRMT-related genes. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	3
3179	Treatment Patterns and Survival in Patients with Intermediate, Advanced, or Terminal Stage of Hepatocellular Carcinoma in France over the Period 2015-2017: A Real-Life Study. <i>GastroHep</i> , 2023, 2023, 1-12.	0.3	1
3181	Three cases of immune-related hypopituitarism after atezolizumabâ€“bevacizumab treatment for hepatocellular carcinoma. <i>Clinical Journal of Gastroenterology</i> , 2023, 16, 422-431.	0.4	2
3182	Recommendation of mHAP and ABCR scoring systems for the decision-making of the first and subsequent TACE session in HCC patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2023, 35, 461-470.	0.8	0
3183	Macrotrabecular-massive subtype-based nomogram to predict early recurrence of hepatocellular carcinoma after surgery. <i>European Journal of Gastroenterology and Hepatology</i> , 2023, 35, 505-511.	0.8	2
3184	Better performance of PIVKA-II for detecting hepatocellular carcinoma in patients with chronic liver disease with normal total bilirubin. <i>World Journal of Gastroenterology</i> , 0, 29, 1359-1373.	1.4	1
3185	Abbreviated <sc>MRI</sc> for Secondary Surveillance of Recurrent Hepatocellular Carcinoma After Presumed Curative Treatment. <i>Journal of Magnetic Resonance Imaging</i> , 2023, 58, 1375-1383.	1.9	1

#	ARTICLE	IF	CITATIONS
3186	Detection of MET gene somatic mutations in hepatocellular carcinoma of Egyptian patients using next-generation sequencing. <i>Biomarkers</i> , 2023, 28, 379-386.	0.9	1
3187	Higher levels of supportive care needs are linked to higher health service use and cost, poor quality of life, and high distress in patients with cirrhosis in Queensland, Australia. <i>Hepatology Communications</i> , 2023, 7, e0066-e0066.	2.0	1
3188	An integrated strategy for deciding open versus laparoscopic hepatectomy for resectable primary liver cancer. <i>BMC Cancer</i> , 2023, 23, .	1.1	0
3189	Autophagy-Related Gene WD Repeat Domain 45B Promotes Tumor Proliferation and Migration of Hepatocellular Carcinoma through the Akt/mTOR Signaling Pathway. <i>Diagnostics</i> , 2023, 13, 906.	1.3	1
3190	Screening and Early Diagnosis of Hepatocellular Cancer and Optimization of Diagnostic Imaging Techniques: A Review and Conclusion of the Expert Panel. <i>Russian Journal of Gastroenterology Hepatology Coloproctology</i> , 2023, 32, 16-23.	0.2	1
3191	Editorial for "Abbreviated MRI for Secondary Surveillance of Recurrent Hepatocellular Carcinoma After Presumed Curative Treatment". <i>Journal of Magnetic Resonance Imaging</i> , 2023, 58, 1384-1385.	1.9	0
3192	Sorafenib increases cytochrome P450 lipid metabolites in patient with hepatocellular carcinoma. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	1
3193	The natural killer cell immunotherapy platform: An overview of the landscape of clinical trials in liquid and solid tumors. <i>Seminars in Hematology</i> , 2023, 60, 42-51.	1.8	2
3194	Could serum serotonin be used as a marker for portal vein invasion in patients with hepatocellular carcinoma?. <i>International Journal of Health Sciences</i> , 0, , 7049-7057.	0.0	0
3195	Hepatoprotective Effect of Roselle ( <i>Hibiscus sabdariffa</i> L.) in N-Diethylnitrosamine Induced Liver Damage in Rats. <i>International Journal of Medical Science and Clinical Research Studies</i> , 2023, 03, .	0.0	0
3196	[ <sup>177</sup> Lu]Lu-PSMA-617 theranostic probe for hepatocellular carcinoma imaging and therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2023, 50, 2342-2352.	3.3	3
3197	Comparison of survival benefit between salvage surgery after conversion therapy versus surgery alone for hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis. <i>Hpb</i> , 2023, 25, 775-787.	0.1	1
3198	A reasonable identification of the early recurrence time based on microvascular invasion for hepatocellular carcinoma after R0 resection: A multicenter retrospective study. <i>Cancer Medicine</i> , 2023, 12, 10294-10302.	1.3	3
3199	TNFR2 is a potent prognostic biomarker for post-transplant lung metastasis in patients with hepatocellular carcinoma. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2023, 35, 66-80.	0.7	3
3200	Impact of metformin on clinical outcomes in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors. <i>Liver Cancer International</i> , 0, , .	0.2	0
3201	Ameliorative Effect of <i>Posidonia oceanica</i> on High Glucose-Related Stress in Human Hepatoma HepG2 Cells. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5203.	1.8	1
3202	Body mass index and serum alpha-fetoprotein level associated with PD1 expression and prognosis in patients with hepatocellular carcinoma. <i>Heliyon</i> , 2023, 9, e14460.	1.4	0
3203	Clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 0, 29, 1470-1482.	1.4	0

#	ARTICLE	IF	CITATIONS
3204	Systemic Therapy for Advanced Hepatocellular Carcinoma: Current Stand and Perspectives. <i>Cancers</i> , 2023, 15, 1680.	1.7	8
3205	Comparison of Child-Pugh, MELD, MELD-Na, and ALBI Scores in Predicting In-Hospital Mortality in Patients with HCC. <i>International Journal of Clinical Medicine</i> , 2023, 14, 148-162.	0.1	0
3206	<sc>SIRT3</sc>-dependent delactylation of cyclin <sc>E2</sc> prevents hepatocellular carcinoma growth. <i>EMBO Reports</i> , 2023, 24, .	2.0	18
3207	Global scientific trends on portal hypertension and cirrhosis in the 21st century: A bibliometric and visualized analysis. , 2023, 2, 46-48.		1
3208	A Comprehensive Overview of In-patients Treated for Hepatocellular Carcinoma at a Tertiary Care Facility in Tanzania. <i>Journal of Renal and Hepatic Disorders</i> , 2023, 7, 22-27.	0.1	0
3209	Advances of High-Intensity Focused Ultrasound Ablation in the Treatment of Primary Liver Cancer. <i>Advances in Clinical Medicine</i> , 2023, 13, 3234-3240.	0.0	0
3210	Significance of anatomical resection and resection margin status in patients with HBV-related hepatocellular carcinoma and microvascular invasion: a multicenter propensity score-matched study. <i>International Journal of Surgery</i> , 2023, 109, 679-688.	1.1	9
3211	Effect of neoadjuvant chemotherapy combined with arterial chemoembolization on short-term clinical outcome of locally advanced gastric cancer. <i>BMC Cancer</i> , 2023, 23, .	1.1	0
3212	Well-Ordered Au Nanoarray for Sensitive and Reproducible Detection of Hepatocellular Carcinoma-Associated miRNA via CHA-Assisted SERS/Fluorescence Dual-Mode Sensing. <i>Analytical Chemistry</i> , 2023, 95, 5955-5966.	3.2	17
3213	The 20 years transition of clinical characteristics and metabolic risk factors in primary liver cancer patients from China. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1
3214	Clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 0, 29, 1614-1626.	1.4	4
3215	A novel risk score model based on pyroptosis-related genes for predicting survival and immunogenic landscape in hepatocellular carcinoma. <i>Aging</i> , 0, , .	1.4	1
3217	Comparative effectiveness of different hepatocellular carcinoma screening intervals or modalities: a systematic review and meta-analysis. <i>Chinese Medical Journal</i> , 0, Publish Ahead of Print, .	0.9	0
3218	An immune-related signature for optimizing prognosis prediction and treatment decision of hepatocellular carcinoma. <i>European Journal of Medical Research</i> , 2023, 28, .	0.9	1
3219	Radiological findings in non-surgical recurrent hepatocellular carcinoma: From locoregional treatments to immunotherapy. <i>World Journal of Gastroenterology</i> , 0, 29, 1669-1684.	1.4	0
3220	An integrated analysis of Dynamin 1 Like: A new potential prognostic indicator in hepatocellular carcinoma. <i>Molecular Carcinogenesis</i> , 2023, 62, 786-802.	1.3	2
3221	Advances in post-operative prognostic models for hepatocellular carcinoma. <i>Journal of Zhejiang University: Science B</i> , 2023, 24, 191-206.	1.3	5
3222	Prognostic Value of Skeletal Muscle Loss in Patients with Hepatocellular Carcinoma Treated with Hepatic Arterial Infusion Chemotherapy. <i>Cancers</i> , 2023, 15, 1834.	1.7	2

#	ARTICLE	IF	CITATIONS
3223	Integrative epigenetic analysis reveals AP-1 promotes activation of tumor-infiltrating regulatory T cells in HCC. <i>Cellular and Molecular Life Sciences</i> , 2023, 80, .	2.4	0
3224	The prognostic role of the AST/ALT ratio in hepatocellular carcinoma patients receiving thermal ablation combined with simultaneous TACE. <i>BMC Gastroenterology</i> , 2023, 23, .	0.8	3
3225	<sc>RHBDF2</sc> is correlated with immune infiltrates in hepatocellular carcinoma and may have potential as a biomarker. <i>FEBS Open Bio</i> , 2023, 13, 881-897.	1.0	0
3226	Prediction of Microvascular Invasion in Solitary AFP-Negative Hepatocellular Carcinoma ≤ 5 cm Using a Combination of Imaging Features and Quantitative Dual-Layer Spectral-Detector CT Parameters. <i>Academic Radiology</i> , 2023, , .	1.3	1
3227	Six immune-related promising biomarkers may promote hepatocellular carcinoma prognosis: a bioinformatics analysis and experimental validation. <i>Cancer Cell International</i> , 2023, 23, .	1.8	3
3228	Progressive erythrocytosis under lenvatinib treatment in patients with advanced hepatocellular carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2023, 91, 337-344.	1.1	1
3229	Prognostic prediction and multidimensional dissections of a macrophages M0-related gene signature in liver cancer. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	1
3231	miR-21-5p Inhibits Ferroptosis in Hepatocellular Carcinoma Cells by Regulating the AKT/mTOR Signaling Pathway through MELK. <i>Journal of Immunology Research</i> , 2023, 2023, 1-20.	0.9	10
3232	ALYREF mediates RNA m5C modification to promote hepatocellular carcinoma progression. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	11
3233	E2F1-mediated KDM4A-AS1 up-regulation promotes EMT of hepatocellular carcinoma cells by recruiting ILF3 to stabilize AURKA mRNA. <i>Cancer Gene Therapy</i> , 2023, 30, 1007-1017.	2.2	3
3234	Splenectomy and azygoportal disconnection decreases the risk of hepatocellular carcinoma for cirrhosis patients with portal hypertension bleeding: a 10-year retrospective follow-up study based on the inverse probability of treatment weighting method. <i>Journal of Gastroenterology</i> , 2023, 58, 503-512.	2.3	2
3235	The predictive value of the modified AFP model for liver transplantation outcomes in multinodular hepatocellular carcinoma patients. <i>World Journal of Surgical Oncology</i> , 2023, 21, .	0.8	0
3236	Stage migration as a surrogate of survival in hepatocellular carcinoma treated with transarterial chemoembolization. <i>Hepatology Communications</i> , 2023, 7, .	2.0	0
3237	A novel predictive model of microvascular invasion in hepatocellular carcinoma based on differential protein expression. <i>BMC Gastroenterology</i> , 2023, 23, .	0.8	0
3238	Identification of biomarkers of hepatocellular carcinoma gene prognosis based on the immune-related lncRNA signature of transcriptome data. <i>Functional and Integrative Genomics</i> , 2023, 23, .	1.4	0
3239	Long-circulating doxorubicin and Schizandrin A liposome with drug-resistant liver cancer activity: <i>in vitro</i> and <i>in vivo</i> evaluation. <i>Journal of Liposome Research</i> , 0, , 1-15.	1.5	0
3240	Expression Patterns of HOX Gene Family Defines Tumor Microenvironment and Immunotherapy in Hepatocellular Carcinoma. <i>Applied Biochemistry and Biotechnology</i> , 0, , .	1.4	0
3241	Radioembolization for Treatment of Hepatocellular Carcinoma: Current Evidence and Patterns of Utilization. <i>Journal of Vascular and Interventional Radiology</i> , 2023, 34, 1200-1213.	0.2	1

#	ARTICLE	IF	CITATIONS
3242	Hepatogastric fistula formation after liver chemoembolization in a patient with hepatocellular carcinoma. <i>Issledovaniã I Praktika V Medicine</i> , 2023, 10, 134-142.	0.1	0
3243	Longer Survival and Preserved Liver Function after Proton Beam Therapy for Patients with Unresectable Hepatocellular Carcinoma. <i>Current Oncology</i> , 2023, 30, 3915-3926.	0.9	1
3244	An Analysis Regarding the Association Between Proteasome (PSM) and Hepatocellular Carcinoma (HCC). <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 10, 497-515.	1.8	1
3245	Radiomics, a Promising New Discipline: Example of Hepatocellular Carcinoma. <i>Diagnostics</i> , 2023, 13, 1303.	1.3	1
3246	Three-dimensional and single-cell sequencing of liver cancer reveals comprehensive host-virus interactions in HBV infection. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	3
3247	Thieno[2,3- <i>b</i> ]isoquinolines: A novel chemotype of antiproliferative agents inducing cellular apoptosis while targeting the G2/M phase and Tubulin. <i>Drug Development Research</i> , 0, , .	1.4	0
3248	Association between antihypertensive drugs and hepatocellular carcinoma: A trans-ancestry and drug-target Mendelian randomization study. <i>Liver International</i> , 2023, 43, 1320-1331.	1.9	3
3249	Transcatheter arterial chemoembolization plus apatinib with or without camrelizumab for unresectable hepatocellular carcinoma: a multicenter retrospective cohort study. <i>Hepatology International</i> , 2023, 17, 915-926.	1.9	2
3250	Interaction of peripheral CD4+CD25+CD127 <sup>hi</sup> Tregs with prolactin in HCV hepatocellular carcinoma: oncogenic or immunogenic mechanisms. <i>Egyptian Liver Journal</i> , 2023, 13, .	0.3	0
3251	Prediction of Outcome of Newly Onset Cerebrovascular Stroke in HCV Infected Patients. <i>Biomedical and Pharmacology Journal</i> , 2023, 16, 405-417.	0.2	0
3252	Virtual screening, molecular docking, molecular dynamics and quantum chemical studies on (2-methoxy-4-prop-2-enylphenyl) <i>N</i> -(2-methoxy-4-nitrophenyl) carbamate: a novel inhibitor of hepatocellular carcinoma. <i>Journal of Biomolecular Structure and Dynamics</i> , 0, , 1-10.	2.0	2
3253	Role of sex in liver tumor occurrence and clinical outcomes: a comprehensive review. <i>Hepatology</i> , 0, Publish Ahead of Print, .	3.6	2
3254	Targeting PPAR-gamma counteracts tumour adaptation to immune-checkpoint blockade in hepatocellular carcinoma. <i>Gut</i> , 2023, 72, 1758-1773.	6.1	14
3255	Inhibition of Annexin A10 Contributes to ZNF281 Mediated Aggressiveness of Hepatocellular Carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 10, 553-571.	1.8	3
3256	Prognostic Analysis of Single Large Hepatocellular Carcinoma Following Radical Resection: A Single-Center Study. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 10, 573-586.	1.8	1
3257	Surgical Treatment of Hepatocellular Carcinoma: Multicenter Competing-risk Analysis of Tumor-related Death Following Liver Resection and Transplantation Under an Intention-to-treat Perspective. <i>Transplantation</i> , 2023, 107, 1965-1975.	0.5	7
3258	Efficacy of adjuvant TACE on the prognosis of patients with HCC after hepatectomy: a multicenter propensity score matching from China. <i>BMC Cancer</i> , 2023, 23, .	1.1	3
3259	Fragment-based investigation of thiourea derivatives as VEGFR-2 inhibitors: a cross-validated approach of ligand-based and structure-based molecular modeling studies. <i>Journal of Biomolecular Structure and Dynamics</i> , 2024, 42, 1047-1063.	2.0	2

#	ARTICLE	IF	CITATIONS
3260	Tumor burden in patients with early and intermediate-stage hepatocellular carcinoma undergoing liver resection: a retrospective multicenter study on clinical and oncological outcomes. <i>Hpb</i> , 2023, .	0.1	1
3261	Hepatocellular carcinoma surveillance in the telehealth era: A single-centre review. <i>Journal of Telemedicine and Telecare</i> , 0, , 1357633X2311660.	1.4	2
3262	The role of positron emission tomography in the diagnosis and treatment of oncological diseases of the hepatobiliary system. <i>Radiation Diagnostics Radiation Therapy</i> , 2022, 13, .	0.2	0
3263	Bench-to bedside development of multifunctional flexible embolic agents. <i>Theranostics</i> , 2023, 13, 2114-2139.	4.6	0
3264	<scp>CircFAM114A2</scp> inhibits the progression of hepatocellular carcinoma via <scp>miR</scp>â€630/<scp>HHIP</scp> axis. <i>Cancer Medicine</i> , 2023, 12, 12553-12568.	1.3	3
3265	LATSâ€regulated nuclearâ€cytoplasmic translocation of SREBP2 inhibits hepatocellular carcinoma cell migration and invasion via epithelialâ€mesenchymal transition. <i>Molecular Carcinogenesis</i> , 2023, 62, 963-974.	1.3	2
3266	Involvement and targeted intervention of benzo(a)pyrene-regulated apoptosis related proteome modification and multi-drug resistance in hepatocellular carcinoma. <i>Cell Death and Disease</i> , 2023, 14, .	2.7	7
3267	Gamabufotalin Induces Apoptosis and Cytoprotective Autophagy through the mTOR Signaling Pathway in Hepatocellular Carcinoma. <i>Journal of Natural Products</i> , 2023, 86, 966-978.	1.5	1
3270	Treatment patterns, risk factors and outcomes for patients with newly diagnosed hepatocellular carcinoma in France: A retrospective database analysis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2023, 47, 102124.	0.7	1
3271	Reversal of liver failure using a bioartificial liver device implanted with clinical-grade human-induced hepatocytes. <i>Cell Stem Cell</i> , 2023, 30, 617-631.e8.	5.2	10
3272	Decoding m6A mRNA methylation by reader proteins in liver diseases. <i>Genes and Diseases</i> , 2024, 11, 711-726.	1.5	1
3273	Radiofrequency Ablation of Hepatocellular Carcinomas Adjacent to the Gallbladder Without Isolation Under Contrast-Enhanced Ultrasound Monitoring: A Comparative Study with Long Term Follow-Up. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 10, 631-642.	1.8	3
3274	Evaluation of Response to Atezolizumab Plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma Using the Combination of Response Evaluation Criteria in Solid Tumors and Alpha-Fetoprotein. <i>Cancers</i> , 2023, 15, 2304.	1.7	4
3275	Early Experience of TACE Combined with Atezolizumab plus Bevacizumab for Patients with Intermediate-Stage Hepatocellular Carcinoma beyond Up-to-Seven Criteria: A Multicenter, Single-Arm Study. <i>Journal of Oncology</i> , 2023, 2023, 1-8.	0.6	3
3276	Thymidine kinase 1 drives hepatocellular carcinoma in enzyme-dependent and -independent manners. <i>Cell Metabolism</i> , 2023, 35, 912-927.e7.	7.2	3
3277	Diagnostic and Prognostic Nomograms for Hepatocellular Carcinoma Based on PIVKA-II and Serum Biomarkers. <i>Diagnostics</i> , 2023, 13, 1442.	1.3	2
3278	Bioinformatics Analysis of the Prognostic Significance of VPS16 in Hepatocellular Carcinoma and Its Role in Drug Screening. <i>BioMed Research International</i> , 2023, 2023, 1-13.	0.9	1
3279	Contrast-enhanced ultrasound liver imaging reporting and data system v2017: patient outcomes after treatment for early-stage hepatocellular carcinoma nodules with category 3-5 and category M. <i>British Journal of Radiology</i> , 0, , .	1.0	0

#	ARTICLE	IF	CITATIONS
3280	Novel insights into the multifaceted roles of m6A-modified LncRNAs in cancers: biological functions and therapeutic applications. <i>Biomarker Research</i> , 2023, 11, .	2.8	3
3281	Prognostic factors and an innovative nomogram model for patients with hepatocellular carcinoma treated with postoperative adjuvant transarterial chemoembolization. <i>Annals of Medicine</i> , 2023, 55, .	1.5	2
3282	Multi-View Radiomics Feature Fusion Reveals Distinct Immuno-Oncological Characteristics and Clinical Prognoses in Hepatocellular Carcinoma. <i>Cancers</i> , 2023, 15, 2338.	1.7	4
3283	Development and validation of prognostic nomograms for large hepatocellular carcinoma after HAIC. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, 175883592311638.	1.4	1
3284	RNF8 Depletion Attenuates Hepatocellular Carcinoma Progression by Inhibiting Epithelial Mesenchymal Transition and Enhancing Drug Sensitivity. <i>Acta Biochimica Et Biophysica Sinica</i> , 2023, , .	0.9	1
3285	The role of NLRP3 inflammasome in hepatocellular carcinoma. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	3
3286	Recent advances in recurrent hepatocellular carcinoma therapy. <i>World Journal of Hepatology</i> , 0, 15, 460-476.	0.8	4
3287	Deep Learning Radiomics Model of Dynamic <i>&lt;scp&gt;Contrast-Enhanced MRI&lt;/scp&gt;</i> for Evaluating Vessels Encapsulating Tumor Clusters and Prognosis in Hepatocellular Carcinoma. <i>Journal of Magnetic Resonance Imaging</i> , 2024, 59, 108-119.	1.9	5
3288	Causes of death among patients with hepatocellular carcinoma in <i>&lt;scp&gt;United States&lt;/scp&gt;</i> from 2000 to 2018. <i>Cancer Medicine</i> , 2023, 12, 13076-13085.	1.3	2
3289	Comprehensive Analysis of NABP2 as a Prognostic Biomarker and Its Correlation with Immune Infiltration in Hepatocellular Carcinoma. <i>Journal of Inflammation Research</i> , 0, Volume 16, 1783-1804.	1.6	0
3290	Role of human body fluid biomarkers in liver cancer: A systematic review. , 2023, , 293-309.		0
3291	Efficacy and safety analysis of transarterial chemoembolization and transarterial radioembolization in advanced hepatocellular carcinoma descending hepatectomy. <i>World Journal of Gastrointestinal Surgery</i> , 0, 15, 687-697.	0.8	1
3444	Major genomic mutations driving hepatocellular carcinoma. <i>Genome Instability &amp; Disease</i> , 2023, 4, 239-253.	0.5	1
3564	Role of phospholipase A2 in squamous cell carcinoma and breast cancer. , 2023, , 315-335.		0
3632	What Are the Causes and Complications of Chronic Liver Disease and What Is the Evidence for Palliative Care Delivery to Those Affected by It?. , 2023, , 357-370.		0
3635	Meta-analysis of Prognostic Factors for Overall Survival Among Resected Patients with Spontaneous Ruptured Hepatocellular Carcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2023, 27, 2983-3000.	0.9	0
3648	Regulation and targeting of SREBP-1 in hepatocellular carcinoma. <i>Cancer and Metastasis Reviews</i> , 0, , .	2.7	3
3659	The progress of research on immune checkpoint inhibitor resistance and reversal strategies for hepatocellular carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 3953-3969.	2.0	0



#	ARTICLE	IF	CITATIONS
3667	Automatic Detection of Focal Liver Lesions in Multi-phase CT Images Using One-Stage Object Detectors. , 2023, , .		0
3702	Nanomaterials for visualized tumor surgical navigation and postoperative recurrence inhibition. Nano Research, 0, , .	5.8	0
3741	Biomarker in Hepatocellular Carcinoma. Indian Journal of Surgical Oncology, 0, , .	0.3	0
3753	Deep learning-based radiomics allows for a more accurate assessment of sarcopenia as a prognostic factor in hepatocellular carcinoma. Journal of Zhejiang University: Science B, 2024, 25, 83-90.	1.3	0
3763	Liver fibrosis: pathological features, clinical treatment and application of therapeutic nanoagents. Journal of Materials Chemistry B, 2024, 12, 1446-1466.	2.9	0
3814	Evaluation of immune microenvironment in hepatocellular carcinoma: current advances in CT and MRI imaging techniques. Chinese Journal of Academic Radiology, 2024, 7, 8-14.	0.4	0
3828	Exploration of multi-walled carbon nanotubes in the treatment of hepatic cancer: An update. AIP Conference Proceedings, 2024, , .	0.3	0
3836	Liver Cancer Surgery. , 2023, , 263-267.		0